Notes_NN
to_PIN
the_DT
financial_JJ
statements_NOMZ
The_DT
financial_JJ
statements_NOMZ
have_VPRT [PEAS]
been_VBN [PASS]
prepared_VBN
in_PIN
accordance_NN
with_PIN
the_DT
1_CD
Presentation_NOMZ
of_PIN
the_DT
financial_JJ
statements_NOMZ
Groups_NN
accounting_VBG [WZPRES]
policies_NN
approved_VBN [WZPAST]
by_PIN
the_DT
Board_NN
and_CC
described_VBN
in_PIN
Description_NOMZ
of_PIN
business_NOMZ
Note_NN
2_CD
._.
GlaxoSmithKline_NN
is_VPRT [BEMA]
a_DT
major_JJ
global_JJ
healthcare_NN
group_NN
which_WDT [WHSUB]
is_VPRT [PASS]
engaged_VBN
in_PIN
the_DT
creation_NOMZ
and_PHC
discovery_NN
,_,
development_NOMZ
,_,
manufacture_NN
and_PHC
Conversion_NN
to_PIN
IFRS_NN
marketing_GER
of_PIN
pharmaceutical_JJ
products_NN
,_,
including_VBG
vaccines_NN
,_,
over-theThis_NN
is_VPRT [BEMA]
the_DT
first_JJ
year_NN
that_TOBJ
GlaxoSmithKline_NN
has_VPRT [PEAS]
produced_VBN
financial_JJ
counter_NN
OTC_NN
medicines_NN
and_CC
health-related_JJ
consumer_NN
products_NN
._.
The_DT
adoption_NOMZ
of_PIN
IFRS_NN
has_VPRT [PEAS]
resulted_VBN
in_PIN
a_DT
number_NN
GlaxoSmithKlines_VPRT
principal_JJ
pharmaceutical_JJ
products_NN
include_VPRT
of_PIN
significant_JJ
adjustments_NOMZ
to_PIN
the_DT
previously_TIME
reported_VBN [PUBV]
results_NN
and_PHC
equity_NOMZ
medicines_NN
in_PIN
the_DT
following_VBG
therapeutic_JJ
areas_NN
:_:
central_JJ
nervous_JJ
system_NN
,_,
shareholders_NN
funds_NN
presented_VBN
under_IN
UK_NN
generally_RB
accepted_VBD [PRIV]
respiratory_JJ
,_,
anti-virals_NN
,_,
anti-bacterials_NN
,_,
vaccines_NN
,_,
oncology_NN
and_PHC
emesis_NN
,_,
accounting_VBG
principles_NN
UK_NN
GAAP_NN
._.
The_DT
main_JJ
changes_NN
were_VBD [BEMA]
in_PIN
relation_NOMZ
metabolic_NN
,_,
cardiovascular_JJ
and_PHC
urogenital_JJ
._.
to_PIN
share-based_JJ
payments_NOMZ
,_,
pensions_NN
,_,
intangible_JJ
assets_NN
,_,
deferred_VBN
taxation_NOMZ
and_CC
financial_JJ
instruments_NOMZ
._.
Compliance_NN
with_PIN
applicable_JJ
law_NN
and_PHC
IFRS_NN
IFRS_NN
1_CD
,_,
First-Time_NN
Adoption_NOMZ
of_PIN
international_JJ
Financial_JJ
Reporting_GER
The_DT
financial_JJ
statements_NOMZ
have_VPRT [PEAS]
been_VBN [PASS]
prepared_VBN
in_PIN
accordance_NN
with_PIN
the_DT
Standards_NN
,_,
permits_VPRT
those_DEMO
companies_NN
adopting_VBG [WZPRES]
IFRS_NN
for_PIN
the_DT
first_JJ
time_NN
Companies_NN
Act_NN
1985_CD
,_,
Article_NN
4_CD
of_PIN
the_DT
IAS_NN
Regulation_NOMZ
and_CC
to_TO
take_VB
some_QUAN
exemptions_NOMZ
from_PIN
the_DT
full_JJ
requirements_NOMZ
of_PIN
IFRS_NN
in_PIN
the_DT
International_NN
Accounting_GER
Standards_NN
IAS_NN
and_PHC
International_NN
Financial_NN
transition_NOMZ
period_NN
._.
GlaxoSmithKline_NN
has_VPRT [PEAS]
adopted_VBN
the_DT
following_VBG
key_JJ
Reporting_GER
Standards_NN
IFRS_NN
and_CC
related_JJ
interpretations_NOMZ
,_,
as_IN
adopted_VBN
for_PIN
exemptions_NOMZ
:_:
use_NN
in_PIN
the_DT
European_NN
Union_NN
._.
Business_NOMZ
combinations_NOMZ
:_:
Business_NOMZ
combinations_NOMZ
prior_RB
to_PIN
the_DT
transition_NOMZ
For_PIN
GSK_NN
,_,
there_EX
are_VPRT
no_SYNE
differences_NN
between_PIN
IFRS_NN
as_IN
adopted_VBN
for_PIN
use_NN
in_PIN
date_NN
1st_CD
January_NN
2003_CD
have_VPRT [PEAS]
not_XX0
been_VBN [PASS]
restated_VBN
onto_PIN
an_DT
IFRS_NN
basis_NN
the_DT
European_NN
Union_NN
and_CC
full_JJ
IFRS_NN
as_IN
published_VBN
by_PIN
the_DT
International_NN
Accounting_GER
Standards_NN
Board_NN
._.
Share-based_JJ
payments_NOMZ
:_:
IFRS_NN
2_CD
,_,
Share-based_JJ
Payment_NOMZ
,_,
applies_VPRT
to_PIN
equity_NOMZ
instruments_NOMZ
,_,
such_JJ
as_IN
share_NN
options_NOMZ
granted_VBN [SUAV]
since_OSUB
7th_NN
Financial_NN
period_NN
November_NN
2002_CD
,_,
but_CC
GlaxoSmithKline_NN
has_VPRT [PEAS]
elected_VBN
to_TO
adopt_VB
full_JJ
These_DEMO
financial_JJ
statements_NOMZ
cover_VPRT
the_DT
financial_JJ
year_NN
from_PIN
1st_CD
January_NN
retrospective_JJ
application_NOMZ
of_PIN
the_DT
standard_NN
to_PIN
31st_CD
December_NN
2005_CD
,_,
with_PIN
comparative_JJ
figures_NN
for_PIN
the_DT
financial_JJ
years_NN
from_PIN
1st_CD
January_NN
to_TO
31st_VB
December_NN
2004_CD
and_CC
from_PIN
1st_CD
January_NN
Financial_NN
instruments_NOMZ
:_:
Financial_NN
instruments_NOMZ
in_PIN
the_DT
comparative_JJ
to_TO
31st_VB
December_NN
2003_CD
._.
periods_NN
presented_VBN [WZPAST]
in_PIN
the_DT
Annual_JJ
Report_NN
2005_CD
i._FW
e._FW
2004_CD
and_CC
2003_CD
are_VPRT [PASS]
recorded_VBN
on_PIN
the_DT
UK_NN
GAAP_NN
basis_NN
applicable_JJ
in_PIN
those_DEMO
years_NN
,_,
rather_CONJ
Composition_NOMZ
of_PIN
the_DT
Group_NN
than_PIN
in_PIN
accordance_NN
with_PIN
IAS_NN
32_CD
Financial_NN
Instruments_NOMZ
:_:
Disclosure_NN
A_DT
list_NN
of_PIN
the_DT
subsidiary_NN
and_CC
associated_VBN
undertakings_GER
which_WDT [WHOBJ]
,_,
in_PIN
the_DT
opinion_NN
and_PHC
Presentation_NOMZ
and_PHC
IAS_NN
39_CD
Financial_NN
Instruments_NOMZ
:_:
Recognition_NOMZ
of_PIN
the_DT
Directors_NN
,_,
principally_RB
affected_VBD
the_DT
amount_NN
of_PIN
profit_NN
or_CC
the_DT
net_NN
and_PHC
Measurement_NOMZ
._.
assets_NN
of_PIN
the_DT
Group_NN
is_VPRT [PASS]
given_VBN
in_PIN
Principal_NN
Group_NN
companies_NN
,_,
Note_VB [PRIV]
39_CD
._.
See_VB [PRIV]
Note_VB [PRIV]
40_CD
for_PIN
further_JJ
details_NN
._.
Composition_NOMZ
of_PIN
financial_JJ
statements_NOMZ
The_DT
consolidated_JJ
financial_JJ
statements_NOMZ
are_VPRT [PASS]
drawn_VBN
up_RP
in_PIN
accordance_NN
Parent_NN
company_NN
financial_JJ
statements_NOMZ
with_PIN
IFRS_NN
and_CC
with_PIN
IFRS_NN
accounting_GER
presentation_NOMZ
._.
The_DT
financial_JJ
The_DT
financial_JJ
statements_NOMZ
of_PIN
the_DT
parent_NN
company_NN
,_,
GlaxoSmithKline_NN
statements_NOMZ
comprise_VPRT
:_:
plc_NN
,_,
have_VPRT [PEAS]
been_VBN [PASS]
prepared_VBN
in_PIN
accordance_NN
with_PIN
UK_NN
GAAP_NN
and_CC
with_PIN
UK_NN
accounting_GER
presentation_NOMZ
._.
The_DT
company_NN
balance_NN
sheet_NN
is_VPRT [PASS]
presented_VBN
on_PIN
Consolidated_NN
income_NN
statement_NOMZ
page_NN
167_CD
._.
Consolidated_NN
balance_NN
sheet_NN
Consolidated_NN
cash_NN
flow_NN
statement_NOMZ
2_CD
Accounting_GER
policies_NN
Consolidated_NN
statement_NOMZ
of_PIN
recognized_VBN [PRIV]
income_NN
and_PHC
expense_NN
Notes_NN
to_PIN
the_DT
financial_JJ
statements_NOMZ
._.
Consolidation_NOMZ
The_DT
consolidated_JJ
financial_JJ
statements_NOMZ
include_VPRT
:_:
Additional_JJ
information_NOMZ
in_PIN
accordance_NN
with_PIN
the_DT
requirements_NOMZ
of_PIN
US_FPP1
generally_RB
accepted_VBD [PRIV]
accounting_GER
principles_NN
US_FPP1
GAAP_NN
is_VPRT [PASS]
included_VBN
in_PIN
the_DT
assets_NN
and_PHC
liabilities_NOMZ
,_,
and_ANDC
the_DT
results_NN
and_PHC
cash_NN
flows_NN
,_,
of_PIN
the_DT
the_DT
notes_NN
to_PIN
the_DT
financial_JJ
statements_NOMZ
._.
In_PIN
Note_NN
38_CD
a_DT
statement_NOMZ
of_PIN
company_NN
and_CC
its_PIT
subsidiaries_NN
,_,
including_VBG
ESOP_NN
Trusts_NN
differences_NN
,_,
and_ANDC
reconciliations_NOMZ
of_PIN
net_JJ
income_NN
and_PHC
shareholders_NN
the_DT
Groups_NN
share_NN
of_PIN
the_DT
net_JJ
assets_NN
and_PHC
results_NN
of_PIN
associates_NN
and_PHC
equity_NOMZ
,_,
between_PIN
IFRS_NN
and_PHC
US_FPP1
GAAP_NN
are_VPRT [PASS]
provided_VBN
._.
Accounting_GER
convention_NOMZ
The_DT
financial_JJ
statements_NOMZ
of_PIN
entities_NOMZ
consolidated_VBN [WZPAST]
are_VPRT [PASS]
made_VBN
up_RP
to_PIN
31st_CD
The_DT
financial_JJ
statements_NOMZ
have_VPRT [PEAS]
been_VBN [PASS]
prepared_VBN
using_VBG
the_DT
historical_JJ
cost_NN
December_NN
._.
convention_NOMZ
,_,
modified_VBN [PASTP]
for_PIN
certain_JJ
items_NN
carried_VBD
at_PIN
fair_JJ
value_NN
,_,
as_IN
stated_VBN [PUBV]
in_PIN
the_DT
accounting_GER
policies_NN
._.
Entities_NOMZ
over_IN
which_WDT
the_DT
Group_NN
has_VPRT
the_DT
ability_NOMZ
to_TO
exercise_VB
control_NN
are_VPRT [PASS]
accounted_VBN
for_PIN
as_IN
subsidiaries_NN
:_:
where_RB
the_DT
Group_NN
has_VPRT
the_DT
ability_NOMZ
to_PIN
Accounting_GER
principles_NN
and_PHC
policies_NN
exercise_VPRT
joint_JJ
control_NN
,_,
they_TPP3
are_VPRT [PASS]
accounted_VBN
for_PIN
as_IN
joint_JJ
ventures_NN
:_:
and_ANDC
The_DT
preparation_NOMZ
of_PIN
the_DT
financial_JJ
statements_NOMZ
in_PIN
conformity_NOMZ
with_PIN
where_RB
the_DT
Group_NN
has_VPRT
the_DT
ability_NOMZ
to_TO
exercise_VB
significant_JJ
influence_NN
,_,
they_TPP3
generally_RB
accepted_VBD [PRIV]
accounting_GER
principles_NN
requires_VPRT [SUAV]
management_NOMZ
to_TO
are_VPRT [PASS]
accounted_VBN
for_PIN
as_IN
associates_NN
._.
make_VB
estimates_NN
and_PHC
assumptions_NOMZ
that_TSUB
affect_VPRT
the_DT
reported_VBN [PUBV]
amounts_NN
of_PIN
assets_NN
and_PHC
liabilities_NOMZ
and_PHC
disclosure_NN
of_PIN
contingent_JJ
assets_NN
and_PHC
liabilities_NOMZ
Interests_NN
acquired_VBN [WZPAST]
in_PIN
entities_NOMZ
are_VPRT [PASS]
consolidated_VBN
from_PIN
the_DT
effective_JJ
date_NN
at_PIN
the_DT
date_NN
of_PIN
the_DT
financial_JJ
statements_NOMZ
and_CC
the_DT
reported_VBN [PUBV]
amounts_NN
of_PIN
of_PIN
acquisition_NOMZ
and_PHC
interests_NN
sold_VBN [WZPAST]
are_VPRT [PASS]
consolidated_VBN
up_RP
to_PIN
the_DT
date_NN
of_PIN
revenues_NN
and_PHC
expenses_NN
during_PIN
the_DT
reporting_GER
period_NN
._.
could_POMD
differ_VB
from_PIN
those_DEMO
estimates_NN
._.
GSK_NN
Annual_JJ
Report_NN
2005_CD
89_CD
FINANCIAL_NN
STATEMENTS_NOMZ
Notes_NN
to_PIN
the_DT
financial_JJ
statements_NOMZ
continued_VBD
Expenditure_NN
2_CD
Accounting_GER
policies_NN
continued_VBD
Expenditure_NN
is_VPRT [PASS]
recognized_VBN [PRIV]
in_PIN
respect_NN
of_PIN
goods_NN
and_PHC
services_NN
received_VBN
Transactions_NOMZ
and_PHC
balances_NN
between_PIN
subsidiaries_NN
are_VPRT [PASS]
eliminated_VBN
:_:
no_DT
when_RB
supplied_VBN
in_PIN
accordance_NN
with_PIN
contractual_JJ
terms_NN
._.
Provision_NN
is_VPRT
profit_NN
before_IN
tax_NN
is_VPRT [PASS]
taken_VBN
on_PIN
sales_NN
between_PIN
subsidiaries_NN
or_CC
on_PIN
sales_NN
to_TO
made_VBN
when_RB
an_DT
obligation_NOMZ
exists_VPRT
for_PIN
a_DT
future_JJ
liability_NOMZ
in_PIN
respect_NN
of_PIN
a_DT
past_JJ
joint_JJ
ventures_NN
and_PHC
associates_NN
until_IN
the_DT
products_NN
are_VPRT [PASS]
sold_VBN
to_PIN
customers_NN
event_NN
and_ANDC
where_RB
the_DT
amount_NN
of_PIN
the_DT
obligation_NOMZ
can_POMD
be_VB
reliably_RB
outside_PLACE
the_DT
Group_NN
._.
Deferred_JJ
tax_NN
relief_NN
on_PIN
unrealised_JJ
intra-Group_JJ
profit_NN
estimated_VBN [PRIV]
._.
Advertising_GER
and_PHC
promotion_NOMZ
expenditure_NN
is_VPRT [PASS]
charged_VBN
to_PIN
the_DT
is_VPRT [PASS]
accounted_VBN
for_PIN
only_DWNT
to_PIN
the_DT
extent_NN
that_TOBJ
it_PIT
is_VPRT [PASS]
considered_VBN [PRIV]
recoverable_JJ
._.
Shipment_NOMZ
costs_NN
on_PIN
intercompany_NN
transfers_NN
are_VPRT [PASS]
charged_VBN
to_PIN
cost_NN
of_PIN
sales_NN
:_:
distribution_NOMZ
costs_NN
on_PIN
sales_NN
to_PIN
Goodwill_NN
arising_VBG [WZPRES]
on_PIN
the_DT
acquisition_NOMZ
of_PIN
interests_NN
in_PIN
subsidiaries_NN
,_,
joint_JJ
customers_NN
are_VPRT [PASS]
included_VBN
in_PIN
selling_GER
,_,
general_JJ
and_PHC
administrative_JJ
ventures_NN
and_PHC
associates_NN
,_,
representing_VBG [PRESP]
the_DT
excess_NN
of_PIN
the_DT
purchase_NN
expenditure_NN
._.
Restructuring_GER
costs_NN
are_VPRT [PASS]
recognized_VBN [PRIV]
in_PIN
respect_NN
of_PIN
the_DT
direct_JJ
consideration_NOMZ
over_IN
the_DT
Groups_NN
share_NN
of_PIN
the_DT
fair_JJ
values_NN
of_PIN
the_DT
expenditure_NN
of_PIN
a_DT
business_NOMZ
reorganisation_NOMZ
where_RB
the_DT
plans_NN
are_VPRT [BEMA]
identifiable_JJ
assets_NN
,_,
liabilities_NOMZ
and_CC
contingent_JJ
liabilities_NOMZ
acquired_VBN
,_,
is_VPRT [SPAU] [PASS]
sufficiently_RB
detailed_VBN
and_CC
well_RB
advanced_VBD
,_,
and_ANDC
where_RB
appropriate_JJ
capitalized_VBN
as_IN
a_DT
separate_JJ
item_NN
in_PIN
the_DT
case_NN
of_PIN
subsidiaries_NN
and_CC
as_IN
part_NN
communication_NOMZ
to_PIN
those_DEMP
affected_VBN
has_VPRT [PEAS]
been_VBN [PASS]
undertaken_VBN
._.
of_PIN
the_DT
cost_NN
of_PIN
investment_NOMZ
in_PIN
the_DT
case_NN
of_PIN
joint_JJ
ventures_NN
and_PHC
associates_NN
._.
Goodwill_NN
is_VPRT [PASS]
denominated_VBN
in_PIN
the_DT
currency_NN
of_PIN
the_DT
operation_NOMZ
acquired_VBN
._.
Research_NN
and_PHC
development_NOMZ
In_PIN
the_DT
case_NN
of_PIN
acquisitions_NOMZ
prior_RB
to_PIN
1998_CD
,_,
goodwill_NN
was_VBD [PASS]
written_VBN [PUBV]
off_PIN
Research_NN
and_PHC
development_NOMZ
expenditure_NN
is_VPRT [PASS]
charged_VBN
to_PIN
the_DT
income_NN
directly_RB
to_PIN
equity_NOMZ
:_:
on_PIN
a_DT
subsequent_JJ
disposal_NN
of_PIN
assets_NN
from_PIN
such_JJ
statement_NOMZ
in_PIN
the_DT
period_NN
in_PIN
which_WDT [PIRE]
it_PIT
is_VPRT [PASS]
incurred_VBN
._.
Development_NOMZ
acquisitions_NOMZ
,_,
any_QUAN
related_JJ
goodwill_NN
remains_VPRT
in_PIN
equity_NOMZ
and_CC
is_VPRT [PASS]
not_XX0
charged_VBN
expenditure_NN
is_VPRT [PASS]
capitalized_VBN
when_RB
the_DT
criteria_NN
for_PIN
recognizing_VBG [PRIV]
an_DT
asset_NN
to_PIN
the_DT
consolidated_JJ
income_NN
statement_NOMZ
._.
Business_NOMZ
combinations_NOMZ
have_VPRT
are_VPRT [PASS]
met_VBN
,_,
usually_RB
when_RB
a_DT
regulatory_JJ
filing_NN
has_VPRT [PEAS]
been_VBN [PASS]
made_VBN
in_PIN
a_DT
major_JJ
not_XX0
been_VBN [PASS]
restated_VBN
in_PIN
2004_CD
and_CC
2003_CD
._.
market_NN
and_PHC
approval_NN
is_VPRT [PASS]
considered_VBN [PRIV]
highly_AMP
probable_JJ
._.
Property_NN
,_,
plant_NN
The_DT
results_NN
and_PHC
assets_NN
and_PHC
liabilities_NOMZ
of_PIN
associates_NN
and_CC
joint_JJ
ventures_NN
and_PHC
equipment_NOMZ
used_VBN [WZPAST]
for_PIN
research_NN
and_PHC
development_NOMZ
is_VPRT [PASS]
depreciated_VBN
in_PIN
are_VPRT [PASS]
incorporated_VBN
into_PIN
the_DT
consolidated_JJ
financial_JJ
statements_NOMZ
using_VBG [WZPRES]
the_DT
accordance_NN
with_PIN
the_DT
Groups_NN
policy_NN
._.
Environmental_NN
expenditure_NN
Environmental_NN
expenditure_NN
related_VBN
to_TO
existing_VBG
conditions_NOMZ
resulting_VBG [WZPRES]
Assets_NN
and_PHC
liabilities_NOMZ
,_,
including_VBG
related_VBN
goodwill_NN
,_,
of_PIN
overseas_PLACE
from_PIN
past_JJ
or_CC
current_JJ
operations_NOMZ
and_CC
from_PIN
which_WDT [PIRE]
no_SYNE
current_JJ
or_CC
future_JJ
subsidiaries_NN
,_,
associates_NN
and_CC
joint_JJ
ventures_NN
,_,
are_VPRT [PASS]
translated_VBN
into_PIN
sterling_GER
benefit_NN
is_VPRT [BEMA]
discernible_PRED
is_VPRT [PASS]
charged_VBN
to_PIN
the_DT
income_NN
statement_NOMZ
._.
The_DT
Group_NN
at_PIN
rates_NN
of_PIN
exchange_NN
ruling_NN
at_PIN
the_DT
balance_NN
sheet_NN
date_NN
._.
The_DT
results_NN
and_CC
recognizes_VPRT [PRIV]
its_PIT
liability_NOMZ
on_PIN
a_DT
site-by-site_JJ
basis_NN
when_RB
it_PIT
can_POMD
be_VB
reliably_RB
cash_NN
flows_NN
of_PIN
overseas_PLACE
subsidiaries_NN
,_,
associates_NN
and_CC
joint_JJ
ventures_NN
are_VPRT [PASS]
estimated_VBN [PRIV]
._.
This_DEMO
liability_NOMZ
includes_VPRT
the_DT
Groups_NN
portion_NOMZ
of_PIN
the_DT
total_JJ
costs_NN
translated_VBN [WZPAST]
into_PIN
sterling_GER
using_VBG [WZPRES]
average_JJ
rates_NN
of_PIN
exchange_NN
._.
Exchange_NN
and_CC
also_RB
a_DT
portion_NOMZ
of_PIN
other_JJ
potentially_RB
responsible_JJ
parties_NN
costs_NN
when_RB
adjustments_NOMZ
arising_VBG [WZPRES]
when_RB
the_DT
opening_GER
net_JJ
assets_NN
and_CC
the_DT
profits_NN
for_PIN
it_PIT
is_VPRT [BEMA]
probable_PRED
that_THAC
they_TPP3
will_PRMD
not_XX0
be_VB [BEMA]
able_PRED
to_TO
satisfy_VB
their_TPP3
respective_JJ
shares_NN
the_DT
year_NN
retained_VBN [WZPAST]
by_PIN
overseas_PLACE
subsidiaries_NN
,_,
associates_NN
and_CC
joint_JJ
ventures_NN
of_PIN
the_DT
clean-up_JJ
obligation_NOMZ
._.
Recoveries_NN
of_PIN
reimbursements_NOMZ
are_VPRT [PASS]
recorded_VBN
are_VPRT [PASS]
translated_VBN
into_PIN
sterling_GER
,_,
less_JJ
exchange_NN
differences_NN
arising_VBG [WZPRES]
on_PIN
related_VBN
as_IN
assets_NN
when_RB
virtually_RB
certain_JJ
._.
foreign_JJ
currency_NN
borrowings_GER
which_WDT [WHSUB]
hedge_VPRT
the_DT
Groups_NN
net_JJ
investment_NOMZ
in_PIN
these_DEMO
operations_NOMZ
,_,
are_VPRT [PASS]
taken_VBN
to_PIN
a_DT
separate_JJ
component_NN
of_PIN
equity_NOMZ
._.
Pensions_NN
and_CC
other_JJ
post-employment_NOMZ
benefits_NN
When_RB
translating_VBG
into_PIN
sterling_GER
the_DT
assets_NN
,_,
liabilities_NOMZ
,_,
results_NN
and_PHC
cash_NN
The_DT
costs_NN
of_PIN
providing_VBG
pensions_NN
under_IN
defined_VBN
benefit_NN
schemes_NN
are_VPRT
flows_NN
of_PIN
overseas_PLACE
subsidiaries_NN
,_,
associates_NN
and_CC
joint_JJ
ventures_NN
which_WDT [WHSUB]
are_VPRT [PASS]
calculated_VBN [PRIV]
using_VBG
the_DT
projected_VBN
unit_NN
credit_NN
method_NN
and_PHC
spread_NN
over_IN
reported_VBN [PUBV]
in_PIN
currencies_NN
of_PIN
hyper-inflationary_JJ
economies_NN
,_,
adjustments_NOMZ
the_DT
period_NN
during_PIN
which_WDT [PIRE]
benefit_NN
is_VPRT [PASS]
expected_VBN [PRIV]
to_TO
be_VB [PASS]
derived_VBN
from_PIN
the_DT
are_VPRT [PASS]
made_VBN
to_TO
reflect_VB [PRIV]
current_JJ
price_NN
levels_NN
._.
Any_QUAN
loss_NN
on_PIN
net_JJ
monetary_JJ
employees_NN
services_NN
,_,
in_PIN
accordance_NN
with_PIN
the_DT
advice_NN
of_PIN
qualified_JJ
assets_NN
is_VPRT [PASS]
charged_VBN
to_PIN
the_DT
consolidated_JJ
income_NN
statement_NOMZ
._.
Pension_NN
obligations_NOMZ
are_VPRT [PASS]
measured_VBN
as_IN
the_DT
present_JJ
value_NN
of_PIN
estimated_JJ
future_JJ
cash_NN
flows_VPRT
discounted_VBN
at_PIN
rates_NN
reflecting_VBG [PRIV] [WZPRES]
the_DT
yields_NN
Foreign_JJ
currency_NN
transactions_NOMZ
of_PIN
high_JJ
quality_NOMZ
corporate_JJ
bonds_NN
._.
Foreign_JJ
currency_NN
transactions_NOMZ
by_PIN
Group_NN
companies_NN
are_VPRT [PASS]
booked_VBN
in_PIN
local_JJ
Pension_NN
scheme_NN
assets_NN
are_VPRT [PASS]
measured_VBN
at_PIN
fair_JJ
value_NN
at_PIN
the_DT
balance_NN
sheet_NN
currency_NN
at_PIN
the_DT
exchange_NN
rate_NN
ruling_NN
on_PIN
the_DT
date_NN
of_PIN
transaction_NOMZ
._.
Actuarial_JJ
gains_NN
and_PHC
losses_NN
,_,
differences_NN
between_PIN
the_DT
expected_VBN [PRIV]
Foreign_JJ
currency_NN
assets_NN
and_PHC
liabilities_NOMZ
are_VPRT [PASS]
retranslated_VBN
into_PIN
local_JJ
and_PHC
actual_JJ
returns_NN
,_,
and_ANDC
the_DT
effect_NN
of_PIN
changes_NN
in_PIN
actuarial_JJ
assumptions_NOMZ
currency_NN
at_PIN
rates_NN
of_PIN
exchange_NN
ruling_NN
at_PIN
the_DT
balance_NN
sheet_NN
date_NN
._.
are_VPRT [PASS]
recognized_VBN [PRIV]
in_PIN
the_DT
statement_NOMZ
of_PIN
recognized_VBN [PRIV]
income_NN
and_PHC
expense_NN
Exchange_NN
differences_NN
are_VPRT [PASS]
included_VBN
in_PIN
the_DT
income_NN
statement_NOMZ
._.
in_PIN
the_DT
year_NN
in_PIN
which_WDT [PIRE]
they_TPP3
arise_VPRT
._.
The_DT
Groups_NN
contributions_NOMZ
to_TO
defined_VBN
Revenue_NN
contribution_NOMZ
plans_NN
are_VPRT [PASS]
charged_VBN
to_PIN
the_DT
income_NN
statement_NOMZ
as_IN
incurred_VBN
._.
Revenue_NN
is_VPRT [PASS]
recognized_VBN [PRIV]
in_PIN
the_DT
income_NN
statement_NOMZ
when_RB
goods_NN
or_CC
services_NN
are_VPRT [PASS]
supplied_VBN
or_CC
made_VBN
available_JJ
to_PIN
external_JJ
customers_NN
against_PIN
The_DT
costs_NN
of_PIN
other_JJ
post-employment_NOMZ
liabilities_NOMZ
are_VPRT [PASS]
calculated_VBN [PRIV]
in_PIN
a_DT
similar_JJ
orders_NN
received_VBN
and_ANDC
when_RB
title_NN
and_PHC
risk_NN
of_PIN
loss_NN
passes_VPRT
to_PIN
the_DT
customer_NN
._.
way_NN
to_TO
defined_VBN
benefit_NN
pension_NN
schemes_NN
and_PHC
spread_NN
over_IN
the_DT
period_NN
Turnover_NN
represents_VPRT
net_JJ
invoice_NN
value_NN
after_IN
the_DT
deduction_NOMZ
of_PIN
discounts_NN
during_PIN
which_WDT [PIRE]
benefit_NN
is_VPRT [PASS]
expected_VBN [PRIV]
to_TO
be_VB [PASS]
derived_VBN
from_PIN
the_DT
employees_NN
services_NN
,_,
in_PIN
accordance_NN
with_PIN
the_DT
advice_NN
of_PIN
qualified_VBN
actuaries_NN
._.
and_ANDC
allowances_NN
given_VBN
and_CC
accruals_NN
for_PIN
estimated_JJ
future_JJ
rebates_NN
and_PHC
returns_NN
._.
The_DT
methodology_NN
and_PHC
assumptions_NOMZ
used_VBN
to_TO
estimate_VB [PRIV]
rebates_NN
Legal_JJ
and_PHC
other_JJ
disputes_NN
and_PHC
returns_NN
are_VPRT [PASS]
monitored_VBN
and_PHC
adjusted_VBN
regularly_RB
in_PIN
the_DT
light_NN
of_PIN
Provision_NN
is_VPRT [PASS]
made_VBN
for_PIN
anticipated_JJ
settlement_NOMZ
costs_NN
where_RB
a_DT
reasonable_JJ
contractual_JJ
and_PHC
historical_JJ
information_NOMZ
and_CC
past_JJ
experience_NN
._.
Turnover_NN
estimate_NN
can_POMD
be_VB [PASS]
made_VBN
of_PIN
the_DT
likely_JJ
outcome_NN
of_PIN
legal_JJ
or_CC
other_JJ
disputes_NN
also_RB
includes_VPRT
co-promotion_JJ
income_NN
where_RB
the_DT
Group_NN
records_NN
its_PIT
share_NN
against_PIN
the_DT
Group_NN
._.
In_CONJ
addition_NULL
,_,
provision_NN
is_VPRT [PASS]
made_VBN
for_PIN
legal_JJ
or_CC
other_JJ
of_PIN
the_DT
revenue_NN
but_CC
no_SYNE
related_JJ
cost_NN
of_PIN
sales_NN
._.
Value_NN
added_VBD [PUBV]
tax_NN
and_CC
other_JJ
expenses_NN
arising_VBG [WZPRES]
from_PIN
claims_NN
received_VBN
or_CC
other_JJ
disputes_NN
._.
sales_NN
taxes_NN
are_VPRT [PASS]
excluded_VBN
from_PIN
revenue_NN
._.
GSK_NN
Annual_JJ
Report_NN
2005_CD
90_CD
FINANCIAL_NN
STATEMENTS_NOMZ
Notes_NN
to_PIN
the_DT
financial_JJ
statements_NOMZ
continued_VBD
Goodwill_NN
2_CD
Accounting_GER
policies_NN
continued_VBD
Goodwill_NN
is_VPRT [PASS]
stated_VBN [PUBV]
at_PIN
cost_NN
less_JJ
impairments_NOMZ
._.
Goodwill_NN
is_VPRT [PASS]
deemed_VBN [PRIV]
to_PIN
In_PIN
respect_NN
of_PIN
product_NN
liability_NOMZ
claims_NN
related_VBN [WZPAST]
to_PIN
products_NN
where_RB
there_EX
have_VPRT
an_DT
indefinite_JJ
useful_JJ
life_NN
and_CC
is_VPRT [PASS]
tested_VBN
for_PIN
impairment_NOMZ
annually_RB
._.
is_VPRT [BEMA]
sufficient_JJ
history_NN
of_PIN
claims_NN
made_VBN
and_CC
settlements_NOMZ
,_,
an_DT
incurred_VBN
but_CC
not_XX0
reported_VBD [PUBV]
IBNR_NN
actuarial_JJ
technique_NN
is_VPRT [PASS]
used_VBN
to_TO
determine_VB [SUAV] [PRIV]
a_DT
Where_RB
the_DT
fair_JJ
value_NN
of_PIN
the_DT
interest_NN
acquired_VBN [WZPAST]
in_PIN
an_DT
entitys_JJ
assets_NN
,_,
reasonable_JJ
estimate_NN
of_PIN
the_DT
Groups_NN
exposure_NN
to_PIN
unasserted_JJ
claims_NN
for_PIN
liabilities_NOMZ
and_CC
contingent_JJ
liabilities_NOMZ
exceeds_VPRT
the_DT
consideration_NOMZ
paid_VBN
,_,
this_DEMO
those_DEMO
products_NN
and_CC
a_DT
provision_NN
is_VPRT [PASS]
made_VBN
on_PIN
that_DEMP
basis_NN
._.
excess_NN
is_VPRT [PASS]
recognized_VBN [PRIV]
immediately_TIME
as_IN
a_DT
gain_NN
in_PIN
the_DT
income_NN
statement_NOMZ
._.
Intangible_JJ
assets_NN
No_SYNE
provision_NN
is_VPRT [PASS]
made_VBN
for_PIN
other_JJ
unasserted_JJ
claims_NN
or_CC
where_RB
an_DT
Intangible_JJ
assets_NN
are_VPRT [PASS]
stated_VBN [PUBV]
at_PIN
cost_NN
less_JJ
provisions_NN
for_PIN
amortisation_NOMZ
and_PHC
obligation_NOMZ
exists_VPRT
under_IN
a_DT
dispute_NN
but_CC
it_PIT
is_VPRT [BEMA]
not_XX0
possible_PRED
to_TO
make_VB
a_DT
impairments_NOMZ
._.
Costs_NN
associated_VBN [WZPAST]
with_PIN
claims_NN
made_VBN [WZPAST]
by_PIN
the_DT
Group_NN
against_PIN
third_JJ
parties_NN
are_VPRT [PASS]
charged_VBN
to_PIN
the_DT
income_NN
statement_NOMZ
as_IN
they_TPP3
are_VPRT
Licences_NN
,_,
patents_NN
,_,
know-how_NN
and_PHC
marketing_GER
rights_NN
separately_RB
incurred_VBN
._.
acquired_VBN
or_CC
acquired_VBN
as_IN
part_NN
of_PIN
a_DT
business_NOMZ
combination_NOMZ
are_VPRT [PASS]
amortised_VBN
Employee_NN
share_NN
plans_VPRT
over_IN
their_TPP3
estimated_VBN [PRIV]
useful_JJ
lives_NN
from_PIN
the_DT
time_NN
they_TPP3
are_VPRT [BEMA]
available_PRED
for_PIN
Incentives_NN
in_PIN
the_DT
form_NN
of_PIN
shares_NN
are_VPRT [PASS]
provided_VBN
to_PIN
employees_NN
under_IN
use_NN
._.
The_DT
estimated_VBN [PRIV]
useful_JJ
lives_NN
for_PIN
determining_VBG [SUAV] [PRIV]
the_DT
amortisation_NOMZ
share_NN
option_NOMZ
and_PHC
share_NN
award_NN
schemes_NN
._.
These_DEMO
options_NOMZ
and_PHC
awards_NN
are_VPRT
charge_NN
are_VPRT [PASS]
reviewed_VBN
annually_RB
,_,
and_ANDC
take_VB
into_PIN
account_NN
the_DT
estimated_VBN [PRIV]
fair_JJ
valued_VBN
at_PIN
their_TPP3
grant_NN
dates_NN
and_CC
the_DT
cost_NN
is_VPRT [PASS]
charged_VBN
to_PIN
the_DT
income_NN
time_NN
it_PIT
takes_VPRT
to_TO
bring_VB
the_DT
compounds_NN
or_CC
products_NN
to_PIN
market_NN
._.
statement_NOMZ
over_IN
the_DT
relevant_JJ
vesting_GER
periods_NN
._.
This_DEMP
has_VPRT [PEAS]
been_VBN [PASS]
applied_VBN
on_PIN
Any_QUAN
development_NOMZ
costs_VPRT
incurred_VBN
by_PIN
the_DT
Group_NN
and_CC
associated_VBN
with_PIN
a_DT
fully_AMP
retrospective_JJ
basis_NN
._.
acquired_VBN
licences_NN
,_,
patents_NN
,_,
know-how_NN
or_CC
marketing_GER
rights_NN
are_VPRT [PASS]
written_VBN [PUBV]
off_PIN
to_PIN
the_DT
income_NN
statement_NOMZ
when_RB
incurred_VBN
,_,
unless_COND
the_DT
criteria_NN
for_PIN
The_DT
Group_NN
provides_VPRT
finance_NN
to_PIN
ESOP_NN
Trusts_NN
to_TO
purchase_VB
company_NN
recognition_NOMZ
of_PIN
an_DT
internally_RB
generated_VBN
intangible_JJ
asset_NN
are_VPRT [PASS]
met_VBN
._.
shares_NN
on_PIN
the_DT
open_JJ
market_NN
to_TO
meet_VB
the_DT
obligation_NOMZ
to_TO
provide_VB
shares_NN
Brands_NN
are_VPRT [PASS]
valued_VBN
independently_RB
as_IN
part_NN
of_PIN
the_DT
fair_JJ
value_NN
of_PIN
businesses_NOMZ
when_RB
employees_NN
exercise_VPRT
their_TPP3
options_NOMZ
or_CC
awards_NN
._.
Costs_NN
of_PIN
running_VBG
acquired_VBN
from_PIN
third_JJ
parties_NN
where_RB
the_DT
brand_NN
has_VPRT
a_DT
value_NN
which_WDT [WHSUB]
is_VPRT [BEMA]
the_DT
ESOP_NN
Trusts_NN
are_VPRT [PASS]
charged_VBN
to_PIN
the_DT
income_NN
statement_NOMZ
._.
Shares_NN
held_VBN [PRIV] [WZPAST]
by_PIN
substantial_JJ
and_PHC
long-term_JJ
and_ANDC
where_RB
the_DT
brands_NN
can_POMD
be_VB [PASS]
sold_VBN
the_DT
ESOP_NN
Trusts_NN
are_VPRT [PASS]
deducted_VBN
from_PIN
other_JJ
reserves_NN
and_CC
held_VBN [PRIV]
at_PIN
the_DT
separately_RB
from_PIN
the_DT
rest_NN
of_PIN
the_DT
businesses_NOMZ
acquired_VBN
._.
Brands_NN
value_NN
of_PIN
the_DT
proceeds_NN
receivable_NN
from_PIN
employees_NN
on_PIN
exercise_NN
._.
If_COND
there_EX
are_VPRT
amortised_PRED
over_IN
their_TPP3
estimated_VBN [PRIV]
useful_JJ
lives_NN
,_,
except_PIN
where_RB
it_PIT
is_VPRT
is_VPRT [PASS]
deemed_VBN [PRIV]
to_TO
be_VB [BEMA]
a_DT
permanent_JJ
impairment_NOMZ
in_PIN
value_NN
this_DEMP
is_VPRT [BYPA]
reflected_VBN [PRIV]
by_PIN
considered_VBN [PRIV]
that_THVC
the_DT
useful_JJ
economic_JJ
life_NN
is_VPRT [BEMA]
indefinite_PRED
._.
Property_NN
,_,
plant_NN
and_PHC
equipment_NOMZ
Prior_RB
to_PIN
1998_CD
,_,
acquired_VBN
minor_JJ
brands_NN
and_CC
similar_JJ
intangibles_NN
were_VBD
Property_NN
,_,
plant_NN
and_PHC
equipment_NOMZ
PP&E_NN
is_VPRT [PASS]
stated_VBN [PUBV]
at_PIN
the_DT
cost_NN
of_PIN
purchase_NN
eliminated_VBN [WZPAST]
in_PIN
the_DT
Group_NN
balance_NN
sheet_NN
against_PIN
reserves_NN
in_PIN
the_DT
year_NN
of_PIN
or_CC
construction_NOMZ
less_RB
provisions_NN
for_PIN
depreciation_NOMZ
and_PHC
impairment_NOMZ
._.
Financing_GER
costs_NN
are_VPRT [PASS]
not_XX0
capitalized_VBN
._.
The_DT
costs_NN
of_PIN
acquiring_VBG
and_PHC
developing_VBG
computer_NN
software_NN
for_PIN
internal_JJ
use_NN
and_PHC
internet_NN
sites_NN
for_PIN
external_JJ
use_NN
are_VPRT [PASS]
capitalized_VBN
as_IN
intangible_JJ
Depreciation_NOMZ
is_VPRT [PASS]
calculated_VBN [PRIV]
to_TO
write_VB [PUBV]
off_PIN
the_DT
cost_NN
of_PIN
PP&E_NN
,_,
excluding_VBG
fixed_JJ
assets_NN
where_RB
the_DT
software_NN
or_CC
site_NN
supports_VPRT
a_DT
significant_JJ
business_NOMZ
freehold_NN
land_NN
,_,
using_VBG [PRESP]
the_DT
straight-line_JJ
basis_NN
over_IN
its_PIT
expected_VBN [PRIV]
useful_JJ
system_NN
and_CC
the_DT
expenditure_NN
leads_VPRT
to_PIN
the_DT
creation_NOMZ
of_PIN
a_DT
durable_JJ
asset_NN
._.
The_DT
normal_JJ
expected_VBN [PRIV]
useful_JJ
lives_NN
of_PIN
the_DT
major_JJ
categories_NN
of_PIN
PP&E_NN
ERP_NN
systems_NN
software_NN
is_VPRT [PASS]
amortised_VBN
over_IN
seven_CD
years_NN
and_CC
other_JJ
are_VPRT [PASS]
reviewed_VBN
annually_RB
and_CC
are_VPRT
:_:
computer_NN
software_NN
over_IN
three_CD
to_PIN
five_CD
years_NN
._.
Freehold_NN
buildings_GER
20_CD
to_PIN
50_CD
years_NN
Impairment_NOMZ
of_PIN
non-current_JJ
assets_NN
Leasehold_NN
land_NN
and_PHC
Lease_NN
term_NN
or_CC
20_CD
to_PIN
50_CD
years_NN
The_DT
carrying_GER
values_NN
of_PIN
all_QUAN
non-current_JJ
assets_NN
are_VPRT [PASS]
reviewed_VBN
for_PIN
buildings_GER
impairment_NOMZ
when_RB
there_EX
is_VPRT
an_DT
indication_NOMZ
that_TOBJ
the_DT
assets_NN
might_POMD
be_VB
Plant_NN
and_PHC
machinery_NN
10_CD
to_PIN
20_CD
years_NN
impaired_VBN
._.
Additionally_RB
,_,
goodwill_NN
,_,
intangible_JJ
assets_NN
with_PIN
indefinite_JJ
Fixtures_NN
and_PHC
equipment_NOMZ
3_CD
to_PIN
10_CD
years_NN
useful_JJ
lives_NN
and_CC
intangible_JJ
assets_NN
which_WDT [WHSUB]
are_VPRT
not_XX0
yet_RB
available_PRED
for_PIN
use_NN
are_VPRT [PASS]
tested_VBN
for_PIN
impairment_NOMZ
annually_RB
._.
Any_QUAN
provision_NN
for_PIN
impairment_NOMZ
is_VPRT [BEMA]
On_PIN
disposal_NN
of_PIN
PP&E_NN
,_,
the_DT
cost_NN
and_CC
related_JJ
accumulated_VBN
depreciation_NOMZ
charged_VBN [WZPAST]
to_PIN
the_DT
income_NN
statement_NOMZ
in_PIN
the_DT
year_NN
concerned_VBN
._.
and_ANDC
impairments_NOMZ
are_VPRT [PASS]
removed_VBN
from_PIN
the_DT
financial_JJ
statements_NOMZ
and_CC
the_DT
net_JJ
amount_NN
,_,
less_JJ
any_QUAN
proceeds_NN
,_,
is_VPRT [PASS]
taken_VBN
to_PIN
the_DT
income_NN
statement_NOMZ
._.
Investments_NOMZ
in_PIN
associates_NN
and_CC
joint_JJ
ventures_NN
Investments_NOMZ
in_PIN
associates_NN
and_CC
joint_JJ
ventures_NN
are_VPRT [PASS]
carried_VBN
in_PIN
the_DT
Leases_NN
consolidated_JJ
balance_NN
sheet_NN
at_PIN
the_DT
Groups_NN
share_NN
of_PIN
their_TPP3
net_JJ
assets_NN
at_PIN
Leasing_GER
agreements_NOMZ
which_WDT [WHSUB]
transfer_VPRT
to_PIN
the_DT
Group_NN
substantially_RB
all_QUAN
the_DT
date_NN
of_PIN
acquisition_NOMZ
and_CC
of_PIN
their_TPP3
post-acquisition_JJ
retained_VBN
profits_NN
or_CC
benefits_NN
and_PHC
risks_NN
of_PIN
ownership_NN
of_PIN
an_DT
asset_NN
are_VPRT [PASS]
treated_VBN
as_IN
finance_NN
losses_NN
together_RB
with_PIN
any_QUAN
goodwill_NN
arising_VBG [WZPRES]
on_PIN
the_DT
acquisition_NOMZ
._.
leases_NN
,_,
as_IN
if_COND
the_DT
asset_NN
had_VBD [PEAS]
been_VBN [PASS]
purchased_VBN
outright_RB
._.
The_DT
assets_NN
are_VPRT [PASS]
included_VBN
in_PIN
PP&E_NN
or_CC
computer_NN
software_NN
and_CC
the_DT
capital_NN
elements_NOMZ
of_PIN
Available-for-sale_JJ
investments_NOMZ
the_DT
leasing_GER
commitments_NOMZ
are_VPRT [PASS]
shown_VBN [PRIV]
as_IN
obligations_NOMZ
under_IN
finance_NN
Available-for-sale_JJ
investments_NOMZ
are_VPRT [SPAU] [PASS]
initially_TIME
recorded_VBN
at_PIN
cost_NN
and_CC
then_RB
leases_NN
._.
Assets_NN
held_VBN [PRIV]
under_IN
finance_NN
leases_NN
are_VPRT [PASS]
depreciated_VBN
on_PIN
a_DT
basis_NN
remeasured_VBD
at_PIN
subsequent_JJ
reporting_GER
dates_NN
to_PIN
fair_JJ
value_NN
._.
Unrealised_JJ
consistent_JJ
with_PIN
similar_JJ
owned_VBN
assets_NN
or_CC
the_DT
lease_NN
term_NN
if_COND
shorter_JJ
._.
The_DT
gains_NN
and_PHC
losses_NN
on_PIN
available-for-sale_JJ
investments_NOMZ
are_VPRT [PASS]
recognized_VBN [PRIV]
interest_NN
element_NOMZ
of_PIN
the_DT
lease_NN
rental_NN
is_VPRT [PASS]
included_VBN
in_PIN
the_DT
income_NN
directly_RB
in_PIN
equity_NOMZ
._.
On_PIN
disposal_NN
or_CC
impairment_NOMZ
of_PIN
the_DT
investments_NOMZ
,_,
the_DT
statement_NOMZ
._.
All_QUAN
other_JJ
leases_NN
are_VPRT
operating_VBG
leases_NN
and_CC
the_DT
annual_JJ
rentals_NN
gains_NN
and_PHC
losses_NN
in_PIN
equity_NOMZ
are_VPRT [PASS]
recycled_VBN
into_PIN
the_DT
income_NN
statement_NOMZ
._.
are_VPRT [PASS]
included_VBN
in_PIN
the_DT
income_NN
statement_NOMZ
on_PIN
a_DT
straight-line_JJ
basis_NN
over_IN
the_DT
Equity_NOMZ
investments_NOMZ
are_VPRT [PASS]
recorded_VBN
in_PIN
non-current_JJ
assets_NN
unless_COND
they_TPP3
are_VPRT
lease_NN
term_NN
._.
expected_VBN [PRIV]
to_TO
be_VB [PASS]
sold_VBN
within_PIN
one_CD
year_NN
._.
GSK_NN
Annual_JJ
Report_NN
2005_CD
91_CD
FINANCIAL_NN
STATEMENTS_NOMZ
Notes_NN
to_PIN
the_DT
financial_JJ
statements_NOMZ
continued_VBD
Derivative_JJ
financial_JJ
instruments_NOMZ
and_CC
hedging_VBG
2004_CD
and_CC
2003_CD
2_CD
Accounting_GER
policies_NN
continued_VBD
IAS_NN
32_CD
and_CC
39_CD
were_VBD [BYPA]
adopted_VBN
by_PIN
the_DT
Group_NN
on_PIN
1st_CD
January_NN
2005_CD
._.
The_DT
Purchases_NN
and_PHC
sales_NN
of_PIN
equity_NOMZ
investments_NOMZ
are_VPRT [PASS]
accounted_VBN
for_PIN
on_PIN
the_DT
2004_CD
and_CC
2003_CD
information_NOMZ
relating_VBG [WZPRES]
to_PIN
financial_JJ
instruments_NOMZ
remains_VPRT
trade_NN
date_NN
and_PHC
purchases_NN
and_PHC
sales_NN
of_PIN
other_JJ
available-for-sale_JJ
as_IN
reported_VBN [PUBV]
under_IN
UK_NN
GAAP_NN
and_CC
applying_VBG
the_DT
following_JJ
policies_NN
._.
investments_NOMZ
are_VPRT [PASS]
accounted_VBN
for_PIN
on_PIN
settlement_NOMZ
date_NN
._.
Derivative_JJ
contracts_NN
are_VPRT [PASS]
treated_VBN
from_PIN
inception_NOMZ
as_IN
an_DT
economic_JJ
hedge_NN
In_PIN
2004_CD
and_CC
2003_CD
equity_NOMZ
investments_NOMZ
are_VPRT [PASS]
recorded_VBN
at_PIN
cost_NN
._.
of_PIN
the_DT
underlying_VBG
financial_JJ
instrument_NOMZ
with_PIN
matching_JJ
accounting_GER
Inventories_NN
treatment_NOMZ
and_PHC
cash_NN
flows_NN
._.
Derivative_JJ
instruments_NOMZ
no_RB
longer_RB
Inventories_NN
are_VPRT [PASS]
included_VBN
in_PIN
the_DT
financial_JJ
statements_NOMZ
at_PIN
the_DT
lower_JJ
of_PIN
cost_NN
designated_VBN
as_IN
hedges_NN
are_VPRT [PASS]
restated_VBN
at_PIN
market_NN
value_NN
and_CC
any_QUAN
future_JJ
including_VBG
raw_JJ
materials_NN
,_,
direct_JJ
labor_NN
,_,
other_JJ
direct_JJ
costs_NN
and_CC
related_VBN
changes_NN
in_PIN
value_NN
are_VPRT [PASS]
taken_VBN
directly_RB
to_PIN
the_DT
profit_NN
and_PHC
loss_NN
account_NN
._.
production_NOMZ
overheads_NN
and_CC
net_JJ
realisable_JJ
value_NN
._.
Cost_NN
is_VPRT
generally_RB
Currency_NN
swaps_NN
and_CC
forward_RB
exchange_NN
contracts_NN
used_VBN
to_TO
fix_VB
the_DT
value_NN
determined_VBN [SUAV] [PRIV] [WZPAST]
on_PIN
a_DT
first_JJ
in_PIN [STPR]
,_,
first_RB
out_PIN
basis_NN
._.
of_PIN
the_DT
related_JJ
asset_NN
or_CC
liability_NOMZ
in_PIN
the_DT
contract_NN
currency_NN
and_CC
at_PIN
the_DT
contract_NN
rate_NN
are_VPRT [PASS]
accrued_VBN
to_PIN
the_DT
profit_NN
and_PHC
loss_NN
account_NN
over_IN
the_DT
life_NN
Taxation_NOMZ
of_PIN
the_DT
contract_NN
._.
Current_JJ
tax_NN
is_VPRT [PASS]
provided_VBN
at_PIN
the_DT
amounts_NN
expected_VBN [PRIV]
to_TO
be_VB [PASS]
paid_VBN
applying_VBG
tax_NN
rates_NN
that_TSUB
have_VPRT [PEAS]
been_VBN [PASS]
enacted_VBN
or_CC
substantially_RB
enacted_VBN
by_PIN
the_DT
Gains_NN
and_PHC
losses_NN
on_PIN
foreign_JJ
exchange_NN
contracts_NN
designated_VBN
as_IN
hedges_NN
balance_NN
sheet_NN
date_NN
._.
of_PIN
forecast_NN
foreign_JJ
exchange_NN
transactions_NOMZ
are_VPRT [PASS]
deferred_VBN
and_PHC
included_VBN
Deferred_JJ
tax_NN
is_VPRT [PASS]
provided_VBN
in_PIN
full_JJ
,_,
using_VBG [PRESP]
the_DT
liability_NOMZ
method_NN
,_,
on_PIN
in_PIN
the_DT
measurement_NOMZ
of_PIN
the_DT
related_VBN
foreign_JJ
currency_NN
transactions_NOMZ
in_PIN
the_DT
temporary_JJ
differences_NN
arising_VBG [WZPRES]
between_PIN
the_DT
tax_NN
bases_NN
of_PIN
assets_NN
and_PHC
period_NN
they_TPP3
occur_VPRT
._.
Gains_NN
and_PHC
losses_NN
on_PIN
balance_NN
sheet_NN
hedges_NN
are_VPRT
liabilities_NOMZ
and_CC
their_TPP3
carrying_VBG
amounts_NN
in_PIN
the_DT
financial_JJ
statements_NOMZ
._.
accrued_VBN
and_PHC
are_VPRT [PASS]
taken_VBN
directly_RB
to_PIN
reserves_NN
except_PIN
that_DEMO
forward_RB
Deferred_JJ
tax_NN
assets_NN
are_VPRT [PASS]
recognized_VBN [PRIV]
to_PIN
the_DT
extent_NN
that_TOBJ
it_PIT
is_VPRT [BEMA]
probable_PRED
that_THAC
premiums_NN
discounts_NN
are_VPRT [PASS]
recognized_VBN [PRIV]
as_IN
interest_NN
over_IN
the_DT
life_NN
of_PIN
the_DT
future_JJ
taxable_JJ
profits_NN
will_PRMD
be_VB [BEMA]
available_PRED
against_PIN
which_WDT [PIRE]
the_DT
temporary_JJ
contracts_NN
._.
Interest_NN
differentials_NN
under_IN
interest_NN
swap_NN
agreements_NOMZ
are_VPRT [PASS]
recognized_VBN [PRIV]
in_PIN
the_DT
profit_NN
and_PHC
loss_NN
account_NN
by_PIN
adjustment_NOMZ
of_PIN
interest_NN
expense_NN
over_IN
Deferred_JJ
tax_NN
is_VPRT [PASS]
provided_VBN
on_PIN
temporary_JJ
differences_NN
arising_VBG [WZPRES]
on_PIN
the_DT
life_NN
of_PIN
the_DT
agreement_NOMZ
._.
investments_NOMZ
in_PIN
subsidiaries_NN
,_,
associates_NN
and_CC
joint_JJ
ventures_NN
,_,
except_PIN
where_RB
the_DT
timing_NN
of_PIN
the_DT
reversal_NN
of_PIN
the_DT
temporary_JJ
difference_NN
can_POMD
be_VB [BEMA]
3_CD
New_NN
accounting_GER
policies_NN
and_CC
future_JJ
requirements_NOMZ
controlled_VBN
and_CC
it_PIT
is_VPRT [BEMA]
probable_PRED
that_THAC
the_DT
temporary_JJ
difference_NN
will_PRMD
not_XX0
reverse_VB
in_PIN
the_DT
foreseeable_JJ
future_NN
._.
The_DT
following_VBG
IFRS_NN
and_PHC
IFRIC_NN
interpretation_NOMZ
have_VPRT [PEAS]
been_VBN [BYPA]
issued_VBN
by_PIN
the_DT
Deferred_JJ
tax_NN
is_VPRT [PASS]
provided_VBN
using_VBG
rates_NN
of_PIN
tax_NN
that_TSUB
have_VPRT [PEAS]
been_VBN [PASS]
enacted_VBN
or_CC
IASB_NN
and_CC
are_VPRT [BEMA]
likely_PRED
to_TO
affect_VB
future_JJ
Annual_JJ
Reports_NN
._.
substantively_RB
enacted_VBN
by_PIN
the_DT
balance_NN
sheet_NN
date_NN
._.
Deferred_JJ
tax_NN
liabilities_NOMZ
IFRS_VPRT
7_CD
Financial_JJ
instruments_NOMZ
:_:
disclosures_NN
was_VBD [PASS]
issued_VBN
in_PIN
August_NN
2005_CD
and_CC
assets_NN
are_VPRT [PASS]
not_XX0
discounted_VBN
._.
and_ANDC
is_VPRT [PASS]
required_VBN [SUAV]
to_TO
be_VB [BYPA]
implemented_VBN
by_PIN
GSK_NN
from_PIN
1st_CD
January_NN
2007_CD
._.
This_DEMO
new_JJ
standard_JJ
incorporates_VPRT
the_DT
disclosure_NN
requirements_NOMZ
of_PIN
IAS_NN
32_CD
,_,
Derivative_JJ
financial_JJ
instruments_NOMZ
and_CC
hedging_VBG
2005_CD
which_WDT
it_PIT
supersedes_VPRT
,_,
and_ANDC
adds_VPRT [PUBV]
further_JJ
quantitative_JJ
and_PHC
qualitative_JJ
Derivative_JJ
financial_JJ
instruments_NOMZ
are_VPRT [PASS]
used_VBN
to_TO
manage_VB
exposure_NN
to_PIN
disclosures_NN
in_PIN
relation_NOMZ
to_PIN
financial_JJ
instruments_NOMZ
._.
market_NN
risks_NN
from_PIN
treasury_NN
operations_NOMZ
._.
The_DT
principal_JJ
derivative_NN
instruments_NOMZ
used_VBN [WZPAST]
by_PIN
GlaxoSmithKline_NN
are_VPRT [BEMA]
foreign_JJ
currency_NN
swaps_NN
,_,
IFRIC_NN
4_CD
Determining_VBG [SUAV] [PRIV]
whether_IN [WHCL]
an_DT
arrangement_NOMZ
contains_VPRT
a_DT
lease_NN
was_VBD
interest_NN
rate_NN
swaps_NN
and_CC
forward_RB
foreign_JJ
exchange_NN
contracts_NN
._.
The_DT
issued_VBN
in_PIN
December_NN
2004_CD
and_CC
is_VPRT [PASS]
required_VBN [SUAV]
to_TO
be_VB [BYPA]
implemented_VBN
by_PIN
GSK_NN
Group_NN
does_VPRT
not_XX0
hold_VB [PRIV]
or_CC
issue_VB
derivative_JJ
financial_JJ
instruments_NOMZ
for_PIN
from_PIN
1st_CD
January_NN
2006_CD
._.
The_DT
interpretation_NOMZ
requires_VPRT [SUAV] [THATD]
arrangements_NOMZ
trading_VBG [WZPRES]
or_CC
speculative_JJ
purposes_NN
._.
which_WDT [SERE]
may_POMD
have_VB
the_DT
nature_NN
,_,
but_CC
not_XX0
the_DT
legal_JJ
form_NN
,_,
of_PIN
a_DT
lease_NN
to_TO
be_VB [BEMA]
Derivative_JJ
financial_JJ
instruments_NOMZ
are_VPRT [SPAU] [PASS]
initially_TIME
recognized_VBN [PRIV]
in_PIN
the_DT
balance_NN
accounted_VBD
for_PIN
in_PIN
accordance_NN
with_PIN
IAS_NN
17_CD
Leases_NN
._.
This_DEMO
interpretation_NOMZ
sheet_NN
at_PIN
cost_NN
and_CC
then_RB
remeasured_VBD
at_PIN
subsequent_JJ
reporting_GER
dates_NN
to_TO
is_VPRT [PASS]
not_XX0
expected_VBN [PRIV]
to_TO
have_VB
a_DT
material_NN
impact_NN
on_PIN
the_DT
Group_NN
._.
Hedging_VBG
derivatives_NN
are_VPRT [PASS]
classified_VBN
on_PIN
inception_NOMZ
as_IN
fair_JJ
value_NN
hedges_NN
,_,
cash_NN
flow_NN
hedges_NN
or_CC
net_JJ
investment_NOMZ
hedges_NN
._.
Changes_NN
in_PIN
the_DT
4_CD
Exchange_NN
rates_NN
fair_JJ
value_NN
of_PIN
derivatives_NN
designated_VBN
as_IN
fair_JJ
value_NN
hedges_NN
are_VPRT [PASS]
recorded_VBN
The_DT
Group_NN
uses_VPRT
the_DT
average_NN
of_PIN
exchange_NN
rates_NN
prevailing_VBG [WZPRES]
during_PIN
the_DT
in_PIN
the_DT
income_NN
statement_NOMZ
,_,
with_PIN
the_DT
changes_NN
in_PIN
the_DT
fair_JJ
value_NN
of_PIN
the_DT
period_NN
to_TO
translate_VB
the_DT
results_NN
and_PHC
cash_NN
flows_NN
of_PIN
overseas_PLACE
subsidiaries_NN
,_,
hedged_VBN
asset_NN
or_CC
liability_NOMZ
._.
joint_JJ
ventures_NN
and_CC
associated_VBN
undertakings_GER
into_PIN
sterling_GER
and_PHC
period_NN
end_NN
rates_NN
to_TO
translate_VB
the_DT
net_JJ
assets_NN
of_PIN
those_DEMO
undertakings_GER
._.
Changes_NN
in_PIN
the_DT
fair_JJ
value_NN
of_PIN
derivatives_NN
designated_VBN
as_IN
cash_NN
flow_NN
hedges_NN
The_DT
currencies_NN
which_WDT [WHSUB]
most_EMPH
influence_VB
these_DEMO
translations_NOMZ
,_,
and_ANDC
the_DT
are_VPRT [PASS]
recognized_VBN [PRIV]
in_PIN
equity_NOMZ
._.
Amounts_NN
deferred_VBN [WZPAST]
in_PIN
equity_NOMZ
are_VPRT [PASS]
transferred_VBN
relevant_JJ
exchange_NN
rates_NN
,_,
were_VBD
:_:
to_PIN
the_DT
income_NN
statement_NOMZ
in_PIN
line_NN
with_PIN
the_DT
hedged_VBN
forecast_NN
transaction_NOMZ
._.
2005 2004 2003_CD
Hedges_NN
of_PIN
net_JJ
investments_NOMZ
in_PIN
foreign_JJ
entities_NOMZ
are_VPRT [PASS]
accounted_VBN
for_PIN
in_PIN
a_DT
Average_JJ
rates_NN
:_:
similar_JJ
way_NN
to_PIN
cash_NN
flow_NN
hedges_NN
._.
US$_$
1.82_CD
1.83_CD
1.64_CD
Euro_NN
1.46_CD
1.47_CD
1.45_CD
Changes_NN
in_PIN
the_DT
fair_JJ
value_NN
of_PIN
any_QUAN
derivative_JJ
instruments_NOMZ
that_TSUB
do_VPRT
not_XX0
Yen_NN
200.00_CD
197.00_CD
191.00_CD
qualify_VB
for_PIN
hedge_JJ
accounting_GER
are_VPRT [PASS]
recognized_VBN [PRIV]
immediately_TIME
in_PIN
the_DT
Period_NN
end_NN
rates_NN
:_:
income_NN
statement_NOMZ
._.
US$_$
1.72_CD
1.92_CD
1.79_CD
Euro_NN
1.46_CD
1.41_CD
1.42_CD
Yen_NN
203.00_CD
197.00_CD
192.00_CD
GSK_NN
Annual_JJ
Report_NN
2005_CD
92_CD
FINANCIAL_NN
STATEMENTS_NOMZ
Notes_NN
to_PIN
the_DT
financial_JJ
statements_NOMZ
continued_VBD
5_CD
Segment_NOMZ
information_NOMZ
The_DT
Groups_NN
primary_JJ
segment_NOMZ
reporting_GER
is_VPRT [BEMA]
by_PIN
business_NOMZ
sector_NN
with_PIN
geographical_JJ
reporting_GER
being_VBG [WZPRES] [BEMA]
the_DT
secondary_JJ
format_NN
._.
The_DT
business_NOMZ
sectors_NN
consist_VPRT
of_PIN
Pharmaceuticals_NN
prescription_NOMZ
pharmaceuticals_NN
and_PHC
vaccines_NN
and_PHC
Consumer_NN
Healthcare_NN
oral_JJ
care_NN
,_,
OTC_NN
medicines_NN
and_CC
nutritional_JJ
healthcare_NN
._.
The_DT
geographical_JJ
sectors_NN
of_PIN
the_DT
USA_NN
,_,
Europe_NN
and_PHC
International_NN
other_JJ
Rest_VB
of_PIN
World_NN
markets_NN
reflect_VPRT [PRIV]
the_DT
Groups_NN
most_EMPH
significant_JJ
regional_JJ
markets_NN
and_CC
are_VPRT [BEMA]
consistent_PRED
with_PIN
the_DT
Groups_NN
regional_JJ
market_NN
management_NOMZ
reporting_VBG [PUBV] [WZPRES]
structure_NN
._.
Business_NOMZ
sector_NN
data_NN
includes_VPRT
an_DT
allocation_NOMZ
of_PIN
corporate_JJ
costs_NN
to_PIN
each_QUAN
sector_NN
on_PIN
an_DT
appropriate_JJ
basis_NN
._.
There_EX
are_VPRT
no_SYNE
sales_NN
between_PIN
business_NOMZ
sectors_NN
._.
The_DT
Groups_NN
activities_NOMZ
are_VPRT [PASS]
organised_VBN
on_PIN
a_DT
global_JJ
basis_NN
._.
The_DT
geographical_JJ
sector_NN
figures_NN
are_VPRT [SPAU] [BYPA]
therefore_CONJ
influenced_VBN
by_PIN
the_DT
location_NOMZ
of_PIN
the_DT
Groups_NN
operating_VBG [WZPRES]
resources_NN
,_,
in_CONJ
particular_NULL
manufacturing_GER
and_PHC
research_NN
,_,
and_ANDC
by_PIN
variations_NOMZ
over_IN
time_NN
in_PIN
intra-Group_JJ
trading_GER
and_PHC
funding_GER
arrangements_NOMZ
._.
Turnover_NN
is_VPRT [BYPA]
shown_VBN [PRIV]
by_PIN
business_NOMZ
sector_NN
and_CC
by_PIN
location_NOMZ
of_PIN
customer_NN
._.
Other_JJ
geographic_JJ
information_NOMZ
is_VPRT [BYPA]
given_VBN
by_PIN
location_NOMZ
of_PIN
subsidiary_NN
._.
The_DT
UK_NN
segment_NOMZ
information_NOMZ
gives_VPRT
turnover_NN
by_PIN
location_NOMZ
of_PIN
customer_NN
and_PHC
location_NOMZ
of_PIN
subsidiary_NN
._.
The_DT
UK_NN
operating_GER
profit_NN
,_,
total_JJ
assets_NN
and_CC
net_JJ
assets_NN
are_VPRT [SPAU] [PASS]
also_RB
shown_VBN [PRIV]
._.
Where_RB
the_DT
Group_NN
co-promotes_NN
a_DT
product_NN
and_CC
the_DT
third_JJ
party_NN
records_NN
the_DT
sale_NN
,_,
the_DT
Group_NN
records_NN
its_PIT
share_NN
of_PIN
revenue_NN
as_IN
co-promotion_JJ
income_NN
within_PIN
turnover_NN
._.
The_DT
nature_NN
of_PIN
co-promotion_NOMZ
activities_NOMZ
is_VPRT [BEMA]
such_OSUB
that_NULL
the_DT
Group_NN
records_NN
no_SYNE
costs_NN
of_PIN
sales_NN
._.
Pharmaceutical_NN
turnover_NN
includes_VPRT
co-promotion_NOMZ
revenue_NN
of_PIN
112_CD
million_CD
2004_CD
65_CD
million_CD
,_,
2003_CD
35_CD
million_CD
._.
2005 2004 2003_CD
Turnover_NN
by_PIN
business_NOMZ
sector_NN
m_NN
m_FW
m_FW
Pharmaceuticals_NN
18,661_CD
17,100_CD
18,114_CD
Consumer_NN
Healthcare_NN
2,999_CD
2,886_CD
2,956_CD
Turnover_NN
21,660_CD
19,986_CD
21,070_CD
Profit_NN
by_PIN
business_NOMZ
sector_NN
Pharmaceuticals_NN
6,159_CD
5,126_CD
5,519_CD
Consumer_NN
Healthcare_NN
715 630 531_CD
Operating_GER
profit_NN
6,874_CD
5,756_CD
6,050_CD
Finance_NN
income_NN
257 176 101_CD
Finance_NN
costs_NN
451 362 254_CD
Share_NN
of_PIN
profits_NN
after_IN
tax_NN
of_PIN
associates_NN
and_CC
joint_JJ
ventures_NN
:_:
Pharmaceuticals_NN
52_CD
60_CD
57_CD
Consumer_NN
Healthcare_NN
Profit_NN
on_PIN
disposal_NN
of_PIN
interest_NN
in_PIN
associates_NN
149_CD
Profit_NN
before_IN
taxation_NOMZ
6,732_CD
5,779_CD
5,954_CD
Taxation_NOMZ
1,916_CD
1,757_CD
1,651_CD
Profit_NN
on_PIN
disposals_NN
of_PIN
businesses_NOMZ
5_CD
Profit_NN
after_IN
taxation_NOMZ
for_PIN
the_DT
year_NN
4,816_CD
4,022_CD
4,308_CD
Investments_NOMZ
in_PIN
associates_NN
and_CC
joint_JJ
ventures_NN
by_PIN
business_NOMZ
sector_NN
Pharmaceuticals_NN
276_CD
209_CD
Consumer_NN
Healthcare_NN
Investment_NOMZ
in_PIN
associates_NN
and_CC
joint_JJ
ventures_NN
276_CD
209_CD
Property_NN
,_,
plant_NN
and_PHC
equipment_NOMZ
and_CC
intangible_JJ
assets_NN
by_PIN
business_NOMZ
sector_NN
Additions_NOMZ
Pharmaceuticals_NN
2,031_CD
1,301_CD
Consumer_NN
Healthcare_NN
164_CD
150_CD
Total_JJ
additions_NOMZ
2,195_CD
1,451_CD
Depreciation_NOMZ
amortisation_NOMZ
Pharmaceuticals_NN
807_CD
766_CD
Consumer_NN
Healthcare_NN
97_CD
93_CD
Total_JJ
depreciation_NOMZ
amortisation_NOMZ
904_CD
859_CD
Impairment_NOMZ
Pharmaceuticals_NN
92_CD
39_CD
Consumer_NN
Healthcare_NN
5_CD
Total_JJ
impairment_NOMZ
92_CD
44_CD
Impairment_NOMZ
reversal_NN
Pharmaceuticals_NN
3_CD
11_CD
Consumer_NN
Healthcare_NN
Total_NN
impairment_NOMZ
reversal_NN
3_CD
11_CD
GSK_NN
Annual_JJ
Report_NN
2005_CD
93_CD
FINANCIAL_NN
STATEMENTS_NOMZ
Notes_NN
to_PIN
the_DT
financial_JJ
statements_NOMZ
continued_VBD
5_CD
Segment_NOMZ
information_NOMZ
continued_VBD
2005_CD
2004_CD
Total_JJ
assets_NN
by_PIN
business_NOMZ
sector_NN
m_NN
m_NN
Pharmaceuticals_NN
16,431_CD
14,239_CD
Consumer_NN
Healthcare_NN
2,446_CD
2,323_CD
Total_JJ
operating_VBG
assets_NN
18,877_CD
16,562_CD
Investments_NOMZ
in_PIN
associates_NN
276_CD
209_CD
Liquid_NN
investments_NOMZ
1,025_CD
1,512_CD
Derivative_JJ
financial_JJ
instruments_NOMZ
179_CD
5_CD
Cash_NN
and_PHC
cash_NN
equivalents_NN
4,209_CD
2,467_CD
Current_JJ
and_PHC
deferred_JJ
taxation_NOMZ
2,630_CD
2,187_CD
Tangible_JJ
assets_NN
held_VBN [PRIV] [WZPAST]
for_PIN
sale_NN
2_CD
2_CD
Total_JJ
assets_NN
27,198_CD
22,944_CD
Total_JJ
liabilities_NOMZ
by_PIN
business_NOMZ
sector_NN
Pharmaceuticals_NN
9,099_CD
7,687_CD
Consumer_NN
healthcare_NN
1,070_CD
963_CD
Total_JJ
operating_VBG
liabilities_NOMZ
10,169_CD
8,650_CD
Short-term_JJ
borrowings_GER
1,200_CD
1,582_CD
Long-term_JJ
borrowings_GER
5,271_CD
4,381_CD
Derivative_JJ
financial_JJ
instruments_NOMZ
150_CD
72_CD
Current_JJ
and_PHC
deferred_JJ
taxation_NOMZ
2,838_CD
2,322_CD
19,628_CD
17,007_CD
2005 2004 2003_CD
Turnover_NN
by_PIN
location_NOMZ
of_PIN
customer_NN
m_NN
m_FW
m_FW
USA_NN
9,867_CD
9,191_CD
10,276_CD
Europe_NN
6,892_CD
6,395_CD
6,346_CD
International_NN
4,901_CD
4,400_CD
4,448_CD
Turnover_NN
21,660_CD
19,986_CD
21,070_CD
2005_CD
2004_CD
Property_NN
,_,
plant_NN
and_PHC
equipment_NOMZ
and_CC
intangible_JJ
asset_NN
additions_NOMZ
by_PIN
location_NOMZ
m_NN
m_NN
USA_NN
509_CD
323_CD
Europe_NN
742_CD
976_CD
International_NN
944_CD
152_CD
Total_JJ
additions_NOMZ
2,195_CD
1,451_CD
Total_JJ
assets_NN
by_PIN
location_NOMZ
USA_NN
4,459_CD
3,588_CD
Europe_NN
16,423_CD
16,536_CD
International_NN
5,020_CD
2,921_CD
Inter-segment_NOMZ
trading_GER
balances_NN
7,025_CD
6,483_CD
Total_JJ
operating_VBG
assets_NN
18,877_CD
16,562_CD
Investments_NOMZ
in_PIN
associates_NN
276_CD
209_CD
Liquid_NN
investments_NOMZ
1,025_CD
1,512_CD
Derivative_JJ
financial_JJ
instruments_NOMZ
179_CD
5_CD
Cash_NN
and_PHC
cash_NN
equivalents_NN
4,209_CD
2,467_CD
Current_JJ
and_PHC
deferred_JJ
taxation_NOMZ
2,630_CD
2,187_CD
Tangible_JJ
assets_NN
held_VBN [PRIV] [WZPAST]
for_PIN
sale_NN
2_CD
2_CD
Total_JJ
assets_NN
27,198_CD
22,944_CD
GSK_NN
Annual_JJ
Report_NN
2005_CD
94_CD
FINANCIAL_NN
STATEMENTS_NOMZ
Notes_NN
to_PIN
the_DT
financial_JJ
statements_NOMZ
continued_VBD
5_CD
Segment_NOMZ
information_NOMZ
continued_VBD
UK_NN
Segment_NOMZ
For_PIN
the_DT
purposes_NN
of_PIN
US_FPP1
GAAP_NN
information_NOMZ
is_VPRT [PASS]
given_VBN
separately_RB
in_PIN
respect_NN
of_PIN
the_DT
UK_NN
,_,
which_WDT [SERE]
,_,
although_CONC
included_VBN
in_PIN
the_DT
Groups_NN
Europe_NN
market_NN
region_NN
,_,
is_VPRT [PASS]
considered_VBN [PRIV]
the_DT
Groups_NN
home_NN
segment_NOMZ
for_PIN
the_DT
purposes_NN
of_PIN
segmental_JJ
reporting_GER
._.
2005 2004 2003_CD
m_FW
m_FW
m_FW
Turnover_NN
by_PIN
location_NOMZ
of_PIN
customer_NN
1,431_CD
1,382_CD
1,338_CD
Turnover_NN
including_VBG [WZPRES]
inter-segment_JJ
turnover_NN
4,414_CD
4,386_CD
4,610_CD
Inter-segment_NOMZ
turnover_NN
2,657_CD
2,709_CD
2,883_CD
Turnover_NN
by_PIN
location_NOMZ
of_PIN
subsidiary_NN
1,757_CD
1,677_CD
1,727_CD
Operating_GER
profit_NN
1,576_CD
1,327_CD
1,438_CD
Total_JJ
assets_NN
7,057_CD
6,521_CD
Net_NN
operating_VBG [WZPRES]
assets_NN
2,290_CD
2,253_CD
6_CD
Other_JJ
operating_GER
income_NN
2005 2004 2003_CD
m_FW
m_FW
m_FW
Royalties_NN
83_CD
96_CD
75_CD
Asset_NN
disposal_NN
profits_NN
290 146 242_CD
Other_JJ
income_NN
including_VBG [WZPRES]
fair_JJ
value_NN
adjustments_NOMZ
9_CD
7_CD
7_CD
364 235 310_CD
Royalties_NN
are_VPRT [BEMA]
principally_RB
a_DT
core_NN
of_PIN
recurring_VBG
income_NN
from_PIN
the_DT
out-licensing_GER
of_PIN
intellectual_JJ
property_NN
._.
Asset_NN
disposal_NN
profits_NN
include_VPRT
product_NN
divestments_NOMZ
and_PHC
disposals_NN
of_PIN
equity_NOMZ
investments_NOMZ
,_,
intellectual_JJ
property_NN
and_CC
tangible_JJ
property_NN
._.
Other_JJ
income_NN
includes_VPRT
equity_NOMZ
investment_NOMZ
carrying_VBG [WZPRES]
value_NN
adjustments_NOMZ
arising_VBG [WZPRES]
from_PIN
stock_NN
market_NN
changes_NN
and_CC
fair_JJ
value_NN
adjustments_NOMZ
arising_VBG [WZPRES]
on_PIN
the_DT
Quest_NN
Collar_NN
and_PHC
Theravance_NN
put_VBD
and_PHC
call_VB
options_NOMZ
._.
7_CD
Operating_GER
profit_NN
2005 2004 2003_CD
m_FW
m_FW
m_FW [BEMA]
The_DT
following_JJ
items_NN
have_VPRT [PEAS]
been_VBN [PASS]
charged_VBN
in_PIN
operating_GER
profit_NN
:_:
Employee_NN
costs_NN
Note_VPRT [PRIV]
8_CD
5,254_CD
5,054_CD
5,461_CD
Advertising_GER
697 599 615_CD
Distribution_NOMZ
costs_NN
270 266 279_CD
Depreciation_NOMZ
of_PIN
property_NN
,_,
plant_NN
and_PHC
equipment_NOMZ
710 691 704_CD
Amortisation_NOMZ
of_PIN
intangible_JJ
assets_NN
194 168 127_CD
Net_JJ
foreign_JJ
exchange_NN
gains_NN
losses_NN
3_CD
72_CD
41_CD
Inventories_NN
:_:
Cost_NN
of_PIN
inventories_NN
included_VBN [WZPAST]
in_PIN
cost_NN
of_PIN
sales_NN
4,335_CD
4,032_CD
4,337_CD
Write-down_NN
of_PIN
inventories_NN
119 142 105_CD
Reversal_NN
of_PIN
prior_JJ
year_NN
write-down_NN
of_PIN
inventories_NN
61_CD
49_CD
20_CD
Operating_GER
lease_NN
rentals_NN
:_:
Minimum_NN
lease_NN
payments_NOMZ
104 110 144_CD
Contingent_JJ
rents_NN
12_CD
98_CD
Sub-lease_NN
payments_NOMZ
1_CD
Audit_NN
fees_NN
8.5_CD
7.2_CD
6.9_CD
Fees_NN
to_PIN
auditors_NN
for_PIN
other_JJ
work_NN
:_:
Auditors_NN
UK_NN
firm_NN
1.8_CD
2.6_CD
1.7_CD
Auditors_NN
overseas_PLACE
firms_NN
4.2_CD
4.7_CD
5.9_CD
GSK_NN
Annual_JJ
Report_NN
2005_CD
95_CD
FINANCIAL_NN
STATEMENTS_NOMZ
Notes_NN
to_PIN
the_DT
financial_JJ
statements_NOMZ
continued_VBD
7_CD
Operating_GER
profit_NN
continued_VBD
2005 2004 2003_CD
m_FW
m_FW
m_FW
Analysis_NN
of_PIN
fees_NN
to_PIN
auditors_NN
for_PIN
other_JJ
work_NN
:_:
Advisory_NN
services_NN
related_VBN [WZPAST]
to_PIN
section_NOMZ
404_CD
of_PIN
Sarbanes-Oxley_NN
Act_NN
2002_CD
2.4_CD
2.0_CD
1.3_CD
Other_JJ
non-statutory_JJ
assurance_NN
services_NN
1.0_CD
1.4_CD
1.3_CD
Tax_NN
compliance_NN
services_NN
0.7_CD
1.0_CD
0.8_CD
Tax_NN
planning_GER
and_PHC
advice_NN
1.6_CD
2.0_CD
3.8_CD
Other_JJ
services_NN
0.3_CD
0.9_CD
0.4_CD
Included_VBN
within_PIN
audit_NN
fees_NN
above_PLACE
is_VPRT [BEMA]
a_DT
fee_NN
of_PIN
10,700_CD
2004_CD
10,000_CD
,_,
2003_CD
10,000_CD
relating_VBG
to_PIN
the_DT
company_NN
audit_NN
of_PIN
GlaxoSmithKline_NN
plc._NN
._.
Included_VBN [PASTP]
within_PIN
other_JJ
non-statutory_JJ
assurance_NN
services_NN
are_VPRT [PASS]
amounts_NN
related_VBN [WZPAST]
to_PIN
the_DT
Groups_NN
preparation_NOMZ
for_PIN
the_DT
adoption_NOMZ
of_PIN
International_NN
Financial_NN
Reporting_GER
Standards_NN
._.
Other_JJ
services_NN
include_VPRT
human_JJ
resources_NN
advisory_JJ
,_,
compliance_NN
and_PHC
treasury_NN
related_VBN
services_NN
._.
At_PIN
31st_CD
December_NN
2005_CD
,_,
the_DT
amount_NN
due_JJ
to_PIN
for_PIN
fees_NN
yet_RB
to_TO
be_VB [PASS]
invoiced_VBN
was_VBD [BEMA]
3.0_CD
million_CD
,_,
comprising_VBG
statutory_JJ
audit_NN
2.1_CD
million_CD
,_,
further_RB
assurance_NN
0.7_CD
million_CD
and_CC
taxation_NOMZ
services_NN
of_PIN
0.2_CD
million_CD
._.
8_CD
Employee_NN
costs_NN
2005 2004 2003_CD
m_FW
m_FW
m_FW
Wages_NN
and_PHC
salaries_NN
4,152_CD
3,864_CD
3,999_CD
Social_NN
security_NOMZ
costs_NN
432 430 444_CD
Pension_NN
and_CC
other_JJ
post-employment_NOMZ
costs_NN
see_VPRT [PRIV]
Note_NN
26 350 347 421_CD
Cost_NN
of_PIN
share-based_JJ
incentive_NN
plans_NN
236 333 375_CD
Severance_NN
and_CC
other_JJ
costs_NN
from_PIN
integration_NOMZ
and_PHC
restructuring_GER
activities_NOMZ
84_CD
80_CD
222_CD
5,254_CD
5,054_CD
5,461_CD
The_DT
Group_NN
provides_VPRT
benefits_NN
to_PIN
employees_NN
,_,
commensurate_JJ
with_PIN
local_JJ
practice_NN
in_PIN
individual_JJ
countries_NN
,_,
including_VBG
,_,
in_PIN
some_QUAN
markets_NN
,_,
healthcare_NN
insurance_NN
,_,
subsidised_VBN
car_NN
schemes_NN
and_CC
personal_JJ
life_NN
assurance_NN
._.
2005 2004 2003_CD
The_DT
average_JJ
number_NN
of_PIN
persons_NN
employed_VBN [WZPAST]
by_PIN
the_DT
Group_NN
including_VBG [WZPRES]
Directors_NN
during_PIN
the_DT
year_NN
Number_NN
Number_NN
Number_NN
Manufacturing_GER
30,906_CD
31,427_CD
34,265_CD
Selling_GER
,_,
general_JJ
and_CC
administration_NOMZ
53,634_CD
53,513_CD
54,128_CD
Research_NN
and_PHC
development_NOMZ
14,963_CD
14,897_CD
14,773_CD
99,503_CD
99,837_CD
103,166_CD
The_DT
average_JJ
number_NN
of_PIN
Group_NN
employees_NN
excludes_VPRT
temporary_JJ
and_CC
contract_NN
staff_NN
._.
The_DT
numbers_NN
of_PIN
Group_NN
employees_NN
at_PIN
the_DT
end_NN
of_PIN
each_QUAN
financial_JJ
year_NN
are_VPRT [PASS]
given_VBN
in_PIN
the_DT
Financial_NN
record_NN
on_PIN
page_NN
180_CD
._.
The_DT
average_JJ
number_NN
of_PIN
persons_NN
employed_VBN [WZPAST]
by_PIN
GlaxoSmithKline_NN
plc_NN
in_PIN
2005_CD
was_VBD [BEMA]
nil_PRED
2004_CD
nil_NN
._.
The_DT
compensation_NOMZ
of_PIN
the_DT
Directors_NN
,_,
the_DT
CET_NN
and_CC
the_DT
Company_NN
Secretary_NN
,_,
in_PIN
aggregate_NN
,_,
was_VBD
as_IN
follows_VPRT
:_:
2005 2004 2003_CD
m_FW
m_FW
m_FW
Wages_NN
and_PHC
salaries_NN
17_CD
13_CD
16_CD
Social_NN
security_NOMZ
costs_NN
1_CD
11_CD
Pension_NN
and_CC
other_JJ
post-employment_NOMZ
costs_NN
3_CD
21_CD
Cost_NN
of_PIN
share-based_JJ
incentive_NN
plans_NN
15_CD
16_CD
19_CD
36_CD
32_CD
37_CD
Information_NOMZ
on_PIN
Directors_NN
remuneration_NOMZ
is_VPRT [PASS]
given_VBN
in_PIN
the_DT
Remuneration_NOMZ
Report_NN
on_PIN
pages_NN
37_CD
to_PIN
54_CD
._.
GSK_NN
Annual_JJ
Report_NN
2005_CD
96_CD
FINANCIAL_NN
STATEMENTS_NOMZ
Notes_NN
to_PIN
the_DT
financial_JJ
statements_NOMZ
continued_VBD
9_CD
Finance_NN
income_NN
2005 2004 2003_CD
m_FW
m_FW
m_FW
Interest_NN
income_NN
268_CD
173_CD
98_CD
Unwinding_GER
of_PIN
discount_NN
on_PIN
assets_NN
33_CD
Interest_NN
on_PIN
extended_JJ
credit_NN
on_PIN
receivables_NN
8_CD
Net_JJ
investment_NOMZ
hedges_NN
17_CD
Fair_NN
value_NN
adjustments_NOMZ
on_PIN
non-hedging_JJ
derivatives_NN
2_CD
257 176 101_CD
10_CD
Finance_NN
costs_NN
2005 2004 2003_CD
m_FW
m_FW
m_FW
Interest_NN
on_PIN
bank_NN
loans_NN
and_PHC
overdrafts_NN
11_CD
6_CD
6_CD
Interest_NN
on_PIN
other_JJ
loans_NN
412 337 226_CD
Interest_NN
in_PIN
respect_NN
of_PIN
finance_NN
leases_NN
4_CD
2_CD
2_CD
Realised_JJ
losses_NN
on_PIN
financial_JJ
instruments_NOMZ
1_CD
Unwinding_GER
of_PIN
discount_NN
on_PIN
provisions_NN
25_CD
16_CD
20_CD
Fair_NN
value_NN
hedges_NN
2_CD
Fair_NN
value_NN
adjustments_NOMZ
on_PIN
non-hedging_JJ
derivatives_NN
1_CD
451 362 254_CD
11_CD
Associates_NN
and_CC
joint_JJ
ventures_NN
2005 2004 2003_CD
m_FW
m_FW
m_FW
Associates_NN
:_:
Share_NN
of_PIN
after_IN
tax_NN
profits_NN
of_PIN
Quest_NN
Diagnostics_NN
Inc._NN
52_CD
59_CD
58_CD
Share_NN
of_PIN
after_IN
tax_NN
losses_NN
of_PIN
other_JJ
associates_NN
1_CD
1_CD
2_CD
51_CD
58_CD
56_CD
Share_NN
of_PIN
after_IN
tax_NN
profits_NN
losses_NN
of_PIN
joint_JJ
ventures_NN
1_CD
21_CD
52_CD
60_CD
57_CD
Share_NN
of_PIN
turnover_NN
of_PIN
joint_JJ
ventures_NN
32_CD
31_CD
31_CD
Sales_NN
to_PIN
joint_JJ
ventures_NN
and_PHC
associates_NN
48_CD
50_CD
51_CD
Summarised_JJ
income_NN
statement_NOMZ
information_NOMZ
in_PIN
respect_NN
of_PIN
the_DT
Groups_NN
associates_NN
is_VPRT [PASS]
set_VBN
out_PIN
below_PLACE
:_:
2005 2004 2003_CD
m_FW
m_FW
m_FW [BEMA]
Total_JJ
turnover_NN
3,029_CD
2,806_CD
2,893_CD
Total_JJ
profit_NN
loss_NN
296 275 268_CD
12_CD
Taxation_NOMZ
2005 2004 2003_CD
Taxation_NOMZ
charge_NN
based_VBN [WZPAST]
on_PIN
profits_NN
for_PIN
the_DT
year_NN
m_FW
m_FW
m_FW
UK_NN
corporation_NOMZ
tax_NN
at_PIN
the_DT
UK_NN
statutory_JJ
rate_NN
589 429 673_CD
Less_RB
double_JJ
taxation_NOMZ
relief_NN
235 156 290 354_CD
273_CD
383_CD
Overseas_PLACE
taxation_NOMZ
1,665_CD
1,394_CD
1,578_CD
Current_JJ
taxation_NOMZ
2,019_CD
1,667_CD
1,961_CD
Deferred_JJ
taxation_NOMZ
103_CD
90_CD
310_CD
1,916_CD
1,757_CD
1,651_CD
GSK_NN
Annual_JJ
Report_NN
2005_CD
97_CD
FINANCIAL_NN
STATEMENTS_NOMZ
Notes_NN
to_PIN
the_DT
financial_JJ
statements_NOMZ
continued_VBD
12_CD
Taxation_NOMZ
continued_VBD
2005 2004 2003_CD
Reconciliation_NOMZ
of_PIN
the_DT
taxation_NOMZ
rate_NN
on_PIN
Group_NN
profits_NN
%_NN
%_NN
%_NN
UK_NN
statutory_JJ
rate_NN
of_PIN
taxation_NOMZ
30.0_CD
30.0_CD
30.0_CD
Overseas_PLACE
taxes_NN
3.0_CD
2.5_CD
1.9_CD
Benefit_NN
of_PIN
special_JJ
tax_NN
status_NN
2.3_CD
3.6_CD
3.8_CD
R&D_NN
credits_NN
1.4_CD
1.5_CD
1.2_CD
Intercompany_NN
stock_NN
profit_NN
1.0_CD
0.3_CD
0.4_CD
Impact_NN
of_PIN
share_NN
based_VBN
payments_NOMZ
0.3_CD
1.5_CD
1.3_CD
Tax_NN
on_PIN
profit_NN
of_PIN
associates_NN
0.4_CD
0.4_CD
0.5_CD
Other_JJ
differences_NN
0.4_CD
0.5_CD
0.6_CD
Prior_RB
year_NN
items_NN
0.7_CD
1.1_CD
1.0_CD
Tax_NN
rate_NN
28.5_CD
30.4_CD
27.7_CD
The_DT
Group_NN
operates_VPRT
in_PIN
countries_NN
where_RB
the_DT
tax_NN
rate_NN
differs_VPRT
from_PIN
the_DT
UK_NN
tax_NN
rate_NN
._.
Profits_NN
arising_VBG [WZPRES]
from_PIN
certain_JJ
operations_NOMZ
in_PIN
Singapore_NN
,_,
Puerto_NN
Rico_NN
,_,
Ireland_NN
and_PHC
Belgium_NN
are_VPRT [PASS]
accorded_VBN
special_JJ
status_NN
and_CC
are_VPRT [PASS]
taxed_VBN
at_PIN
reduced_JJ
rates_NN
compared_VBN [WZPAST]
with_PIN
the_DT
normal_JJ
rates_NN
of_PIN
tax_NN
in_PIN
these_DEMO
territories_NN
._.
The_DT
effect_NN
of_PIN
this_DEMO
reduction_NOMZ
in_PIN
the_DT
taxation_NOMZ
charge_NN
increased_VBD
earnings_GER
per_PIN
share_NN
by_PIN
2.7_CD
p_NN
in_PIN
2005_CD
,_,
3.6_CD
p_NN
in_PIN
2004_CD
and_CC
3.9_CD
p_NN
in_PIN
2003_CD
._.
The_DT
Group_NN
is_VPRT [PASS]
required_VBN [SUAV]
under_IN
IFRS_NN
to_TO
create_VB
a_DT
deferred_JJ
tax_NN
asset_NN
in_PIN
respect_NN
of_PIN
unrealised_JJ
intercompany_NN
profit_NN
arising_VBG [WZPRES]
on_PIN
stock_NN
held_VBN [PRIV] [WZPAST]
by_PIN
the_DT
Group_NN
at_PIN
the_DT
year_NN
end_NN
by_PIN
applying_VBG
the_DT
tax_NN
rate_NN
of_PIN
the_DT
country_NN
in_PIN
which_WDT [PIRE]
the_DT
stock_NN
is_VPRT [PASS]
held_VBN [PRIV]
rather_RB
than_PIN
the_DT
tax_NN
rate_NN
of_PIN
the_DT
country_NN
where_RB
the_DT
profit_NN
was_VBD [SPAU] [PASS]
originally_TIME
made_VBN
and_CC
tax_NN
paid_VBN
,_,
which_WDT [SERE]
is_VPRT [BEMA]
the_DT
practice_NN
under_IN
UK_NN
and_PHC
US_FPP1
GAAP_NN
._.
The_DT
Group_NN
tax_NN
rate_NN
was_VBD [BYPA]
increased_VBN
by_PIN
1.0_CD
%_NN
in_PIN
2005_CD
2004_CD
0.3_CD
%_NN
,_,
2003_CD
0.4_CD
%_NN
decrease_NN
as_CONJ
a_NULL
result_NULL
of_PIN
reductions_NOMZ
in_PIN
work-in-progress_NN
and_CC
finished_VBD
goods_NN
._.
The_DT
integrated_JJ
nature_NN
of_PIN
the_DT
Groups_NN
worldwide_JJ
operations_NOMZ
,_,
involving_VBG
significant_JJ
investment_NOMZ
in_PIN
research_NN
and_CC
strategic_JJ
manufacture_NN
at_PIN
a_DT
limited_JJ
number_NN
of_PIN
locations_NOMZ
,_,
with_PIN
consequential_JJ
cross-border_JJ
supply_NN
routes_NN
into_PIN
numerous_JJ
end-markets_NN
,_,
gives_VPRT
rise_NN
to_PIN
complexity_NOMZ
and_PHC
delay_NN
in_PIN
negotiations_NOMZ
with_PIN
revenue_NN
authorities_NOMZ
as_IN
to_PIN
the_DT
profits_NN
on_PIN
which_WDT [PIRE]
individual_JJ
Group_NN
companies_NN
are_VPRT [BEMA]
liable_PRED
to_PIN
tax_NN
._.
Disagreements_NOMZ
with_PIN [STPR]
,_,
and_ANDC
between_PIN [STPR]
,_,
revenue_NN
authorities_NOMZ
as_IN
to_PIN
intra-Group_JJ
transactions_NOMZ
,_,
in_CONJ
particular_NULL
the_DT
price_NN
at_PIN
which_WDT [PIRE]
goods_NN
should_NEMD
be_VB [PASS]
transferred_VBN
between_PIN
Group_NN
companies_NN
in_PIN
different_JJ
tax_NN
jurisdictions_NOMZ
,_,
can_POMD
produce_VB
conflicting_VBG
claims_NN
from_PIN
revenue_NN
authorities_NOMZ
as_IN
to_PIN
the_DT
profits_NN
to_TO
be_VB [PASS]
taxed_VBN
in_PIN
individual_JJ
territories_NN
._.
Resolution_NOMZ
of_PIN
such_JJ
issues_NN
is_VPRT [BEMA]
a_DT
continuing_VBG
fact_NN
of_PIN
life_NN
for_PIN
GSK_NN
._.
The_DT
Group_NN
has_VPRT
open_JJ
issues_NN
with_PIN
the_DT
revenue_NN
authorities_NOMZ
in_PIN
the_DT
USA_NN
,_,
UK_NN
,_,
Japan_NN
and_PHC
Canada_NN
:_:
by_PIN
far_PLACE
the_DT
largest_JJ
relates_VPRT
to_PIN
Glaxo_NN
heritage_NN
products_NN
,_,
in_PIN
respect_NN
of_PIN
which_WDT [PIRE]
the_DT
US_FPP1
Internal_NN
Revenue_NN
Service_NN
IRS_NN
and_PHC
HM_NN
Revenue_NN
&_CC
Customs_NN
HMRC_NN
in_PIN
the_DT
UK_NN
have_VPRT [PEAS]
made_VBN
competing_VBG
and_CC
contradictory_JJ
claims_NN
._.
GSK_NN
has_VPRT [PEAS]
attempted_VBN
to_TO
settle_VB
the_DT
US_FPP1
dispute_NN
,_,
first_RB
through_PIN
direct_JJ
discussion_NN
with_PIN
the_DT
IRS_NN
and_CC
subsequently_TIME
through_PIN
discussions_NN
between_PIN
the_DT
US_FPP1
and_PHC
UK_NN
authorities_NOMZ
under_IN
the_DT
terms_NN
of_PIN
the_DT
double_JJ
tax_NN
convention_NOMZ
between_PIN
the_DT
two_CD
countries_NN
:_:
these_DEMO
discussions_NN
were_VBD [PASS]
terminated_VBN
in_PIN
July_NN
2003_CD
._.
On_PIN
6th_JJ
January_NN
2004_CD
the_DT
IRS_NN
issued_VBD
a_DT
Notice_NN
of_PIN
Deficiency_NN
for_PIN
the_DT
years_NN
1989-1996_CD
claiming_VBG [PUBV]
additional_JJ
taxes_NN
of_PIN
$_$
2.7_CD
billion_CD
._.
On_PIN
2nd_JJ
April_NN
2004_CD
the_DT
Group_NN
filed_VBD
a_DT
petition_NOMZ
in_PIN
the_DT
US_FPP1
Tax_NN
Court_NN
disputing_VBG [WZPRES]
the_DT
IRS_NN
claim_NN
and_CC
seeking_VBG
a_DT
refund_NN
of_PIN
$_$
1_CD
billion_CD
in_PIN
taxes_NN
._.
On_PIN
25th_JJ
January_NN
2005_CD
the_DT
IRS_NN
issued_VBD
a_DT
further_JJ
Notice_NN
of_PIN
Deficiency_NN
for_PIN
the_DT
years_NN
1997-2000_CD
claiming_VBG [PUBV]
additional_JJ
federal_JJ
taxes_NN
of_PIN
$_$
1.9_CD
billion_CD
,_,
which_WDT [SERE]
the_DT
Group_NN
contested_VBN [WZPAST]
by_PIN
filing_VBG
a_DT
petition_NOMZ
in_PIN
the_DT
US_FPP1
Tax_NN
Court_NN
on_PIN
12th_JJ
April_NN
2005_CD
,_,
to_PIN
which_WDT [PIRE]
the_DT
IRS_NN
filed_VBD
its_PIT
statutory_JJ
Answer_NN
on_PIN
7th_JJ
June_NN
2005_CD
._.
In_PIN
September_NN
2005_CD
the_DT
Court_NN
agreed_VBD [SUAV] [PUBV]
to_TO
consolidate_VB
the_DT
IRS_NN
claims_NN
for_PIN
1997-2000_CD
with_PIN
those_DEMO
for_PIN
1989-1996_CD
into_PIN
a_DT
single_JJ
trial_NN
._.
The_DT
total_JJ
claims_NN
for_PIN
these_DEMO
periods_NN
amount_NN
to_TO
$_$
4.6_CD
billion_CD
of_PIN
additional_JJ
federal_JJ
taxes_NN
and_CC
related_JJ
interest_NN
to_PIN
31st_CD
December_NN
2005_CD
of_PIN
$_$
3.7_CD
billion_CD
,_,
net_NN
of_PIN
federal_JJ
tax_NN
relief_NN
,_,
giving_VBG [PRESP]
a_DT
total_NN
of_PIN
$_$
8.3_CD
billion_CD
._.
The_DT
Groups_NN
petitions_NOMZ
against_PIN
the_DT
IRS_NN
claims_NN
include_VPRT
counter-claims_NN
for_PIN
repayment_NOMZ
of_PIN
federal_JJ
taxes_NN
totalling_VBG [WZPRES]
$_$
1.8_CD
billion_CD
,_,
based_VBN [PASTP]
partly_DWNT
by_PIN
reference_NN
to_PIN
an_DT
Advance_NN
Pricing_GER
Agreement_NOMZ
APA_NN
between_PIN
SmithKline_NN
Beecham_NN
and_CC
the_DT
IRS_NN
covering_VBG [WZPRES]
the_DT
transfer_NN
pricing_GER
of_PIN
Tagamet_NN
between_PIN
1991_CD
and_CC
1993_CD
._.
On_PIN
23rd_JJ
December_NN
2004_CD
the_DT
IRS_NN
filed_VBD
a_DT
motion_NOMZ
for_PIN
summary_NN
judgement_NOMZ
to_TO
exclude_VB
any_QUAN
evidence_NN
relating_VBG [WZPRES]
to_PIN
APAs_NN
from_PIN
the_DT
court_NN
proceedings_GER
._.
On_PIN
31st_CD
March_NN
2005_CD
the_DT
trial_NN
judge_NN
denied_VBD [PUBV]
the_DT
IRS_NN
motion_NOMZ
and_CC
reserved_VBN
ruling_NN
on_PIN
the_DT
admissibility_NOMZ
of_PIN
APA_NN
evidence_NN
until_IN
full_JJ
trial_NN
,_,
which_WDT [SERE]
is_VPRT [PASS]
scheduled_VBN
to_TO
commence_VB
on_PIN
16th_JJ
October_NN
2006_CD
._.
As_IN
similar_JJ
tax_NN
issues_NN
remain_VPRT
open_JJ
for_PIN
2001_CD
to_PIN
date_NN
,_,
GSK_NN
expects_VPRT [PRIV]
to_TO
receive_VB
further_JJ
substantial_JJ
claims_NN
by_PIN
the_DT
IRS_NN
for_PIN
these_DEMO
years_NN
._.
GSK_NN
continues_VPRT
to_TO
believe_VB [PRIV]
that_THVC
the_DT
profits_NN
reported_VBN [PUBV] [WZPAST]
by_PIN
its_PIT
US_FPP1
subsidiaries_NN
for_PIN
the_DT
period_NN
1989_CD
to_PIN
date_NN
,_,
on_PIN
which_WDT [PIRE]
it_PIT
has_VPRT [PEAS]
paid_VBN
taxes_NN
in_PIN
the_DT
USA_NN
,_,
are_VPRT [BEMA]
more_EMPH
than_PIN
sufficient_JJ
to_TO
reflect_VB [PRIV]
the_DT
activities_NOMZ
of_PIN
its_PIT
US_FPP1
operations_NOMZ
._.
However_CONJ
,_,
the_DT
Group_NN
tax_NN
creditor_NN
balance_NN
at_PIN
31st_CD
December_NN
2005_CD
of_PIN
2.3_CD
billion_CD
2004_CD
1.8_CD
billion_CD
includes_VPRT
a_DT
provision_NN
for_PIN
the_DT
estimated_VBN [PRIV]
amount_NN
at_PIN
which_WDT [PIRE]
the_DT
IRS_NN
dispute_NN
might_POMD [SPAU]
ultimately_RB
be_VB [PASS]
settled_VBN
._.
If_COND
the_DT
IRS_NN
were_VBD
to_TO
follow_VB
the_DT
same_JJ
methodology_NN
as_IN
applied_VBN
previously_TIME
in_PIN
respect_NN
of_PIN
these_DEMO
later_TIME
years_NN
,_,
GSK_NN
estimates_VPRT [PRIV]
that_THVC
the_DT
potential_JJ
unprovided_JJ
exposure_NN
in_PIN
respect_NN
of_PIN
this_DEMO
dispute_NN
with_PIN
the_DT
IRS_NN
for_PIN
the_DT
years_NN
1989-2005_CD
amounted_VBD
to_TO
approximately_RB
$_$
11.5_CD
billion_CD
at_PIN
31st_CD
December_NN
2005_CD
2004_CD
$_$
10.1_CD
billion_CD
._.
GSK_NN
is_VPRT [BEMA]
in_PIN
continuing_VBG
discussions_NN
with_PIN
HMRC_NN
in_PIN
respect_NN
of_PIN
UK_NN
transfer_NN
pricing_GER
and_CC
other_JJ
matters_NN
which_WDT [WHSUB]
are_VPRT [BEMA]
in_PIN
dispute_NN
for_PIN
the_DT
years_NN
1995_CD
to_PIN
date_NN
._.
However_CONJ
little_JJ
progress_NN
has_VPRT [PEAS]
been_VBN [PASS]
made_VBN
over_IN
the_DT
past_JJ
year_NN
and_ANDC
consequently_CONJ
these_DEMO
matters_NN
may_POMD
become_VB
subject_JJ
to_PIN
litigation_NOMZ
in_PIN
due_JJ
course_NN
._.
GSK_NN
Annual_JJ
Report_NN
2005_CD
98_CD
FINANCIAL_NN
STATEMENTS_NOMZ
Notes_NN
to_PIN
the_DT
financial_JJ
statements_NOMZ
continued_VBD
12_CD
Taxation_NOMZ
continued_VBD
GSK_NN
uses_VPRT
the_DT
best_JJ
advice_NN
in_PIN
determining_VBG [SUAV] [PRIV]
its_PIT
transfer_NN
pricing_GER
methodology_NN
and_CC
in_PIN
seeking_VBG
to_TO
manage_VB
transfer_NN
pricing_GER
issues_NN
to_PIN
a_DT
satisfactory_JJ
conclusion_NN
and_CC
,_,
on_PIN
the_DT
basis_NN
of_PIN
external_JJ
professional_JJ
advice_NN
,_,
continues_VPRT
to_TO
believe_VB [PRIV]
that_THVC
it_PIT
has_VPRT [PEAS]
made_VBN
adequate_JJ
provision_NN
for_PIN
the_DT
liabilities_NOMZ
likely_JJ
to_TO
arise_VB
from_PIN
open_JJ
assessments_NOMZ
._.
However_CONJ
,_,
there_EX
continues_VPRT
to_TO
be_VB [BEMA]
a_DT
wide_JJ
difference_NN
of_PIN
views_NN
between_PIN
the_DT
Group_NN
,_,
the_DT
IRS_NN
,_,
HMRC_NN
and_CC
other_JJ
relevant_JJ
taxation_NOMZ
authorities_NOMZ
where_RB
open_JJ
issues_NN
exist_VPRT
._.
The_DT
ultimate_JJ
liability_NOMZ
for_PIN
such_JJ
matters_NN
may_POMD
vary_VB
from_PIN
the_DT
amounts_NN
provided_VBN
and_PHC
is_VPRT [BEMA]
dependent_PRED
upon_PIN
the_DT
outcome_NN
of_PIN
litigation_NOMZ
proceedings_GER
and_PHC
negotiations_NOMZ
with_PIN
the_DT
relevant_JJ
tax_NN
authorities_NOMZ
._.
Except_PIN
as_IN
shown_VBN [PRIV]
in_PIN
this_DEMO
Annual_JJ
Report_NN
,_,
no_SYNE
provision_NN
has_VPRT [PEAS]
been_VBN [PASS]
made_VBN
for_PIN
taxation_NOMZ
which_WDT [WHSUB]
would_PRMD
arise_VB
on_PIN
the_DT
distribution_NOMZ
of_PIN
profits_NN
retained_VBN [WZPAST]
by_PIN
overseas_PLACE
subsidiary_NN
and_CC
associated_VBN
undertakings_GER
,_,
on_PIN
the_DT
grounds_NN
that_TOBJ
no_SYNE
remittance_NN
of_PIN
profit_NN
retained_VBN [WZPAST]
at_PIN
31st_CD
December_NN
2005_CD
is_VPRT [PASS]
required_VBN [SUAV]
in_PIN
such_EMPH
a_NULL
way_NN
that_TOBJ
incremental_JJ
tax_NN
will_PRMD
arise_VB
._.
The_DT
aggregate_JJ
amount_NN
of_PIN
these_DEMO
unremitted_JJ
profits_NN
at_PIN
the_DT
balance_NN
sheet_NN
date_NN
was_VBD [BEMA]
approximately_RB
24_CD
billion_CD
._.
At_PIN
31st_CD
December_NN
2005_CD
the_DT
Group_NN
had_VBD [PEAS]
recognized_VBN [PRIV]
a_DT
deferred_JJ
tax_NN
asset_NN
of_PIN
87_CD
million_CD
2004_CD
20_CD
million_CD
in_PIN
respect_NN
of_PIN
income_NN
tax_NN
losses_NN
of_PIN
approximately_RB
291_CD
million_CD
2004_CD
63_CD
million_CD
._.
Of_PIN
these_DEMO
losses_NN
,_,
64_CD
million_CD
2004_CD
28_CD
million_CD
are_VPRT [BEMA]
due_PRED
to_TO
expire_VB
between_PIN
20072012_CD
,_,
184_CD
million_CD
2004_CD
19_CD
million_CD
are_VPRT [BEMA]
due_PRED
to_TO
expire_VB
between_PIN
20182025_CD
and_CC
43_CD
million_CD
2004_CD
16_CD
million_CD
are_VPRT [BEMA]
available_JJ
indefinitely_RB
._.
At_PIN
31st_CD
December_NN
2005_CD
the_DT
Group_NN
had_VBD [PEAS]
not_XX0
recognized_VBN [PRIV]
any_QUAN
deferred_JJ
tax_NN
asset_NN
in_PIN
respect_NN
of_PIN
income_NN
tax_NN
losses_NN
of_PIN
approximately_RB
217_CD
million_CD
2004_CD
387_CD
million_CD
,_,
of_PIN
which_WDT [PIRE]
28_CD
million_CD
2004_CD
358_CD
million_CD
are_VPRT [BEMA]
due_PRED
to_TO
expire_VB
between_PIN
20072012_CD
,_,
79_CD
million_CD
2004_CD
nil_NN
are_VPRT [BEMA]
due_PRED
to_TO
expire_VB
between_PIN
20182025_CD
and_CC
110_CD
million_CD
2004_CD
29_CD
million_CD
are_VPRT [BEMA]
available_JJ
indefinitely_RB
._.
The_DT
Group_NN
had_VBD
capital_NN
losses_NN
at_PIN
31st_CD
December_NN
2005_CD
estimated_VBN [PRIV]
to_TO
be_VB [BEMA]
in_PIN
excess_NN
of_PIN
10_CD
billion_CD
in_PIN
respect_NN
of_PIN
which_WDT [PIRE]
no_SYNE
deferred_JJ
tax_NN
asset_NN
has_VPRT [PEAS]
been_VBN [PASS]
recognized_VBN [PRIV]
._.
Deferred_JJ
tax_NN
assets_NN
are_VPRT [PASS]
not_XX0
recognized_VBN [PRIV]
where_RB [WHCL]
there_EX
is_VPRT
insufficient_JJ
evidence_NN
that_TOBJ
losses_NN
will_PRMD
be_VB [PASS]
utilised_VBN
._.
Payable_JJ
Recoverable_JJ
Net_NN
Movement_NOMZ
on_PIN
current_JJ
tax_NN
account_NN
m_NN
m_FW
m_FW [BEMA]
At_PIN
1st_CD
January_NN
2005_CD
1,753_CD
155_CD
1,598_CD
Exchange_NN
adjustments_NOMZ
183_CD
2_CD
181_CD
Charge_NN
to_TO
profit_VB
and_CC
loss_NN
account_NN
1,591_CD
428_CD
2,019_CD
Cash_NN
paid_VBN
1,195_CD
512_CD
1,707_CD
Other_JJ
movements_NOMZ
63 175 238_CD
At_PIN
31st_CD
December_NN
2005_CD
2,269_CD
416_CD
1,853_CD
Movement_NOMZ
in_PIN
deferred_JJ
tax_NN
assets_NN
and_PHC
liabilities_NOMZ
Pensions_NN
&_CC
Share_NN
Other_JJ
Accelerated_NN
Product_NN
&_CC
other_JJ
post_NN
Legal_NN
ManuStock_NN
option_NOMZ
net_NN
Deferred_VBN
taxation_NOMZ
capital_NN
Intra-group_NN
business_NOMZ
retirement_NOMZ
Tax_NN
&_CC
other_JJ
facturing_VBG
valuation_NOMZ
and_PHC
award_NN
temporary_JJ
asset_NN
liability_NOMZ
allowances_NN
Intangibles_NN
profit_NN
disposals_NN
benefits_NN
Losses_NN
disputes_NN
restructuring_VBG [WZPRES]
adjustments_NOMZ
schemes_NN
differences_NN
Total_JJ
Deferred_JJ
tax_NN
asset_NN
at_PIN
1st_CD
January_NN
2005_CD
54 34 759 524_CD
19_CD
149_CD
73_CD
62_CD
67_CD
523_CD
2,032_CD
Deferred_JJ
tax_NN
liability_NOMZ
at_PIN
1st_CD
January_NN
2005 558 328_CD
32_CD
294_CD
1_CD
10_CD
26_CD
52_CD
70_CD
569_CD
At_PIN
1st_CD
January_NN
2005 612 294 759_CD
32_CD
818_CD
20_CD
159_CD
99_CD
114_CD
67_CD
593_CD
1,463_CD
IAS_NN
39_CD
adjustments_NOMZ
5_CD
5_CD
At_PIN
1st_CD
January_NN
2005_CD
,_,
as_IN
adjusted_VBN
612 294 759_CD
32_CD
818_CD
20_CD
159_CD
99_CD
114_CD
67_CD
588_CD
1,458_CD
Exchange_NN
adjustments_NOMZ
9_CD
6_CD
45_CD
19_CD
1_CD
6_CD
55_CD
99_CD
Credit_NN
charge_NN
to_PIN
income_NN
10_CD
16_CD
50_CD
3_CD
29_CD
24_CD
62_CD
20_CD
5_CD
59_CD
49_CD
103_CD
Credit_NN
charge_NN
to_PIN
equity_NOMZ
257_CD
25_CD
18_CD
264_CD
Transfer_NN
to_PIN
from_PIN
current_JJ
tax_NN
10_CD
39_CD
88_CD
79_CD
7_CD
3_CD
13_CD
135_CD
Acquisitions_NOMZ
6_CD
258_CD
86_CD
4_CD
162_CD
Other_JJ
movements_NOMZ
2_CD
1_CD
5_CD
12_CD
18_CD
At_PIN
31st_CD
December_NN
2005 615 540 709_CD
4_CD
1,060_CD
87_CD
161 73 122 151_CD
677_CD
1,645_CD
Deferred_JJ
tax_NN
asset_NN
at_PIN
31st_CD
December_NN
2005_CD
492_CD
18_CD
709_CD
9_CD
1,035_CD
63_CD
160_CD
73 72 151 614_CD
2,214_CD
Deferred_JJ
tax_NN
liability_NOMZ
at_PIN
31st_CD
December_NN
2005 123 522_CD
13_CD
25_CD
24_CD
1_CD
50 63 569 615_CD
540_CD
709_CD
4_CD
1,060_CD
87_CD
161 73 122 151_CD
677_CD
1,645_CD
Deferred_VBN
taxation_NOMZ
provided_VBN [WZPAST]
on_PIN
stock_NN
valuation_NOMZ
adjustments_NOMZ
,_,
intra-Group_JJ
profit_NN
and_CC
other_JJ
temporary_JJ
differences_NN
shown_VBN [PRIV]
above_PLACE
are_VPRT [BEMA]
current_PRED
._.
All_QUAN
deferred_VBN
taxation_NOMZ
movements_NOMZ
arise_VPRT
from_PIN
the_DT
origination_NOMZ
and_PHC
reversal_NN
of_PIN
temporary_JJ
differences_NN
._.
Other_JJ
net_JJ
temporary_JJ
differences_NN
include_VPRT
accrued_VBN
expenses_NN
and_CC
other_JJ
provisions_NN
._.
GSK_NN
Annual_JJ
Report_NN
2005_CD
99_CD
FINANCIAL_NN
STATEMENTS_NOMZ
Notes_NN
to_PIN
the_DT
financial_JJ
statements_NOMZ
continued_VBD
13_CD
Earnings_GER
per_PIN
share_NN
2005 2004 2003_CD
p_NN
pp_NN
Basic_JJ
earnings_GER
per_PIN
share_NN
82.6_CD
68.1_CD
72.3_CD
Diluted_VBN
earnings_GER
per_PIN
share_NN
82.0_CD
68.0_CD
72.1_CD
Earnings_GER
per_PIN
share_NN
has_VPRT [PEAS]
been_VBN [BYPA]
calculated_VBN [PRIV]
by_PIN
dividing_VBG
the_DT
profit_NN
attributable_JJ
to_PIN
shareholders_NN
by_PIN
the_DT
weighted_JJ
average_JJ
number_NN
of_PIN
shares_NN
in_PIN
issue_NN
during_PIN
the_DT
period_NN
._.
The_DT
number_NN
of_PIN
shares_NN
used_VBN [WZPAST]
in_PIN
calculating_VBG [PRIV]
basic_JJ
and_PHC
diluted_JJ
earnings_GER
per_PIN
share_NN
are_VPRT [PASS]
reconciled_VBN
below_PLACE
._.
Weighted_JJ
average_JJ
number_NN
of_PIN
shares_NN
in_PIN
issue_NN
millions_NN
millions_NN
millions_NN
Basic_JJ
5,674_CD
5,736_CD
5,806_CD
Dilution_NOMZ
for_PIN
share_NN
options_NOMZ
46_CD
12_CD
18_CD
Diluted_NN
5,720_CD
5,748_CD
5,824_CD
Shares_NN
held_VBN [PRIV] [WZPAST]
by_PIN
the_DT
ESOP_NN
Trusts_NN
are_VPRT [PASS]
excluded_VBN
._.
The_DT
trustees_NN
have_VPRT [PEAS]
waived_VBN
their_TPP3
rights_NN
to_PIN
dividends_NN
on_PIN
the_DT
shares_NN
held_VBN [PRIV] [WZPAST]
by_PIN
the_DT
ESOP_NN
Trusts_NN
._.
14_CD
Dividends_NN
2005_CD
First_JJ
interim_JJ
Second_JJ
interim_JJ
Third_JJ
interim_JJ
Fourth_JJ
interim_JJ
Total_JJ
Total_JJ
dividend_NN
m_NN [BEMA]
568 567 568 792_CD
2,495_CD
Dividend_NN
per_PIN
share_NN
pence_NN
10_CD
10_CD
10_CD
14_CD
44_CD
Paid_VBN
payable_JJ
7th_JJ
July_NN
2005_CD
6th_JJ
October_NN
2005_CD
5th_JJ
January_NN
2006_CD
6th_JJ
April_NN
2006_CD
2004_CD
Total_JJ
dividend_NN
m_NN [BEMA]
575 573 571 684_CD
2,403_CD
Dividend_NN
per_PIN
share_NN
pence_NN
10_CD
10_CD
10_CD
12_CD
42_CD
Paid_VBN
1st_CD
July_NN
2004_CD
30th_JJ
September_NN
2004_CD
6th_JJ
January_NN
2005_CD
7th_JJ
April_NN
2005_CD
2003_CD
Total_JJ
dividend_NN
m_NN [BEMA]
524 522 520 808_CD
2,374_CD
Dividend_NN
per_PIN
share_NN
pence_NN
9_CD
9_CD
9_CD
14_CD
41_CD
Paid_VBN
3rd_CD
July_NN
2003_CD
2nd_JJ
October_NN
2003_CD
6th_JJ
January_NN
2004_CD
15th_JJ
April_NN
2004_CD
Under_IN
IFRS_NN
interim_JJ
dividends_NN
are_VPRT [SPAU] [PASS]
only_DWNT
recognized_VBN [PRIV]
in_PIN
the_DT
financial_JJ
statements_NOMZ
when_RB
paid_VBN
and_CC
not_XX0
when_RB
declared_VBN [PUBV]
._.
GSK_NN
normally_RB
pays_VPRT
a_DT
dividend_NN
two_CD
quarters_NN
after_IN
the_DT
quarter_NN
to_PIN
which_WDT [PIRE]
it_PIT
relates_VPRT
and_CC
one_CD
quarter_NN
after_IN
it_PIT
is_VPRT [PASS]
declared_VBN [PUBV]
._.
The_DT
2005_CD
financial_JJ
statements_NOMZ
recognize_VPRT [PRIV]
those_DEMO
dividends_NN
paid_VBN [WZPAST]
in_PIN
2005_CD
,_,
namely_CONJ
the_DT
third_JJ
and_PHC
fourth_JJ
interim_JJ
dividends_NN
for_PIN
2004_CD
and_CC
the_DT
first_JJ
and_PHC
second_JJ
interim_JJ
dividends_NN
for_PIN
2005_CD
._.
The_DT
amounts_NN
recognized_VBN [PRIV] [WZPAST]
in_PIN
each_QUAN
year_NN
are_VPRT
as_IN
follows_VPRT
:_:
2005 2004 2003_CD
m_FW
m_FW
m_FW
Dividends_NN
to_PIN
shareholders_NN
2,390_CD
2,476_CD
2,333_CD
GSK_NN
Annual_JJ
Report_NN
2005_CD
100_CD
FINANCIAL_NN
STATEMENTS_NOMZ
Notes_NN
to_PIN
the_DT
financial_JJ
statements_NOMZ
continued_VBD
15_CD
Property_NN
,_,
plant_NN
and_PHC
equipment_NOMZ
Plant_NN
,_,
Land_NN
and_PHC
equipment_NOMZ
Assets_NN
in_PIN
buildings_GER
and_PHC
vehicles_NN
construction_NOMZ
Total_JJ
m_NN
m_FW
m_FW
m_FW
Cost_NN
at_PIN
1st_CD
January_NN
2004_CD
3,999_CD
7,214_CD
650_CD
11,863_CD
Exchange_NN
adjustments_NOMZ
78_CD
93_CD
11_CD
182_CD
Additions_NOMZ
81 333 473 887_CD
Additions_NOMZ
through_PIN
business_NOMZ
combinations_NOMZ
10_CD
28_CD
-_:
38_CD
Disposals_NN
58_CD
267_CD
6_CD
331_CD
Reclassifications_NOMZ
113 300 424_CD
11_CD
Transfer_NN
to_PIN
assets_NN
held_VBN [PRIV] [WZPAST]
for_PIN
sale_NN
5_CD
3_LS
-_:
8_CD
Cost_NN
at_PIN
31st_CD
December_NN
2004_CD
4,062_CD
7,512_CD
682_CD
12,256_CD
Exchange_NN
adjustments_NOMZ
136_CD
183_CD
19_CD
338_CD
Additions_NOMZ
54 307 640_CD
1,001_CD
Additions_NOMZ
through_PIN
business_NOMZ
combinations_NOMZ
32_CD
45_CD
33_CD
110_CD
Disposals_NN
82_CD
404_CD
4_CD
490_CD
Reclassifications_NOMZ
83 255 348_CD
10_CD
Transfer_NN
to_PIN
assets_NN
held_VBN [PRIV] [WZPAST]
for_PIN
sale_NN
4_CD
11_CD
15_CD
Cost_NN
at_PIN
31st_CD
December_NN
2005_CD
4,281_CD
7,887_CD
1,022_CD
13,190_CD
Depreciation_NOMZ
at_PIN
1st_CD
January_NN
2004_CD
1,111_CD
4,281_CD
-_:
5,392_CD
Exchange_NN
adjustments_NOMZ
25_CD
63_CD
-_:
88_CD
Provision_NN
for_PIN
the_DT
year_NN
123_CD
568_CD
-_:
691_CD
Disposals_NN
29_CD
208_CD
-_:
237_CD
Reclassifications_NOMZ
8_CD
5_LS
-_:
3_CD
Transfer_NN
to_PIN
assets_NN
held_VBN [PRIV] [WZPAST]
for_PIN
sale_NN
1_CD
5_LS
-_:
6_CD
Depreciation_NOMZ
at_PIN
31st_CD
December_NN
2004_CD
1,171_CD
4,578_CD
-_:
5,749_CD
Exchange_NN
adjustments_NOMZ
38 119 157_CD
Provision_NN
for_PIN
the_DT
year_NN
125 585 710_CD
Disposals_NN
43 356 399_CD
Reclassifications_NOMZ
1_CD
1_CD
Transfer_NN
to_PIN
assets_NN
held_VBN [PRIV] [WZPAST]
for_PIN
sale_NN
1_CD
10_CD
11_CD
Depreciation_NOMZ
at_PIN
31st_CD
December_NN
2005_CD
1,290_CD
4,915_CD
6,205_CD
Impairment_NOMZ
at_PIN
1st_CD
January_NN
2004 130 157_CD
28_CD
315_CD
Exchange_NN
adjustments_NOMZ
4_CD
1_CD
5_CD
Disposals_NN
617_CD
1_CD
24_CD
Impairment_NOMZ
losses_NN
24_CD
11_CD
35_CD
Reversal_NN
of_PIN
impairments_NOMZ
8_CD
3_CD
11_CD
Impairment_NOMZ
at_PIN
31st_CD
December_NN
2004 136 147_CD
27_CD
310_CD
Exchange_NN
adjustments_NOMZ
9_CD
2_CD
11_CD
Disposals_NN
10_CD
2_CD
2_CD
14_CD
Impairment_NOMZ
losses_NN
13_CD
18_CD
31_CD
Reversal_NN
of_PIN
impairments_NOMZ
3_CD
3_CD
Transfer_NN
to_PIN
assets_NN
held_VBN [PRIV] [WZPAST]
for_PIN
sale_NN
2_CD
2_CD
Impairment_NOMZ
at_PIN
31st_CD
December_NN
2005 146 162_CD
25_CD
333_CD
Total_JJ
depreciation_NOMZ
and_PHC
impairment_NOMZ
at_PIN
31st_CD
December_NN
2004_CD
1,307_CD
4,725_CD
27_CD
6,059_CD
Total_JJ
depreciation_NOMZ
and_PHC
impairment_NOMZ
at_PIN
31st_CD
December_NN
2005_CD
1,436_CD
5,077_CD
25_CD
6,538_CD
Net_JJ
book_NN
value_NN
at_PIN
1st_CD
January_NN
2004_CD
2,758_CD
2,776_CD
622_CD
6,156_CD
Net_JJ
book_NN
value_NN
at_PIN
31st_CD
December_NN
2004_CD
2,755_CD
2,787_CD
655_CD
6,197_CD
Net_JJ
book_NN
value_NN
at_PIN
31st_CD
December_NN
2005_CD
2,845_CD
2,810_CD
997_CD
6,652_CD
GSK_NN
Annual_JJ
Report_NN
2005_CD
101_CD
FINANCIAL_NN
STATEMENTS_NOMZ
Notes_NN
to_PIN
the_DT
financial_JJ
statements_NOMZ
continued_VBD
15_CD
Property_NN
,_,
plant_NN
and_PHC
equipment_NOMZ
continued_VBD
The_DT
net_JJ
book_NN
value_NN
at_PIN
31st_CD
December_NN
2005_CD
of_PIN
the_DT
Groups_NN
land_NN
and_PHC
buildings_GER
comprises_VPRT
freehold_NN
properties_NN
2,635_CD
million_CD
2004_CD
2,556_CD
million_CD
,_,
properties_NN
with_PIN
leases_NN
of_PIN
50_CD
years_NN
or_CC
more_EMPH
155_CD
million_CD
2004_CD
143_CD
million_CD
and_CC
properties_NN
with_PIN
leases_NN
of_PIN
less_JJ
than_PIN
50_CD
years_NN
55_CD
million_CD
2004_CD
56_CD
million_CD
._.
Included_VBN [PASTP]
in_PIN
land_NN
and_PHC
buildings_GER
at_PIN
31st_CD
December_NN
2005_CD
are_VPRT [PASS]
leased_VBN
assets_NN
with_PIN
a_DT
cost_NN
of_PIN
165_CD
million_CD
2004_CD
155_CD
million_CD
,_,
accumulated_VBN
amortisation_NOMZ
of_PIN
49_CD
million_CD
2004_CD
46_CD
million_CD
and_CC
a_DT
net_JJ
book_NN
value_NN
of_PIN
116_CD
million_CD
2004_CD
109_CD
million_CD
._.
Included_VBN [PASTP]
in_PIN
plant_NN
,_,
equipment_NOMZ
and_PHC
vehicles_NN
at_PIN
31st_CD
December_NN
2005_CD
are_VPRT [PASS]
leased_VBN
assets_NN
with_PIN
a_DT
cost_NN
of_PIN
153_CD
million_CD
2004_CD
93_CD
million_CD
,_,
accumulated_VBN
amortisation_NOMZ
of_PIN
57_CD
million_CD
2004_CD
25_CD
million_CD
and_CC
a_DT
net_JJ
book_NN
value_NN
of_PIN
96_CD
million_CD
at_PIN
1st_CD
January_NN
2005_CD
68_CD
million_CD
._.
The_DT
impairment_NOMZ
losses_NN
principally_RB
arise_VB
from_PIN
decisions_NN
to_TO
rationalise_VB
facilities_NOMZ
and_CC
are_VPRT [PASS]
calculated_VBN [PRIV]
based_VBN
on_PIN
either_DT
fair_JJ
value_NN
less_RB
costs_NN
to_TO
sell_VB
or_CC
value_NN
in_PIN
use_NN
._.
The_DT
value_NN
in_PIN
use_NN
calculations_NOMZ
determine_VPRT [SUAV] [PRIV]
the_DT
net_JJ
present_JJ
value_NN
of_PIN
the_DT
projected_VBN
risk-adjusted_JJ
,_,
post-tax_JJ
cash_NN
flows_NN
of_PIN
the_DT
relevant_JJ
asset_NN
or_CC
cash_NN
generating_VBG [WZPRES]
unit_NN
,_,
applying_VBG [PRESP]
a_DT
discount_NN
rate_NN
of_PIN
the_DT
Group_NN
post-tax_NN
weighted_VBN
average_JJ
cost_NN
of_PIN
capital_NN
of_PIN
8_CD
%_NN
,_,
adjusted_VBN
where_RB
appropriate_JJ
for_PIN
country_NN
specific_JJ
risks_NN
._.
This_DEMP
approximates_VPRT
to_TO
applying_VBG
a_DT
pre-tax_JJ
discount_NN
rate_NN
to_PIN
pre-tax_JJ
cash_NN
flows_NN
._.
These_DEMO
losses_NN
have_VPRT [PEAS]
been_VBN [PASS]
charged_VBN
through_PIN
Cost_NN
of_PIN
sales_NN
,_,
16_CD
million_CD
,_,
Research_NN
and_PHC
development_NOMZ
,_,
2_CD
million_CD
,_,
and_ANDC
Selling_GER
,_,
general_JJ
and_CC
administration_NOMZ
,_,
13_CD
million_CD
._.
16_CD
Goodwill_NN
2005_CD
2004_CD
m_NN
m_NN
Cost_NN
at_PIN
1st_CD
January_NN
304_CD
294_CD
Exchange_NN
adjustments_NOMZ
10_CD
11_CD
Additions_NOMZ
through_PIN
business_NOMZ
combinations_NOMZ
383_CD
Disposals_NN
1_CD
Assets_NN
written_VBN [PUBV] [WZPAST]
off_PIN
1_CD
Cost_NN
at_PIN
31st_CD
December_NN
696_CD
304_CD
Net_JJ
book_NN
value_NN
at_PIN
1st_CD
January_NN
304_CD
294_CD
Net_JJ
book_NN
value_NN
at_PIN
31st_CD
December_NN
696_CD
304_CD
The_DT
additions_NOMZ
for_PIN
the_DT
year_NN
comprise_VPRT
357_CD
million_CD
on_PIN
the_DT
acquisition_NOMZ
of_PIN
ID_NN
Biomedical_NN
Corporation_NOMZ
and_CC
26_CD
million_CD
on_PIN
the_DT
acquisition_NOMZ
of_PIN
Corixa_NN
Corporation_NOMZ
._.
See_VB [PRIV]
Note_VB [PRIV]
34_CD
for_PIN
further_JJ
details_NN
._.
Goodwill_NN
is_VPRT [PASS]
not_XX0
amortised_VBN
but_CC
is_VPRT [PASS]
tested_VBN
for_PIN
impairment_NOMZ
at_PIN
least_JJ
annually_RB
._.
Value_NN
in_PIN
use_NN
calculations_NOMZ
are_VPRT [SPAU] [PASS]
generally_RB
utilised_VBN
to_TO
calculate_VB [PRIV]
recoverable_JJ
amount_NN
._.
Value_NN
in_PIN
use_NN
is_VPRT [PASS]
calculated_VBN [PRIV]
as_IN
the_DT
net_JJ
present_JJ
value_NN
of_PIN
the_DT
projected_VBN
risk-adjusted_JJ
,_,
post-tax_JJ
cash_NN
flows_NN
of_PIN
the_DT
cash_NN
generating_VBG [WZPRES]
unit_NN
in_PIN
which_WDT [PIRE]
the_DT
goodwill_NN
is_VPRT [PASS]
contained_VBN
,_,
applying_VBG [PRESP]
a_DT
discount_NN
rate_NN
of_PIN
the_DT
Group_NN
post-tax_NN
weighted_VBN
average_JJ
cost_NN
of_PIN
capital_NN
of_PIN
8_CD
%_NN
,_,
adjusted_VBN
where_RB
appropriate_JJ
for_PIN
country_NN
specific_JJ
risks_NN
._.
GSK_NN
Annual_JJ
Report_NN
2005_CD
102_CD
FINANCIAL_NN
STATEMENTS_NOMZ
Notes_NN
to_PIN
the_DT
financial_JJ
statements_NOMZ
continued_VBD
Computer_NN
Licences_NN
,_,
17_CD
Other_JJ
intangible_JJ
assets_NN
software_NN
patents_NN
,_,
etc._FW
._.
Brands_NN
Total_NN
m_FW
m_FW
m_FW
m_FW
Cost_NN
at_PIN
1st_CD
January_NN
2004_CD
541_CD
1,059_CD
1,169_CD
2,769_CD
Exchange_NN
adjustments_NOMZ
6_CD
39_CD
25_CD
70_CD
Additions_NOMZ
77 449 526_CD
Disposals_NN
9_CD
1_CD
1_CD
11_CD
Assets_NN
written_VBN [PUBV] [WZPAST]
off_PIN
5_CD
19_CD
24_CD
Reclassications_NOMZ
from_PIN
property_NN
,_,
plant_NN
and_PHC
equipment_NOMZ
11_CD
11_CD
Cost_NN
at_PIN
31st_CD
December2004_JJ
609_CD
1,449_CD
1,143_CD
3,201_CD
Exchange_NN
adjustments_NOMZ
13_CD
72_CD
41_CD
126_CD
Additions_NOMZ
62 207 269_CD
Additions_NOMZ
through_PIN
business_NOMZ
combinations_NOMZ
816_CD
816_CD
Disposals_NN
1_CD
29_CD
28_CD
Assets_NN
written_VBN [PUBV] [WZPAST]
off_PIN
10_CD
43_CD
53_CD
Reclassications_NOMZ
from_PIN
property_NN
,_,
plant_NN
and_PHC
equipment_NOMZ
10_CD
10_CD
Cost_NN
at_PIN
31st_CD
December_NN
2005_CD
685_CD
2,472_CD
1,184_CD
4,341_CD
Amortisation_NOMZ
at_PIN
1st_CD
January_NN
2004 234 202 436_CD
Exchange_NN
adjustments_NOMZ
3_CD
11_CD
14_CD
Provision_NN
for_PIN
the_DT
year_NN
93_CD
75_CD
168_CD
Disposals_NN
9_CD
9_CD
Assets_NN
written_VBN [PUBV] [WZPAST]
off_PIN
41_CD
5_CD
Reclassications_NOMZ
from_PIN
property_NN
,_,
plant_NN
and_PHC
equipment_NOMZ
3_CD
3_CD
Amortisation_NOMZ
at_PIN
31st_CD
December_NN
2004 314 265 579_CD
Exchange_NN
adjustments_NOMZ
6_CD
21_CD
27_CD
Provision_NN
for_PIN
the_DT
year_NN
85 109 194_CD
Disposals_NN
5_CD
5_CD
Assets_NN
written_VBN [PUBV] [WZPAST]
off_PIN
75_CD
12_CD
Reclassications_NOMZ
from_PIN
property_NN
,_,
plant_NN
and_PHC
equipment_NOMZ
1_CD
1_CD
Amortisation_NOMZ
at_PIN
31st_CD
December_NN
2005 399 385 784_CD
Impairment_NOMZ
at_PIN
1st_CD
January_NN
2004_CD
22_CD
58_CD
23_CD
103_CD
Exchange_NN
adjustments_NOMZ
1_CD
1_CD
2_CD
Impairment_NOMZ
losses_NN
1_CD
8_CD
9_CD
Disposals_NN
1_CD
1_CD
Impairment_NOMZ
at_PIN
31st_CD
December_NN
2004_CD
23_CD
65_CD
21_CD
109_CD
Exchange_NN
adjustments_NOMZ
2_CD
2_CD
4_CD
Impairment_NOMZ
losses_NN
1_CD
60_CD
1_CD
62_CD
Assets_NN
written_VBN [PUBV] [WZPAST]
off_PIN
1_CD
1_CD
Impairment_NOMZ
at_PIN
31st_CD
December_NN
2005_CD
23_CD
127_CD
24_CD
174_CD
Total_JJ
amortisation_NOMZ
and_PHC
impairment_NOMZ
at_PIN
31st_CD
December_NN
2004 337 330_CD
21_CD
688_CD
Total_JJ
amortisation_NOMZ
and_PHC
impairment_NOMZ
at_PIN
31st_CD
December_NN
2005 422 512_CD
24_CD
958_CD
Net_JJ
book_NN
value_NN
at_PIN
1st_CD
January_NN
2004 285 799_CD
1,146_CD
2,230_CD
Net_JJ
book_NN
value_NN
at_PIN
31st_CD
December_NN
2004_CD
272_CD
1,119_CD
1,122_CD
2,513_CD
Net_JJ
book_NN
value_NN
at_PIN
31st_CD
December_NN
2005_CD
263_CD
1,960_CD
1,160_CD
3,383_CD
GSK_NN
Annual_JJ
Report_NN
2005_CD
103_CD
FINANCIAL_NN
STATEMENTS_NOMZ
Notes_NN
to_PIN
the_DT
financial_JJ
statements_NOMZ
continued_VBD
17_CD
Other_JJ
intangible_JJ
assets_NN
continued_VBD
Amortisation_NOMZ
and_PHC
impairment_NOMZ
has_VPRT [PEAS]
been_VBN [PASS]
charged_VBN
through_PIN
Research_NN
and_PHC
development_NOMZ
,_,
and_ANDC
Selling_GER
,_,
general_JJ
and_CC
administration_NOMZ
._.
At_PIN
31st_CD
December_NN
2005_CD
,_,
the_DT
net_JJ
book_NN
value_NN
of_PIN
computer_NN
software_NN
included_VBD
24_CD
million_CD
that_DEMP
had_VBD [PEAS]
been_VBN [SPAU] [PASS]
internally_RB
generated_VBN
._.
The_DT
additions_NOMZ
through_PIN
business_NOMZ
combinations_NOMZ
in_PIN
the_DT
year_NN
of_PIN
816_CD
million_CD
comprise_VPRT
701_CD
million_CD
from_PIN
the_DT
acquisition_NOMZ
of_PIN
ID_NN
Biomedical_NN
Corporation_NOMZ
and_CC
115_CD
million_CD
from_PIN
the_DT
acquisition_NOMZ
of_PIN
Corixa_NN
Corporation_NOMZ
see_VPRT [PRIV]
Note_NN
34_CD
._.
Other_JJ
additions_NOMZ
to_PIN
licences_NN
and_PHC
patents_NN
in_PIN
the_DT
year_NN
relate_VPRT
to_PIN
the_DT
purchase_NN
of_PIN
development_NOMZ
and_PHC
commercialisation_NOMZ
rights_NN
for_PIN
Botox_NN
in_PIN
certain_JJ
territories_NN
acquired_VBN [WZPAST]
from_PIN
Allergan_NN
and_CC
various_JJ
other_JJ
compounds_NN
rights_NN
see_VPRT [PRIV]
Note_NN
35_CD
._.
Brands_NN
comprise_VPRT
a_DT
portfolio_NN
of_PIN
products_NN
acquired_VBN [WZPAST]
with_PIN
the_DT
acquisitions_NOMZ
of_PIN
Sterling_GER
Winthrop_NN
Inc._NN
in_PIN
1994_CD
,_,
and_ANDC
The_DT
Block_NN
Drug_NN
Company_NN
in_PIN
2001_CD
._.
The_DT
net_JJ
book_NN
values_NN
of_PIN
the_DT
major_JJ
brands_NN
are_VPRT
as_IN
follows_VPRT
:_:
2005_CD
2004_CD
m_NN
m_NN
Panadol_NN
340_CD
322_CD
Sensodyne_NN
230_CD
226_CD
Polident_NN
97_CD
96_CD
Corega_NN
87_CD
85_CD
Poligrip_NN
60_CD
59_CD
Solpadeine_NN
56_CD
57_CD
Others_NN
290_CD
277_CD
1,160_CD
1,122_CD
Each_QUAN
of_PIN
these_DEMO
brands_NN
is_VPRT [PASS]
considered_VBN [PRIV]
to_TO
have_VB
an_DT
indefinite_JJ
life_NN
,_,
given_VBN
the_DT
strength_NN
and_PHC
durability_NOMZ
of_PIN
the_DT
brand_NN
and_CC
the_DT
level_NN
of_PIN
marketing_GER
support_NN
._.
The_DT
brands_NN
are_VPRT [BEMA]
in_PIN
relatively_RB
stable_JJ
and_PHC
profitable_JJ
market_NN
sectors_NN
,_,
and_ANDC
their_TPP3
size_NN
,_,
diversication_NOMZ
and_PHC
market_NN
shares_NN
mean_VPRT [PRIV]
that_THVC
the_DT
risk_NN
of_PIN
marketrelated_JJ
factors_NN
causing_VBG [WZPRES]
a_DT
shortening_VBG
of_PIN
the_DT
brands_NN
lives_NN
is_VPRT [PASS]
considered_VBN [PRIV]
to_TO
be_VB [BEMA]
relatively_RB
low_PRED
._.
The_DT
Group_NN
is_VPRT [BEMA]
not_XX0
aware_PRED
of_PIN
any_QUAN
material_JJ
legal_JJ
,_,
regulatory_JJ
,_,
contractual_JJ
,_,
competitive_JJ
,_,
economic_JJ
or_CC
other_JJ
factor_NN
which_WDT [WHSUB]
could_POMD
limit_VB
their_TPP3
useful_JJ
lives_NN
._.
Accordingly_RB
,_,
they_TPP3
are_VPRT [PASS]
not_XX0
amortised_VBN
._.
Each_QUAN
brand_NN
is_VPRT [PASS]
tested_VBN
annually_RB
for_PIN
impairment_NOMZ
applying_VBG [WZPRES]
a_DT
fair_JJ
value_NN
less_RB
costs_NN
to_TO
sell_VB
methodology_NN
and_CC
using_VBG
five_CD
year_NN
post-tax_JJ
cash_NN
ow_NN
forecasts_NN
with_PIN
a_DT
terminal_NN
value_NN
calculation_NOMZ
and_CC
applying_VBG
a_DT
discount_NN
rate_NN
of_PIN
the_DT
Group_NN
post-tax_NN
weighted_VBN
average_JJ
cost_NN
of_PIN
capital_NN
of_PIN
8_CD
%_NN
,_,
adjusted_VBN
where_RB
appropriate_JJ
for_PIN
country-specic_JJ
risks_NN
._.
This_DEMP
approximates_VPRT
to_TO
applying_VBG
a_DT
pre-tax_JJ
discount_NN
rate_NN
to_PIN
pre-tax_JJ
cash_NN
ows_NN
._.
The_DT
main_JJ
assumptions_NOMZ
include_VPRT
future_JJ
sales_NN
prices_NN
and_PHC
volumes_NN
,_,
product_NN
contribution_NOMZ
and_CC
the_DT
future_JJ
development_NOMZ
expenditure_NN
required_VBN [SUAV]
to_TO
maintain_VB [PUBV]
the_DT
products_NN
marketability_NOMZ
and_PHC
registration_NOMZ
in_PIN
the_DT
relevant_JJ
jurisdiction_NOMZ
and_CC
the_DT
products_NN
life_NN
._.
These_DEMO
assumptions_NOMZ
are_VPRT [PASS]
reviewed_VBN
as_IN
part_NN
of_PIN
managements_NOMZ
budgeting_GER
and_CC
strategic_JJ
planning_GER
cycle_NN
for_PIN
changes_NN
in_PIN
market_NN
conditions_NOMZ
and_PHC
product_NN
erosion_NN
,_,
through_PIN
generic_JJ
competition_NOMZ
._.
18_CD
Investments_NOMZ
in_PIN
associates_NN
and_CC
joint_JJ
ventures_NN
Joint_NN
Associated_NN
2005_CD
2004_CD
ventures_NN
undertakings_GER
Total_JJ
Total_JJ
m_NN
m_FW
m_FW
m_FW [BEMA]
At_PIN
1st_CD
January_NN
14 195 209 210_CD
Implementation_NOMZ
of_PIN
accounting_GER
for_PIN
financial_JJ
instruments_NOMZ
under_IN
IAS_NN
39_CD
7_CD
7_CD
At_PIN
1st_CD
January_NN
,_,
as_IN
adjusted_VBN
14 188 202 210_CD
Exchange_NN
adjustments_NOMZ
1_CD
25_CD
26_CD
14_CD
Additions_NOMZ
2_CD
2_CD
2_CD
Transfers_NN
1_CD
Disposals_NN
36_CD
Retained_VBN
profit_NN
for_PIN
the_DT
year_NN
1_CD
47_CD
46_CD
48_CD
At_PIN
31st_CD
December_NN
14 262 276 209_CD
The_DT
principal_NN
associated_VBN
undertaking_GER
is_VPRT
Quest_NN
Diagnostics_NN
Inc._NN
a_DT
US_FPP1
clinical_JJ
laboratory_NN
business_NOMZ
listed_VBN [WZPAST]
on_PIN
the_DT
New_NN
York_NN
Stock_NN
Exchange_NN
._.
The_DT
investment_NOMZ
had_VBD
a_DT
book_NN
value_NN
at_PIN
31st_CD
December_NN
2005_CD
of_PIN
244_CD
million_CD
2004_CD
173_CD
million_CD
and_CC
a_DT
market_NN
value_NN
of_PIN
1,093_CD
million_CD
2004_CD
908_CD
million_CD
._.
Although_CONC
the_DT
Group_NN
holds_VPRT [PRIV]
less_JJ
than_PIN
20_CD
%_NN
of_PIN
the_DT
ownership_NN
interest_NN
and_PHC
voting_NN
control_NN
in_PIN
Quest_NN
,_,
the_DT
Group_NN
has_VPRT
the_DT
ability_NOMZ
to_TO
exercise_VB
significant_JJ
inuence_NN
through_PIN
its_PIT
active_JJ
participation_NOMZ
on_PIN
the_DT
Quest_NN
Board_NN
of_PIN
Directors_NN
and_PHC
Board_NN
sub-committees_NN
._.
GSK_NN
Annual_JJ
Report_NN
2005_CD
104_CD
FINANCIAL_NN
STATEMENTS_NOMZ
Notes_NN
to_PIN
the_DT
financial_JJ
statements_NOMZ
continued_VBD
18_CD
Investments_NOMZ
in_PIN
associates_NN
and_CC
joint_JJ
ventures_NN
continued_VBD
Summarised_JJ
balance_NN
sheet_NN
information_NOMZ
in_PIN
respect_NN
of_PIN
the_DT
Groups_NN
associates_NN
is_VPRT [PASS]
set_VBN
out_PIN
below_PLACE
:_:
2005_CD
2004_CD
m_NN
m_NN [BEMA]
Total_JJ
assets_NN
3,134_CD
2,233_CD
Total_JJ
liabilities_NOMZ
1,481_CD
999_CD
Net_JJ
assets_NN
1,653_CD
1,234_CD
Groups_NN
share_NN
of_PIN
associates_NN
net_JJ
assets_NN
262_CD
195_CD
Investments_NOMZ
in_PIN
joint_JJ
ventures_NN
comprise_VPRT
17_CD
million_CD
share_NN
of_PIN
gross_JJ
assets_NN
2004_CD
16_CD
million_CD
and_CC
3_CD
million_CD
share_NN
of_PIN
gross_JJ
liabilities_NOMZ
2004_CD
2_CD
million_CD
._.
These_DEMO
principally_RB
arise_VB
from_PIN
50_CD
%_NN
interests_NN
in_PIN
two_CD
joint_JJ
ventures_NN
,_,
Holdings_GER
,_,
L._NN
P._NN
which_WDT [WHSUB]
is_VPRT
developing_VBG
specified_VBN
chemical_NN
compounds_NN
,_,
and_ANDC
GlaxoSmithKline_NN
Shire_NN
BioChem_NN
,_,
which_WDT [SERE]
primarily_RB
co-markets_VPRT
Combivir_NN
,_,
Trizivir_NN
and_PHC
Epivir_NN
in_PIN
certain_JJ
territories_NN
._.
2005_CD
2004_CD
19_CD
Other_JJ
investments_NOMZ
Total_JJ
Total_JJ
m_NN
m_NN [BEMA]
At_PIN
1st_CD
January_NN
298_CD
262_CD
Implementation_NOMZ
of_PIN
accounting_GER
for_PIN
financial_JJ
instruments_NOMZ
under_IN
IAS_NN
39_CD
61_CD
At_PIN
1st_CD
January_NN
as_IN
adjusted_JJ
359_CD
262_CD
Exchange_NN
adjustments_NOMZ
33_CD
11_CD
Additions_NOMZ
23_CD
103_CD
Fair_NN
value_NN
movements_NOMZ
14_CD
Impairments_NOMZ
35_CD
25_CD
Transfers_NN
12_CD
1_CD
Disposals_NN
20_CD
32_CD
At_PIN
31st_CD
December_NN
362_CD
298_CD
Other_JJ
investments_NOMZ
comprise_VPRT
non-current_JJ
equity_NOMZ
investments_NOMZ
which_WDT [WHSUB]
are_VPRT [BEMA]
available-for-sale_JJ
investments_NOMZ
that_TSUB
are_VPRT [PASS]
recorded_VBN
at_PIN
fair_JJ
value_NN
at_PIN
each_QUAN
balance_NN
sheet_NN
date_NN
._.
For_PIN
investments_NOMZ
traded_VBN [WZPAST]
in_PIN
an_DT
active_JJ
market_NN
,_,
the_DT
fair_JJ
value_NN
is_VPRT [BYPA]
determined_VBN [SUAV] [PRIV]
by_PIN
reference_NN
to_PIN
the_DT
relevant_JJ
stock_NN
exchange_NN
quoted_VBN
bid_NN
price_NN
._.
For_PIN
other_JJ
investments_NOMZ
,_,
the_DT
fair_JJ
value_NN
is_VPRT [BYPA]
estimated_VBN [PRIV]
by_PIN
reference_NN
to_PIN
the_DT
current_JJ
market_NN
value_NN
of_PIN
similar_JJ
instruments_NOMZ
or_CC
by_PIN
reference_NN
to_PIN
the_DT
discounted_JJ
cash_NN
ows_NN
of_PIN
the_DT
underlying_VBG
net_JJ
assets_NN
._.
The_DT
Group_NN
holds_VPRT [PRIV]
a_DT
number_NN
of_PIN
equity_NOMZ
investments_NOMZ
,_,
frequently_RB
in_PIN
entities_NOMZ
where_RB
the_DT
Group_NN
has_VPRT [PEAS]
entered_VBN
into_PIN
research_NN
collaborations_NOMZ
._.
Equity_NOMZ
investments_NOMZ
are_VPRT [PASS]
recorded_VBN
as_IN
non-current_JJ
assets_NN
unless_COND
they_TPP3
are_VPRT [PASS]
expected_VBN [PRIV]
to_TO
be_VB [PASS]
sold_VBN
within_PIN
one_CD
year_NN
,_,
in_PIN
which_WDT [PIRE]
case_NN
they_TPP3
are_VPRT [PASS]
recorded_VBN
as_IN
current_JJ
assets_NN
._.
Non-current_JJ
equity_NOMZ
investments_NOMZ
include_VPRT
listed_VBN
investments_NOMZ
of_PIN
268_CD
million_CD
2004_CD
270_CD
million_CD
that_DEMP
offer_VPRT
the_DT
Group_NN
the_DT
opportunity_NOMZ
for_PIN
return_NN
through_PIN
dividend_NN
income_NN
and_CC
fair_JJ
value_NN
gains_NN
._.
On_PIN
disposal_NN
investments_NOMZ
fair_JJ
value_NN
movements_NOMZ
are_VPRT [PASS]
reclassied_VBN
from_PIN
reserves_NN
to_PIN
the_DT
income_NN
statement_NOMZ
based_VBN [WZPAST]
on_PIN
average_JJ
cost_NN
._.
The_DT
impairment_NOMZ
losses_NN
recorded_VBN [WZPAST]
in_PIN
the_DT
tables_NN
above_PLACE
have_VPRT [PEAS]
been_VBN [PASS]
recognized_VBN [PRIV]
in_PIN
the_DT
income_NN
statement_NOMZ
for_PIN
the_DT
year_NN
within_PIN
other_JJ
operating_GER
income_NN
,_,
together_RB
with_PIN
amounts_NN
recycled_VBN [WZPAST]
from_PIN
the_DT
fair_JJ
value_NN
reserve_NN
Note_VB [PRIV]
32_CD
on_PIN
recognition_NOMZ
of_PIN
the_DT
impairments_NOMZ
._.
These_DEMO
impairments_NOMZ
initially_TIME
result_VPRT
from_PIN
prolonged_VBN
or_CC
significant_JJ
declines_NN
in_PIN
the_DT
fair_JJ
value_NN
of_PIN
the_DT
equity_NOMZ
investments_NOMZ
below_PLACE
acquisition_NOMZ
cost_NN
,_,
subsequent_JJ
to_PIN
which_WDT [PIRE]
any_QUAN
further_JJ
declines_NN
in_PIN
fair_JJ
value_NN
are_VPRT [SPAU] [PASS]
immediately_TIME
taken_VBN
to_PIN
the_DT
income_NN
statement_NOMZ
._.
20_CD
Other_JJ
non-current_JJ
assets_NN
Other_JJ
non-current_JJ
assets_NN
comprise_VPRT
of_PIN
sundry_JJ
receivables_NN
which_WDT [WHSUB]
are_VPRT [BEMA]
due_PRED
in_PIN
more_EMPH
than_PIN
one_CD
year_NN
,_,
including_VBG
insurance_NN
recovery_NN
receivables_NN
which_WDT [WHSUB]
have_VPRT [PEAS]
been_VBN [PASS]
discounted_VBN
using_VBG
risk-free_JJ
rates_NN
of_PIN
return_NN
and_CC
derivative_JJ
financial_JJ
instruments_NOMZ
._.
21_CD
Inventories_NN
2005_CD
2004_CD
m_NN
m_NN
Raw_NN
materials_NN
and_PHC
consumables_NN
721_CD
629_CD
Work_NN
in_PIN
progress_NN
552_CD
644_CD
Finished_VBN
goods_NN
904_CD
920_CD
2,177_CD
2,193_CD
GSK_NN
Annual_JJ
Report_NN
2005_CD
105_CD
FINANCIAL_NN
STATEMENTS_NOMZ
Notes_NN
to_PIN
the_DT
financial_JJ
statements_NOMZ
continued_VBD
22_CD
Trade_NN
and_CC
other_JJ
receivables_NN
2005_CD
2004_CD
m_NN
m_NN
Trade_NN
receivables_NN
4,411_CD
3,786_CD
Prepaid_JJ
pension_NN
contributions_NOMZ
1_CD
9_CD
Other_JJ
prepayments_NOMZ
and_CC
accrued_VBN
income_NN
285_CD
226_CD
Interest_NN
receivable_NN
42_CD
56_CD
Employee_NN
loans_NN
and_PHC
advances_NN
59_CD
49_CD
Derivative_JJ
financial_JJ
instruments_NOMZ
180_CD
5_CD
Other_JJ
receivables_NN
370_CD
320_CD
5,348_CD
4,451_CD
Trade_NN
receivables_NN
include_VPRT
2_CD
million_CD
2004_CD
7_CD
million_CD
due_JJ
from_PIN
associates_NN
and_CC
joint_JJ
ventures_NN
,_,
and_ANDC
are_VPRT [PASS]
shown_VBN [PRIV]
after_IN
deducting_VBG
provisions_NN
for_PIN
bad_JJ
and_PHC
doubtful_JJ
debts_NN
of_PIN
140_CD
million_CD
2004_CD
128_CD
million_CD
._.
23_CD
Cash_NN
and_PHC
cash_NN
equivalents_NN
2005_CD
2004_CD
m_NN
m_NN
Cash_NN
at_PIN
bank_NN
and_CC
in_PIN
hand_NN
686_CD
408_CD
Short-term_JJ
deposits_NN
1,677_CD
884_CD
Commercial_JJ
paper_NN
1,846_CD
1,175_CD
4,209_CD
2,467_CD
Cash_NN
and_PHC
cash_NN
equivalents_NN
include_VPRT
highly_AMP
liquid_JJ
investments_NOMZ
with_PIN
maturities_NOMZ
of_PIN
three_CD
months_NN
or_CC
less_JJ
._.
24_CD
Assets_NN
held_VBN [PRIV] [WZPAST]
for_PIN
sale_NN
2005_CD
2004_CD
m_NN
m_NN
Land_NN
and_PHC
buildings_GER
1_CD
2_CD
Plant_NN
,_,
equipment_NOMZ
and_PHC
vehicles_NN
1_CD
2_CD
2_CD
25_CD
Trade_NN
and_CC
other_JJ
payables_NN
2005_CD
2004_CD
m_NN
m_NN
Trade_NN
payables_NN
819_CD
707_CD
Wages_NN
and_PHC
salaries_NN
804_CD
639_CD
Social_NN
security_NOMZ
102_CD
114_CD
Other_JJ
payables_NN
240_CD
269_CD
Deferred_JJ
income_NN
34_CD
27_CD
Customer_NN
return_NN
and_PHC
rebate_NN
accruals_NN
1,187_CD
982_CD
Other_JJ
accruals_NN
1,784_CD
1,451_CD
Derivative_JJ
financial_JJ
instruments_NOMZ
171_CD
72_CD
Dividends_NN
payable_JJ
6_CD
6_CD
5,147_CD
4,267_CD
Customer_NN
return_NN
and_PHC
rebate_NN
accruals_NN
are_VPRT [PASS]
provided_VBN
for_PIN
by_PIN
the_DT
Group_NN
at_PIN
the_DT
point_NN
of_PIN
sale_NN
in_PIN
respect_NN
of_PIN
the_DT
estimated_JJ
rebates_NN
,_,
discounts_NN
or_CC
allowances_NN
payable_JJ
to_PIN
customers_NN
,_,
principally_RB
in_PIN
the_DT
USA_NN
._.
Provisions_NN
are_VPRT [PASS]
made_VBN
at_PIN
the_DT
time_NN
of_PIN
sale_NN
but_CC
the_DT
actual_JJ
amounts_NN
paid_VBN [WZPAST]
are_VPRT [PASS]
based_VBN
on_PIN
claims_NN
made_VBD
some_QUAN
time_NN
after_IN
the_DT
initial_JJ
recognition_NOMZ
of_PIN
the_DT
sale_NN
._.
Because_CAUS
the_DT
amounts_NN
are_VPRT [PASS]
estimated_VBN [PRIV] [THATD]
they_TPP3
may_POMD
not_XX0
fully_AMP
reect_VB
the_DT
final_JJ
outcome_NN
and_CC
the_DT
amounts_NN
are_VPRT [BEMA]
subject_PRED
to_TO
change_VB
dependent_JJ
upon_PIN [STPR]
,_,
amongst_PIN
other_JJ
things_NN
,_,
the_DT
types_NN
of_PIN
buying_VBG
group_NN
and_PHC
product_NN
sales_NN
mix_NN
._.
The_DT
level_NN
of_PIN
provision_NN
is_VPRT [PASS]
reviewed_VBN
and_PHC
adjusted_VBN
quarterly_JJ
in_PIN
the_DT
light_NN
of_PIN
historical_JJ
experience_NN
of_PIN
actual_JJ
rebates_NN
,_,
discounts_NN
or_CC
allowances_NN
given_VBN
and_CC
returns_NN
made_VBN
and_CC
any_QUAN
changes_NN
in_PIN
arrangements_NOMZ
._.
Future_JJ
events_NN
could_POMD
cause_VB
the_DT
assumptions_NOMZ
on_PIN
which_WDT [PIRE]
the_DT
provisions_NN
are_VPRT [PASS]
based_VBN
to_TO
change_VB
,_,
which_WDT [SERE]
could_POMD
affect_VB
the_DT
future_JJ
results_NN
of_PIN
the_DT
Group_NN
._.
GSK_NN
Annual_JJ
Report_NN
2005_CD
106_CD
FINANCIAL_NN
STATEMENTS_NOMZ
Notes_NN
to_PIN
the_DT
financial_JJ
statements_NOMZ
continued_VBD
26_CD
Pensions_NN
and_CC
other_JJ
post-employment_NOMZ
benets_NN
2005 2004 2003_CD
Pension_NN
and_CC
other_JJ
post-employment_NOMZ
costs_NN
m_VPRT
m_FW
m_FW
UK_NN
pension_NN
schemes_NN
124 119 163_CD
US_FPP1
pension_NN
schemes_NN
41_CD
44_CD
83_CD
Other_JJ
overseas_PLACE
pensions_NN
schemes_NN
83_CD
74_CD
61_CD
Unfunded_JJ
post-retirement_NOMZ
healthcare_NN
schemes_NN
100_CD
92_CD
90_CD
Other_JJ
post-employment_NOMZ
costs_NN
2_CD
18 24 350 347_CD
421_CD
Analysed_VBN
as_IN
:_:
Funded_VBN
dened_VBN
benefit_NN
hybrid_NN
schemes_NN
198 192 263_CD
Unfunded_JJ
dened_VBN
benefit_NN
schemes_NN
25_CD
22_CD
19_CD
Dened_VBN
contribution_NOMZ
schemes_NN
25_CD
23_CD
25_CD
Unfunded_JJ
post-retirement_NOMZ
healthcare_NN
schemes_NN
100_CD
92_CD
90_CD
Other_JJ
post-employment_NOMZ
costs_NN
2_CD
18 24 350 347_CD
421_CD
The_DT
costs_NN
of_PIN
the_DT
dened_VBN
benefit_NN
pension_NN
and_CC
post-retirement_JJ
healthcare_NN
schemes_NN
are_VPRT [PASS]
charged_VBN
in_PIN
the_DT
income_NN
statement_NOMZ
as_IN
follows_VPRT
:_:
Cost_NN
of_PIN
sales_NN
71_CD
68_CD
84_CD
Selling_GER
,_,
general_JJ
and_CC
administration_NOMZ
75_CD
72_CD
101_CD
Research_NN
and_PHC
development_NOMZ
177 166 187 323_CD
306_CD
372_CD
GSK_NN
entities_NOMZ
operate_VPRT
pension_NN
arrangements_NOMZ
which_WDT [WHSUB]
cover_VPRT
the_DT
Groups_NN
material_NN
obligations_NOMZ
to_TO
provide_VB
pensions_NN
to_PIN
retired_JJ
employees_NN
._.
These_DEMO
arrangements_NOMZ
have_VPRT [PEAS]
been_VBN [PASS]
developed_VBN
in_PIN
accordance_NN
with_PIN
local_JJ
practices_NN
in_PIN
the_DT
countries_NN
concerned_VBN
._.
Pension_NN
benets_NN
can_POMD
be_VB [BYPA]
provided_VBN
by_PIN
state_NN
schemes_NN
:_:
by_PIN
dened_VBN
contribution_NOMZ
schemes_NN
,_,
whereby_OSUB
retirement_NOMZ
benets_NN
are_VPRT [BYPA]
determined_VBN [SUAV] [PRIV]
by_PIN
the_DT
value_NN
of_PIN
funds_NN
arising_VBG [WZPRES]
from_PIN
contributions_NOMZ
paid_VBN [WZPAST]
in_PIN
respect_NN
of_PIN
each_QUAN
employee_NN
,_,
or_CC
by_PIN
dened_JJ
benefit_NN
schemes_NN
,_,
whereby_OSUB
retirement_NOMZ
benets_NN
are_VPRT [PASS]
based_VBN
on_PIN
employee_NN
pensionable_JJ
remuneration_NOMZ
and_PHC
length_NN
of_PIN
service_NN
._.
Some_QUAN
hybrid_JJ
dened_VBN
benefit_NN
schemes_NN
also_RB
include_VPRT
dened_VBN
contribution_NOMZ
sections_NOMZ
._.
Contributions_NOMZ
to_PIN
dened_JJ
benefit_NN
schemes_NN
are_VPRT [PASS]
determined_VBN [SUAV] [PRIV]
in_PIN
accordance_NN
with_PIN
the_DT
advice_NN
of_PIN
independent_JJ
,_,
professionally_RB
qualied_VBD
actuaries_NN
._.
Pension_NN
costs_NN
of_PIN
dened_VBN
benefit_NN
schemes_NN
for_PIN
accounting_GER
purposes_NN
have_VPRT [PEAS]
been_VBN [PASS]
assessed_VBN
in_PIN
accordance_NN
with_PIN
independent_JJ
actuarial_JJ
advice_NN
,_,
using_VBG [PRESP]
the_DT
projected_VBN
unit_NN
method_NN
._.
In_PIN
certain_JJ
countries_NN
pension_NN
benets_NN
are_VPRT [PASS]
provided_VBN
on_PIN
an_DT
unfunded_JJ
basis_NN
,_,
some_QUAN
administered_VBN
by_PIN
trustee_NN
companies_NN
._.
Liabilities_NOMZ
are_VPRT [SPAU] [PASS]
generally_RB
assessed_VBN
annually_RB
in_PIN
accordance_NN
with_PIN
the_DT
advice_NN
of_PIN
independent_JJ
actuaries_NN
._.
Formal_JJ
,_,
independent_JJ
,_,
actuarial_JJ
valuations_NOMZ
of_PIN
the_DT
Groups_NN
main_JJ
plans_NN
are_VPRT [PASS]
undertaken_VBN
regularly_RB
,_,
normally_RB
at_PIN
least_JJ
every_QUAN
three_CD
years_NN
._.
The_DT
assets_NN
of_PIN
funded_JJ
schemes_NN
are_VPRT [SPAU] [PASS]
generally_RB
held_VBN [PRIV]
in_PIN
separately_RB
administered_VBN
trusts_NN
or_CC
are_VPRT [PASS]
insured_VBN [PRIV]
._.
Assets_NN
are_VPRT [PASS]
invested_VBN
in_PIN
different_JJ
classes_NN
in_PIN
order_NN
to_TO
maintain_VB [PUBV]
a_DT
balance_NN
between_PIN
risk_NN
and_PHC
return_NN
._.
Investments_NOMZ
are_VPRT [PASS]
diversied_VBN
to_TO
limit_VB
the_DT
financial_JJ
effect_NN
of_PIN
the_DT
failure_NN
of_PIN
any_QUAN
individual_JJ
investment_NOMZ
._.
During_PIN
2005_CD
,_,
the_DT
target_NN
asset_NN
allocations_NOMZ
for_PIN
the_DT
UK_NN
schemes_NN
were_VBD [BEMA]
65_CD
%_NN
equities_NOMZ
and_CC
35_CD
%_NN
bonds_NN
and_CC
for_PIN
the_DT
US_FPP1
scheme_NN
were_VBD [BEMA]
77_CD
%_NN
equities_NOMZ
,_,
20_CD
%_NN
bonds_NN
and_CC
3_CD
%_NN
property_NN
._.
The_DT
longer_JJ
term_NN
aim_NN
is_VPRT
to_TO
increase_VB
the_DT
property_NN
element_NOMZ
to_PIN
10_CD
%_NN
with_PIN
a_DT
consequent_JJ
reduction_NOMZ
in_PIN
equities_NOMZ
._.
Actuarial_JJ
movements_NOMZ
in_PIN
the_DT
year_NN
are_VPRT [PASS]
recognized_VBN [PRIV]
in_PIN
full_JJ
through_PIN
the_DT
statement_NOMZ
of_PIN
recognized_VBN [PRIV]
income_NN
and_PHC
expense_NN
._.
The_DT
UK_NN
discount_NN
rate_NN
is_VPRT [PASS]
based_VBN
on_PIN
the_DT
iBoxx_NN
over_IN
15_CD
year_NN
AA_NN
index_NN
and_CC
the_DT
US_FPP1
discount_NN
rate_NN
is_VPRT [PASS]
based_VBN
on_PIN
Moodys_NN
Aa_NN
index_NN
._.
The_DT
expected_VBN [PRIV]
return_NN
on_PIN
bonds_NN
reects_VPRT
the_DT
portfolio_NN
mix_NN
of_PIN
index-linked_JJ
,_,
government_NOMZ
and_CC
corporate_JJ
bonds_NN
._.
An_DT
equity_NOMZ
risk_NN
premium_NN
of_PIN
between_PIN
3_CD
%_NN
and_CC
4_CD
%_NN
is_VPRT [PASS]
added_VBN [PUBV]
to_PIN
this_DEMO
for_PIN
equities_NOMZ
._.
Projected_VBN
ination_NOMZ
rate_NN
and_PHC
pension_NN
increases_NN
are_VPRT [BEMA]
long_JJ
term_NN
predictions_NOMZ
based_VBN [WZPAST]
on_PIN
the_DT
yield_NN
gap_NN
between_PIN
long_JJ
term_NN
indexlinked_VBD
and_PHC
xed_VBD
interest_NN
Gilts_NN
._.
In_PIN
the_DT
UK_NN
,_,
mortality_NOMZ
rates_NN
are_VPRT [PASS]
calculated_VBN [PRIV]
using_VBG
the_DT
PA92_JJ
standard_JJ
mortality_NOMZ
tables_NN
projected_VBN [WZPAST]
to_PIN
2006_CD
._.
Plan_NN
obligations_NOMZ
are_VPRT [SPAU] [BYPA]
then_RB
increased_VBN
by_PIN
between_PIN
3_CD
%_NN
and_CC
10_CD
%_NN
,_,
depending_VBG [PRESP]
on_PIN
each_QUAN
individual_JJ
schemes_NN
mortality_NOMZ
experience_NN
,_,
to_TO
make_VB
allowance_NN
for_PIN
future_JJ
improvements_NOMZ
in_PIN
life_NN
expectancy_NN
._.
In_PIN
the_DT
USA_NN
,_,
mortality_NOMZ
rates_NN
are_VPRT [PASS]
calculated_VBN [PRIV]
using_VBG
the_DT
RP2000_CD
fully_AMP
generational_JJ
table_NN
,_,
projected_VBN
using_VBG
scale_NN
AA_NN
,_,
with_PIN
the_DT
white_JJ
collar_NN
adjustment_NOMZ
._.
This_DEMP
builds_VPRT
in_PIN
a_DT
full_JJ
allowance_NN
for_PIN
future_JJ
improvements_NOMZ
in_PIN
life_NN
expectancy_NN
._.
During_PIN
2005_CD
,_,
the_DT
Group_NN
made_VBD
special_JJ
funding_GER
contributions_NOMZ
to_PIN
the_DT
UK_NN
and_PHC
US_FPP1
pension_NN
schemes_NN
totalling_VBG [WZPRES]
366_CD
million_CD
._.
GSK_NN
has_VPRT [PEAS]
agreed_VBN [SUAV] [PUBV]
with_PIN
the_DT
trustees_NN
of_PIN
the_DT
UK_NN
and_PHC
US_FPP1
dened_VBD
benefit_NN
pension_NN
schemes_NN
that_TOBJ
the_DT
Group_NN
would_PRMD
make_VB
additional_JJ
contributions_NOMZ
of_PIN
approximately_RB
370_CD
million_CD
per_PIN
year_NN
over_IN
a_DT
five-year_JJ
period_NN
ending_VBG [WZPRES]
31st_CD
December_NN
2009_CD
in_PIN
order_NN
to_TO
eliminate_VB
the_DT
deficits_NN
on_PIN
an_DT
IAS_NN
19_CD
basis_NN
,_,
by_PIN
that_DEMO
point_NN
._.
In_PIN
the_DT
UK_NN
the_DT
dened_VBN
benefit_NN
pension_NN
schemes_NN
operated_VBD
for_PIN
the_DT
benefit_NN
of_PIN
former_JJ
Glaxo_NN
Wellcome_NN
employees_NN
and_CC
former_JJ
SmithKline_NN
Beecham_NN
employees_NN
remain_VPRT
separate_JJ
._.
These_DEMO
schemes_NN
were_VBD [PASS]
closed_VBN
to_PIN
new_JJ
entrants_NN
in_PIN
2001_CD
and_CC
subsequent_JJ
UK_NN
employees_NN
are_VPRT [PASS]
entitled_VBN
to_TO
join_VB
a_DT
dened_VBN
contribution_NOMZ
scheme_NN
._.
In_PIN
the_DT
USA_NN
the_DT
former_JJ
Glaxo_NN
Wellcome_NN
and_PHC
SmithKline_NN
Beecham_NN
dened_VBD
benefit_NN
schemes_NN
were_VBD [PASS]
merged_VBN
during_PIN
2001_CD
._.
In_CONJ
addition_NULL
,_,
the_DT
Group_NN
operates_VPRT
a_DT
number_NN
of_PIN
post-retirement_JJ
healthcare_NN
schemes_NN
,_,
the_DT
principal_NN
one_CD
of_PIN
which_WDT [PIRE]
is_VPRT [BEMA]
in_PIN
the_DT
USA_NN
._.
The_DT
following_VBG
information_NOMZ
relates_VPRT
to_PIN
the_DT
Groups_NN
dened_VBD
benefit_NN
pension_NN
and_CC
post-retirement_JJ
healthcare_NN
schemes_NN
._.
GSK_NN
Annual_JJ
Report_NN
2005_CD
107_CD
FINANCIAL_NN
STATEMENTS_NOMZ
Notes_NN
to_PIN
the_DT
financial_JJ
statements_NOMZ
continued_VBD
26_CD
Pensions_NN
and_CC
other_JJ
post-employment_NOMZ
benets_NN
continued_VBD
The_DT
Group_NN
has_VPRT [PEAS]
applied_VBN
the_DT
following_VBG
assumptions_NOMZ
in_PIN
assessing_VBG
the_DT
liabilities_NOMZ
:_:
UK_NN
USA_NN
Rest_VPRT
of_PIN
World_NN
2005 2004 2003 2005_CD
2004 2003 2005 2004_CD
2003_CD
%_NN
pa_CD
%_NN
pa_CD
%_NN
pa_CD
%_NN
pa_CD
%_NN
pa_CD
%_NN
pa_CD
%_NN
pa_CD
%_NN
pa_CD
%_NN
pa_NN
Rate_NN
of_PIN
increase_NN
of_PIN
future_JJ
earnings_GER
4.00_CD
4.00_CD
4.00_CD
5.00_CD
5.00_CD
5.50_CD
3.25_CD
3.25_CD
3.00_CD
Discount_NN
rate_NN
4.75_CD
5.25_CD
5.25_CD
5.50_CD
5.75_CD
6.25_CD
3.75_CD
4.25_CD
4.75_CD
Expected_VBN [PRIV]
pension_NN
increases_NN
2.75_CD
2.50_CD
2.50_CD
n_VBD
a_DT
n_NN
a_DT
n_NN
a_DT
2.00_CD
2.00_CD
2.00_CD
Cash_NN
balance_NN
credit_NN
conversion_NN
rate_NN
n_VBD
a_DT
n_NN
a_DT
n_NN
a_DT
4.50_CD
4.75_CD
5.25_CD
1.75_CD
1.75_CD
1.50_CD
Ination_JJ
rate_NN
2.75_CD
2.50_CD
2.50_CD
2.50_CD
2.50_CD
2.50_CD
1.75_CD
1.75_CD
1.50_CD
The_DT
amounts_NN
recorded_VBN [WZPAST]
in_PIN
the_DT
income_NN
statement_NOMZ
and_PHC
statement_NOMZ
of_PIN
recognized_VBN [PRIV]
income_NN
and_PHC
expense_NN
for_PIN
the_DT
three_CD
years_NN
ended_VBN
31st_CD
December_NN
2005_CD
in_PIN
relation_NOMZ
to_PIN
the_DT
dened_VBN
benefit_NN
pension_NN
and_CC
post-retirement_JJ
healthcare_NN
schemes_NN
were_VBD
as_IN
follows_VPRT
:_:
Post-retirement_NOMZ
Pensions_NN
benets_VPRT
2005_CD
UK_NN
USA_NN
Rest_VPRT
of_PIN
World_NN
Group_NN
Group_NN
m_FW
m_FW
m_FW
m_FW
m_FW [PASS]
Amounts_NN
charged_VBD
to_TO
operating_VBG
profit_NN
Current_JJ
service_NN
cost_NN
117_CD
63_CD
52_CD
232_CD
46_CD
Past_JJ
service_NN
cost_NN
1_CD
Expected_VBN [PRIV]
return_NN
on_PIN
pension_NN
scheme_NN
assets_NN
285_CD
126_CD
28_CD
439_CD
Interest_NN
on_PIN
scheme_NN
liabilities_NOMZ
276_CD
104_CD
34_CD
414_CD
53_CD
Settlements_NOMZ
and_PHC
curtailments_NOMZ
16_CD
16_CD
124_CD
41 58 223 100_CD
Actuarial_JJ
losses_NN
recorded_VBN [WZPAST]
in_PIN
the_DT
statement_NOMZ
of_PIN
recognized_VBN [PRIV]
income_NN
and_PHC
expense_NN
490_CD
109 93 692 102_CD
Post-retirement_NOMZ
Pensions_NN
benets_VPRT
2004_CD
UK_NN
USA_NN
Rest_VPRT
of_PIN
World_NN
Group_NN
Group_NN
m_FW
m_FW
m_FW
m_FW
m_FW [PASS]
Amounts_NN
charged_VBD
to_TO
operating_VBG
profit_NN
Current_JJ
service_NN
cost_NN
117_CD
58_CD
42_CD
217_CD
37_CD
Past_JJ
service_NN
cost_NN
2_CD
2_CD
Expected_VBN [PRIV]
return_NN
on_PIN
pension_NN
scheme_NN
assets_NN
272_CD
118_CD
20_CD
410_CD
Interest_NN
on_PIN
scheme_NN
liabilities_NOMZ
269_CD
104_CD
27_CD
400_CD
55_CD
Settlements_NOMZ
and_PHC
curtailments_NOMZ
5_CD
5_CD
119_CD
44_CD
51_CD
214_CD
92_CD
Actuarial_JJ
gains_NN
losses_NN
recorded_VBN [WZPAST]
in_PIN
the_DT
statement_NOMZ
of_PIN
recognized_VBN [PRIV]
income_NN
and_PHC
expense_NN
162_CD
26_CD
26_CD
162_CD
54_CD
Post-retirement_NOMZ
Pensions_NN
benets_VPRT
2003_CD
UK_NN
USA_NN
Rest_VPRT
of_PIN
World_NN
Group_NN
Group_NN
m_FW
m_FW
m_FW
m_FW
m_FW [PASS]
Amounts_NN
charged_VBD
to_TO
operating_VBG
profit_NN
Current_JJ
service_NN
cost_NN
109_CD
67_CD
44_CD
220_CD
29_CD
Past_JJ
service_NN
cost_NN
3_CD
7_CD
16_CD
20_CD
3_CD
Expected_VBN [PRIV]
return_NN
on_PIN
pension_NN
scheme_NN
assets_NN
231_CD
111_CD
17_CD
359_CD
Interest_NN
on_PIN
scheme_NN
liabilities_NOMZ
246_CD
119_CD
25_CD
390_CD
64_CD
Settlements_NOMZ
and_PHC
curtailments_NOMZ
36_CD
15_CD
51_CD
163_CD
83_CD
36_CD
282_CD
90_CD
Actuarial_JJ
losses_NN
gains_NN
recorded_VBN [WZPAST]
in_PIN
the_DT
statement_NOMZ
of_PIN
recognized_VBN [PRIV]
income_NN
and_PHC
expense_NN
452_CD
174_CD
7_CD
285_CD
147_CD
The_DT
total_JJ
actuarial_JJ
losses_NN
recorded_VBN [WZPAST]
in_PIN
the_DT
statement_NOMZ
of_PIN
recognized_VBN [PRIV]
income_NN
and_PHC
expense_NN
since_OSUB
1st_CD
January_NN
2003_CD
amount_NN
to_PIN
1,118_CD
million_CD
._.
GSK_NN
Annual_JJ
Report_NN
2005_CD
108_CD
FINANCIAL_NN
STATEMENTS_NOMZ
Notes_NN
to_PIN
the_DT
financial_JJ
statements_NOMZ
continued_VBD
26_CD
Pensions_NN
and_CC
other_JJ
post-employment_NOMZ
benets_NN
continued_VBD
The_DT
fair_JJ
values_NN
of_PIN
the_DT
assets_NN
and_PHC
liabilities_NOMZ
of_PIN
the_DT
UK_NN
and_PHC
US_FPP1
dened_VBD
benefit_NN
schemes_NN
,_,
together_RB
with_PIN
aggregated_JJ
data_NN
for_PIN
other_JJ
dened_VBN
benefit_NN
schemes_NN
in_PIN
the_DT
Group_NN
are_VPRT
as_IN
follows_VPRT
:_:
UK_NN
USA_NN
Rest_VPRT
of_PIN
World_NN
Group_NN
Average_JJ
At_PIN
31st_CD
December_NN
2005_CD
Expected_VBN [PRIV]
rate_NN
Fair_NN
Expected_VBN [PRIV]
rate_NN
Fair_NN
expected_VBN [PRIV]
rate_NN
Fair_NN
Fair_NN
of_PIN
return_NN
value_NN
of_PIN
return_NN
value_NN
of_PIN
return_NN
value_NN
value_NN
%_NN
m_CD
%_NN
m_CD
%_NN
m_NN
m_NN
Equities_NOMZ
7.75_CD
3,895_CD
8.50_CD
1,440_CD
7.00_CD
192_CD
5,527_CD
Property_NN
7.50_CD
106_CD
6.25_CD
11_CD
117_CD
Bonds_NN
4.25_CD
1,764_CD
5.50_CD
352_CD
3.50_CD
302_CD
2,418_CD
Other_JJ
assets_NN
4.00_CD
85_CD
4.00_CD
78_CD
3.25_CD
152_CD
315_CD
Fair_NN
value_NN
of_PIN
assets_NN
5,744_CD
1,976_CD
657_CD
8,377_CD
Present_JJ
value_NN
of_PIN
scheme_NN
obligations_NOMZ
7,054_CD
2,150_CD
922_CD
10,126_CD
1,310_CD
174_CD
265_CD
1,749_CD
Included_VBN
in_PIN
other_JJ
non-current_JJ
assets_NN
12_CD
12_CD
Included_VBN
in_PIN
pensions_NN
and_CC
other_JJ
post-employment_NOMZ
benets_NN
1,310_CD
174_CD
277_CD
1,761_CD
1,310_CD
174_CD
265_CD
1,749_CD
Actual_JJ
return_NN
on_PIN
plan_NN
assets_NN
940_CD
130_CD
48_CD
1,118_CD
UK_NN
USA_NN
Rest_VPRT
of_PIN
World_NN
Group_NN
Average_JJ
At_PIN
31st_CD
December_NN
2004_CD
Expected_VBN [PRIV]
rate_NN
Fair_NN
Expected_VBN [PRIV]
rate_NN
Fair_NN
expected_VBN [PRIV]
rate_NN
Fair_NN
Fair_NN
of_PIN
return_NN
value_NN
of_PIN
return_NN
value_NN
of_PIN
return_NN
value_NN
value_NN
%_NN
m_CD
%_NN
m_CD
%_NN
m_NN
m_NN
Equities_NOMZ
8.25_CD
3,053_CD
8.50_CD
1,223_CD
7.50_CD
208_CD
4,484_CD
Property_NN
6.50_CD
58_CD
6.25_CD
7_CD
65_CD
Bonds_NN
4.50_CD
1,428_CD
5.75_CD
307_CD
3.75_CD
270_CD
2,005_CD
Other_JJ
assets_NN
4.00_CD
80_CD
2.50_CD
50_CD
2.25_CD
62_CD
192_CD
Fair_NN
value_NN
of_PIN
assets_NN
4,561_CD
1,638_CD
547_CD
6,746_CD
Present_JJ
value_NN
of_PIN
scheme_NN
obligations_NOMZ
5,735_CD
1,750_CD
761_CD
8,246_CD
1,174_CD
112_CD
214_CD
1,500_CD
Included_VBN
in_PIN
other_JJ
non-current_JJ
assets_NN
14_CD
14_CD
Included_VBN
in_PIN
pensions_NN
and_CC
other_JJ
post-employment_NOMZ
benets_NN
1,174_CD
112_CD
228_CD
1,514_CD
1,174_CD
112_CD
214_CD
1,500_CD
Actual_JJ
return_NN
on_PIN
plan_NN
assets_NN
430_CD
199_CD
28_CD
657_CD
UK_NN
USA_NN
Rest_VPRT
of_PIN
World_NN
Group_NN
Average_JJ
At_PIN
31st_CD
December_NN
2003_CD
Expected_VBN [PRIV]
rate_NN
Fair_NN
Expected_VBN [PRIV]
rate_NN
Fair_NN
expected_VBN [PRIV]
rate_NN
Fair_NN
Fair_NN
of_PIN
return_NN
value_NN
of_PIN
return_NN
value_NN
of_PIN
return_NN
value_NN
value_NN
%_NN
m_CD
%_NN
m_CD
%_NN
mm_NN
Equities_NOMZ
8.25_CD
3,147_CD
8.50_CD
1,191_CD
7.75_CD
194_CD
4,532_CD
Property_NN
6.50_CD
52_CD
6.50_CD
6_CD
58_CD
Bonds_NN
4.50_CD
594_CD
5.75_CD
314_CD
4.00_CD
226_CD
1,134_CD
Other_JJ
assets_NN
4.00_CD
214_CD
1.00_CD
26_CD
2.00_CD
18_CD
258_CD
Fair_NN
value_NN
of_PIN
assets_NN
3,955_CD
1,583_CD
444_CD
5,982_CD
Present_JJ
value_NN
of_PIN
scheme_NN
obligations_NOMZ
5,508_CD
1,751_CD
707_CD
7,966_CD
1,553_CD
168_CD
263_CD
1,984_CD
Included_VBN
in_PIN
other_JJ
non-current_JJ
assets_NN
9_CD
9_CD
Included_VBN
in_PIN
pensions_NN
and_CC
other_JJ
post-employment_NOMZ
benets_NN
1,553_CD
168_CD
272_CD
1,993_CD
1,553_CD
168_CD
263_CD
1,984_CD
Actual_JJ
return_NN
on_PIN
plan_NN
assets_NN
610_CD
341_CD
30_CD
981_CD
GSK_NN
Annual_JJ
Report_NN
2005_CD
109_CD
FINANCIAL_NN
STATEMENTS_NOMZ
Notes_NN
to_PIN
the_DT
financial_JJ
statements_NOMZ
continued_VBD
26_CD
Pensions_NN
and_CC
other_JJ
post-employment_NOMZ
benets_NN
continued_VBD
Post-retirement_JJ
Pensions_NN
benets_VPRT
Movements_NOMZ
in_PIN
dened_VBN
benefit_NN
obligations_NOMZ
UK_NN
USA_NN
Rest_VPRT
of_PIN
World_NN
Group_NN
Group_NN
m_FW
m_FW
m_FW
m_FW
m_FW
Obligations_NOMZ
at_PIN
1st_CD
January_NN
2003_CD
4,503_CD
1,789_CD
602_CD
6,894_CD
834_CD
Exchange_NN
adjustments_NOMZ
190_CD
47_CD
143_CD
79_CD
Service_NN
cost_NN
112_CD
60_CD
28_CD
200_CD
26_CD
Interest_NN
cost_NN
246_CD
119_CD
25_CD
390_CD
64_CD
Actuarial_JJ
losses_NN
788_CD
57 40 885 147_CD
Scheme_NN
participants_NN
contributions_NOMZ
13_CD
3_CD
16_CD
8_CD
Benets_NN
paid_VBD
190_CD
99_CD
38_CD
327_CD
49_CD
Settlements_NOMZ
and_PHC
curtailments_NOMZ
36_CD
15_CD
51_CD
Obligations_NOMZ
at_PIN
31st_CD
December_NN
2003_CD
5,508_CD
1,751_CD
707_CD
7,966_CD
951_CD
Exchange_NN
adjustments_NOMZ
126_CD
31_CD
157_CD
52_CD
Service_NN
cost_NN
117_CD
58_CD
44_CD
219_CD
37_CD
Interest_NN
cost_NN
269_CD
104_CD
27_CD
400_CD
55_CD
Actuarial_JJ
losses_NN
34_CD
60_CD
49_CD
143_CD
54_CD
Scheme_NN
participants_NN
contributions_NOMZ
12_CD
3_CD
15_CD
8_CD
Benets_NN
paid_VBD
210_CD
97_CD
38_CD
345_CD
48_CD
Settlements_NOMZ
and_PHC
curtailments_NOMZ
5_CD
5_CD
Obligations_NOMZ
at_PIN
31st_CD
December_NN
2004_CD
5,735_CD
1,750_CD
761_CD
8,246_CD
1,005_CD
Exchange_NN
adjustments_NOMZ
217 14 203 138_CD
Service_NN
cost_NN
117_CD
63_CD
52_CD
232_CD
47_CD
Interest_NN
cost_NN
276_CD
104_CD
34_CD
414_CD
53_CD
Actuarial_JJ
losses_NN
1,137_CD
112_CD
128_CD
1,377_CD
102_CD
Scheme_NN
participants_NN
contributions_NOMZ
12_CD
3_CD
15_CD
9_CD
Benets_NN
paid_VBD
239_CD
96_CD
42_CD
377_CD
46_CD
Settlements_NOMZ
and_PHC
curtailments_NOMZ
16_CD
16_CD
Obligations_NOMZ
at_PIN
31st_CD
December_NN
2005_CD
7,054_CD
2,150_CD
922_CD
10,126_CD
1,308_CD
The_DT
liability_NOMZ
for_PIN
the_DT
US_FPP1
post-retirement_NOMZ
healthcare_NN
scheme_NN
has_VPRT [PEAS]
been_VBN [PASS]
assessed_VBN
using_VBG
the_DT
same_JJ
assumptions_NOMZ
as_IN
for_PIN
the_DT
US_FPP1
pension_NN
scheme_NN
,_,
together_RB
with_PIN
the_DT
assumption_NOMZ
for_PIN
future_JJ
medical_JJ
ination_NOMZ
of_PIN
10_CD
%_NN
,_,
reducing_VBG [PRESP]
by_PIN
0.75_CD
%_NN
per_PIN
year_NN
to_PIN
5_CD
%_NN
in_PIN
2013_CD
and_CC
thereafter_RB
._.
On_PIN
this_DEMO
basis_NN
the_DT
liability_NOMZ
for_PIN
the_DT
US_FPP1
scheme_NN
has_VPRT [PEAS]
been_VBN [PASS]
assessed_VBN
at_PIN
1,133_CD
million_CD
2004_CD
895_CD
million_CD
:_:
2003_CD
851_CD
million_CD
._.
The_DT
dened_VBN
benefit_NN
pension_NN
obligation_NOMZ
is_VPRT [PASS]
analyzed_VBN
as_IN
follows_VPRT
:_:
2005 2004 2003_CD
m_FW
m_FW
m_FW [PASS]
Funded_VBN
9,858_CD
8,029_CD
7,758_CD
Unfunded_JJ
268 217 208_CD
10,126_CD
8,246_CD
7,966_CD
Post-retirement_NOMZ
benets_NN
are_VPRT [BEMA]
unfunded_PRED
._.
GSK_NN
Annual_JJ
Report_NN
2005_CD
110_CD
FINANCIAL_NN
STATEMENTS_NOMZ
Notes_NN
to_PIN
the_DT
financial_JJ
statements_NOMZ
continued_VBD
26_CD
Pensions_NN
and_CC
other_JJ
post-employment_NOMZ
benets_NN
continued_VBD
Post-retirement_JJ
Pensions_NN
benets_VPRT
Movements_NOMZ
in_PIN
fair_JJ
value_NN
of_PIN
assets_NN
UK_NN
USA_NN
Rest_VPRT
of_PIN
World_NN
Group_NN
Group_NN
m_FW
m_FW
m_FW
m_FW
m_FW
Assets_NN
at_PIN
1st_CD
January_NN
2003_CD
3,224_CD
1,351_CD
348_CD
4,923_CD
Exchange_NN
adjustments_NOMZ
170_CD
17_CD
187_CD
Expected_VBN [PRIV]
return_NN
on_PIN
assets_NN
231_CD
111_CD
17_CD
359_CD
Actuarial_JJ
gains_NN
336_CD
231_CD
33_CD
600_CD
Employer_NN
contributions_NOMZ
341_CD
159_CD
98_CD
598_CD
41_CD
Scheme_NN
participants_NN
contributions_NOMZ
13_CD
3_CD
16_CD
8_CD
Benets_NN
paid_VBD
190_CD
99_CD
38_CD
327_CD
49_CD
Assets_NN
at_PIN
31st_CD
December_NN
2003_CD
3,955_CD
1,583_CD
444_CD
5,982_CD
Exchange_NN
adjustments_NOMZ
117_CD
27_CD
90_CD
Expected_VBN [PRIV]
return_NN
on_PIN
assets_NN
272_CD
118_CD
20_CD
410_CD
Actuarial_JJ
gains_NN
196_CD
86_CD
23_CD
305_CD
Employer_NN
contributions_NOMZ
336_CD
65_CD
68_CD
469_CD
40_CD
Scheme_NN
participants_NN
contributions_NOMZ
12_CD
3_CD
15_CD
8_CD
Benets_NN
paid_VBD
210_CD
97_CD
38_CD
345_CD
48_CD
Assets_NN
at_PIN
31st_CD
December_NN
2004_CD
4,561_CD
1,638_CD
547_CD
6,746_CD
Exchange_NN
adjustments_NOMZ
200_CD
4_CD
196_CD
Expected_VBN [PRIV]
return_NN
on_PIN
assets_NN
285_CD
126_CD
28_CD
439_CD
Actuarial_JJ
gains_NN
647_CD
3_CD
35_CD
685_CD
Employer_NN
contributions_NOMZ
478_CD
105_CD
90_CD
673_CD
37_CD
Scheme_NN
participants_NN
contributions_NOMZ
12_CD
3_CD
15_CD
9_CD
Benets_NN
paid_VBD
239_CD
96_CD
42_CD
377_CD
46_CD
Assets_NN
at_PIN
31st_CD
December_NN
2005_CD
5,744_CD
1,976_CD
657_CD
8,377_CD
The_DT
UK_NN
dened_VBD
benefit_NN
schemes_NN
include_VPRT
dened_VBN
contribution_NOMZ
sections_NOMZ
with_PIN
account_NN
balances_NN
totalling_VBG [WZPRES]
515_CD
million_CD
at_PIN
31st_CD
December_NN
2005 2004 404_CD
million_CD
,_,
2003_CD
327_CD
million_CD
._.
Information_NOMZ
on_PIN
scheme_NN
assets_NN
under_IN
US_FPP1
GAAP_NN
is_VPRT [PASS]
given_VBN
in_PIN
Note_NN
38_CD
._.
Employer_NN
contributions_NOMZ
for_PIN
2006_CD
are_VPRT [PASS]
estimated_VBN [PRIV]
to_TO
be_VB [BEMA]
approximately_RB
700_CD
million_CD
in_PIN
respect_NN
of_PIN
deferred_VBN
benefit_NN
pension_NN
schemes_NN
and_CC
50_CD
million_CD
in_PIN
respect_NN
of_PIN
post-retirement_JJ
benets_NN
._.
The_DT
transition_NOMZ
date_NN
for_PIN
conversion_NN
to_PIN
IFRS_NN
for_PIN
GSK_NN
was_VBD [BEMA]
1st_CD
January_NN
2003_CD
and_ANDC
therefore_CONJ
the_DT
following_VBG
historical_JJ
data_NN
has_VPRT [PEAS]
been_VBN [PASS]
presented_VBN
from_PIN
that_DEMO
date_NN
._.
This_DEMP
will_PRMD
be_VB [PASS]
built_VBN
up_RP
to_PIN
a_DT
rolling_VBG
five_CD
year_NN
record_NN
over_IN
the_DT
next_JJ
two_CD
years_NN
._.
Post-retirement_NOMZ
Pensions_NN
benets_VPRT
History_NN
of_PIN
actuarial_JJ
gains_NN
and_PHC
losses_NN
UK_NN
USA_NN
Rest_VPRT
of_PIN
World_NN
Group_NN
Group_NN
m_FW
m_FW
m_FW
m_FW
m_FW [BEMA]
2005_CD
Actuarial_JJ
gains_NN
of_PIN
scheme_NN
assets_NN
m_VPRT [BEMA]
647_CD
3_CD
35_CD
685_CD
Percentage_NN
of_PIN
scheme_NN
assets_NN
at_PIN
31st_CD
December_NN
2005_CD
11_CD
%_NN
5_CD
%_NN
8_CD
%_NN
Actuarial_JJ
losses_NN
of_PIN
scheme_NN
liabilities_NOMZ
m_VPRT [BEMA]
1,137_CD
112_CD
128_CD
1,377_CD
102_CD
Percentage_NN
of_PIN
scheme_NN
obligations_NOMZ
at_PIN
31st_CD
December_NN
2005_CD
16_CD
%_NN
5_CD
%_NN
14_CD
%_NN
14_CD
%_NN
8_CD
%_NN
Fair_NN
value_NN
of_PIN
assets_NN
5,744_CD
1,976_CD
657_CD
8,377_CD
Present_JJ
value_NN
of_PIN
scheme_NN
obligations_NOMZ
7,054_CD
2,150_CD
922_CD
10,126_CD
1,308_CD
deficits_NN
in_PIN
the_DT
schemes_NN
1,310_CD
174_CD
265_CD
1,749_CD
1,308_CD
GSK_NN
Annual_JJ
Report_NN
2005_CD
111_CD
FINANCIAL_NN
STATEMENTS_NOMZ
Notes_NN
to_PIN
the_DT
financial_JJ
statements_NOMZ
continued_VBD
26_CD
Pensions_NN
and_CC
other_JJ
post-employment_NOMZ
benets_NN
continued_VBD
Post-retirement_JJ
Pensions_NN
benets_VPRT
History_NN
of_PIN
actuarial_JJ
gains_NN
and_PHC
losses_NN
UK_NN
USA_NN
Rest_VPRT
of_PIN
World_NN
Group_NN
Group_NN
m_FW
m_FW
m_FW
m_FW
m_FW [BEMA]
2004_CD
Actuarial_JJ
gains_NN
of_PIN
scheme_NN
assets_NN
m_VPRT [BEMA]
196_CD
86_CD
23_CD
305_CD
Percentage_NN
of_PIN
scheme_NN
assets_NN
at_PIN
31st_CD
December_NN
2004_CD
4_CD
%_NN
5_CD
%_NN
4_CD
%_NN
5_CD
%_NN
Actuarial_JJ
losses_NN
gains_NN
of_PIN
scheme_NN
liabilities_NOMZ
m_VPRT [BEMA]
34_CD
60_CD
49_CD
143_CD
54_CD
Percentage_NN
of_PIN
of_PIN
scheme_NN
obligations_NOMZ
at_PIN
31st_CD
December_NN
2004_CD
1_CD
%_NN
3_CD
%_NN
6_CD
%_NN
2_CD
%_NN
5_CD
%_NN
Fair_NN
value_NN
of_PIN
assets_NN
4,561_CD
1,638_CD
547_CD
6,746_CD
Present_JJ
value_NN
of_PIN
scheme_NN
obligations_NOMZ
5,735_CD
1,750_CD
761_CD
8,246_CD
1,005_CD
deficits_NN
in_PIN
the_DT
schemes_NN
1,174_CD
112_CD
214_CD
1,500_CD
1,005_CD
2003_CD
Actuarial_JJ
gains_NN
losses_NN
of_PIN
scheme_NN
assets_NN
m_VPRT [BEMA]
336_CD
231_CD
33_CD
600_CD
Percentage_NN
of_PIN
scheme_NN
assets_NN
at_PIN
31st_CD
December_NN
2003_CD
8_CD
%_NN
15_CD
%_NN
7_CD
%_NN
10_CD
%_NN
Actuarial_JJ
losses_NN
gains_NN
of_PIN
scheme_NN
liabilities_NOMZ
m_VPRT [BEMA]
788_CD
57 40 885 147_CD
Percentage_NN
of_PIN
scheme_NN
obligations_NOMZ
at_PIN
31st_CD
December_NN
2003_CD
14_CD
%_NN
3_CD
%_NN
6_CD
%_NN
11_CD
%_NN
15_CD
%_NN
Fair_NN
value_NN
of_PIN
assets_NN
3,955_CD
1,583_CD
444_CD
5,982_CD
Present_JJ
value_NN
of_PIN
scheme_NN
obligations_NOMZ
5,508_CD
1,751_CD
707_CD
7,966_CD
951_CD
deficits_NN
in_PIN
the_DT
schemes_NN
1,553_CD
168_CD
263_CD
1,984_CD
951_CD
Sensitivity_NOMZ
analysis_NN
Changes_NN
in_PIN
the_DT
assumptions_NOMZ
used_VBN
may_POMD
have_VB
a_DT
material_NN
impact_NN
on_PIN
the_DT
annual_JJ
dened_VBN
benefit_NN
pension_NN
and_PHC
post-retirement_NOMZ
costs_NN
or_CC
the_DT
benefit_NN
obligations_NOMZ
._.
m_FW [BEMA]
A_DT
0.25_CD
%_NN
decrease_NN
in_PIN
discount_NN
rate_NN
would_PRMD
have_VB
the_DT
following_VBG
approximate_JJ
effect_NN
:_:
Increase_VB
in_PIN
annual_JJ
pension_NN
cost_NN
6_CD
Increase_VPRT
in_PIN
annual_JJ
post-retirement_JJ
benets_NN
cost_VBD
1_CD
Increase_VPRT
in_PIN
pension_NN
obligation_NOMZ
400_CD
Increase_VPRT
in_PIN
post-retirement_JJ
benets_NN
obligation_NOMZ
40_CD
A_DT
one_CD
year_NN
increase_NN
in_PIN
life_NN
expectancy_NN
would_PRMD
have_VB
the_DT
following_VBG
approximate_JJ
effect_NN
:_:
Increase_VB
in_PIN
annual_JJ
pension_NN
cost_NN
19_CD
Increase_VPRT
in_PIN
annual_JJ
post-retirement_JJ
benets_NN
cost_NN
4_CD
Increase_VPRT
in_PIN
pension_NN
obligation_NOMZ
270_CD
Increase_VPRT
in_PIN
post-retirement_JJ
benets_NN
obligation_NOMZ
50_CD
A_DT
0.25_CD
%_NN
decrease_NN
in_PIN
expected_JJ
rates_NN
of_PIN
returns_NN
on_PIN
assets_NN
would_PRMD
have_VB
the_DT
following_VBG
approximate_JJ
effect_NN
:_:
Increase_VB
in_PIN
annual_JJ
pension_NN
cost_NN
20_CD
A_DT
1_CD
%_NN
increase_NN
in_PIN
the_DT
rate_NN
of_PIN
future_JJ
healthcare_NN
ination_NOMZ
would_PRMD
have_VB
the_DT
following_VBG
approximate_JJ
effect_NN
:_:
Increase_VB
in_PIN
annual_JJ
post-retirement_JJ
benets_NN
cost_VBD
10_CD
Increase_VPRT
in_PIN
post-retirement_JJ
benets_NN
obligation_NOMZ
90_CD
GSK_NN
Annual_JJ
Report_NN
2005_CD
112_CD
FINANCIAL_NN
STATEMENTS_NOMZ
Notes_NN
to_PIN
the_DT
financial_JJ
statements_NOMZ
continued_VBD
27_CD
Other_JJ
provisions_NN
Legal_JJ
Manufacturing_GER
Merger_NN
and_CC
other_JJ
Other_JJ
restructuring_GER
integration_NOMZ
disputes_NN
provisions_NN
Total_JJ
m_NN
m_FW
m_FW
m_FW
m_FW [BEMA]
At_PIN
1st_CD
January_NN
2005_CD
46_CD
224_CD
1,074_CD
187_CD
1,531_CD
Exchange_NN
adjustments_NOMZ
2_CD
6_CD
88_CD
8_CD
104_CD
Additions_NOMZ
through_PIN
business_NOMZ
combinations_NOMZ
37_CD
37_CD
Charge_NN
for_PIN
the_DT
year_NN
16 380 102 498_CD
Unwinding_GER
of_PIN
discount_NN
18_CD
6_CD
24_CD
Applied_NN
10 42 297 100_CD
449_CD
Reversed_VBN
unused_JJ
12_CD
8_CD
76_CD
16_CD
112_CD
Reclassications_NOMZ
and_CC
other_JJ
movements_NOMZ
4_CD
22_CD
29_CD
3_CD
At_PIN
31st_CD
December_NN
2005_CD
26_CD
192_CD
1,165_CD
253_CD
1,636_CD
To_TO
be_VB [PASS]
settled_VBN
within_PIN
one_CD
year_NN
10 77 657 151_CD
895_CD
To_TO
be_VB [PASS]
settled_VBN
after_IN
one_CD
year_NN
16 115 508 102_CD
741_CD
At_PIN
31st_CD
December_NN
2005_CD
26_CD
192_CD
1,165_CD
253_CD
1,636_CD
The_DT
Group_NN
has_VPRT [PEAS]
recognized_VBN [PRIV]
costs_NN
in_PIN
previous_JJ
years_NN
in_PIN
respect_NN
of_PIN
plans_NN
for_PIN
manufacturing_GER
and_CC
other_JJ
restructuring_GER
initiated_VBN [WZPAST]
in_PIN
1998_CD
,_,
1999_CD
and_CC
in_PIN
2001_CD
following_VBG
the_DT
merger_NN
of_PIN
Glaxo_NN
Wellcome_NN
and_PHC
SmithKline_NN
Beecham_NN
and_CC
the_DT
acquisition_NOMZ
of_PIN
Block_NN
Drug_NN
._.
These_DEMO
plans_NN
are_VPRT [SPAU] [PASS]
largely_RB
completed_VBN
._.
Costs_NN
recognized_VBD [PRIV]
as_IN
a_DT
provision_NN
,_,
principally_RB
in_PIN
respect_NN
of_PIN
identied_JJ
severances_NN
at_PIN
sites_NN
where_RB
it_PIT
has_VPRT [PEAS]
been_VBN [PASS]
announced_VBN [PUBV] [THATD]
that_DEMP
manufacturing_VBG
activities_NOMZ
will_PRMD
cease_VB
and_CC
site_NN
closure_NN
and_PHC
cleaning_GER
costs_NN
are_VPRT [PASS]
expected_VBN [PRIV]
to_TO
be_VB [PASS]
incurred_VBN
mainly_RB
within_PIN
the_DT
next_JJ
three_CD
years_NN
._.
Costs_NN
of_PIN
asset_NN
write-downs_NN
have_VPRT [PEAS]
been_VBN [PASS]
recognized_VBN [PRIV]
as_IN
impairments_NOMZ
of_PIN
property_NN
,_,
plant_NN
and_PHC
equipment_NOMZ
._.
The_DT
Group_NN
has_VPRT [PEAS]
recognized_VBN [PRIV]
costs_NN
in_PIN
previous_JJ
years_NN
in_PIN
respect_NN
of_PIN
plans_NN
for_PIN
the_DT
integration_NOMZ
of_PIN
the_DT
Glaxo_NN
Wellcome_NN
and_PHC
SmithKline_NN
Beecham_NN
businesses_NOMZ
._.
Implementation_NOMZ
of_PIN
the_DT
integration_NOMZ
following_VBG [WZPRES]
the_DT
merger_NN
is_VPRT [BEMA]
substantially_RB
complete_PRED
._.
Costs_NN
recognized_VBD [PRIV]
as_IN
a_DT
provision_NN
in_PIN
respect_NN
of_PIN
identied_JJ
severances_NN
are_VPRT [PASS]
expected_VBN [PRIV]
to_TO
be_VB [PASS]
incurred_VBN
in_PIN
2006_CD
and_CC
in_PIN
respect_NN
of_PIN
the_DT
program_NN
to_TO
encourage_VB
staff_NN
to_TO
convert_VB
Glaxo_NN
Wellcome_NN
or_CC
SmithKline_NN
Beecham_NN
share_NN
options_NOMZ
into_PIN
GlaxoSmithKline_NN
share_NN
options_NOMZ
when_RB
employees_NN
exercise_VPRT
these_DEMO
options_NOMZ
up_IN
to_PIN
2010_CD
._.
The_DT
discount_NN
on_PIN
this_DEMO
latter_JJ
provision_NN
increased_VBN [WZPAST]
by_PIN
4_CD
million_CD
in_PIN
2005_CD
2004_CD
4_CD
million_CD
,_,
and_ANDC
was_VBD [PASS]
calculated_VBN [PRIV]
using_VBG
risk-free_JJ
rates_NN
of_PIN
return_NN
._.
GlaxoSmithKline_NN
is_VPRT [PASS]
involved_VBN
in_PIN
a_DT
number_NN
of_PIN
legal_JJ
and_PHC
other_JJ
disputes_NN
,_,
including_VBG
notication_NOMZ
of_PIN
possible_JJ
claims_NN
._.
Provisions_NN
for_PIN
legal_JJ
and_PHC
other_JJ
disputes_NN
include_VPRT
amounts_NN
relating_VBG [WZPRES]
to_PIN
US_FPP1
anti-trust_NN
,_,
product_NN
liability_NOMZ
,_,
contract_NN
terminations_NOMZ
,_,
self-insurance_NN
,_,
environmental_JJ
clean-up_JJ
and_CC
property_NN
rental_NN
._.
The_DT
companys_NN
Directors_NN
,_,
having_VBG [PEAS]
taken_VBN
legal_JJ
advice_NN
,_,
have_VPRT [PEAS]
established_VBN [PRIV]
provisions_NN
after_IN
taking_VBG
into_PIN
account_NN
insurance_NN
and_CC
other_JJ
agreements_NOMZ
and_CC
having_VBG
regard_NN
to_PIN
the_DT
relevant_JJ
facts_NN
and_PHC
circumstances_NN
of_PIN
each_QUAN
matter_NN
and_CC
in_PIN
accordance_NN
with_PIN
accounting_GER
requirements_NOMZ
._.
These_DEMO
provisions_NN
were_VBD [BYPA]
discounted_VBN
by_PIN
71_CD
million_CD
in_PIN
2005_CD
2004_CD
11_CD
million_CD
using_VBG
risk-free_JJ
rates_NN
of_PIN
return_NN
._.
The_DT
effect_NN
of_PIN
the_DT
change_NN
in_PIN
the_DT
discount_NN
rate_NN
in_PIN
2005_CD
is_VPRT
to_TO
increase_VB
the_DT
discount_NN
at_PIN
31st_CD
December_NN
by_PIN
20_CD
million_CD
._.
A_DT
number_NN
of_PIN
products_NN
have_VPRT
a_DT
history_NN
of_PIN
claims_NN
made_VBN
and_CC
settlements_NOMZ
which_WDT [WHSUB]
makes_VPRT
it_PIT
possible_JJ
to_TO
use_VB
an_DT
IBNR_NN
incurred_VBN
but_CC
not_XX0
reported_VBD [PUBV]
actuarial_JJ
technique_NN
to_TO
determine_VB [SUAV] [PRIV]
a_DT
reasonable_JJ
estimate_NN
of_PIN
the_DT
Groups_NN
exposure_NN
for_PIN
unasserted_JJ
claims_NN
in_PIN
relation_NOMZ
to_PIN
those_DEMO
products_NN
._.
Apart_RB
from_PIN
the_DT
IBNR_NN
provision_NN
,_,
no_SYNE
provisions_NN
have_VPRT [PEAS]
been_VBN [PASS]
made_VBN
for_PIN
unasserted_JJ
claims_NN
._.
The_DT
ultimate_JJ
liability_NOMZ
for_PIN
such_JJ
matters_NN
may_POMD
vary_VB
from_PIN
the_DT
amounts_NN
provided_VBN
and_PHC
is_VPRT [BEMA]
dependent_PRED
upon_PIN
the_DT
outcome_NN
of_PIN
litigation_NOMZ
proceedings_GER
,_,
investigations_NOMZ
and_CC
possible_JJ
settlement_NOMZ
negotiations_NOMZ
._.
It_PIT
is_VPRT [BEMA]
in_PIN
the_DT
nature_NN
of_PIN
the_DT
Groups_NN
business_NOMZ
that_TOBJ
a_DT
number_NN
of_PIN
these_DEMO
matters_NN
,_,
including_VBG [PRESP]
those_DEMP
provided_VBN
using_VBG
the_DT
IBNR_NN
actuarial_JJ
technique_NN
,_,
may_POMD
be_VB [BEMA]
the_DT
subject_NN
of_PIN
negotiation_NOMZ
and_PHC
litigation_NOMZ
over_IN
several_QUAN
years_NN
._.
The_DT
largest_JJ
individual_JJ
amounts_NN
provided_VBN [WZPAST]
are_VPRT [PASS]
expected_VBN [PRIV]
to_TO
be_VB [PASS]
settled_VBN
within_PIN
three_CD
years_NN
._.
At_PIN
31st_CD
December_NN
2005_CD
,_,
it_PIT
is_VPRT [PASS]
expected_VBN [PRIV]
that_THVC
115_CD
million_CD
2004_CD
236_CD
million_CD
of_PIN
the_DT
provision_NN
made_VBN [WZPAST]
for_PIN
legal_JJ
and_PHC
other_JJ
disputes_NN
will_PRMD
be_VB [PASS]
reimbursed_VBN
._.
This_DEMO
amount_NN
is_VPRT [PASS]
included_VBN
within_PIN
non-current_JJ
assets_NN
._.
For_PIN
a_DT
discussion_NN
of_PIN
legal_JJ
issues_NN
,_,
refer_VPRT
to_TO
Note_VB [PRIV]
41_CD
Legal_JJ
proceedings_GER
._.
28_CD
Other_JJ
non-current_JJ
liabilities_NOMZ
2005_CD
2004_CD
m_NN
m_NN
Accruals_NN
and_CC
deferred_JJ
income_NN
58_CD
66_CD
Derivative_JJ
financial_JJ
instruments_NOMZ
26_CD
Other_JJ
payables_NN
383_CD
339_CD
._.
467_CD
405_CD
GSK_NN
Annual_JJ
Report_NN
2005_CD
113_CD
FINANCIAL_NN
STATEMENTS_NOMZ
Notes_NN
to_PIN
the_DT
financial_JJ
statements_NOMZ
continued_VBD
29_CD
Contingent_JJ
liabilities_NOMZ
At_PIN
31st_CD
December_NN
2005_CD
contingent_JJ
liabilities_NOMZ
,_,
comprising_VBG
guarantees_NN
,_,
discounted_VBD
bills_NN
and_CC
other_JJ
items_NN
arising_VBG [WZPRES]
in_PIN
the_DT
normal_JJ
course_NN
of_PIN
business_NOMZ
,_,
amounted_VBD
to_PIN
342_CD
million_CD
2004_CD
207_CD
million_CD
._.
At_PIN
31st_CD
December_NN
2005_CD
,_,
96_CD
million_CD
2004_CD
134_CD
million_CD
financial_JJ
assets_NN
were_VBD [PASS]
pledged_VBN [SUAV]
as_IN
collateral_NN
for_PIN
contingent_JJ
liabilities_NOMZ
._.
For_PIN
a_DT
discussion_NN
of_PIN
tax_NN
issues_NN
,_,
refer_VPRT
to_TO
Note_VB [PRIV]
12_CD
,_,
Taxation_NOMZ
and_CC
of_PIN
legal_JJ
issues_NN
,_,
refer_VPRT
to_TO
Note_VB [PRIV]
41_CD
,_,
Legal_NN
proceedings_GER
._.
30_CD
Net_JJ
debt_NN
2005_CD
2004_CD
m_NN
m_NN [BEMA]
Current_JJ
assets_NN
:_:
Liquid_NN
investments_NOMZ
1,025_CD
1,512_CD
Cash_NN
and_PHC
cash_NN
equivalents_NN
4,209_CD
2,467_CD
5,234_CD
3,979_CD
Short-term_JJ
borrowings_GER
:_:
7.375_CD
%_NN
US$_$
US_FPP1
Medium_NN
Term_NN
Note_VB [PRIV]
2005_CD
52_CD
8.75_CD
%_NN
Eurobond_NN
2005_CD
500_CD
6.125_CD
%_NN
US$_$
Notes_NN
2006_CD
291_CD
Commercial_JJ
paper_NN
576_CD
830_CD
Bank_NN
loans_NN
and_PHC
overdrafts_NN
249_CD
163_CD
Other_JJ
loans_NN
46_CD
2_CD
Obligations_NOMZ
under_IN
finance_NN
leases_NN
38_CD
35_CD
1,200_CD
1,582_CD
Long-term_JJ
borrowings_GER
:_:
6.125_CD
%_NN
US$_$
Notes_NN
2006_CD
260_CD
2.375_CD
%_NN
US$_$
US_FPP1
Medium_NN
Term_NN
Note_VB [PRIV]
2007 283 260_CD
3.375_CD
%_NN
European_JJ
Medium_NN
Term_NN
Note_VB [PRIV]
2008 689 705_CD
4.875_CD
%_NN
European_JJ
Medium_NN
Term_NN
Note_VB [PRIV]
2008 502 498_CD
3.25_CD
%_NN
European_JJ
Medium_NN
Term_NN
Note_VB [PRIV]
2009 342 348_CD
3.00_CD
%_NN
European_JJ
Medium_NN
Term_NN
Note_VB [PRIV]
2012_CD
510_CD
4.375_CD
%_NN
US$_$
US_FPP1
Medium_NN
Term_NN
Note_VB [PRIV]
2014 825 772_CD
4.00_CD
%_NN
European_JJ
Medium_NN
Term_NN
Note_VB [PRIV]
2025_CD
503_CD
5.25_CD
%_NN
European_JJ
Medium_NN
Term_NN
Note_VB [PRIV]
2033 976 975_CD
5.375_CD
%_NN
US$_$
US_FPP1
Medium_NN
Term_NN
Note_VB [PRIV]
2034 288 258_CD
Loan_NN
stock_NN
11_CD
12_CD
Bank_NN
loans_NN
3_CD
4_CD
Other_JJ
loans_NN
and_CC
private_JJ
nancing_GER
256_CD
231_CD
Obligations_NOMZ
under_IN
finance_NN
leases_VPRT
83_CD
58_CD
5,271_CD
4,381_CD
Net_JJ
debt_NN
1,237_CD
1,984_CD
Current_JJ
assets_NN
Liquid_NN
investments_NOMZ
are_VPRT [PASS]
classied_VBN
as_IN
available-for-sale_JJ
investments_NOMZ
._.
At_PIN
31st_CD
December_NN
2005_CD
,_,
they_TPP3
included_VBD
redeemable_JJ
shares_NN
,_,
which_WDT [SERE]
were_VBD [SPAU] [PASS]
fully_AMP
collateralised_VBN
with_PIN
highly_AMP
rated_VBN
bonds_NN
,_,
of1_CD
billion_CD
685_CD
million_CD
._.
The_DT
1_CD
billion_CD
redeemable_JJ
preference_NN
shares_NN
held_VBN [PRIV] [WZPAST]
at_PIN
31st_CD
December_NN
2004_CD
were_VBD [PASS]
redeemed_VBN
during_PIN
the_DT
year_NN
._.
The_DT
effective_JJ
interest_NN
rate_NN
on_PIN
liquid_JJ
investments_NOMZ
at_PIN
31st_CD
December_NN
2005_CD
was_VBD [BEMA]
approximately_RB
2.8_CD
%_NN
._.
The_DT
effective_JJ
interest_NN
rate_NN
on_PIN
cash_NN
and_PHC
cash_NN
equivalents_NN
at_PIN
31st_CD
December_NN
2005_CD
was_VBD [BEMA]
approximately_RB
4.0_CD
%_NN
._.
GSK_NN
Annual_JJ
Report_NN
2005_CD
114_CD
FINANCIAL_NN
STATEMENTS_NOMZ
Notes_NN
to_PIN
the_DT
financial_JJ
statements_NOMZ
continued_VBD
30_CD
Net_JJ
debt_NN
continued_VBD
Short-term_JJ
borrowings_GER
Commercial_JJ
paper_NN
comprises_VPRT
a_DT
US$_$
10_CD
billion_CD
program_NN
,_,
of_PIN
which_WDT [PIRE]
$_$
991_CD
million_CD
576_CD
million_CD
was_VBD [BEMA]
in_PIN
issue_NN
at_PIN
31st_CD
December_NN
2005_CD
2004_CD
$_$
1,593_CD
million_CD
830_CD
million_CD
,_,
backed_VBD
up_RP
by_PIN
committed_JJ
facilities_NOMZ
of_PIN
364_CD
days_NN
duration_NOMZ
of_PIN
$_$
900_CD
million_CD
523_CD
million_CD
2004_CD
$_$
900_CD
million_CD
469_CD
million_CD
renewable_JJ
annually_RB
,_,
and_ANDC
liquid_JJ
investments_NOMZ
,_,
cash_NN
and_PHC
cash_NN
equivalents_NN
as_IN
shown_VBN [PRIV]
in_PIN
the_DT
table_NN
above_PLACE
._.
The_DT
weighted_JJ
average_JJ
interest_NN
rate_NN
on_PIN
commercial_JJ
paper_NN
borrowings_GER
at_PIN
31st_CD
December_NN
2005_CD
was_VBD [BEMA]
4.4_CD
%_NN
2004_CD
2.4_CD
%_NN
._.
The_DT
weighted_JJ
average_JJ
interest_NN
rate_NN
on_PIN
current_JJ
bank_NN
loans_NN
and_PHC
overdrafts_NN
at_PIN
31st_CD
December_NN
2005_CD
was_VBD [BEMA]
4.0_CD
%_NN
2004_CD
3.0_CD
%_NN
._.
Long-term_JJ
borrowings_GER
In_PIN
2005_CD
,_,
two_CD
bonds_NN
were_VBD [PASS]
issued_VBN
under_IN
the_DT
European_JJ
Medium_NN
Term_NN
Note_NN
program_NN
:_:
a_DT
750_CD
million_CD
,_,
7_CD
year_NN
,_,
3_CD
%_NN
coupon_NN
bond_NN
and_CC
a_DT
750_CD
million_CD
,_,
20_CD
year_NN
,_,
4_CD
%_NN
coupon_NN
bond_NN
._.
Loans_NN
due_JJ
after_IN
one_CD
year_NN
are_VPRT [BEMA]
repayable_PRED
over_IN
various_JJ
periods_NN
as_IN
follows_VPRT
:_:
2005_CD
2004_CD
m_NN
m_NN [BEMA]
Between_PIN
one_CD
and_CC
two_CD
years_NN
317_CD
289_CD
Between_PIN
two_CD
and_CC
three_CD
years_NN
1,224_CD
279_CD
Between_PIN
three_CD
and_CC
four_CD
years_NN
354_CD
1,210_CD
Between_PIN
four_CD
and_CC
five_CD
years_NN
9_CD
352_CD
After_IN
five_CD
years_NN
3,367_CD
2,251_CD
5,271_CD
4,381_CD
The_DT
loans_NN
repayable_JJ
after_IN
five_CD
years_NN
carry_VPRT
interest_NN
at_PIN
effective_JJ
rates_NN
between_PIN
3.0_CD
%_NN
and_CC
5.4_CD
%_NN
._.
The_DT
repayment_NOMZ
dates_NN
range_VPRT
from_PIN
2012_CD
to_PIN
2034_CD
._.
The_DT
average_JJ
effective_JJ
interest_NN
rate_NN
of_PIN
all_QUAN
Notes_NN
at_PIN
31st_CD
December_NN
2005_CD
was_VBD [BEMA]
approximately_RB
4.5_CD
%_NN
._.
Secured_JJ
loans_NN
Loans_NN
amounting_VBG [WZPRES]
to_PIN
20_CD
million_CD
2004_CD
11_CD
million_CD
are_VPRT [BYPA]
secured_VBN
by_PIN
charges_NN
on_PIN
non-current_JJ
and_PHC
current_JJ
assets_NN
._.
2005_CD
2004_CD
Finance_NN
lease_NN
obligations_NOMZ
m_VPRT
m_FW [BEMA]
Rental_JJ
payments_NOMZ
due_JJ
within_PIN
one_CD
year_NN
41_CD
36_CD
Rental_JJ
payments_NOMZ
due_JJ
between_PIN
one_CD
and_CC
two_CD
years_NN
33_CD
28_CD
Rental_JJ
payments_NOMZ
due_JJ
between_PIN
two_CD
and_CC
three_CD
years_NN
23_CD
17_CD
Rental_JJ
payments_NOMZ
due_JJ
between_PIN
three_CD
and_CC
four_CD
years_NN
13_CD
5_CD
Rental_JJ
payments_NOMZ
due_JJ
between_PIN
four_CD
and_CC
five_CD
years_NN
9_CD
3_CD
Rental_JJ
payments_NOMZ
due_JJ
after_IN
five_CD
years_NN
15_CD
7_CD
Total_JJ
future_JJ
rental_JJ
payments_NOMZ
134_CD
96_CD
Future_NN
finance_NN
charges_NN
13_CD
3_CD
Total_JJ
finance_NN
lease_NN
obligations_NOMZ
121_CD
93_CD
GSK_NN
Annual_JJ
Report_NN
2005_CD
115_CD
FINANCIAL_NN
STATEMENTS_NOMZ
Notes_NN
to_PIN
the_DT
financial_JJ
statements_NOMZ
continued_VBD
31_CD
Share_NN
capital_NN
and_PHC
share_NN
premium_NN
account_NN
Share_NN
Ordinary_NN
shares_NN
of_PIN
25p_JJ
each_QUAN
premium_NN
Number_NN
m_FW
m_FW
Share_NN
capital_NN
authorised_VBN [WZPAST]
At_PIN
31st_CD
December_NN
2003_CD
10,000,000,000_CD
2,500_CD
At_PIN
31st_CD
December_NN
2004_CD
10,000,000,000_CD
2,500_CD
At_PIN
31st_CD
December_NN
2005_CD
10,000,000,000_CD
2,500_CD
Share_NN
capital_NN
issued_VBN
and_CC
fully_AMP
paid_VBN
At_PIN
1st_CD
January_NN
2003_CD
6,024,266,345_CD
1,506_CD
224_CD
Issued_VBN
under_IN
share_NN
options_NOMZ
schemes_NN
6,041,283_CD
1_CD
40_CD
Purchased_VBN
and_PHC
canceled_VBN
80,844,000_CD
20_CD
At_PIN
31st_CD
December_NN
2003_CD
5,949,463,628_CD
1,487_CD
264_CD
Issued_VBN
under_IN
share_NN
option_NOMZ
schemes_NN
6,300,203_CD
2_CD
40_CD
Purchased_VBN
and_PHC
canceled_VBN
18,075,000_CD
5_CD
At_PIN
31st_CD
December_NN
2004_CD
5,937,688,831_CD
1,484_CD
304_CD
Issued_VBN
under_IN
share_NN
option_NOMZ
schemes_NN
25,162,425_CD
7_CD
245_CD
At_PIN
31st_CD
December_NN
2005_CD
5,962,851,256_CD
1,491_CD
549_CD
31st_CD
December_NN
31st_CD
December_NN
31st_CD
December_NN
2005 2004 2003_CD
Number_NN
000_CD
of_PIN
shares_NN
issuable_JJ
under_IN
outstanding_JJ
options_NOMZ
Note_VPRT [PRIV]
37_CD
221,293_CD
276,954_CD
259,990_CD
Number_NN
000_CD
of_PIN
unissued_JJ
shares_NN
not_XX0
under_IN
option_NOMZ
3,815,856_CD
3,785,358_CD
3,790,546_CD
At_PIN
31st_CD
December_NN
2005_CD
,_,
of_PIN
the_DT
issued_VBN
share_NN
capital_NN
,_,
167,436,200_CD
shares_NN
were_VBD [PASS]
held_VBN [PRIV]
in_PIN
the_DT
ESOP_NN
Trust_NN
,_,
142,779,678_CD
shares_NN
were_VBD [PASS]
held_VBN [PRIV]
as_IN
Treasury_NN
shares_NN
and_CC
5,652,635,378_CD
shares_NN
were_VBD [BEMA]
in_PIN
free_JJ
issue_NN
._.
All_QUAN
issued_VBN
shares_NN
are_VPRT [SPAU] [PASS]
fully_AMP
paid_VBN
._.
A_DT
total_NN
of_PIN
6.5_CD
billion_CD
has_VPRT [PEAS]
been_VBN [BYPA]
spent_VBN
by_PIN
the_DT
company_NN
since_OSUB
2001_CD
on_PIN
buying_VBG
its_PIT
own_JJ
shares_NN
for_PIN
cancellation_NOMZ
or_CC
to_TO
be_VB [PASS]
held_VBN [PRIV]
as_IN
Treasury_NN
shares_NN
,_,
of_PIN
which_WDT [PIRE]
1_CD
billion_CD
was_VBD [PASS]
spent_VBN
in_PIN
2005_CD
._.
The_DT
exact_JJ
amount_NN
and_PHC
timing_NN
of_PIN
future_JJ
purchases_NN
,_,
and_ANDC
the_DT
extent_NN
to_PIN
which_WDT [PIRE]
repurchased_VBD
shares_NN
will_PRMD
be_VB [PASS]
held_VBN [PRIV]
as_IN
Treasury_NN
shares_NN
rather_RB
than_PIN
being_VBG [PASS]
canceled_VBN
,_,
will_PRMD
be_VB [BYPA]
determined_VBN [SUAV] [PRIV]
by_PIN
the_DT
company_NN
and_CC
is_VPRT [BEMA]
dependent_PRED
on_PIN
market_NN
conditions_NOMZ
and_CC
other_JJ
factors_NN
._.
No_SYNE
shares_NN
were_VBD [PASS]
purchased_VBN
in_PIN
the_DT
period_NN
1st_CD
January_NN
2006_CD
to_PIN
8th_JJ
February_NN
2006_CD
._.
In_PIN
the_DT
period_NN
9th_CD
February_NN
2006_CD
to_PIN
24th_JJ
February_NN
2006_CD
a_DT
further_JJ
2.7_CD
million_CD
shares_NN
have_VPRT [PEAS]
been_VBN [PASS]
purchased_VBN
at_PIN
a_DT
cost_NN
of_PIN
40_CD
million_CD
._.
All_QUAN
purchases_NN
were_VBD [BEMA]
through_PIN
the_DT
publicly_RB
announced_VBN [PUBV]
buy-back_JJ
program_NN
._.
The_DT
table_NN
below_PLACE
sets_NN
out_PIN
the_DT
monthly_JJ
purchases_NN
under_IN
the_DT
share_NN
buy-back_NN
program_NN
:_:
Average_JJ
share_NN
price_NN
excluding_VBG [WZPRES]
Number_NN
of_PIN
shares_NN
commission_NN
and_CC
stamp_VB
duty_NN
Month_NN
000_CD
January_NN
2005_CD
Nil_NN
February_NN
2005_CD
6,300_CD
12.56_CD
March_NN
2005_CD
10,090_CD
12.44_CD
April_NN
2005_CD
Nil_NN
May_POMD
2005_CD
6,895_CD
13.45_CD
June_NN
2005_CD
6,670_CD
13.53_CD
July_NN
2005_CD
Nil_NN
August_NN
2005_CD
8,720_CD
13.29_CD
September_NN
2005_CD
9,510_CD
13.77_CD
October_NN
2005_CD
2,250_CD
14.73_CD
November_NN
2005_CD
5,875_CD
14.73_CD
December_NN
2005_CD
16,522_CD
14.52_CD
Total_JJ
72,832_CD
13.65_CD
All_QUAN
shares_NN
purchased_VBN [WZPAST]
in_PIN
2005_CD
are_VPRT [PASS]
held_VBN [PRIV]
as_IN
Treasury_NN
shares_NN
._.
For_PIN
details_NN
of_PIN
substantial_JJ
shareholdings_GER
refer_VPRT
to_PIN
Substantial_NN
shareholdings_GER
on_PIN
page_NN
183_CD
._.
GSK_NN
Annual_JJ
Report_NN
2005_CD
116_CD
FINANCIAL_NN
STATEMENTS_NOMZ
Notes_NN
to_PIN
the_DT
financial_JJ
statements_NOMZ
continued_VBD
32_CD
Movements_NOMZ
in_PIN
equity_NOMZ
Shareholders_NN
equity_NOMZ
Share_NN
Share_NN
Retained_VBN
Other_JJ
Minority_NOMZ
Total_JJ
capital_NN
premium_NN
earnings_GER
reserves_NN
Total_JJ
interests_NN
equity_NOMZ
m_NN
m_FW
m_FW
m_FW
m_FW
m_FW
m_FW [BEMA]
At_PIN
1st_CD
January_NN
2003_CD
1,506_CD
224_CD
3,065_CD
926_CD
3,869_CD
743_CD
4,612_CD
Recognised_JJ
income_NN
and_PHC
expense_NN
for_PIN
the_DT
year_NN
3,919_CD
3,919_CD
34_CD
3,953_CD
Distributions_NOMZ
to_PIN
minority_NOMZ
shareholders_NN
96_CD
96_CD
Dividends_NN
to_PIN
shareholders_NN
2,333_CD
2,333_CD
2,333_CD
Ordinary_NN
shares_NN
issued_VBD
1_CD
40_CD
41_CD
41_CD
Ordinary_NN
shares_NN
purchased_VBD
and_PHC
canceled_VBD
20_CD
980 20 980 980_CD
Ordinary_NN
shares_NN
transferred_VBN [WZPAST]
by_PIN
ESOP_NN
Trusts_NN
26_CD
26_CD
26_CD
Write-down_NN
of_PIN
shares_NN
held_VBN [PRIV] [WZPAST]
by_PIN
ESOP_NN
Trusts_NN
87_CD
87_CD
Share-based_JJ
incentive_NN
plans_NN
375 375 375_CD
At_PIN
31st_CD
December_NN
2003_CD
1,487_CD
264_CD
3,959_CD
793_CD
4,917_CD
681_CD
5,598_CD
Recognised_JJ
income_NN
and_PHC
expense_NN
for_PIN
the_DT
year_NN
3,906_CD
3,906_CD
93_CD
3,999_CD
Changes_NN
in_PIN
minority_NOMZ
shareholdings_GER
489_CD
489_CD
Distributions_NOMZ
to_PIN
minority_NOMZ
shareholders_NN
72_CD
72_CD
Dividends_NN
to_PIN
shareholders_NN
2,476_CD
2,476_CD
2,476_CD
Ordinary_NN
shares_NN
issued_VBD
2_CD
40_CD
42_CD
42_CD
Ordinary_NN
shares_NN
purchased_VBD
and_PHC
canceled_VBD
5_CD
201_CD
5_CD
201_CD
201_CD
Ordinary_JJ
shares_NN
purchased_VBN
and_PHC
held_VBN [PRIV]
as_IN
Treasury_NN
shares_NN
799 799 799_CD
Ordinary_NN
shares_NN
transferred_VBN [WZPAST]
by_PIN
ESOP_NN
Trusts_NN
23_CD
23_CD
23_CD
Write-down_NN
of_PIN
shares_NN
held_VBN [PRIV] [WZPAST]
by_PIN
ESOP_NN
Trusts_NN
180_CD
180_CD
Share-based_JJ
incentive_NN
plans_NN
333 21 312 312_CD
At_PIN
31st_CD
December_NN
2004_CD
1,484_CD
304_CD
4,542_CD
606_CD
5,724_CD
213_CD
5,937_CD
Implementation_NOMZ
of_PIN
accounting_GER
for_PIN
financial_JJ
instruments_NOMZ
under_IN
IAS_NN
39_CD
94_CD
78_CD
16_CD
4_CD
12_CD
At_PIN
1st_CD
January_NN
2005_CD
,_,
as_IN
adjusted_VBN
1,484_CD
304_CD
4,448_CD
528_CD
5,708_CD
217_CD
5,925_CD
Recognised_JJ
income_NN
and_PHC
expense_NN
for_PIN
the_DT
year_NN
4,426_CD
3_CD
4,423_CD
153_CD
4,576_CD
Changes_NN
in_PIN
minority_NOMZ
shareholdings_GER
15_CD
15_CD
25_CD
40_CD
Distributions_NOMZ
to_PIN
minority_NOMZ
shareholders_NN
86_CD
86_CD
Dividends_NN
to_PIN
shareholders_NN
2,390_CD
2,390_CD
2,390_CD
Ordinary_NN
shares_NN
issued_VBD
7_CD
245 252 252_CD
Ordinary_NN
shares_NN
purchased_VBD
and_PHC
held_VBD [PRIV]
as_IN
Treasury_NN
shares_NN
1,000_CD
1,000_CD
1,000_CD
Ordinary_NN
shares_NN
transferred_VBN [WZPAST]
by_PIN
ESOP_NN
Trusts_NN
68_CD
68_CD
68_CD
Write-down_NN
of_PIN
shares_NN
held_VBN [PRIV] [WZPAST]
by_PIN
ESOP_NN
Trusts_NN
155_CD
155_CD
Share-based_JJ
incentive_NN
plans_NN
240 240 240_CD
Tax_NN
on_PIN
share-based_JJ
incentive_NN
plans_NN
25_CD
25_CD
25_CD
At_PIN
31st_CD
December_NN
2005_CD
1,491_CD
549_CD
5,579_CD
308_CD
7,311_CD
259_CD
7,570_CD
Retained_VBN
earnings_GER
and_CC
other_JJ
reserves_NN
amounted_VBD
to_PIN
5,271_CD
million_CD
at_PIN
31st_CD
December_NN
2005_CD
2004_CD
3,936_CD
million_CD
,_,
2003_CD
3,166_CD
million_CD
of_PIN
which_WDT [PIRE]
8,067_CD
million_CD
2004_CD
10,243_CD
million_CD
,_,
2003_CD
10,785_CD
million_CD
relates_VPRT
to_PIN
the_DT
company_NN
and_CC
180_CD
million_CD
2004_CD
108_CD
million_CD
,_,
2003_CD
93_CD
million_CD
relates_VPRT
to_PIN
joint_JJ
ventures_NN
and_CC
associated_VBN
undertakings_GER
._.
The_DT
cumulative_JJ
translation_NOMZ
exchange_NN
in_PIN
equity_NOMZ
at_PIN
31st_CD
December_NN
2005_CD
since_OSUB
1st_CD
January_NN
2003_CD
is_VPRT [BEMA]
217_CD
million_CD
2004_CD
5_CD
million_CD
,_,
2003_CD
46_CD
million_CD
._.
2005_CD
share_NN
based_VBN
incentive_NN
plans_NN
of_PIN
240_CD
million_CD
,_,
includes_VPRT
4_CD
million_CD
relating_VBG
to_PIN
an_DT
associate_JJ
undertaking_GER
._.
GSK_NN
Annual_JJ
Report_NN
2005_CD
117_CD
FINANCIAL_NN
STATEMENTS_NOMZ
Notes_NN
to_PIN
the_DT
financial_JJ
statements_NOMZ
continued_VBD
32_CD
Movements_NOMZ
in_PIN
equity_NOMZ
continued_VBD
Other_JJ
reserves_NN
is_VPRT [PASS]
analyzed_VBN
as_IN
follows_VPRT
:_:
Cash_NN
ow_NN
ESOP_NN
Trust_NN
Fair_NN
value_NN
hedge_NN
Other_JJ
shares_NN
reserve_NN
reserve_NN
reserves_NN
Total_JJ
m_NN
m_FW
m_FW
m_FW
m_FW [BEMA]
At_PIN
1st_CD
January_NN
2003_CD
2,831_CD
1,905_CD
926_CD
Ordinary_JJ
shares_NN
purchased_VBN
and_PHC
canceled_VBN
20_CD
20_CD
Ordinary_NN
shares_NN
transferred_VBN [WZPAST]
by_PIN
ESOP_NN
Trusts_NN
26_CD
26_CD
Write-down_NN
of_PIN
shares_NN
held_VBN [PRIV] [WZPAST]
by_PIN
ESOP_NN
Trusts_NN
87_CD
87_CD
At_PIN
31st_CD
December_NN
2003_CD
2,718_CD
1,925_CD
793_CD
Ordinary_JJ
shares_NN
purchased_VBN
and_PHC
canceled_VBN
5_CD
5_CD
Ordinary_NN
shares_NN
transferred_VBN [WZPAST]
by_PIN
ESOP_NN
Trusts_NN
23_CD
23_CD
Write-down_NN
of_PIN
shares_NN
held_VBN [PRIV] [WZPAST]
by_PIN
ESOP_NN
Trusts_NN
180_CD
180_CD
Share-based_JJ
incentive_NN
plans_NN
21_CD
21_CD
At_PIN
31st_CD
December_NN
2004_CD
2,536_CD
1,930_CD
606_CD
Implementation_NOMZ
of_PIN
accounting_GER
for_PIN
financial_JJ
instruments_NOMZ
under_IN
IAS_NN
39_CD
76_CD
2_CD
78_CD
At_PIN
1st_CD
January_NN
2005_CD
,_,
as_IN
adjusted_VBN
2,536_CD
76_CD
2_CD
1,930_CD
528_CD
Recognised_JJ
income_NN
and_PHC
expense_NN
for_PIN
the_DT
year_NN
3_CD
3_CD
Ordinary_NN
shares_NN
transferred_VBN [WZPAST]
by_PIN
ESOP_NN
Trusts_NN
68_CD
68_CD
Write-down_NN
of_PIN
shares_NN
held_VBN [PRIV] [WZPAST]
by_PIN
ESOP_NN
Trusts_NN
155_CD
155_CD
At_PIN
31st_CD
December_NN
2005_CD
2,313_CD
76_CD
1_CD
1,930_CD
308_CD
Other_JJ
reserves_NN
include_VPRT
the_DT
merger_NN
reserve_NN
created_VBN [WZPAST]
on_PIN
the_DT
merger_NN
of_PIN
Glaxo_NN
Wellcome_NN
and_PHC
SmithKline_NN
Beecham_NN
amounting_VBG [WZPRES]
to_PIN
1,561_CD
million_CD
at_PIN
31st_CD
December_NN
2005_CD
2004_CD
1,561_CD
million_CD
:_:
2003_CD
1,561_CD
million_CD
._.
Other_JJ
reserves_NN
also_RB
include_VPRT
the_DT
capital_NN
redemption_NOMZ
reserve_NN
created_VBN
as_CONJ
a_NULL
result_NULL
of_PIN
the_DT
share_NN
buy-back_JJ
program_NN
amounting_GER
to_PIN
81_CD
million_CD
at_PIN
31st_CD
December_NN
2005_CD
2004_CD
81_CD
million_CD
,_,
2003_CD
76_CD
million_CD
._.
33_CD
Related_VBN
party_NN
transactions_NOMZ
GlaxoSmithKline_NN
held_VBD [PRIV]
an_DT
18.4_CD
%_NN
interest_NN
in_PIN
Quest_NN
Diagnostics_NN
Inc._NN
at_PIN
31st_CD
December_NN
2005_CD
2004_CD
18.6_CD
%_NN
._.
The_DT
Group_NN
and_PHC
Quest_NN
Diagnostics_NN
are_VPRT
parties_NN
to_PIN
a_DT
long-term_JJ
contractual_JJ
relationship_NN
under_IN
which_WDT
Quest_NN
Diagnostics_NN
is_VPRT [BEMA]
the_DT
primary_JJ
provider_NN
of_PIN
clinical_JJ
laboratory_NN
testing_GER
to_TO
support_VB
the_DT
Groups_NN
clinical_JJ
trials_NN
testing_GER
requirements_NOMZ
worldwide_VPRT
._.
During_PIN
2005_CD
,_,
Quest_NN
Diagnostics_NN
provided_VBD
services_NN
of_PIN
39_CD
million_CD
2004_CD
35_CD
million_CD
to_PIN
the_DT
Group_NN
._.
At_PIN
31st_CD
December_NN
2005_CD
the_DT
balance_NN
payable_JJ
by_PIN
GlaxoSmithKline_NN
to_PIN
Quest_NN
Diagnostics_NN
was_VBD [BEMA]
5_CD
million_CD
2004_CD
6_CD
million_CD
._.
In_PIN
2005_CD
,_,
both_CC
the_DT
Group_NN
and_PHC
Shionogi_NN
&_CC
Co._NN
._.
Ltd._NN
entered_VBD
into_PIN
transactions_NOMZ
with_PIN
their_TPP3
50_CD
50_CD
US_FPP1
joint_JJ
venture_NN
company_NN
in_PIN
support_NN
of_PIN
the_DT
research_NN
and_PHC
development_NOMZ
activities_NOMZ
conducted_VBN [WZPAST]
by_PIN
that_DEMO
joint_JJ
venture_NN
company_NN
._.
During_PIN
2005_CD
,_,
GlaxoSmithKline_NN
provided_VBD
services_NN
to_PIN
the_DT
joint_JJ
venture_NN
of_PIN
1_CD
million_CD
2004_CD
1_CD
million_CD
._.
At_PIN
31st_CD
December_NN
2005_CD
the_DT
balance_NN
due_JJ
to_PIN
GlaxoSmithKline_NN
from_PIN
the_DT
joint_JJ
venture_NN
was_VBD [BEMA]
1_CD
million_CD
2004_CD
2_CD
million_CD
._.
Dr_NN
Shapiro_NN
,_,
a_DT
Non-Executive_JJ
Director_NN
of_PIN
GlaxoSmithKline_NN
plc_NN
,_,
received_VBD
fees_NN
of_PIN
$_$
85,000_CD
2004_CD
$_$
85,000_CD
of_PIN
which_WDT [PIRE]
$_$
30,000_CD
2004_CD
$_$
30,000_CD
was_VBD [BEMA]
in_PIN
the_DT
form_NN
of_PIN
ADSs_NN
,_,
from_PIN
a_DT
subsidiary_NN
of_PIN
the_DT
company_NN
,_,
for_PIN
her_TPP3
membership_NN
of_PIN
the_DT
Groups_NN
scientific_JJ
Advisory_NN
Board_NN
._.
These_DEMO
fees_NN
are_VPRT [PASS]
included_VBN
within_PIN
Annual_JJ
remuneration_NOMZ
in_PIN
the_DT
Remuneration_NOMZ
Report_NN
on_PIN
pages_NN
37_CD
to_PIN
54_CD
._.
Dr_NN
Barzach_NN
,_,
a_DT
former_JJ
Non-Executive_NN
Director_NN
of_PIN
GlaxoSmithKline_NN
plc_NN
,_,
received_VBD
fees_NN
of84_JJ
,244_CD
2004_CD
83,005_CD
from_PIN
a_DT
subsidiary_NN
of_PIN
the_DT
company_NN
for_PIN
healthcare_NN
consultancy_NN
provided_VBN
._.
These_DEMP
are_VPRT [PASS]
included_VBN
within_PIN
Annual_JJ
remuneration_NOMZ
in_PIN
the_DT
Remuneration_NOMZ
Report_NN
._.
The_DT
aggregate_JJ
compensation_NOMZ
of_PIN
the_DT
Directors_NN
,_,
CET_NN
and_PHC
Company_NN
Secretary_NN
is_VPRT [PASS]
given_VBN
in_PIN
Note_NN
8_CD
,_,
Employee_NN
Costs_NN
._.
GSK_NN
Annual_JJ
Report_NN
2005_CD
118_CD
FINANCIAL_NN
STATEMENTS_NOMZ
Notes_NN
to_PIN
the_DT
financial_JJ
statements_NOMZ
continued_VBD
34_CD
Acquisitions_NOMZ
and_PHC
disposals_NN
Details_NN
of_PIN
the_DT
acquisition_NOMZ
and_PHC
disposal_NN
of_PIN
subsidiary_NN
and_CC
associated_VBN
undertakings_GER
,_,
joint_JJ
ventures_NN
and_CC
other_JJ
businesses_NOMZ
are_VPRT [PASS]
given_VBN
below_PLACE
:_:
2005_CD
Acquisitions_NOMZ
On_PIN
8th_JJ
December_NN
2005_CD
,_,
the_DT
Group_NN
acquired_VBD
100_CD
%_NN
of_PIN
the_DT
issued_VBN
share_NN
capital_NN
of_PIN
ID_NN
Biomedical_NN
Corporation_NOMZ
,_,
a_DT
biotechnology_NN
company_NN
based_VBN [WZPAST]
in_PIN
Canada_NN
specialising_VBG [WZPRES]
in_PIN
the_DT
development_NOMZ
and_PHC
manufacture_NN
of_PIN
vaccines_NN
,_,
particularly_RB
inuenza_NN
vaccines_NN
,_,
for_PIN
a_DT
cash_NN
consideration_NOMZ
of_PIN
874_CD
million_CD
._.
This_DEMO
transaction_NOMZ
has_VPRT [PEAS]
been_VBN [PASS]
accounted_VBN
for_PIN
by_PIN
the_DT
purchase_NN
method_NN
of_PIN
accounting_GER
._.
The_DT
goodwill_NN
arising_VBG [WZPRES]
on_PIN
the_DT
acquisition_NOMZ
results_NN
from_PIN
benets_NN
which_WDT [WHSUB]
can_POMD
not_XX0
be_VB [SPAU] [PASS]
separately_RB
quantied_VBN
and_PHC
recorded_VBN
,_,
including_VBG
immediate_JJ
access_NN
to_PIN
additional_JJ
u_NN
vaccines_NN
manufacturing_VBG [WZPRES]
capacity_NOMZ
,_,
particularly_RB
in_PIN
the_DT
event_NN
of_PIN
a_DT
pandemic_NN
,_,
a_DT
skilled_JJ
workforce_NN
and_CC
good_JJ
relations_NOMZ
with_PIN
the_DT
US_FPP1
and_CC
Canadian_JJ
governments_NOMZ
regarding_VBG [WZPRES]
the_DT
supply_NN
of_PIN
u_JJ
vaccines_NN
._.
ID_NN
Biomedical_NN
Corporation_NOMZ
had_VBD
a_DT
turnover_NN
of_PIN
30_CD
million_CD
2004_CD
23_CD
million_CD
and_CC
a_DT
loss_NN
of_PIN
83_CD
million_CD
2004_CD
loss_NN
17_CD
million_CD
for_PIN
the_DT
year_NN
,_,
of_PIN
which_WDT [PIRE]
1_CD
million_CD
of_PIN
turnover_NN
and_CC
11_CD
million_CD
of_PIN
loss_NN
related_VBN [WZPAST]
to_PIN
the_DT
period_NN
since_OSUB
acquisition_NOMZ
and_CC
are_VPRT [PASS]
included_VBN
in_PIN
the_DT
Group_NN
accounts_NN
._.
Book_NN
Fair_NN
value_NN
Fair_NN
value_NN
adjustment_NOMZ
value_NN
m_NN
m_FW
m_FW [BEMA]
Net_JJ
assets_NN
acquired_VBD
Intangible_JJ
assets_NN
15 686 701_CD
Property_NN
,_,
plant_NN
and_PHC
equipment_NOMZ
88_CD
88_CD
Other_JJ
assets_NN
74_CD
23_CD
97_CD
Deferred_JJ
tax_NN
provision_NN
225_CD
225_CD
Other_JJ
liabilities_NOMZ
136_CD
8_CD
144 41 476 517_CD
Goodwill_NN
357_CD
357_CD
Total_JJ
consideration_NOMZ
41 833 874_CD
The_DT
total_JJ
consideration_NOMZ
included_VBD
directly_RB
attributable_JJ
costs_NN
of_PIN
3_CD
million_CD
._.
On_PIN
12th_JJ
July_NN
2005_CD
,_,
the_DT
Group_NN
acquired_VBD
92_CD
%_NN
of_PIN
the_DT
issued_VBN
share_NN
capital_NN
of_PIN
Corixa_NN
Corporation_NOMZ
,_,
a_DT
biotechnology_NN
company_NN
specialising_VBG [WZPRES]
in_PIN
developing_VBG
vaccine_NN
adjuvants_NN
and_PHC
immunology_NN
based_VBN
products_NN
,_,
for_PIN
a_DT
cash_NN
consideration_NOMZ
of_PIN
150_CD
million_CD
._.
This_DEMO
investment_NOMZ
increased_VBD
the_DT
Groups_NN
holding_VBG [PRIV] [WZPRES]
in_PIN
Corixa_NN
to_PIN
100_CD
%_NN
._.
The_DT
Group_NN
had_VBD
a_DT
number_NN
of_PIN
business_NOMZ
relationships_NN
with_PIN
Corixa_NN
prior_RB
to_PIN
the_DT
acquisition_NOMZ
date_NN
,_,
principally_RB
in_PIN
relation_NOMZ
to_PIN
an_DT
adjuvant_JJ
developed_VBN
by_PIN
Corixa_NN
and_CC
used_VBN
in_PIN
some_QUAN
of_PIN
the_DT
Groups_NN
vaccines_NN
._.
The_DT
existing_VBG
8_CD
%_NN
investment_NOMZ
in_PIN
Corixa_NN
,_,
with_PIN
a_DT
book_NN
value_NN
of_PIN
12_CD
million_CD
,_,
was_VBD [SPAU] [PASS]
previously_TIME
classied_VBN
as_IN
an_DT
available-for-sale_JJ
investment_NOMZ
and_CC
now_TIME
forms_NN
part_NN
of_PIN
the_DT
investment_NOMZ
in_PIN
the_DT
subsidiary_NN
._.
The_DT
existing_VBG
8_CD
%_NN
of_PIN
the_DT
issued_VBN
share_NN
capital_NN
had_VBD [PEAS]
been_VBN [PASS]
acquired_VBN
,_,
in_PIN
previous_JJ
years_NN
,_,
for_PIN
a_DT
cash_NN
consideration_NOMZ
of_PIN
24_CD
million_CD
._.
Corixa_NN
Corporation_NOMZ
had_VBD
a_DT
turnover_NN
of_PIN
3_CD
million_CD
and_CC
a_DT
loss_NN
of_PIN
49_CD
million_CD
for_PIN
the_DT
year_NN
,_,
of_PIN
which_WDT [PIRE]
1_CD
million_CD
of_PIN
turnover_NN
and_CC
24_CD
million_CD
of_PIN
loss_NN
related_VBN [WZPAST]
to_PIN
the_DT
period_NN
since_OSUB
acquisition_NOMZ
and_CC
are_VPRT [PASS]
included_VBN
in_PIN
the_DT
Group_NN
accounts_NN
._.
Book_NN
Fair_NN
value_NN
Fair_NN
value_NN
adjustment_NOMZ
value_NN
m_NN
m_FW
m_FW [BEMA]
Net_JJ
assets_NN
acquired_VBD
Intangible_JJ
assets_NN
115_CD
115_CD
Other_JJ
assets_NN
91_CD
29_CD
120_CD
Other_JJ
liabilities_NOMZ
95_CD
4_CD
99_CD
4_CD
140_CD
136_CD
Goodwill_NN
2626_CD
Existing_VBG
investment_NOMZ
12_CD
12_CD
Total_JJ
consideration_NOMZ
16 166 150_CD
The_DT
total_JJ
consideration_NOMZ
included_VBD
directly_RB
attributable_JJ
costs_NN
of_PIN
1_CD
million_CD
._.
GSK_NN
Annual_JJ
Report_NN
2005_CD
119_CD
FINANCIAL_NN
STATEMENTS_NOMZ
Notes_NN
to_PIN
the_DT
financial_JJ
statements_NOMZ
continued_VBD
34_CD
Acquisitions_NOMZ
and_PHC
disposals_NN
continued_VBD
Euclid_NN
SR_NN
Partners_NN
,_,
LP_NN
During_PIN
2005_CD
an_DT
additional_JJ
2_CD
million_CD
was_VBD [PASS]
invested_VBN
in_PIN
Euclid_NN
SR_NN
Partners_NN
,_,
LP_NN
,_,
an_DT
associate_NN
in_PIN
which_WDT [PIRE]
the_DT
Group_NN
has_VPRT
a_DT
38.7_CD
%_NN
interest_NN
._.
GlaxoSmithKline_NN
Consumer_NN
Healthcare_NN
Limited_NN
In_PIN
April_NN
2005_CD
,_,
an_DT
Indian_JJ
subsidiary_NN
of_PIN
the_DT
Group_NN
purchased_VBD
3.16_CD
%_NN
of_PIN
the_DT
share_NN
capital_NN
held_VBN [PRIV] [WZPAST]
by_PIN
minority_NOMZ
shareholders_NN
,_,
for_PIN
a_DT
cash_NN
consideration_NOMZ
of_PIN
16_CD
million_CD
._.
GlaxoSmithKline_NN
Pharmaceuticals_NN
Limited_NN
In_PIN
May_POMD
and_PHC
June_NN
2005_CD
,_,
an_DT
Indian_JJ
subsidiary_NN
of_PIN
the_DT
Group_NN
purchased_VBD
1.52_CD
%_NN
of_PIN
the_DT
share_NN
capital_NN
held_VBN [PRIV] [WZPAST]
by_PIN
minority_NOMZ
shareholders_NN
,_,
for_PIN
a_DT
cash_NN
consideration_NOMZ
of_PIN
26_CD
million_CD
._.
GlaxoSmithKline_NN
Biologicals_NN
Shanghai_NN
Limited_NN
During_PIN
2005_CD
,_,
a_DT
Chinese_JJ
subsidiary_NN
of_PIN
the_DT
Group_NN
purchased_VBD
all_QUAN
of_PIN
the_DT
share_NN
capital_NN
held_VBN [PRIV] [WZPAST]
by_PIN
minority_NOMZ
shareholders_NN
for_PIN
a_DT
cash_NN
consideration_NOMZ
of_PIN
4_CD
million_CD
._.
Disposals_NN
Ideapharm_NN
SA_NN
In_PIN
December_NN
2005_CD
,_,
the_DT
Group_NN
disposed_VBD
of_PIN
Ideapharm_NN
SA_NN
,_,
a_DT
subsidiary_NN
located_VBN [WZPAST]
in_PIN
Romania_NN
,_,
for_PIN
cash_NN
proceeds_NN
of_PIN
3_CD
million_CD
,_,
which_WDT [SERE]
were_VBD [PASS]
received_VBN
in_PIN
January_NN
2006_CD
._.
The_DT
net_JJ
assets_NN
disposed_VBN [WZPAST]
of_PIN
in_PIN
the_DT
year_NN
included_VBD
cash_NN
of_PIN
2_CD
million_CD
._.
In_PIN
April_NN
2005_CD
,_,
the_DT
Group_NN
disposed_VBD
of_PIN
16.22_CD
%_NN
of_PIN
Aseptic_NN
Technologies_NN
S._NN
A._NN
to_PIN
Societe_NN
Regionale_NN
dInvestissement_NOMZ
fide_VBD
Wallonie_NN
S._NN
A._NN
for_PIN
cash_NN
proceeds_NN
of_PIN
10_CD
million_CD
._.
GSK_NN
GSK_NN
GSK_NN
Biologicals_NN
Aseptic_NN
PharmaConsumer_NN
Euclid_NN
ID_NN
Shanghai_NN
Tech_NN
._.
ceuticals_NN
Healthcare_NN
Ideapharm_NN
SR_NN
Corixa_NN
Biomedical_NN
Cash_NN
ows_VPRT
m_FW
m_FW
m_FW
m_FW
m_FW
m_FW
m_FW
m_FW [BEMA]
Total_JJ
Cash_NN
consideration_NOMZ
4_CD
26_CD
16_CD
2_CD
150_CD
874_CD
1,072_CD
Cash_NN
and_PHC
cash_NN
equivalents_NN
acquired_VBD
7_CD
9_CD
2_CD
Net_JJ
cash_NN
payment_NOMZ
on_PIN
acquisitions_NOMZ
4_CD
26_CD
16_CD
2_CD
143_CD
883_CD
1,074_CD
Cash_NN
and_PHC
cash_NN
equivalents_NN
disposed_VBD
2_CD
2_CD
Net_JJ
cash_NN
proceeds_NN
from_PIN
disposals_NN
10_CD
10_CD
GSK_NN
Annual_JJ
Report_NN
2005_CD
120_CD
FINANCIAL_NN
STATEMENTS_NOMZ
Notes_NN
to_PIN
the_DT
financial_JJ
statements_NOMZ
continued_VBD
34_CD
Acquisitions_NOMZ
and_PHC
disposals_NN
continued_VBD
2004_CD
Acquisitions_NOMZ
Fraxiparine_NN
,_,
Fraxodi_NN
and_PHC
Arixtra_NN
In_PIN
September_NN
2004_CD
,_,
the_DT
Group_NN
acquired_VBD
Fraxiparine_NN
,_,
Fraxodi_NN
and_PHC
Arixtra_NN
and_CC
related_JJ
assets_NN
including_VBG [WZPRES]
a_DT
manufacturing_GER
facility_NOMZ
for_PIN
a_DT
cash_NN
consideration_NOMZ
of_PIN
297_CD
million_CD
._.
Book_NN
Fair_NN
value_NN
Net_JJ
assets_NN
value_NN
adjustment_NOMZ
acquired_VBD
m_FW
m_FW
m_FW [BEMA]
Intangible_JJ
assets_NN
262_CD
262_CD
Tangible_JJ
xed_JJ
assets_NN
56_CD
24_CD
32_CD
Inventory_NN
79_CD
79_CD
Provisions_NN
for_PIN
onerous_JJ
contracts_NN
76 76 135 162_CD
297_CD
Euclid_JJ
SR_NN
Partners_NN
,_,
LP_NN
During_PIN
2004_CD
an_DT
additional_JJ
2_CD
million_CD
was_VBD [PASS]
invested_VBN
in_PIN
Euclid_NN
SR_NN
Partners_NN
,_,
LP_NN
,_,
an_DT
associate_JJ
company_NN
in_PIN
which_WDT [PIRE]
the_DT
Group_NN
has_VPRT
a_DT
38.7_CD
%_NN
interest_NN
._.
Disposals_NN
Quest_NN
Diagnostics_NN
Inc._NN
._.
During_PIN
2004_CD
,_,
the_DT
Group_NN
disposed_VBD
of_PIN
3.8_CD
million_CD
shares_NN
from_PIN
its_PIT
investment_NOMZ
in_PIN
Quest_NN
Diagnostics_NN
Inc._NN
for_PIN
cash_NN
proceeds_NN
of_PIN
188_CD
million_CD
,_,
reducing_VBG [PRESP]
the_DT
Groups_NN
shareholding_GER
at_PIN
31st_CD
December_NN
2004_CD
to_PIN
18.6_CD
%_NN
._.
A_DT
profit_NN
of_PIN
150_CD
million_CD
was_VBD [PASS]
recognized_VBN [PRIV]
._.
GlaxoSmithKline_NN
Vehicle_NN
Finance_NN
Ltd_NN
During_PIN
2004_CD
,_,
the_DT
Group_NN
disposed_VBD
of_PIN
its_PIT
employee_NN
vehicle_NN
nancing_VBG [WZPRES]
subsidiary_NN
resulting_VBG [WZPRES]
in_PIN
a_DT
loss_NN
of_PIN
3_CD
million_CD
._.
GlaxoSmithKline_NN
Pharmaceuticals_NN
Chongqing_GER
Ltd_NN
During_PIN
2004_CD
,_,
the_DT
Group_NN
disposed_VBD
of_PIN
GlaxoSmithKline_NN
Pharmaceuticals_NN
Chongqing_GER
Ltd_NN
,_,
a_DT
Group_NN
subsidiary_NN
located_VBN [WZPAST]
in_PIN
China_NN
,_,
for_PIN
7_CD
million_CD
._.
A_DT
profit_NN
on_PIN
disposal_NN
of_PIN
2_CD
million_CD
was_VBD [PASS]
realized_VBN [PRIV]
._.
Beeyar_NN
Investments_NOMZ
Pty_NN
Ltd_NN
In_PIN
July_NN
2004_CD
,_,
the_DT
Group_NN
disposed_VBD
of_PIN
Beeyar_NN
Investments_NOMZ
Pty_NN
Ltd_NN
,_,
a_DT
subsidiary_NN
located_VBN [WZPAST]
in_PIN
South_NN
Africa_NN
,_,
for_PIN
cash_NN
proceeds_NN
of_PIN
1_CD
million_CD
,_,
realizing_VBG [PRIV] [PRESP]
a_DT
profit_NN
of_PIN
1_CD
million_CD
._.
OptiLead_NN
S._NN
r._NN
l._VBD
During_PIN
the_DT
year_NN
,_,
part_NN
of_PIN
the_DT
Groups_NN
holding_VBG [PRIV] [WZPRES]
in_PIN
an_DT
associated_VBN
undertaking_GER
,_,
OptiLead_NN
S._NN
r._NN
l._NN
was_VBD [PASS]
sold_VBN
,_,
resulting_VBG [PRESP]
in_PIN
a_DT
loss_NN
of_PIN
1_CD
million_CD
._.
Fraxiparine_NN
GSK_NN
GSK_NN
Fraxodi_NN
Quest_NN
Vehicle_NN
Pharmaceuticals_NN
Beeyar_NN
and_PHC
Arixtra_NN
Euclid_NN
SR_NN
Diagnostics_NN
Finance_NN
Chongqing_GER
Investments_NOMZ
Total_NN
Cash_NN
ows_VPRT
m_FW
m_FW
m_FW
m_FW
m_FW
m_FW
m_FW
Cash_NN
consideration_NOMZ
paid_VBD
297_CD
2_CD
299_CD
Net_JJ
cash_NN
proceeds_NN
from_PIN
disposals_NN
188_CD
34_CD
7_CD
1_CD
230_CD
GSK_NN
Annual_JJ
Report_NN
2005_CD
121_CD
FINANCIAL_NN
STATEMENTS_NOMZ
Notes_NN
to_PIN
the_DT
financial_JJ
statements_NOMZ
continued_VBD
34_CD
Acquisitions_NOMZ
and_PHC
disposals_NN
continued_VBD
2003_CD
Acquisitions_NOMZ
Europharm_NN
During_PIN
2003_CD
,_,
the_DT
Group_NN
completed_VBD
the_DT
buyout_NN
of_PIN
the_DT
minority_NOMZ
interests_NN
in_PIN
Europharm_NN
Holdings_GER
SA_NN
,_,
a_DT
Group_NN
subsidiary_NN
located_VBN [WZPAST]
in_PIN
Romania_NN
,_,
for_PIN
3_CD
million_CD
,_,
giving_VBG
rise_NN
to_PIN
goodwill_NN
of_PIN
a_DT
further_RB
2_CD
million_CD
,_,
which_WDT [SERE]
has_VPRT [PEAS]
been_VBN [PASS]
capitalized_VBN
._.
Book_NN
Fair_NN
value_NN
Net_JJ
assets_NN
Goodwill_NN
Cost_NN
of_PIN
values_NN
adjustments_NOMZ
acquired_VBD
capitalized_JJ
acquisition_NOMZ
m_NN
m_FW
m_FW
m_FW
m_FW
Europharm_FW
1_CD
1_CD
2_CD
3_CD
Iter_NN
Sterilyo_NN
During_PIN
2003_CD
,_,
a_DT
further_JJ
payment_NOMZ
of_PIN
9_CD
million_CD
was_VBD [PASS]
made_VBN
pursuant_JJ
to_PIN
the_DT
2002_CD
acquisition_NOMZ
agreement_NOMZ
based_VBN [WZPAST]
on_PIN
the_DT
financial_JJ
performance_NN
of_PIN
the_DT
acquired_VBN
company_NN
._.
This_DEMO
amount_NN
has_VPRT [PEAS]
been_VBN [PASS]
included_VBN
as_IN
deferred_VBN
compensation_NOMZ
in_PIN
2002_CD
._.
Disposals_NN
SB_NN
Clinical_NN
Laboratories_NN
An_DT
additional_JJ
cash_NN
refund_NN
of_PIN
3_CD
million_CD
was_VBD [PASS]
received_VBN
during_PIN
2003_CD
in_PIN
respect_NN
of_PIN
indemnified_JJ
liabilities_NOMZ
arising_VBG [WZPRES]
from_PIN
the_DT
SB_NN
Clinical_NN
Laboratories_NN
disposal_NN
which_WDT [WHSUB]
occurred_VBD
in_PIN
1999_CD
._.
This_DEMO
refund_NN
follows_VPRT
the_DT
successful_JJ
outcome_NN
of_PIN
a_DT
case_NN
in_PIN
the_DT
US_FPP1
Court_NN
of_PIN
Appeal_NN
._.
IterSB_NN
Clinical_NN
Sterilyo_NN
Europharm_NN
Laboratories_NN
Other_JJ
Total_NN
Cash_NN
ows_VPRT
m_FW
m_FW
m_FW
m_FW
m_FW
Cash_NN
consideration_NOMZ
paid_VBD
9_CD
3_CD
3_CD
15_CD
Net_JJ
cash_NN
proceeds_NN
from_PIN
disposals_NN
3_CD
3_CD
35_CD
Commitments_NOMZ
2005_CD
2004_CD
Contractual_JJ
obligations_NOMZ
and_PHC
commitments_NOMZ
m_VPRT
m_FW [PASS]
Contracted_VBN
for_PIN
but_CC
not_XX0
provided_VBN
in_PIN
the_DT
financial_JJ
statements_NOMZ
:_:
Intangible_JJ
assets_NN
1,833_CD
1,278_CD
Plant_NN
,_,
property_NN
and_PHC
equipment_NOMZ
376_CD
213_CD
Pensions_NN
2,200_CD
Other_JJ
commitments_NOMZ
64_CD
84_CD
Interest_NN
on_PIN
loans_NN
3,067_CD
2,648_CD
7,540_CD
4,223_CD
A_DT
number_NN
of_PIN
commitments_NOMZ
were_VBD [PASS]
made_VBN
in_PIN
2005_CD
under_IN
licensing_GER
and_CC
other_JJ
agreements_NOMZ
,_,
principally_RB
with_PIN
Vertex_NN
Pharmaceuticals_NN
Inc._NN
._.
The_DT
commitments_NOMZ
related_VBN [WZPAST]
to_PIN
intangible_JJ
assets_NN
include_VPRT
milestone_NN
payments_NOMZ
,_,
which_WDT [SERE]
are_VPRT [BEMA]
dependent_PRED
on_PIN
successful_JJ
clinical_JJ
development_NOMZ
and_ANDC
which_WDT
represent_VPRT
the_DT
maximum_NN
that_TSUB
would_PRMD
be_VB [PASS]
paid_VBN
if_COND
all_QUAN
milestones_NN
are_VPRT [PASS]
achieved_VBN
._.
GSK_NN
has_VPRT [PEAS]
agreed_VBN [SUAV] [PUBV]
with_PIN
the_DT
trustees_NN
of_PIN
the_DT
UK_NN
and_PHC
US_FPP1
pension_NN
schemes_NN
to_TO
make_VB
additional_JJ
contributions_NOMZ
of_PIN
approximately_RB
370_CD
million_CD
per_PIN
year_NN
over_IN
a_DT
five-year_JJ
period_NN
ending_VBG [WZPRES]
31st_CD
December_NN
2009_CD
in_PIN
order_NN
to_TO
eliminate_VB
the_DT
pension_NN
deficits_NN
on_PIN
a_DT
IAS_NN
19_CD
basis_NN
,_,
by_PIN
that_DEMO
point_NN
._.
The_DT
table_NN
shows_VPRT [PRIV]
this_DEMO
commitment_NOMZ
,_,
which_WDT [SERE]
on_PIN
the_DT
basis_NN
of_PIN
the_DT
deficits_NN
at_PIN
31st_CD
December_NN
2005_CD
amounts_NN
to_PIN
total_JJ
contributions_NOMZ
normal_JJ
plus_PIN
additional_JJ
of_PIN
approximately_RB
550_CD
million_CD
per_PIN
year_NN
._.
No_SYNE
commitments_NOMZ
have_VPRT [PEAS]
been_VBN [PASS]
made_VBN
past_JJ
31st_CD
December_NN
2009_CD
._.
The_DT
Group_NN
also_RB
has_VPRT
other_JJ
commitments_NOMZ
relating_VBG [WZPRES]
to_PIN
revenue_NN
payments_NOMZ
to_TO
be_VB [PASS]
made_VBN
under_IN
licences_NN
and_CC
other_JJ
alliances_NN
,_,
principally_RB
to_PIN
Exelixis_NN
Inc._NN
._.
Commitments_NOMZ
in_PIN
respect_NN
of_PIN
future_JJ
interest_NN
payable_JJ
on_PIN
loans_NN
are_VPRT [PASS]
disclosed_VBN [PUBV]
after_IN
taking_VBG
into_PIN
account_NN
the_DT
effect_NN
of_PIN
interest_NN
rate_NN
swaps_NN
._.
2005_CD
2004_CD
Commitments_NOMZ
under_IN
operating_VBG
leases_NN
m_FW
m_FW [BEMA]
Rental_JJ
payments_NOMZ
due_JJ
within_PIN
one_CD
year_NN
111_CD
83_CD
Rental_JJ
payments_NOMZ
due_JJ
between_PIN
one_CD
and_CC
two_CD
years_NN
78_CD
73_CD
Rental_JJ
payments_NOMZ
due_JJ
between_PIN
two_CD
and_CC
three_CD
years_NN
60_CD
54_CD
Rental_JJ
payments_NOMZ
due_JJ
between_PIN
three_CD
and_CC
four_CD
years_NN
45_CD
42_CD
Rental_JJ
payments_NOMZ
due_JJ
between_PIN
four_CD
and_CC
five_CD
years_NN
40_CD
36_CD
Rental_JJ
payments_NOMZ
due_JJ
after_IN
five_CD
years_NN
103_CD
119_CD
Total_JJ
commitments_NOMZ
under_IN
operating_VBG
lease_NN
437_CD
407_CD
GSK_NN
Annual_JJ
Report_NN
2005_CD
122_CD
FINANCIAL_NN
STATEMENTS_NOMZ
Notes_NN
to_PIN
the_DT
financial_JJ
statements_NOMZ
continued_VBD
Borrowings_GER
denominated_VBD
in_PIN [STPR]
,_,
or_CC
swapped_VBD
into_PIN [STPR]
,_,
foreign_JJ
currencies_NN
that_TOBJ
36_CD
Financial_NN
instruments_NOMZ
and_CC
related_VBN
disclosures_NN
match_VPRT
investments_NOMZ
in_PIN
overseas_PLACE
Group_NN
assets_NN
are_VPRT [PASS]
treated_VBN
as_IN
a_DT
hedge_NN
Financial_NN
risk_NN
management_NOMZ
against_PIN
the_DT
relevant_JJ
net_JJ
assets_NN
._.
GlaxoSmithKline_NN
plc_NN
reports_NN
in_PIN
sterling_GER
and_CC
pays_VPRT
dividends_NN
out_PIN
of_PIN
sterling_GER
profits_NN
._.
The_DT
role_NN
of_PIN
Corporate_JJ
Treasury_NN
in_PIN
GSK_NN
is_VPRT
to_TO
manage_VB
At_PIN
31st_CD
December_NN
2005_CD
,_,
the_DT
Group_NN
had_VBD
outstanding_JJ
contracts_NN
to_TO
sell_VB
and_PHC
monitor_VB
the_DT
Groups_NN
external_JJ
and_PHC
internal_JJ
funding_GER
requirements_NOMZ
or_CC
purchase_NN
foreign_JJ
currency_NN
having_VBG [WZPRES]
a_DT
total_JJ
gross_JJ
notional_JJ
principal_NN
and_CC
financial_JJ
risks_NN
in_PIN
support_NN
of_PIN
Group_NN
corporate_JJ
objectives_NN
._.
Treasury_NN
amount_NN
of_PIN
15,974_CD
million_CD
2004_CD
11,137_CD
million_CD
._.
The_DT
majority_NOMZ
of_PIN
activities_NOMZ
are_VPRT [BYPA]
governed_VBN
by_PIN
policies_NN
and_PHC
procedures_NN
approved_VBN [WZPAST]
by_PIN
the_DT
contracts_NN
are_VPRT [BEMA]
for_PIN
periods_NN
of_PIN
12_CD
months_NN
or_CC
less_JJ
._.
Board_NN
and_CC
monitored_VBN
by_PIN
a_DT
treasury_NN
management_NOMZ
group_NN
._.
Based_VBN [PASTP]
on_PIN
the_DT
composition_NOMZ
of_PIN
net_JJ
debt_NN
at_PIN
31st_CD
December_NN
2005_CD
,_,
a_DT
10_CD
%_NN
appreciation_NOMZ
in_PIN
sterling_GER
against_PIN
major_JJ
currencies_NN
would_PRMD
result_VB
in_PIN
a_DT
GSK_NN
maintains_VPRT [PUBV]
treasury_NN
control_NN
systems_NN
and_PHC
procedures_NN
to_TO
monitor_VB
reduction_NOMZ
in_PIN
the_DT
Groups_NN
net_JJ
debt_NN
of_PIN
approximately_RB
61_CD
million_CD
._.
A_DT
foreign_JJ
exchange_NN
,_,
interest_NN
rate_NN
,_,
liquidity_NOMZ
,_,
credit_NN
and_CC
other_JJ
financial_JJ
risks_NN
._.
10_CD
%_NN
weakening_GER
in_PIN
sterling_GER
against_PIN
major_JJ
currencies_NN
would_PRMD
result_VB
in_PIN
GSK_NN
uses_VPRT
a_DT
variety_NN
of_PIN
financial_JJ
instruments_NOMZ
,_,
including_VBG
derivatives_NN
,_,
to_PIN
an_DT
increase_NN
in_PIN
the_DT
Groups_NN
net_JJ
debt_NN
of_PIN
approximately_RB
75_CD
million_CD
._.
finance_NN
its_PIT
operation_NOMZ
and_CC
to_TO
manage_VB
market_NN
risks_NN
from_PIN
these_DEMO
Interest_NN
rate_NN
risk_NN
management_NOMZ
operations_NOMZ
._.
Financial_NN
instruments_NOMZ
include_VPRT
cash_NN
and_CC
liquid_JJ
resources_NN
,_,
GSKs_NN
policy_NN
on_PIN
interest_NN
rate_NN
risk_NN
management_NOMZ
requires_VPRT [SUAV]
that_THVC
the_DT
borrowings_GER
and_PHC
spot_NN
foreign_JJ
exchange_NN
contracts_NN
._.
amount_NN
of_PIN
net_JJ
borrowings_GER
at_PIN
xed_JJ
rates_NN
increases_NN
with_PIN
the_DT
ratio_NN
of_PIN
A_DT
number_NN
of_PIN
derivative_JJ
financial_JJ
instruments_NOMZ
are_VPRT [PASS]
used_VBN
to_TO
manage_VB
the_DT
forecast_NN
net_JJ
interest_NN
payable_JJ
to_PIN
trading_GER
profit_NN
._.
market_NN
risks_NN
from_PIN
Treasury_NN
operations_NOMZ
._.
Derivative_JJ
instruments_NOMZ
,_,
The_DT
Group_NN
uses_VPRT
a_DT
limited_JJ
number_NN
of_PIN
interest_NN
rate_NN
swaps_NN
to_TO [SPIN]
principally_RB
comprising_VBG
forward_RB
foreign_JJ
currency_NN
contracts_NN
and_PHC
interest_NN
redenominate_NN
external_JJ
borrowings_GER
into_PIN
the_DT
interest_NN
rate_NN
coupon_NN
rate_NN
and_PHC
currency_NN
swaps_NN
,_,
are_VPRT [PASS]
used_VBN
to_TO
swap_VB
borrowings_GER
and_PHC
liquid_NN
required_VBN [SUAV] [WZPAST]
for_PIN
Group_NN
purposes_NN
._.
The_DT
duration_NOMZ
of_PIN
these_DEMO
swaps_NN
matches_VPRT
assets_NN
into_PIN
the_DT
currencies_NN
required_VBN [SUAV] [WZPAST]
for_PIN
Group_NN
purposes_NN
and_CC
to_TO
manage_VB
the_DT
duration_NOMZ
of_PIN
the_DT
principal_NN
instruments_NOMZ
._.
Interest_NN
rate_NN
derivative_JJ
exposure_NN
to_TO
funding_VBG
risks_NN
from_PIN
changes_NN
in_PIN
foreign_JJ
exchange_NN
rates_NN
and_PHC
instruments_NOMZ
are_VPRT [PASS]
accounted_VBN
for_PIN
as_IN
fair_JJ
value_NN
or_CC
cash_NN
ow_NN
hedges_NN
of_PIN
the_DT
interest_NN
rates_NN
._.
GSK_NN
balances_VPRT
the_DT
use_NN
of_PIN
borrowings_GER
and_CC
liquid_JJ
assets_NN
having_VBG [WZPRES]
regard_NN
The_DT
Group_NN
manages_VPRT
centrally_RB
the_DT
short-term_JJ
cash_NN
surpluses_NN
or_CC
to_PIN
the_DT
cash_NN
ow_NN
from_PIN
operating_VBG
activities_NOMZ
and_CC
the_DT
currencies_NN
in_PIN
which_WDT [PIRE]
borrowing_GER
requirements_NOMZ
of_PIN
subsidiary_NN
companies_NN
and_CC
uses_VPRT
forward_RB
it_PIT
is_VPRT [PASS]
earned_VBN
:_:
the_DT
tax_NN
cost_NN
of_PIN
intra-Group_JJ
distributions_NOMZ
:_:
the_DT
currencies_NN
contracts_NN
to_TO
hedge_VB
future_JJ
repayments_NOMZ
back_RB
into_PIN
originating_VBG
currency_NN
._.
in_PIN
which_WDT [PIRE]
business_NOMZ
assets_NN
are_VPRT [PASS]
denominated_VBN
:_:
and_ANDC
the_DT
post-tax_JJ
cost_NN
of_PIN
borrowings_GER
compared_VBN [WZPAST]
to_PIN
the_DT
post-tax_JJ
return_NN
on_PIN
liquid_JJ
assets_NN
._.
Sensitivity_NOMZ
analysis_NN
considers_VPRT [PRIV]
the_DT
sensitivity_NOMZ
of_PIN
the_DT
Groups_NN
net_JJ
debt_NN
to_PIN
hypothetical_JJ
changes_NN
in_PIN
market_NN
rates_NN
and_CC
assumes_VPRT [PRIV]
that_THVC
all_QUAN
other_JJ
Liquid_NN
assets_NN
surplus_NN
to_PIN
the_DT
immediate_JJ
operating_GER
requirements_NOMZ
of_PIN
variables_NN
remain_VPRT
constant_JJ
._.
Based_VBN [PASTP]
on_PIN
the_DT
composition_NOMZ
of_PIN
net_JJ
debt_NN
and_PHC
Group_NN
companies_NN
are_VPRT [SPAU] [PASS]
generally_RB
invested_VBN
and_PHC
managed_VBN
centrally_RB
by_PIN
nancing_VBG
arrangements_NOMZ
at_PIN
31st_CD
December_NN
2005_CD
,_,
and_ANDC
taking_VBG
into_PIN
Corporate_JJ
Treasury_NN
._.
Requirements_NOMZ
of_PIN
Group_NN
companies_NN
for_PIN
operating_VBG
consideration_NOMZ
all_QUAN
xed_VBN
rate_NN
borrowings_GER
in_PIN
place_NN
,_,
a_DT
one_CD
percentage_NN
finance_NN
are_VPRT [PASS]
met_VBN
whenever_RB
possible_JJ
from_PIN
central_JJ
resources_NN
._.
point_NN
100_CD
basis_NN
points_NN
decrease_VPRT
in_PIN
average_JJ
interest_NN
rates_NN
would_PRMD
result_VB
External_NN
borrowings_GER
,_,
mainly_RB
managed_VBD
centrally_RB
by_PIN
Corporate_JJ
Treasury_NN
,_,
in_PIN
an_DT
increase_NN
in_PIN
the_DT
Groups_NN
annual_JJ
net_JJ
interest_NN
charge_NN
of_PIN
comprise_VB
a_DT
portfolio_NN
of_PIN
long_JJ
and_PHC
medium-term_JJ
instruments_NOMZ
and_CC
shortapproximately_RB
19_CD
million_CD
._.
Market_NN
risk_NN
of_PIN
financial_JJ
assets_NN
GSK_NN
does_VPRT
not_XX0
hold_VB [PRIV]
or_CC
issue_VB
derivative_JJ
financial_JJ
instruments_NOMZ
for_PIN
The_DT
Group_NN
invests_VPRT
centrally_RB
managed_VBN
liquid_JJ
assets_NN
in_PIN
government_NOMZ
trading_GER
purposes_NN
and_CC
the_DT
Groups_NN
Treasury_NN
policies_NN
specically_RB
bonds_NN
,_,
short-term_JJ
corporate_JJ
debt_NN
instruments_NOMZ
with_PIN
a_DT
minimum_NN
prohibit_VPRT
such_JJ
activity_NOMZ
._.
All_QUAN
transactions_NOMZ
in_PIN
financial_JJ
instruments_NOMZ
are_VPRT [BEMA]
short-term_JJ
credit_NN
rating_NN
of_PIN
A-1_NN
P-1_NN
,_,
money_NN
market_NN
funds_NN
with_PIN
a_DT
undertaken_VBN
to_TO
manage_VB
the_DT
risks_NN
arising_VBG [WZPRES]
from_PIN
underlying_VBG
business_NOMZ
credit_NN
rating_NN
of_PIN
AAA_NN
Aaa_JJ
and_PHC
other_JJ
structured_JJ
investments_NOMZ
credit_NN
activities_NOMZ
,_,
not_XX0
for_PIN
speculation_NOMZ
._.
ratings_GER
shown_VBN [PRIV] [WZPAST]
are_VPRT [BEMA]
from_PIN
Standard_NN
and_PHC
Poors_NN
and_PHC
Moodys_NN
Investors_NN
Services_NN
,_,
respectively_RB
._.
These_DEMO
investments_NOMZ
are_VPRT [PASS]
classied_VBN
as_IN
availableForeign_NN
exchange_NN
risk_NN
management_NOMZ
for-sale_NN
._.
In_PIN
GSK_NN
foreign_JJ
currency_NN
transaction_NOMZ
exposure_NN
arising_VBG [WZPRES]
on_PIN
normal_JJ
trade_NN
ows_NN
,_,
in_PIN
respect_NN
of_PIN
both_DT
external_JJ
and_PHC
intra-Group_JJ
trade_NN
,_,
is_VPRT
not_XX0
Equity_NOMZ
investments_NOMZ
are_VPRT [PASS]
classied_VBN
as_IN
available-for-sale_JJ
investments_NOMZ
and_CC
hedged_VBN
._.
GSKs_NN
policy_NN
is_VPRT
to_TO
minimize_VB
the_DT
exposure_NN
of_PIN
overseas_PLACE
the_DT
Group_NN
manages_VPRT
disposals_NN
to_TO
meet_VB
overall_JJ
business_NOMZ
requirements_NOMZ
operating_VBG [WZPRES]
subsidiaries_NN
to_PIN
transaction_NOMZ
risk_NN
by_PIN
matching_VBG
local_JJ
currency_NN
as_IN
they_TPP3
arise_VPRT
._.
The_DT
Group_NN
regularly_RB
monitors_VPRT
the_DT
value_NN
of_PIN
its_PIT
equity_NOMZ
income_NN
with_PIN
local_JJ
currency_NN
costs_NN
._.
For_PIN
this_DEMO
purpose_NN
,_,
intra-Group_JJ
trading_GER
investments_NOMZ
and_CC
only_DWNT
enters_VPRT
into_PIN
hedges_NN
selectively_RB
with_PIN
the_DT
approval_NN
transactions_NOMZ
are_VPRT [PASS]
matched_VBN
centrally_RB
and_CC
intra-Group_JJ
payment_NOMZ
terms_NN
are_VPRT [BEMA]
of_PIN
the_DT
Board_NN
._.
Exceptional_JJ
foreign_JJ
currency_NN
cash_NN
ows_NN
are_VPRT
Credit_NN
risk_NN
hedged_VBD
selectively_RB
under_IN
the_DT
management_NOMZ
of_PIN
Corporate_JJ
Treasury_NN
._.
In_PIN
the_DT
USA_NN
,_,
in_PIN
line_NN
with_PIN
other_JJ
pharmaceutical_JJ
companies_NN
,_,
the_DT
Group_NN
A_NN
significant_JJ
proportion_NOMZ
of_PIN
Group_NN
borrowings_GER
,_,
including_VBG [PRESP]
the_DT
sells_VPRT
its_PIT
products_NN
through_PIN
a_DT
small_JJ
number_NN
of_PIN
wholesalers_NN
in_CONJ
addition_NULL
commercial_JJ
paper_NN
program_NN
,_,
is_VPRT [BEMA]
in_PIN
US_FPP1
dollars_NN
,_,
to_TO
benefit_VB
from_PIN
the_DT
to_PIN
hospitals_NN
,_,
pharmacies_NN
,_,
physicians_NN
and_CC
other_JJ
groups_NN
._.
Sales_NN
to_PIN
the_DT
liquidity_NOMZ
of_PIN
US_FPP1
dollar_NN
denominated_VBD
capital_NN
markets_NN
._.
Certain_NN
of_PIN
these_DEMO
three_CD
largest_JJ
wholesalers_NN
amounted_VBD
to_TO
approximately_RB
80_CD
%_NN
of_PIN
the_DT
and_CC
other_JJ
borrowings_GER
are_VPRT [PASS]
swapped_VBN
into_PIN
other_JJ
currencies_NN
as_IN
required_JJ
Groups_NN
US_FPP1
pharmaceutical_JJ
sales_NN
._.
At_PIN
31st_CD
December_NN
2005_CD
,_,
the_DT
Group_NN
for_PIN
Group_NN
purposes_NN
._.
The_DT
Group_NN
seeks_VPRT
to_TO
denominate_VB
borrowings_GER
in_PIN
had_VBD
trade_NN
receivables_NN
due_JJ
from_PIN
these_DEMO
three_CD
wholesalers_NN
totalling_VBG [WZPRES]
the_DT
currencies_NN
of_PIN
its_PIT
principal_JJ
assets_NN
and_PHC
cash_NN
ows_NN
._.
GSK_NN
Annual_JJ
Report_NN
2005_CD
123_CD
FINANCIAL_NN
STATEMENTS_NOMZ
Notes_NN
to_PIN
the_DT
financial_JJ
statements_NOMZ
continued_VBD
Equity_NOMZ
investments_NOMZ
investments_NOMZ
traded_VBN [WZPAST]
in_PIN
an_DT
active_JJ
market_NN
,_,
36_CD
Financial_NN
instruments_NOMZ
and_CC
related_VBN
disclosures_NN
determined_VBN [SUAV] [PRIV] [WZPAST]
by_PIN
reference_NN
to_PIN
the_DT
relevant_JJ
stock_NN
exchange_NN
quoted_VBN
bid_NN
continued_VBN
price_NN
:_:
other_JJ
investments_NOMZ
determined_VBN [SUAV] [PRIV] [WZPAST]
by_PIN
reference_NN
to_PIN
the_DT
current_JJ
The_DT
Group_NN
is_VPRT [PASS]
exposed_VBN
to_PIN
a_DT
concentration_NOMZ
of_PIN
credit_NN
risk_NN
in_PIN
respect_NN
of_PIN
market_NN
value_NN
of_PIN
similar_JJ
instruments_NOMZ
or_CC
by_PIN
reference_NN
to_PIN
the_DT
discounted_VBN
these_DEMO
wholesalers_NN
such_OSUB
that_NULL
,_,
if_COND
one_CD
or_CC
more_EMPH
of_PIN
them_TPP3
is_VPRT [BYPA]
affected_VBN
by_PIN
cash_NN
ows_NN
of_PIN
the_DT
underlying_VBG
net_JJ
assets_NN
financial_JJ
difficulty_NN
,_,
it_PIT
could_POMD
materially_RB
and_PHC
adversely_RB
affect_VB
the_DT
Groups_NN
Cash_NN
and_PHC
cash_NN
equivalents_NN
approximates_VPRT
to_PIN
the_DT
carrying_VBG
amount_NN
financial_JJ
results_NN
._.
Liquid_NN
investments_NOMZ
based_VBN [WZPAST]
on_PIN
quoted_VBN
market_NN
prices_NN
in_PIN
the_DT
case_NN
of_PIN
marketable_JJ
securities_NOMZ
:_:
based_VBN [PASTP]
on_PIN
principal_JJ
amounts_NN
in_PIN
the_DT
case_NN
of_PIN
The_DT
Group_NN
does_VPRT
not_XX0
believe_VB [PRIV] [THATD]
it_PIT
is_VPRT [PASS]
exposed_VBN
to_PIN
major_JJ
concentrations_NOMZ
of_PIN
non-marketable_JJ
securities_NOMZ
because_CAUS
of_PIN
their_TPP3
short_JJ
repricing_GER
periods_NN
credit_NN
risk_NN
on_PIN
other_JJ
classes_NN
of_PIN
financial_JJ
instruments_NOMZ
._.
The_DT
Group_NN
is_VPRT [BEMA]
Short-term_JJ
loans_NN
and_PHC
overdrafts_NN
approximates_VPRT
to_PIN
the_DT
carrying_VBG
exposed_VBN
to_PIN
credit-related_JJ
losses_NN
in_PIN
the_DT
event_NN
of_PIN
non-performance_JJ
by_PIN
amount_NN
because_CAUS
of_PIN
the_DT
short_JJ
maturity_NOMZ
of_PIN
these_DEMO
instruments_NOMZ
counterparties_NN
to_PIN
financial_JJ
instruments_NOMZ
,_,
but_CC
does_VPRT
not_XX0
expect_VB [PRIV] [THATD]
any_QUAN
Long-term_JJ
loans_NN
based_VBN [WZPAST]
on_PIN
quoted_VBN
market_NN
prices_NN
in_PIN
the_DT
case_NN
of_PIN
the_DT
counterparties_NN
to_TO
fail_VB
to_TO
meet_VB
their_TPP3
obligations_NOMZ
._.
Where_RB
the_DT
Group_NN
has_VPRT
Eurobonds_NN
and_CC
other_JJ
xed_JJ
rate_NN
borrowings_GER
:_:
approximates_VPRT
to_PIN
the_DT
significant_JJ
investments_NOMZ
with_PIN
a_DT
single_JJ
counterparty_NN
,_,
collateral_NN
is_VPRT
carrying_VBG
amount_NN
in_PIN
the_DT
case_NN
of_PIN
oating_NN
rate_NN
bank_NN
loans_NN
and_CC
other_JJ
obtained_VBN
in_PIN
order_NN
to_TO
reduce_VB
risk_NN
._.
loans_NN
The_DT
Group_NN
applies_VPRT
Board-approved_JJ
limits_NN
to_PIN
the_DT
amount_NN
of_PIN
credit_NN
Forward_RB
exchange_NN
contracts_NN
based_VBN [WZPAST]
on_PIN
market_NN
prices_NN
and_PHC
exchange_NN
exposure_NN
to_PIN
any_QUAN
one_CD
counterparty_NN
and_CC
employs_VPRT
strict_JJ
minimum_NN
credit_NN
rates_NN
at_PIN
the_DT
balance_NN
sheet_NN
date_NN
worthiness_NOMZ
criteria_NN
as_IN
to_PIN
the_DT
choice_NN
of_PIN
counterparty_NN
._.
Currency_NN
swaps_NN
based_VBN [WZPAST]
on_PIN
market_NN
valuations_NOMZ
at_PIN
the_DT
balance_NN
sheet_NN
date_NN
Liquidity_NOMZ
Quest_NN
equity_NOMZ
collar_NN
and_PHC
Theravance_NN
put_VBD
and_PHC
call_VB
options_NOMZ
based_VBN
The_DT
Group_NN
operates_VPRT
globally_RB
,_,
primarily_RB
through_PIN
subsidiary_NN
companies_NN
on_PIN
an_DT
option_NOMZ
pricing_GER
model_NN
which_WDT [WHSUB]
uses_VPRT
significant_JJ
assumptions_NOMZ
in_PIN
established_VBN [PRIV]
in_PIN
the_DT
markets_NN
in_PIN
which_WDT [PIRE]
the_DT
Group_NN
trades_NN
._.
Due_JJ
to_PIN
the_DT
respect_NN
of_PIN
price_NN
volatility_NOMZ
,_,
dividend_NN
yield_NN
and_PHC
interest_NN
rates_NN
nature_NN
of_PIN
the_DT
Groups_NN
business_NOMZ
with_PIN
patent_NN
protection_NOMZ
on_PIN
many_QUAN
Interest_NN
rate_NN
instruments_NOMZ
based_VBN [WZPAST]
on_PIN
the_DT
net_JJ
present_JJ
value_NN
of_PIN
products_NN
in_PIN
the_DT
Groups_NN
portfolio_NN
,_,
the_DT
Groups_NN
products_NN
compete_VPRT
discounted_JJ
cash_NN
ows_VPRT
largely_RB
on_PIN
product_NN
efcacy_NN
rather_RB
than_PIN
on_PIN
price_NN
._.
Selling_VBG
margins_NN
are_VPRT
Receivables_NN
and_PHC
payables_NN
approximates_VPRT
to_PIN
the_DT
carrying_VBG
amount_NN
sufficient_JJ
to_TO
exceed_VB
normal_JJ
operating_GER
costs_NN
and_CC
the_DT
Groups_NN
operating_VBG [WZPRES]
Provisions_NN
approximates_VPRT
to_PIN
the_DT
carrying_VBG
amount_NN
subsidiaries_NN
are_VPRT
substantially_RB
cash_NN
generative_NN
._.
Lease_NN
obligations_NOMZ
approximates_VPRT
to_PIN
the_DT
carrying_VBG
value_NN
._.
Operating_VBG
cash_NN
ow_NN
is_VPRT [PASS]
used_VBN
to_TO
fund_VB
investment_NOMZ
in_PIN
the_DT
research_NN
and_CC
In_PIN
the_DT
year_NN
ended_VBD
31st_CD
December_NN
2005_CD
,_,
the_DT
total_JJ
amount_NN
of_PIN
the_DT
development_NOMZ
of_PIN
new_JJ
products_NN
as_RB
well_RB
as_IN
routine_JJ
outows_NN
of_PIN
capital_NN
change_NN
in_PIN
fair_JJ
values_NN
estimated_VBN [PRIV]
using_VBG
valuation_NOMZ
techniques_NN
referred_VBD
to_PIN
expenditure_NN
,_,
tax_NN
,_,
dividends_NN
and_PHC
repayment_NOMZ
of_PIN
maturing_VBG
debt_NN
._.
The_DT
above_PLACE
resulted_VBD
in_PIN
a_DT
credit_NN
to_PIN
the_DT
income_NN
statement_NOMZ
of_PIN
1_CD
million_CD
._.
Group_NN
may_POMD
,_,
from_PIN
time_NN
to_PIN
time_NN
,_,
have_VPRT
additional_JJ
demands_NN
for_PIN
finance_NN
,_,
such_JJ
as_IN
for_PIN
share_NN
purchases_NN
and_PHC
acquisitions_NOMZ
._.
Fair_NN
value_NN
of_PIN
investments_NOMZ
in_PIN
GSK_NN
shares_NN
At_PIN
31st_CD
December_NN
2005_CD
the_DT
ESOP_NN
Trusts_NN
held_VBD [PRIV]
GSK_NN
ordinary_JJ
shares_NN
GSK_NN
operates_VPRT
with_PIN
a_DT
high_JJ
level_NN
of_PIN
interest_NN
cover_NN
and_CC
at_PIN
low_JJ
levels_NN
of_PIN
with_PIN
a_DT
carrying_VBG
value_NN
of_PIN
2,313_CD
million_CD
2004_CD
2,574_CD
million_CD
with_PIN
net_JJ
debt_NN
relative_JJ
to_PIN
its_PIT
market_NN
capitalization_NOMZ
._.
In_CONJ
addition_NULL
to_PIN
the_DT
strong_JJ
a_DT
fair_JJ
value_NN
of_PIN
2,459_CD
million_CD
2004_CD
2,123_CD
million_CD
based_VBN
on_PIN
quoted_VBN
positive_JJ
cash_NN
ow_NN
from_PIN
normal_JJ
trading_GER
activities_NOMZ
,_,
additional_JJ
liquidity_NOMZ
market_NN
price_NN
._.
The_DT
shares_NN
represent_VPRT
purchases_NN
by_PIN
the_DT
ESOP_NN
Trusts_NN
to_TO
is_VPRT [BEMA]
readily_RB
available_PRED
via_PIN
its_PIT
commercial_JJ
paper_NN
program_NN
and_CC
shortsatisfy_JJ
future_JJ
exercises_NN
of_PIN
options_NOMZ
and_PHC
awards_NN
under_IN
employee_NN
term_NN
investments_NOMZ
._.
The_DT
Group_NN
also_RB
has_VPRT
a_DT
European_JJ
Medium_NN
Term_NN
Note_NN
incentive_NN
schemes_NN
._.
The_DT
carrying_VBG
value_NN
,_,
which_WDT [SERE]
is_VPRT [BEMA]
the_DT
lower_JJ
of_PIN
cost_NN
or_CC
program_NN
of_PIN
5_CD
billion_CD
,_,
of_PIN
which_WDT [PIRE]
3.5_CD
billion_CD
was_VBD [BEMA]
in_PIN
issue_NN
at_PIN
31st_CD
expected_VBN [PRIV]
proceeds_NN
,_,
of_PIN
these_DEMO
shares_NN
has_VPRT [PEAS]
been_VBN [PASS]
recognized_VBN [PRIV]
as_IN
a_DT
December_NN
2005_CD
._.
In_PIN
March_NN
2004_CD
,_,
the_DT
Group_NN
established_VBD [PRIV]
a_DT
US_FPP1
Shelf_NN
deduction_NOMZ
from_PIN
other_JJ
reserves_NN
._.
At_PIN
31st_CD
December_NN
2005_CD
,_,
GSK_NN
held_VBD [PRIV]
Registration_NOMZ
of_PIN
$_$
5_CD
billion_CD
:_:
at_PIN
31st_CD
December_NN
2005_CD
$_$
2.4_CD
billion_CD
1.4_CD
Treasury_NN
shares_NN
at_PIN
a_DT
cost_NN
of_PIN
1,799_CD
million_CD
2004_CD
799_CD
million_CD
which_WDT
billion_CD
was_VBD [BEMA]
in_PIN
issue_NN
._.
has_VPRT [PEAS]
been_VBN [PASS]
deducted_VBN
from_PIN
retained_VBN
earnings_GER
._.
Fair_NN
value_NN
of_PIN
financial_JJ
assets_NN
and_PHC
liabilities_NOMZ
Committed_VBN
facilities_NOMZ
The_DT
table_NN
on_PIN
page_NN
125_CD
presents_VPRT
the_DT
carrying_VBG
amounts_NN
under_IN
IFRS_NN
and_PHC
The_NN
Group_NN
has_VPRT [PEAS]
committed_VBN
facilities_NOMZ
to_TO
back_VB
up_RP
the_DT
commercial_JJ
paper_NN
the_DT
fair_JJ
values_NN
of_PIN
the_DT
Groups_NN
financial_JJ
assets_NN
and_PHC
liabilities_NOMZ
at_PIN
31st_CD
program_NN
of_PIN
$_$
900_CD
million_CD
523_CD
million_CD
2004_CD
$_$
900_CD
million_CD
469_CD
December_NN
2005_CD
._.
Comparative_JJ
information_NOMZ
is_VPRT [PASS]
presented_VBN
in_PIN
the_DT
table_NN
million_CD
of_PIN
364_CD
days_NN
duration_NOMZ
,_,
renewable_JJ
annually_RB
._.
The_DT
carrying_VBG
amounts_NN
at_PIN
31st_CD
December_NN
2004_CD
are_VPRT [BEMA]
2005_CD
,_,
undrawn_JJ
committed_JJ
facilities_NOMZ
totalled_VBD
$_$
900_CD
million_CD
523_CD
recorded_VBN
on_PIN
the_DT
UK_NN
GAAP_NN
basis_NN
applicable_JJ
at_PIN
that_DEMO
date_NN
rather_RB
than_PIN
million_CD
2004_CD
$_$
900_CD
million_CD
469_CD
million_CD
._.
in_PIN
accordance_NN
with_PIN
IAS_NN
32_CD
and_CC
IAS_NN
39_CD
as_IN
described_VBN
in_PIN
Note_NN
1_CD
._.
The_DT
fair_JJ
values_NN
of_PIN
the_DT
financial_JJ
assets_NN
and_PHC
liabilities_NOMZ
are_VPRT [PASS]
included_VBN
at_PIN
the_DT
amount_NN
at_PIN
which_WDT [PIRE]
the_DT
instrument_NOMZ
could_POMD
be_VB [PASS]
exchanged_VBN
in_PIN
a_DT
current_JJ
transaction_NOMZ
between_PIN
willing_JJ
parties_NN
,_,
other_JJ
than_PIN
in_PIN
a_DT
forced_VBN
or_CC
liquidation_NOMZ
sale_NN
._.
The_DT
following_VBG
methods_NN
and_PHC
assumptions_NOMZ
were_VBD [PASS]
used_VBN
to_TO
estimate_VB [PRIV]
the_DT
fair_JJ
values_NN
:_:
GSK_NN
Annual_JJ
Report_NN
2005_CD
124_CD
FINANCIAL_NN
STATEMENTS_NOMZ
Notes_NN
to_PIN
the_DT
financial_JJ
statements_NOMZ
continued_VBD
36_CD
Financial_NN
instruments_NOMZ
and_CC
related_VBN
disclosures_NN
continued_VBD
2005_CD
IFRS_NN
disclosures_NN
The_DT
Group_NN
adopted_VBD
IAS_NN
32_CD
and_CC
IAS_NN
39_CD
on_PIN
1st_CD
January_NN
2005_CD
._.
The_DT
following_VBG
disclosures_NN
are_VPRT [PASS]
included_VBN
as_RB
at_PIN
31st_CD
December_NN
2005_CD
to_TO
meet_VB
the_DT
requirements_NOMZ
of_PIN
IAS_NN
32_CD
._.
Classication_NOMZ
and_CC
fair_JJ
values_NN
of_PIN
financial_JJ
assets_NN
and_PHC
liabilities_NOMZ
The_DT
following_JJ
table_NN
sets_VPRT
out_PIN
the_DT
classication_NOMZ
of_PIN
financial_JJ
assets_NN
and_PHC
liabilities_NOMZ
._.
Receivables_NN
and_PHC
payables_NN
have_VPRT [PEAS]
been_VBN [PASS]
included_VBN
to_PIN
the_DT
extent_NN
they_TPP3
are_VPRT [PASS]
classied_VBN
as_IN
financial_JJ
assets_NN
and_PHC
liabilities_NOMZ
in_PIN
accordance_NN
with_PIN
IAS_NN
32_CD
._.
Provisions_NN
have_VPRT [PEAS]
been_VBN [PASS]
included_VBN
where_RB
there_EX
is_VPRT
a_DT
contractual_JJ
obligation_NOMZ
to_TO
settle_VB
in_PIN
cash_NN
._.
Where_RB
appropriate_JJ
,_,
currency_NN
and_PHC
interest_NN
rate_NN
swaps_NN
have_VPRT [PEAS]
been_VBN [PASS]
presented_VBN
alongside_PLACE
the_DT
underlying_VBG
principal_NN
instrument_NOMZ
._.
The_DT
carrying_VBG
amounts_NN
of_PIN
these_DEMO
instruments_NOMZ
have_VPRT [PEAS]
been_VBN [PASS]
adjusted_VBN
for_PIN
the_DT
effect_NN
of_PIN
the_DT
currency_NN
and_PHC
interest_NN
rate_NN
swaps_NN
acting_VBG [WZPRES]
as_IN
hedges_NN
._.
Carrying_VBG
Fair_NN
value_NN
value_NN
At_PIN
31st_CD
December_NN
2005_CD
mm_NN
Liquid_NN
investments_NOMZ
1,025_CD
1,025_CD
Cash_NN
and_PHC
cash_NN
equivalents_NN
4,209_CD
4,209_CD
Current_JJ
asset_NN
financial_JJ
instruments_NOMZ
5,234_CD
5,234_CD
notes_NN
and_PHC
bonds_NN
976_CD
1,097_CD
US$_$
notes_NN
,_,
bonds_NN
and_CC
private_JJ
nancing_GER
1,929_CD
1,932_CD
Notes_NN
and_PHC
bonds_NN
swapped_VBD
into_PIN
US$_$
502_CD
501_CD
Currency_NN
swaps_NN
54_CD
54_CD
Interest_NN
rate_NN
swaps_NN
47_CD
47_CD
2,424_CD
2,426_CD
Notes_NN
swapped_VBD
into_PIN
Yen_NN
342_CD
348_CD
Currency_NN
swaps_NN
10 10 332 338_CD
notes_NN
1,702_CD
1,705_CD
Interest_NN
rate_NN
swap_NN
55_CD
1,697_CD
1,700_CD
Other_JJ
short-term_JJ
borrowings_GER
909_CD
909_CD
Other_JJ
long-term_JJ
borrowings_GER
111_CD
111_CD
Total_JJ
borrowings_GER
and_CC
related_VBN
swaps_NN
6,449_CD
6,581_CD
Equity_NOMZ
investments_NOMZ
362_CD
362_CD
Receivables_NN
4,934_CD
4,934_CD
Payables_NN
4,754_CD
4,754_CD
Provisions_NN
1,533_CD
1,533_CD
Other_JJ
derivatives_NN
assets_NN
126_CD
126_CD
Other_JJ
derivatives_NN
liabilities_NOMZ
150_CD
150_CD
Other_JJ
financial_JJ
assets_NN
271_CD
271_CD
Other_JJ
financial_JJ
liabilities_NOMZ
391_CD
391_CD
Total_JJ
financial_JJ
assets_NN
and_PHC
liabilities_NOMZ
2,350_CD
2,482_CD
Total_JJ
financial_JJ
assets_NN
10,996_CD
10,996_CD
Total_JJ
financial_JJ
liabilities_NOMZ
13,346_CD
13,478_CD
Reconciliation_NOMZ
to_PIN
net_JJ
debt_NN
Liquid_NN
investments_NOMZ
1,025_CD
1,025_CD
Cash_NN
and_PHC
cash_NN
equivalents_NN
4,209_CD
4,209_CD
Total_JJ
borrowings_GER
6,449_CD
6,581_CD
1,215_CD
1,347_CD
Less_RB
net_JJ
effect_NN
of_PIN
interest_NN
rate_NN
and_PHC
currency_NN
swaps_NN
22_CD
22_CD
Net_JJ
debt_NN
1,237_CD
1,369_CD
GSK_NN
Annual_JJ
Report_NN
2005_CD
125_CD
FINANCIAL_NN
STATEMENTS_NOMZ
Notes_NN
to_PIN
the_DT
financial_JJ
statements_NOMZ
continued_VBD
36_CD
Financial_NN
instruments_NOMZ
and_CC
related_VBN
disclosures_NN
continued_VBD
Interest_NN
rate_NN
proles_NN
of_PIN
financial_JJ
assets_NN
and_PHC
liabilities_NOMZ
The_DT
following_JJ
tables_NN
set_VBN [WZPAST]
out_PIN
the_DT
exposure_NN
of_PIN
financial_JJ
assets_NN
and_PHC
liabilities_NOMZ
to_PIN
either_DT
xed_VBN
interest_NN
rates_NN
,_,
oating_NN
interest_NN
rates_NN
or_CC
no_SYNE
interest_NN
rates_NN
._.
The_DT
maturity_NOMZ
prole_NN
of_PIN
financial_JJ
assets_NN
and_PHC
liabilities_NOMZ
exposed_VBN [WZPAST]
to_PIN
interest_NN
rate_NN
risk_NN
in_PIN
the_DT
tables_NN
below_PLACE
indicates_VPRT [PRIV]
the_DT
contractual_JJ
repricing_GER
and_PHC
maturity_NOMZ
dates_NN
of_PIN
these_DEMO
instruments_NOMZ
._.
Cash_NN
and_CC
Other_JJ
Liquid_NN
cash_NN
financial_JJ
At_PIN
31st_CD
December_NN
2005_CD
Investments_NOMZ
investments_NOMZ
equivalents_NN
Receivables_NN
assets_NN
Total_NN
Financial_NN
assets_NN
m_VPRT
m_FW
m_FW
m_FW
m_FW
m_FW [BEMA]
Less_RB
than_PIN
one_CD
year_NN
1,025_CD
4,188_CD
204_CD
94_CD
5,511_CD
Between_PIN
one_CD
and_CC
two_CD
years_NN
8_CD
8_CD
Between_PIN
two_CD
and_CC
three_CD
years_NN
13_CD
13_CD
Between_PIN
three_CD
and_CC
four_CD
years_NN
12_CD
12_CD
Between_PIN
four_CD
and_CC
five_CD
years_NN
Greater_NN
than_PIN
five_CD
years_NN
117_CD
117_CD
Total_JJ
interest_NN
earning_VBG [WZPRES]
1,025_CD
4,188_CD
237_CD
211_CD
5,661_CD
Analysed_NN
as_IN
:_:
Fixed_JJ
rate_NN
interest_NN
292 207 117 616_CD
Floating_VBG
rate_NN
interest_NN
733_CD
4,188_CD
30_CD
94_CD
5,045_CD
Total_JJ
interest_NN
earning_VBG [WZPRES]
1,025_CD
4,188_CD
237_CD
211_CD
5,661_CD
Non-interest_JJ
earning_VBG
362_CD
21_CD
4,697_CD
255_CD
5,335_CD
Total_JJ
362_CD
1,025_CD
4,209_CD
4,934_CD
466_CD
10,996_CD
Effect_NN
of_PIN
Obligations_NOMZ
Other_JJ
interest_NN
rate_NN
under_IN
finance_NN
financial_JJ
At_PIN
31st_CD
December_NN
2005_CD
Debt_NN
swaps_NN
leases_VPRT
Payables_NN
Provisions_NN
liabilities_NOMZ
Total_NN
Financial_NN
liabilities_NOMZ
m_VPRT
m_FW
m_FW
m_FW
m_FW
m_FW
m_FW [BEMA]
Less_RB
than_PIN
one_CD
year_NN
1,176_CD
2,348_CD
103_CD
148_CD
61_CD
3,836_CD
Between_PIN
one_CD
and_CC
two_CD
years_NN
287_CD
291_CD
3_CD
23_CD
22_CD
Between_PIN
two_CD
and_CC
three_CD
years_NN
1,190_CD
1,185_CD
3_CD
8_CD
Between_PIN
three_CD
and_CC
four_CD
years_NN
343_CD
2_CD
345_CD
Between_PIN
four_CD
and_CC
five_CD
years_NN
2_CD
2_CD
Greater_NN
than_PIN
five_CD
years_NN
3,354_CD
872_CD
8_CD
2,490_CD
Total_JJ
interest_NN
bearing_GER
6,350_CD
121_CD
148_CD
84_CD
6,703_CD
Analysed_NN
as_IN
:_:
Fixed_JJ
rate_NN
interest_NN
5,527_CD
2,348_CD
21_CD
24_CD
3,224_CD
Floating_VBG
rate_NN
interest_NN
823_CD
2,348_CD
100_CD
148_CD
60_CD
3,479_CD
Total_JJ
interest_NN
bearing_GER
6,350_CD
121_CD
148_CD
84_CD
6,703_CD
Non-interest_JJ
bearing_GER
4,606_CD
1,533_CD
504_CD
6,643_CD
Total_JJ
6,350_CD
121_CD
4,754_CD
1,533_CD
588_CD
13,346_CD
Maturity_NOMZ
analysis_NN
of_PIN
interest_NN
earning_VBG [WZPRES]
financial_JJ
assets_NN
The_DT
maturity_NOMZ
analysis_NN
of_PIN
interest_NN
earning_VBG [WZPRES]
financial_JJ
assets_NN
is_VPRT [BEMA]
equivalent_PRED
to_PIN
the_DT
maturity_NOMZ
analysis_NN
presented_VBN [WZPAST]
in_PIN
the_DT
interest_NN
rate_NN
prole_JJ
table_NN
above_PLACE
._.
Maturity_NOMZ
analysis_NN
of_PIN
interest_NN
bearing_GER
financial_JJ
liabilities_NOMZ
Other_JJ
Finance_NN
financial_JJ
At_PIN
31st_CD
December_NN
2005_CD
Debt_NN
leases_NN
Payables_NN
liabilities_NOMZ
Total_NN
Financial_NN
liabilities_NOMZ
m_VPRT
m_FW
m_FW
m_FW
m_FW [BEMA]
Within_PIN
one_CD
year_NN
or_CC
on_PIN
demand_NN
1,162_CD
38_CD
148_CD
61_CD
1,409_CD
Between_PIN
one_CD
and_CC
two_CD
years_NN
287_CD
30_CD
23_CD
340_CD
Between_PIN
two_CD
and_CC
three_CD
years_NN
1,203_CD
21_CD
1,224_CD
Between_PIN
three_CD
and_CC
four_CD
years_NN
343_CD
11_CD
354_CD
Between_PIN
four_CD
and_CC
five_CD
years_NN
1_CD
8_CD
9_CD
After_IN
five_CD
years_NN
3,354_CD
13_CD
3,367_CD
6,350_CD
121_CD
148_CD
84_CD
6,703_CD
GSK_NN
Annual_JJ
Report_NN
2005_CD
126_CD
FINANCIAL_NN
STATEMENTS_NOMZ
Notes_NN
to_PIN
the_DT
financial_JJ
statements_NOMZ
continued_VBD
36_CD
Financial_NN
instruments_NOMZ
and_CC
related_VBN
disclosures_NN
continued_VBD
Currency_NN
proles_NN
of_PIN
financial_JJ
assets_NN
and_PHC
liabilities_NOMZ
The_DT
Groups_NN
currency_NN
exposures_NN
that_TSUB
give_VPRT
rise_VB
to_PIN
net_JJ
currency_NN
gains_NN
and_PHC
losses_NN
that_TSUB
are_VPRT [PASS]
recognized_VBN [PRIV]
in_PIN
the_DT
income_NN
statement_NOMZ
arise_VB
principally_RB
in_PIN
companies_NN
with_PIN
sterling_GER
functional_JJ
currency_NN
._.
The_DT
table_NN
below_PLACE
sets_NN
out_PIN
these_DEMO
exposures_NN
on_PIN
financial_JJ
assets_NN
and_PHC
liabilities_NOMZ
held_VBN [PRIV] [WZPAST]
in_PIN
currencies_NN
other_JJ
than_PIN
the_DT
functional_JJ
currencies_NN
of_PIN
Group_NN
companies_NN
after_IN
the_DT
effect_NN
of_PIN
currency_NN
swaps_NN
._.
At_PIN
31st_CD
December_NN
2005_CD
Sterling_GER
US$_$
Euro_NN
Yen_NN
Other_JJ
Total_NN
Financial_NN
assets_NN
m_VPRT
m_FW
m_FW
m_FW
m_FW
m_FW
Investments_NOMZ
8_CD
108_CD
3_CD
11_CD
130_CD
Cash_NN
and_PHC
cash_NN
equivalents_NN
1_CD
46_CD
10_CD
2_CD
19_CD
78_CD
Receivables_NN
7_CD
123_CD
89_CD
91_CD
310 16 277 102_CD
2_CD
121_CD
518_CD
At_PIN
31st_CD
December_NN
2005_CD
Sterling_GER
US$_$
Euro_NN
Yen_NN
Other_JJ
Total_NN
Financial_NN
liabilities_NOMZ
m_VPRT
m_FW
m_FW
m_FW
m_FW
m_FW
Debt_NN
497_CD
497_CD
Obligations_NOMZ
under_IN
finance_NN
lease_NN
2_CD
2_CD
Payables_NN
7_CD
18_CD
13_CD
1_CD
30_CD
69_CD
Provisions_NN
56_CD
56_CD
7_CD
76_CD
510_CD
1_CD
30_CD
624_CD
Derivative_JJ
financial_JJ
instruments_NOMZ
The_DT
table_NN
below_PLACE
sets_NN
out_PIN
the_DT
net_NN
principal_NN
amount_NN
and_CC
fair_JJ
value_NN
of_PIN
derivative_JJ
contracts_NN
held_VBN [PRIV] [WZPAST]
by_PIN
GSK_NN
:_:
Fair_NN
value_NN
Contract_NN
or_CC
underlying_VBG
principal_JJ
amount_NN
Assets_NN
Liabilities_NOMZ
2005 2005 2005_CD
m_FW
m_FW
m_FW
Currency_NN
and_PHC
interest_NN
related_VBN
instruments_NOMZ
:_:
Foreign_JJ
exchange_NN
contracts_NN
4,665_CD
102_CD
85_CD
Cross_NN
currency_NN
swaps_NN
842_CD
64_CD
Interest_NN
rate_NN
swaps_NN
1,848_CD
5_CD
47_CD
Equity_NOMZ
related_VBN
instruments_NOMZ
:_:
Options_NOMZ
and_PHC
warrants_NN
290_CD
21_CD
49_CD
Equity_NOMZ
collar_NN
299_CD
14_CD
Embedded_VBN
derivatives_NN
34_CD
3_CD
2_CD
Total_JJ
derivative_JJ
financial_JJ
instruments_NOMZ
195_CD
197_CD
In_PIN
2002_CD
,_,
GSK_NN
hedged_VBD
part_NN
of_PIN
the_DT
equity_NOMZ
value_NN
of_PIN
its_PIT
holdings_GER
in_PIN
its_PIT
largest_JJ
equity_NOMZ
investment_NOMZ
Quest_NN
Diagnostics_NN
Inc._NN
through_PIN
a_DT
series_NN
of_PIN
variable_JJ
sale_NN
forward_RB
contracts_NN
._.
The_DT
contracts_NN
the_DT
equity_NOMZ
collar_NN
are_VPRT [PASS]
structured_VBN
in_PIN
five_CD
series_NN
,_,
each_QUAN
over_IN
one_CD
million_CD
Quest_NN
shares_NN
,_,
and_ANDC
mature_VPRT
between_PIN
2006_CD
and_CC
2008_CD
._.
The_DT
Group_NN
has_VPRT [PEAS]
entered_VBN
into_PIN
a_DT
put_NN
option_NOMZ
agreement_NOMZ
whereby_OSUB
Theravances_NN
shareholders_NN
can_POMD
sell_VB
up_RP
to_PIN
half_DT
of_PIN
their_TPP3
Theravance_NN
shares_NN
to_PIN
GSK_NN
at_PIN
a_DT
pre-determined_JJ
price_NN
$_$
19.375_CD
._.
Given_VBN
the_DT
maximum_JJ
number_NN
of_PIN
shares_NN
subject_JJ
to_PIN
the_DT
put_NN
option_NOMZ
,_,
the_DT
Groups_NN
obligation_NOMZ
is_VPRT [PASS]
capped_VBN
at_PIN
$_$
525_CD
million_CD
._.
At_PIN
31st_CD
December_NN
2005_CD
,_,
this_DEMO
option_NOMZ
is_VPRT [PASS]
recorded_VBN
as_IN
a_DT
liability_NOMZ
of_PIN
$_$
81_CD
million_CD
2004_CD
$_$
132_CD
million_CD
._.
As_IN
at_PIN
31st_CD
December_NN
2005_CD
,_,
the_DT
maximum_NN
potential_JJ
exposure_NN
to_PIN
GSK_NN
from_PIN
fair_JJ
value_NN
movements_NOMZ
of_PIN
these_DEMO
options_NOMZ
is_VPRT
therefore_CONJ
approximately_RB
$_$
444_CD
million_CD
._.
The_DT
expiry_NN
date_NN
is_VPRT
August_NN
2007_CD
._.
The_DT
Group_NN
has_VPRT [PEAS]
entered_VBN
into_PIN
a_DT
call_NN
option_NOMZ
agreement_NOMZ
whereby_OSUB
it_PIT
can_POMD
purchase_VB
half_NN
of_PIN
the_DT
outstanding_JJ
Theravance_NN
shares_NN
in_PIN
issue_NN
at_PIN
a_DT
predetermined_VBN
price_NN
$_$
54.25_CD
._.
At_PIN
31st_CD
December_NN
2005_CD
,_,
this_DEMO
option_NOMZ
is_VPRT [PASS]
recorded_VBN
as_IN
an_DT
asset_NN
of_PIN
$_$
28_CD
million_CD
2004_CD
$_$
31_CD
million_CD
._.
As_IN
at_PIN
31st_CD
December_NN
2005_CD
,_,
the_DT
maximum_NN
potential_JJ
exposure_NN
to_PIN
GSK_NN
from_PIN
fair_JJ
value_NN
movements_NOMZ
of_PIN
this_DEMO
option_NOMZ
is_VPRT
therefore_CONJ
$_$
28_CD
million_CD
._.
GSK_NN
Annual_JJ
Report_NN
2005_CD
127_CD
FINANCIAL_NN
STATEMENTS_NOMZ
Notes_NN
to_PIN
the_DT
financial_JJ
statements_NOMZ
continued_VBD
36_CD
Financial_NN
instruments_NOMZ
and_CC
related_VBN
disclosures_NN
continued_VBD
The_DT
following_JJ
table_NN
sets_VPRT
out_PIN
the_DT
principal_JJ
amount_NN
and_CC
fair_JJ
values_NN
of_PIN
derivative_JJ
contracts_NN
which_WDT [WHSUB]
qualify_VPRT
for_PIN
hedge_JJ
accounting_GER
treatment_NOMZ
Contract_NN
or_CC
underlying_VBG
Fair_NN
value_NN
of_PIN
principal_JJ
amount_NN
derivative_JJ
contract_NN
2005_CD
2005_CD
m_FW
m_FW
Cash_NN
ow_NN
hedges_NN
:_:
Cross_NN
currency_NN
swaps_NN
342_CD
10_CD
Fair_NN
value_NN
hedges_NN
:_:
Foreign_JJ
exchange_NN
contracts_NN
2,151_CD
74_CD
Interest_NN
rate_NN
swaps_NN
1,848_CD
42_CD
Cross_NN
currency_NN
swaps_NN
500_CD
3_CD
Net_JJ
investment_NOMZ
hedges_NN
:_:
Foreign_JJ
exchange_NN
contracts_NN
6,816_CD
57_CD
Cross_NN
currency_NN
swaps_NN
500_CD
51_CD
Cash_NN
ow_NN
hedges_NN
The_DT
Group_NN
has_VPRT [PEAS]
entered_VBN
into_PIN
a_DT
cross_JJ
currency_NN
swap_NN
and_CC
designated_VBN
it_PIT
a_DT
cash_NN
ow_NN
hedge_NN
converting_VBG [WZPRES]
xed_VBD
Euro_NN
coupons_NN
,_,
payable_JJ
annually_RB
,_,
to_TO
xed_VB
Yen_NN
payments_NOMZ
._.
The_DT
risk_NN
being_VBG [WZPRES] [PASS]
hedged_VBN
is_VPRT [BEMA]
the_DT
variability_NOMZ
of_PIN
cash_NN
ows_NN
arising_VBG [WZPRES]
from_PIN
currency_NN
uctuations_NOMZ
._.
Fair_NN
value_NN
hedges_NN
Foreign_JJ
exchange_NN
contracts_NN
,_,
designated_VBN
as_IN
fair_JJ
value_NN
hedges_NN
,_,
have_VPRT [PEAS]
been_VBN [PASS]
entered_VBN
in_PIN
order_NN
to_TO
hedge_VB
the_DT
foreign_JJ
currency_NN
risk_NN
associated_VBN [WZPAST]
with_PIN
intercompany_NN
loans_NN
and_PHC
deposits_NN
,_,
commercial_JJ
paper_NN
borrowings_GER
and_CC
other_JJ
liabilities_NOMZ
._.
The_DT
Group_NN
has_VPRT [PEAS]
designated_VBN
interest_NN
rate_NN
swaps_NN
and_CC
the_DT
interest_NN
element_NOMZ
of_PIN
cross_JJ
currency_NN
swaps_NN
as_IN
fair_JJ
value_NN
hedges_NN
._.
The_DT
risk_NN
being_VBG [WZPRES] [PASS]
hedged_VBN
is_VPRT [BEMA]
the_DT
variability_NOMZ
of_PIN
the_DT
fair_JJ
value_NN
of_PIN
the_DT
bonds_NN
arising_VBG [WZPRES]
from_PIN
interest_NN
rate_NN
uctuations_NOMZ
._.
Net_JJ
investment_NOMZ
hedges_NN
Foreign_JJ
exchange_NN
contracts_NN
and_CC
the_DT
currency_NN
element_NOMZ
of_PIN
cross_JJ
currency_NN
swaps_NN
have_VPRT [PEAS]
been_VBN [PASS]
designated_VBN
as_IN
net_JJ
investment_NOMZ
hedges_NN
in_PIN
respect_NN
of_PIN
the_DT
foreign_JJ
currency_NN
translation_NOMZ
risk_NN
arising_VBG [WZPRES]
on_PIN
consolidation_NOMZ
of_PIN
the_DT
Groups_NN
net_JJ
investment_NOMZ
in_PIN
its_PIT
US_FPP1
dollar_NN
,_,
Euro_NN
and_PHC
Yen_NN
foreign_JJ
operations_NOMZ
._.
2004_CD
UK_NN
GAAP_NN
disclosures_NN
The_DT
Group_NN
exercised_VBD
the_DT
IFRS_NN
1_CD
exemption_NOMZ
to_TO
record_VB
financial_JJ
instruments_NOMZ
in_PIN
the_DT
comparative_JJ
period_NN
on_PIN
the_DT
existing_VBG
UK_NN
GAAP_NN
basis_NN
._.
The_DT
following_VBG
disclosures_NN
are_VPRT [PASS]
included_VBN
,_,
as_IN
at_PIN
31st_CD
December_NN
2004_CD
to_TO
meet_VB
the_DT
requirements_NOMZ
of_PIN
Financial_NN
Reporting_GER
Standard_NN
13_CD
Derivatives_NN
and_CC
other_JJ
financial_JJ
instruments_NOMZ
:_:
disclosures_NN
._.
UK_NN
GAAP_NN
accounting_GER
policy_NN
for_PIN
derivative_JJ
financial_JJ
instruments_NOMZ
The_DT
Group_NN
does_VPRT
not_XX0
hold_VB [PRIV]
or_CC
issue_VB
derivative_JJ
financial_JJ
instruments_NOMZ
for_PIN
trading_GER
purposes_NN
._.
Derivative_JJ
financial_JJ
instruments_NOMZ
are_VPRT [PASS]
used_VBN
to_TO
manage_VB
exposure_NN
to_PIN
market_NN
risks_NN
from_PIN
treasury_NN
operations_NOMZ
._.
The_DT
principal_JJ
derivative_NN
instruments_NOMZ
are_VPRT
currency_NN
swaps_NN
,_,
forward_RB
foreign_JJ
exchange_NN
contracts_NN
and_PHC
interest_NN
rate_NN
swaps_NN
._.
The_DT
derivative_JJ
contracts_NN
are_VPRT [PASS]
treated_VBN
from_PIN
inception_NOMZ
as_IN
an_DT
economic_JJ
hedge_NN
of_PIN
the_DT
underlying_VBG
financial_JJ
instrument_NOMZ
,_,
with_PIN
matching_JJ
accounting_GER
treatment_NOMZ
and_PHC
cash_NN
ows_NN
._.
The_DT
derivative_JJ
contracts_NN
have_VPRT
a_DT
high_JJ
correlation_NOMZ
with_PIN
the_DT
specic_JJ
financial_JJ
instrument_NOMZ
being_VBG [WZPRES] [PASS]
hedged_VBN
both_DT
at_PIN
inception_NOMZ
and_CC
throughout_PIN
the_DT
hedge_JJ
period_NN
._.
Derivative_JJ
instruments_NOMZ
no_RB
longer_RB
designated_VBN
as_IN
hedges_NN
are_VPRT [PASS]
restated_VBN
at_PIN
market_NN
value_NN
and_CC
any_QUAN
future_JJ
changes_NN
in_PIN
value_NN
are_VPRT [PASS]
taken_VBN
directly_RB
to_PIN
the_DT
income_NN
statement_NOMZ
._.
Currency_NN
swaps_NN
and_CC
forward_RB
foreign_JJ
exchange_NN
contracts_NN
used_VBN
to_TO
x_SYM
the_DT
value_NN
of_PIN
the_DT
related_JJ
asset_NN
or_CC
liability_NOMZ
in_PIN
the_DT
contract_NN
currency_NN
and_CC
at_PIN
the_DT
contract_NN
rate_NN
are_VPRT [PASS]
accrued_VBN
to_PIN
the_DT
income_NN
statement_NOMZ
over_IN
the_DT
life_NN
of_PIN
the_DT
contract_NN
._.
Gains_NN
and_PHC
losses_NN
on_PIN
foreign_JJ
forward_RB
exchange_NN
contracts_NN
designated_VBN
as_IN
hedges_NN
of_PIN
forecast_NN
foreign_JJ
exchange_NN
transactions_NOMZ
are_VPRT [PASS]
deferred_VBN
and_PHC
included_VBN
in_PIN
the_DT
measurement_NOMZ
of_PIN
the_DT
related_VBN
foreign_JJ
currency_NN
transactions_NOMZ
in_PIN
the_DT
period_NN
they_TPP3
occur_VPRT
._.
Gains_NN
and_PHC
losses_NN
on_PIN
balance_NN
sheet_NN
hedges_NN
are_VPRT [PASS]
accrued_VBN
and_PHC
are_VPRT [PASS]
taken_VBN
directly_RB
to_PIN
reserves_NN
,_,
except_PIN
that_DEMO
forward_RB
premiums_NN
discounts_NN
are_VPRT [PASS]
recognized_VBN [PRIV]
as_IN
interest_NN
over_IN
the_DT
life_NN
of_PIN
the_DT
contracts_NN
._.
Interest_NN
differentials_NN
under_IN
interest_NN
swap_NN
agreements_NOMZ
are_VPRT [PASS]
recognized_VBN [PRIV]
in_PIN
the_DT
income_NN
statement_NOMZ
by_PIN
adjustment_NOMZ
of_PIN
interest_NN
expense_NN
over_IN
the_DT
life_NN
of_PIN
the_DT
agreement_NOMZ
._.
GSK_NN
Annual_JJ
Report_NN
2005_CD
128_CD
FINANCIAL_NN
STATEMENTS_NOMZ
Notes_NN
to_PIN
the_DT
financial_JJ
statements_NOMZ
continued_VBD
36_CD
Financial_NN
instruments_NOMZ
and_CC
related_VBN
disclosures_NN
continued_VBD
Classication_NOMZ
and_CC
fair_JJ
values_NN
of_PIN
financial_JJ
assets_NN
and_PHC
liabilities_NOMZ
The_DT
following_JJ
table_NN
sets_VPRT
out_PIN
the_DT
classication_NOMZ
of_PIN
financial_JJ
assets_NN
and_PHC
liabilities_NOMZ
and_CC
provides_VPRT
a_DT
reconciliation_NOMZ
to_PIN
Group_NN
net_JJ
debt_NN
in_PIN
Note_NN
30_CD
._.
Shortterm_JJ
payables_NN
and_PHC
receivables_NN
have_VPRT [PEAS]
been_VBN [PASS]
excluded_VBN
from_PIN
financial_JJ
assets_NN
and_PHC
liabilities_NOMZ
._.
Carrying_VBG
Fair_NN
At_PIN
31st_CD
December_NN
2004_CD
value_NN
value_NN
Net_JJ
debt_NN
m_NN
m_NN
Liquid_NN
investments_NOMZ
1,512_CD
1,514_CD
Cash_NN
and_PHC
cash_NN
equivalents_NN
2,467_CD
2,467_CD
Current_JJ
asset_NN
financial_JJ
instruments_NOMZ
3,979_CD
3,981_CD
notes_NN
and_PHC
bonds_NN
1,475_CD
1,533_CD
1,475_CD
1,533_CD
US$_$
notes_NN
,_,
bonds_NN
and_CC
private_JJ
nancing_GER
1,828_CD
1,817_CD
Notes_NN
and_PHC
bonds_NN
swapped_VBD
into_PIN
US$_$
498_CD
497_CD
Currency_NN
swaps_NN
92_CD
Interest_NN
rate_NN
swaps_NN
28_CD
2,326_CD
2,250_CD
Notes_NN
swapped_VBD
into_PIN
Yen_NN
348_CD
338_CD
Currency_NN
swaps_NN
10 348 328_CD
notes_NN
705_CD
717_CD
Interest_NN
rate_NN
swap_NN
12 705 705_CD
Other_JJ
long-term_JJ
borrowings_GER
79_CD
79_CD
Other_JJ
short-term_JJ
loans_NN
and_PHC
overdrafts_NN
1,030_CD
1,030_CD
Total_JJ
borrowings_GER
and_CC
related_VBN
swaps_NN
5,963_CD
5,925_CD
Total_JJ
net_JJ
debt_NN
1,984_CD
1,944_CD
Equity_NOMZ
investments_NOMZ
298_CD
350_CD
Receivables_NN
597_CD
499_CD
Payables_NN
244_CD
244_CD
Provisions_NN
256_CD
256_CD
Other_JJ
foreign_JJ
exchange_NN
derivatives_NN
67_CD
79_CD
Non-hedging_JJ
derivatives_NN
59_CD
Total_JJ
financial_JJ
assets_NN
and_PHC
liabilities_NOMZ
1,656_CD
1,733_CD
Total_JJ
financial_JJ
assets_NN
4,874_CD
4,830_CD
Total_JJ
financial_JJ
liabilities_NOMZ
6,530_CD
6,563_CD
GSK_NN
Annual_JJ
Report_NN
2005_CD
129_CD
FINANCIAL_NN
STATEMENTS_NOMZ
Notes_NN
to_PIN
the_DT
financial_JJ
statements_NOMZ
continued_VBD
36_CD
Financial_NN
instruments_NOMZ
and_CC
related_VBN
disclosures_NN
continued_VBD
Currency_NN
and_PHC
interest_NN
rate_NN
risk_NN
prole_NN
of_PIN
financial_JJ
liabilities_NOMZ
Financial_JJ
liabilities_NOMZ
,_,
after_IN
taking_VBG
account_NN
of_PIN
currency_NN
and_PHC
interest_NN
rate_NN
swaps_NN
,_,
are_VPRT [PASS]
analyzed_VBN
below_PLACE
._.
Total_JJ
financial_JJ
liabilities_NOMZ
comprise_VPRT
total_JJ
borrowings_GER
of_PIN
5,963_CD
million_CD
,_,
other_JJ
long-term_JJ
payables_NN
of_PIN
244_CD
million_CD
and_CC
provisions_NN
of_PIN
256_CD
million_CD
but_CC
exclude_VB
short-term_JJ
payables_NN
and_CC
foreign_JJ
exchange_NN
derivatives_NN
of_PIN
67_CD
million_CD
._.
The_DT
benchmark_JJ
rate_NN
for_PIN
determining_VBG [SUAV] [PRIV]
interest_NN
payments_NOMZ
for_PIN
all_QUAN
oating_NN
rate_NN
financial_JJ
liabilities_NOMZ
in_PIN
the_DT
tables_NN
below_PLACE
is_VPRT
LIBOR_NN
._.
Non-interest_JJ
Fixed_JJ
rate_NN
Floating_VBG [WZPRES]
rate_NN
bearing_GER
Weighted_NN
Weighted_NN
average_JJ
average_JJ
Weighted_JJ
interest_NN
years_NN
for_PIN
average_JJ
At_PIN
31st_CD
December_NN
2004_CD
rate_NN
which_WDT [WHOBJ]
rate_NN
years_NN
to_PIN
Total_JJ
Currency_NN
m_CD
%_NN
is_VPRT [PASS]
xed_VBN
m_FW
m_FW
maturity_NOMZ
m_NN
US$_$
571_CD
5.9_CD
13.8_CD
1,764_CD
411_CD
8.9_CD
2,746_CD
Sterling_GER
1,489_CD
6.4_CD
19.3_CD
842_CD
123_CD
2.1_CD
2,454_CD
Euro_NN
747_CD
44_CD
5.3_CD
791_CD
Yen_NN
348_CD
0.4_CD
4.6_CD
348_CD
Other_JJ
currencies_NN
89_CD
35_CD
6.1_CD
124_CD
2,408_CD
5.4_CD
15.9_CD
3,442_CD
613_CD
4.6_CD
6,463_CD
Currency_NN
and_PHC
interest_NN
rate_NN
risk_NN
prole_NN
of_PIN
financial_JJ
assets_NN
Total_JJ
financial_JJ
assets_NN
comprise_VPRT
other_JJ
investments_NOMZ
of_PIN
298_CD
million_CD
,_,
liquid_JJ
investments_NOMZ
of_PIN
1,512_CD
million_CD
,_,
cash_NN
and_PHC
cash_NN
equivalents_NN
of_PIN
2,467_CD
million_CD
and_CC
long-term_JJ
receivables_NN
of_PIN
597_CD
million_CD
._.
The_DT
benchmark_JJ
rate_NN
for_PIN
determining_VBG [SUAV] [PRIV]
interest_NN
receipts_NN
for_PIN
all_QUAN
oating_NN
rate_NN
assets_NN
in_PIN
the_DT
tables_NN
below_PLACE
is_VPRT
LIBID_NN
._.
Non-interest_JJ
Fixed_JJ
rate_NN
Floating_VBG [WZPRES]
rate_NN
bearing_GER
Weighted_NN
Weighted_NN
average_JJ
average_JJ
Fixed_JJ
interest_NN
years_NN
for_PIN
At_PIN
31st_CD
December_NN
2004_CD
rate_NN
rate_NN
which_WDT [WHOBJ]
rate_NN
Total_JJ
Currency_NN
m_CD
%_NN
is_VPRT [PASS]
xed_VBN
m_FW
m_FW
m_FW
US$_$
164_CD
6.2_CD
11.9_CD
1,429_CD
757_CD
2,350_CD
Sterling_GER
1,088_CD
89_CD
1,177_CD
Euro_NN
629_CD
57_CD
686_CD
Yen_NN
1_CD
28_CD
29_CD
Other_JJ
currencies_NN
155_CD
3.0_CD
0.2_CD
353 124 632 319_CD
4.7_CD
6.2_CD
3,500_CD
1,055_CD
4,874_CD
GSK_NN
Annual_JJ
Report_NN
2005_CD
130_CD
FINANCIAL_NN
STATEMENTS_NOMZ
Notes_NN
to_PIN
the_DT
financial_JJ
statements_NOMZ
continued_VBD
36_CD
Financial_NN
instruments_NOMZ
and_CC
related_VBN
disclosures_NN
continued_VBD
Currency_NN
exposure_NN
of_PIN
net_JJ
monetary_JJ
assets_NN
liabilities_NOMZ
The_DT
Groups_NN
currency_NN
exposures_NN
that_TSUB
give_VPRT
rise_VB
to_PIN
net_JJ
currency_NN
gains_NN
and_PHC
losses_NN
that_TSUB
are_VPRT [PASS]
recognized_VBN [PRIV]
in_PIN
the_DT
income_NN
statement_NOMZ
arise_VB
principally_RB
in_PIN
companies_NN
with_PIN
sterling_GER
functional_JJ
currency_NN
._.
Monetary_NN
assets_NN
and_PHC
liabilities_NOMZ
denominated_VBN [WZPAST]
in_PIN
overseas_PLACE
functional_JJ
currency_NN
and_PHC
borrowings_GER
designated_VBN
as_IN
a_DT
hedge_NN
against_PIN
overseas_PLACE
net_JJ
assets_NN
are_VPRT [PASS]
excluded_VBN
from_PIN
the_DT
table_NN
below_PLACE
._.
At_PIN
31st_CD
December_NN
2004_CD
Functional_JJ
currency_NN
of_PIN
Group_NN
operation_NOMZ
Net_JJ
monetary_JJ
assets_NN
liabilities_NOMZ
Sterling_GER
US$_$
Euro_NN
Yen_NN
Other_JJ
Total_NN
held_VBD [PRIV]
in_PIN
non-functional_JJ
currency_NN
m_NN
m_FW
m_FW
m_FW
m_FW
m_FW
Sterling_GER
5_CD
53 130 178_CD
US$_$
234_CD
18_CD
1_CD
23_CD
228_CD
Euro_NN
97_CD
15_CD
46_CD
158_CD
Yen_NN
29_CD
1_CD
1_CD
31_CD
Other_JJ
39_CD
8_CD
4_CD
27_CD
205_CD
18_CD
38_CD
1_CD
198_CD
50_CD
Finance_NN
Total_NN
Debt_NN
leases_VPRT
Other_JJ
2004_CD
Maturity_NOMZ
of_PIN
financial_JJ
liabilities_NOMZ
m_VPRT
m_FW
m_FW
m_FW [BEMA]
Within_PIN
one_CD
year_NN
or_CC
on_PIN
demand_NN
1,547_CD
35_CD
120_CD
1,702_CD
Between_PIN
one_CD
and_CC
two_CD
years_NN
262_CD
27_CD
88_CD
377_CD
Between_PIN
two_CD
and_CC
five_CD
years_NN
1,817_CD
24_CD
132_CD
1,973_CD
After_IN
five_CD
years_NN
2,244_CD
7_CD
227_CD
2,478_CD
5,870_CD
93_CD
567_CD
6,530_CD
2004_CD
Gains_NN
Losses_NN
Net_JJ
Hedges_NN
m_FW
m_FW
m_FW [BEMA]
Unrecognised_JJ
gains_NN
and_PHC
losses_NN
at_PIN
the_DT
beginning_GER
of_PIN
the_DT
year_NN
171_CD
60_CD
111_CD
Unrecognised_JJ
gains_NN
and_PHC
losses_NN
arising_VBG [WZPRES]
in_PIN
previous_JJ
years_NN
and_CC
recognized_VBN [PRIV]
in_PIN
the_DT
year_NN
27_CD
27_CD
Unrecognised_JJ
gains_NN
and_PHC
losses_NN
arising_VBG [WZPRES]
in_PIN
the_DT
year_NN
8_CD
77_CD
69_CD
Total_JJ
unrecognised_JJ
gains_NN
and_PHC
losses_NN
at_PIN
the_DT
end_NN
of_PIN
the_DT
year_NN
152_CD
137_CD
15_CD
Expected_VBN [PRIV]
to_TO
be_VB [PASS]
recognized_VBN [PRIV]
within_PIN
one_CD
year_NN
9_CD
9_CD
Expected_VBN [PRIV]
to_TO
be_VB [PASS]
recognized_VBN [PRIV]
after_IN
one_CD
year_NN
152_CD
128_CD
24_CD
Total_JJ
unrecognised_JJ
gains_NN
and_PHC
losses_NN
at_PIN
the_DT
end_NN
of_PIN
the_DT
year_NN
152_CD
137_CD
15_CD
The_DT
unrecognised_JJ
gains_NN
and_PHC
losses_NN
above_PLACE
represent_VPRT
the_DT
difference_NN
between_PIN
the_DT
carrying_VBG
amount_NN
and_CC
the_DT
fair_JJ
value_NN
of_PIN
the_DT
currency_NN
swaps_NN
,_,
interest_NN
rate_NN
swaps_NN
,_,
equity_NOMZ
collar_NN
and_CC
other_JJ
foreign_JJ
exchange_NN
derivatives_NN
._.
Impact_NN
of_PIN
IAS_NN
32_CD
and_CC
IAS_NN
39_CD
adoption_NOMZ
on_PIN
comparative_JJ
information_NOMZ
The_DT
nature_NN
of_PIN
the_DT
main_JJ
adjustment_NOMZ
that_TSUB
would_PRMD
make_VB
the_DT
comparative_JJ
information_NOMZ
comply_VB
with_PIN
IAS_NN
32_CD
and_CC
IAS_NN
39_CD
would_PRMD
be_VB [BEMA]
the_DT
recognition_NOMZ
at_PIN
fair_JJ
value_NN
of_PIN
financial_JJ
instruments_NOMZ
classied_VBD
as_IN
fair_JJ
valued_VBN
through_PIN
profit_NN
and_PHC
loss_NN
and_CC
as_IN
available-for-sale_JJ
._.
GSK_NN
Annual_JJ
Report_NN
2005_CD
131_CD
FINANCIAL_NN
STATEMENTS_NOMZ
Notes_NN
to_PIN
the_DT
financial_JJ
statements_NOMZ
continued_VBD
37_CD
Employee_NN
share_NN
schemes_NN
The_DT
Group_NN
operates_VPRT
share_NN
option_NOMZ
schemes_NN
,_,
whereby_OSUB
options_NOMZ
are_VPRT [PASS]
granted_VBN [SUAV]
to_PIN
employees_NN
to_TO
acquire_VB
shares_NN
or_CC
ADSs_NN
in_PIN
GlaxoSmithKline_NN
plc_NN
at_PIN
the_DT
grant_NN
price_NN
,_,
and_ANDC
share_NN
award_NN
schemes_NN
,_,
whereby_OSUB
awards_NN
are_VPRT [PASS]
granted_VBN [SUAV]
to_PIN
employees_NN
to_TO
acquire_VB
shares_NN
or_CC
ADSs_NN
in_PIN
GlaxoSmithKline_NN
plc_NN
at_PIN
no_SYNE
cost_NN
,_,
subject_JJ
to_PIN
the_DT
achievement_NOMZ
by_PIN
the_DT
Group_NN
of_PIN
specified_VBN
performance_NN
targets_NN
._.
In_PIN
2004_CD
,_,
the_DT
Group_NN
introduced_VBD
a_DT
new_JJ
share_NN
award_NN
scheme_NN
,_,
the_DT
Restricted_NN
Share_NN
Plan_NN
,_,
whereby_OSUB
awards_NN
are_VPRT [PASS]
granted_VBN [SUAV]
to_PIN
employees_NN
to_TO
acquire_VB
shares_NN
or_CC
ADSs_NN
in_PIN
GlaxoSmithKline_NN
plc_NN
at_PIN
no_SYNE
cost_NN
after_IN
a_DT
three_CD
year_NN
vesting_VBG [WZPRES]
period_NN
._.
The_DT
granting_VBG [SUAV]
of_PIN
restricted_JJ
share_NN
awards_NN
has_VPRT [PEAS]
replaced_VBN
the_DT
granting_VBG [SUAV]
of_PIN
options_NOMZ
to_PIN
certain_JJ
employees_NN
as_IN
the_DT
cost_NN
of_PIN
the_DT
scheme_NN
more_EMPH
readily_RB
equates_VPRT
to_PIN
the_DT
potential_JJ
gain_NN
to_TO
be_VB [BYPA]
made_VBN
by_PIN
the_DT
employee_NN
._.
The_DT
Group_NN
operates_VPRT
share_NN
option_NOMZ
schemes_NN
and_CC
savings-related_JJ
share_NN
option_NOMZ
schemes_NN
._.
Grants_NN
under_IN
share_NN
option_NOMZ
schemes_NN
are_VPRT [BEMA]
normally_RB
exercisable_PRED
between_PIN
three_CD
and_CC
ten_CD
years_NN
from_PIN
the_DT
date_NN
of_PIN
grant_NN
._.
Grants_NN
of_PIN
restricted_JJ
shares_NN
and_PHC
share_NN
awards_NN
are_VPRT [BEMA]
normally_RB
exercisable_PRED
at_PIN
the_DT
end_NN
of_PIN
the_DT
three_CD
year_NN
vesting_VBG [WZPRES]
performance_NN
period_NN
._.
Grants_NN
under_IN
savings-related_JJ
share_NN
option_NOMZ
schemes_NN
are_VPRT [BEMA]
normally_RB
exercisable_PRED
after_IN
three_CD
years_NN
saving_VBG [WZPRES]
._.
Options_NOMZ
under_IN
the_DT
share_NN
option_NOMZ
schemes_NN
are_VPRT [SPAU] [PASS]
normally_RB
granted_VBN [SUAV]
at_PIN
the_DT
market_NN
price_NN
ruling_NN
at_PIN
the_DT
date_NN
of_PIN
grant_NN
._.
In_PIN
accordance_NN
with_PIN
UK_NN
practice_NN
,_,
the_DT
majority_NOMZ
of_PIN
options_NOMZ
under_IN
the_DT
savings-related_JJ
share_NN
option_NOMZ
schemes_NN
are_VPRT [PASS]
granted_VBN [SUAV]
at_PIN
a_DT
price_NN
20_CD
%_NN
below_PLACE
the_DT
market_NN
price_NN
ruling_NN
at_PIN
the_DT
date_NN
of_PIN
grant_NN
._.
Share_NN
options_NOMZ
awarded_VBN [WZPAST]
to_PIN
the_DT
Directors_NN
and_CC
,_,
with_PIN
effect_NN
from_PIN
the_DT
2004_CD
grant_NN
,_,
the_DT
CET_NN
are_VPRT [BEMA]
subject_PRED
to_PIN
performance_NN
criteria_NN
as_IN
laid_VBN
out_PIN
in_PIN
the_DT
Remuneration_NOMZ
Report_NN
._.
Option_NOMZ
pricing_GER
For_PIN
the_DT
purposes_NN
of_PIN
valuing_VBG
options_NOMZ
to_TO
arrive_VB
at_PIN
the_DT
stock-based_JJ
compensation_NOMZ
charge_NN
,_,
the_DT
Black-Scholes_NN
option_NOMZ
pricing_GER
model_NN
has_VPRT [PEAS]
been_VBN [PASS]
used_VBN
._.
The_DT
assumptions_NOMZ
used_VBN [WZPAST]
in_PIN
the_DT
model_NN
for_PIN
2003_CD
,_,
2004_CD
and_CC
2005_CD
are_VPRT
as_IN
follows_VPRT
:_:
2005 2004 2003_CD
Risk-free_JJ
interest_NN
rate_NN
4.0_CD
%_NN
4.8_CD
%_NN
3.3_CD
%_NN
4.6_CD
%_NN
4.2_CD
%_NN
4.9_CD
%_NN
Dividend_NN
yield_NN
3.0_CD
%_NN
3.2_CD
%_NN
2.9_CD
%_NN
Volatility_NOMZ
21_CD
%_NN
28_CD
%_NN
26_CD
%_NN
29_CD
%_NN
34_CD
%_NN
Expected_VBN [PRIV]
lives_NN
of_PIN
options_NOMZ
granted_VBN [SUAV]
under_IN
:_:
Share_NN
option_NOMZ
schemes_NN
5_CD
years_NN
5_CD
years_NN
5_CD
years_NN
Savings-related_JJ
share_NN
option_NOMZ
schemes_NN
3_CD
years_NN
3_CD
years_NN
3_CD
years_NN
Weighted_VBN
average_JJ
share_NN
price_NN
for_PIN
grants_NN
in_PIN
the_DT
year_NN
:_:
Ordinary_JJ
shares_NN
13.15_CD
11.25_CD
12.66_CD
ADSs_NN
$_$
47.42_CD
$_$
43.23_CD
$_$
43.39_CD
Volatility_NOMZ
was_VBD [PASS]
determined_VBN [SUAV] [PRIV]
based_VBN
on_PIN
the_DT
three_CD
year_NN
share_NN
price_NN
history_NN
._.
The_DT
fair_JJ
value_NN
of_PIN
performance_NN
share_NN
plan_NN
grants_NN
take_VPRT
into_PIN
account_NN
market_NN
conditions_NOMZ
._.
Expected_VBN [PRIV]
lives_NN
of_PIN
options_NOMZ
were_VBD [PASS]
determined_VBN [SUAV] [PRIV]
based_VBN
on_PIN
weighted_JJ
average_JJ
historic_JJ
exercises_NN
of_PIN
options_NOMZ
._.
The_DT
stock-based_JJ
compensation_NOMZ
charge_NN
has_VPRT [PEAS]
been_VBN [PASS]
recorded_VBN
in_PIN
the_DT
income_NN
statement_NOMZ
as_IN
follows_VPRT
:_:
2005 2004 2003_CD
Cost_NN
of_PIN
sales_NN
17_CD
35_CD
42_CD
Selling_GER
,_,
general_JJ
and_CC
administration_NOMZ
150 207 224_CD
Research_NN
and_PHC
development_NOMZ
69 91 109 236_CD
333_CD
375_CD
Share_NN
option_NOMZ
Share_NN
option_NOMZ
Savings-related_JJ
Options_NOMZ
outstanding_JJ
schemes_NN
shares_NN
schemes_NN
ADSs_NN
share_NN
option_NOMZ
schemes_NN
Weighted_NN
Weighted_NN
Weighted_NN
Weighted_NN
Weighted_NN
Weighted_NN
Number_NN
exercise_NN
fair_JJ
Number_NN
exercise_NN
fair_JJ
Number_NN
exercise_NN
fair_JJ
000_CD
price_NN
value_NN
000_CD
price_NN
value_NN
000_CD
price_NN
value_NN
At_PIN
1st_CD
January_NN
2003_CD
197,472_CD
15.20_CD
90,877_CD
$_$
47.34_CD
12,988_CD
10.29_CD
Options_NOMZ
granted_VBN [SUAV]
32,750_CD
12.88_CD
3.13_CD
23,630_CD
$_$
43.36_CD
$_$
10.92_CD
1,416_CD
10.20_CD
4.15_CD
Options_NOMZ
exercised_VBN
4,728_CD
7.92_CD
1,828_CD
$_$
24.33_CD
112_CD
10.23_CD
Options_NOMZ
canceled_VBN
19,789_CD
16.48_CD
6,150_CD
$_$
52.65_CD
3,709_CD
12.23_CD
At_PIN
31st_CD
December_NN
2003_CD
205,705_CD
14.89_CD
106,529_CD
$_$
46.58_CD
10,583_CD
9.59_CD
Options_NOMZ
granted_VBN [SUAV]
9,837_CD
11.23_CD
2.49_CD
9,222_CD
$_$
42.99_CD
$_$
8.54_CD
1,580_CD
9.52_CD
3.30_CD
Options_NOMZ
exercised_VBN
5,764_CD
6.54_CD
1,845_CD
$_$
25.65_CD
232_CD
9.18_CD
Options_NOMZ
canceled_VBN
11,997_CD
15.33_CD
3,427_CD
$_$
48.28_CD
1,790_CD
10.46_CD
At_PIN
31st_CD
December_NN
2004_CD
197,781_CD
14.92_CD
110,479_CD
$_$
46.57_CD
10,141_CD
9.44_CD
Options_NOMZ
granted_VBN [SUAV]
516_CD
12.57_CD
2.76_CD
956_CD
$_$
45.66_CD
$_$
9.90_CD
5,167_CD
11.45_CD
3.68_CD
Options_NOMZ
exercised_VBN
10,483_CD
9.91_CD
7,537_CD
$_$
38.83_CD
5,732_CD
9.16_CD
Options_NOMZ
canceled_VBN
20,888_CD
17.16_CD
8,306_CD
$_$
50.26_CD
810_CD
11.02_CD
At_PIN
31st_CD
December_NN
2005_CD
166,926_CD
14.97_CD
95,592_CD
$_$
46.86_CD
8,766_CD
10.66_CD
Range_NN
of_PIN
exercise_NN
prices_NN
5.61_CD
19.77_CD
$_$
22.32_CD
$_$
61.35_CD
9.16_CD
11.45_CD
The_DT
average_JJ
share_NN
price_NN
in_PIN
2005_CD
was_VBD [BEMA]
13.42_CD
and_CC
$_$
48.88_CD
GSK_NN
Annual_JJ
Report_NN
2005_CD
132_CD
FINANCIAL_NN
STATEMENTS_NOMZ
Notes_NN
to_PIN
the_DT
financial_JJ
statements_NOMZ
continued_VBD
37_CD
Employee_NN
share_NN
schemes_NN
continued_VBD
In_PIN
order_NN
to_TO
encourage_VB
employees_NN
to_TO
convert_VB
options_NOMZ
,_,
excluding_VBG
savings-related_JJ
share_NN
options_NOMZ
,_,
held_VBN [PRIV]
over_IN
Glaxo_NN
Wellcome_NN
or_CC
SmithKline_NN
Beecham_NN
shares_NN
or_CC
ADSs_NN
,_,
into_PIN
those_DEMO
over_IN
GlaxoSmithKline_NN
shares_NN
or_CC
ADSs_NN
,_,
a_DT
program_NN
was_VBD [PASS]
established_VBN [PRIV]
to_TO
give_VB
an_DT
additional_JJ
cash_NN
benefit_NN
of_PIN
10_CD
%_NN
of_PIN
the_DT
exercise_NN
price_NN
of_PIN
the_DT
original_JJ
option_NOMZ
provided_VBD
that_DEMO
the_DT
employee_NN
did_VBD
not_XX0
voluntarily_RB
leave_VB
the_DT
Group_NN
for_PIN
two_CD
years_NN
from_PIN
the_DT
date_NN
of_PIN
the_DT
merger_NN
and_CC
did_VBD
not_XX0
exercise_VB
the_DT
option_NOMZ
before_IN
the_DT
earlier_TIME
of_PIN
six_CD
months_NN
from_PIN
the_DT
expiry_NN
date_NN
of_PIN
the_DT
original_JJ
option_NOMZ
and_CC
two_CD
years_NN
from_PIN
the_DT
date_NN
of_PIN
the_DT
merger_NN
._.
The_DT
cash_NN
benefit_NN
will_PRMD [SPAU]
also_RB
be_VB [PASS]
paid_VBN
if_COND
the_DT
options_NOMZ
expire_VPRT
unexercised_JJ
if_COND
the_DT
market_NN
price_NN
is_VPRT
below_PLACE
the_DT
exercise_NN
price_NN
on_PIN
the_DT
date_NN
of_PIN
expiry_NN
._.
There_EX
has_VPRT [PEAS]
been_VBN
no_SYNE
change_NN
in_PIN
the_DT
effective_JJ
exercise_NN
price_NN
of_PIN
any_QUAN
outstanding_JJ
options_NOMZ
during_PIN
the_DT
year_NN
._.
Share_NN
option_NOMZ
Share_NN
option_NOMZ
Savings-related_JJ
Options_NOMZ
exercisable_JJ
schemes_NN
shares_NN
schemes_NN
ADSs_NN
share_NN
option_NOMZ
schemes_NN
Weighted_NN
Weighted_NN
Weighted_NN
Number_NN
exercise_NN
Number_NN
exercise_NN
Number_NN
exercise_NN
000_CD
price_NN
000_CD
price_NN
000_CD
price_NN
At_PIN
31st_CD
December_NN
2003_CD
79,693_CD
14.56_CD
22,364_CD
$_$
49.82_CD
192_CD
16.48_CD
At_PIN
31st_CD
December_NN
2004_CD
126,917_CD
16.49_CD
57,421_CD
$_$
51.75_CD
270_CD
14.12_CD
At_PIN
31st_CD
December_NN
2005_CD
128,316_CD
15.77_CD
64,265_CD
$_$
48.56_CD
1,429_CD
9.16_CD
GlaxoSmithKline_NN
share_NN
award_NN
schemes_NN
Performance_NN
Share_NN
Plan_NN
The_NN
Group_NN
operates_VPRT
a_DT
Performance_NN
Share_NN
Plan_NN
whereby_OSUB
awards_NN
are_VPRT [PASS]
granted_VBN [SUAV]
to_PIN
Directors_NN
and_CC
senior_JJ
executives_NN
at_PIN
no_SYNE
cost_NN
._.
The_DT
percentage_NN
of_PIN
each_QUAN
award_NN
that_TOBJ
vests_NN
is_VPRT [PASS]
based_VBN
upon_PIN
the_DT
performance_NN
of_PIN
the_DT
Group_NN
over_IN
a_DT
three_CD
year_NN
measurement_NOMZ
period_NN
._.
The_DT
performance_NN
conditions_NOMZ
consist_VPRT
of_PIN
two_CD
parts_NN
,_,
each_QUAN
of_PIN
which_WDT [PIRE]
applies_VPRT
to_PIN
50_CD
%_NN
of_PIN
the_DT
award_NN
._.
For_PIN
awards_NN
granted_VBN [SUAV] [WZPAST]
in_PIN
2003_CD
,_,
the_DT
first_JJ
part_NN
of_PIN
the_DT
condition_NOMZ
compares_VPRT
GlaxoSmithKlines_NN
Total_NN
Shareholder_NN
Return_NN
TSR_NN
over_IN
the_DT
period_NN
with_PIN
the_DT
TSR_NN
of_PIN
companies_NN
in_PIN
the_DT
UK_NN
FTSE_NN
100_CD
Index_NN
over_IN
the_DT
same_JJ
period_NN
._.
For_PIN
awards_NN
granted_VBN [SUAV] [WZPAST]
in_PIN
2004_CD
,_,
and_ANDC
subsequent_JJ
years_NN
,_,
the_DT
first_JJ
part_NN
of_PIN
the_DT
condition_NOMZ
compares_VPRT
GlaxoSmithKlines_NN
TSR_NN
over_IN
the_DT
period_NN
with_PIN
the_DT
TSR_NN
of_PIN
13_CD
pharmaceutical_JJ
companies_NN
in_PIN
the_DT
comparator_NN
group_NN
over_IN
the_DT
same_JJ
period_NN
._.
The_DT
second_JJ
part_NN
of_PIN
the_DT
performance_NN
condition_NOMZ
compares_VPRT
GlaxoSmithKlines_NN
earnings_GER
per_PIN
share_NN
growth_NN
to_PIN
the_DT
increase_NN
in_PIN
the_DT
UK_NN
Retail_NN
Prices_NN
Index_NN
over_IN
the_DT
three_CD
year_NN
performance_NN
period_NN
._.
Awards_RB
granted_VBN [SUAV]
to_PIN
Directors_NN
and_PHC
members_NN
of_PIN
the_DT
CET_NN
from_PIN
15th_JJ
December_NN
2003_CD
are_VPRT [BEMA]
subject_PRED
to_PIN
a_DT
single_JJ
performance_NN
condition_NOMZ
which_WDT [WHSUB]
compares_VPRT
GlaxoSmithKlines_NN
TSR_NN
over_IN
the_DT
period_NN
with_PIN
the_DT
TSR_NN
of_PIN
companies_NN
in_PIN
the_DT
comparator_NN
group_NN
over_IN
the_DT
same_JJ
period_NN
._.
GSK_NN
Annual_JJ
Report_NN
2005_CD
133_CD
FINANCIAL_NN
STATEMENTS_NOMZ
Notes_NN
to_PIN
the_DT
financial_JJ
statements_NOMZ
continued_VBD
37_CD
Employee_NN
share_NN
schemes_NN
continued_VBD
Shares_NN
Weighted_NN
ADSs_NN
Weighted_NN
Number_NN
of_PIN
shares_NN
and_PHC
ADSs_NN
issuable_JJ
Number_NN
000_CD
fair_JJ
value_NN
Number_NN
000_CD
fair_JJ
value_NN
At_PIN
1st_CD
January_NN
2003_CD
3,164_CD
1,943_CD
Awards_NN
granted_VBD [SUAV]
1,070_CD
7.00_CD
832_CD
$_$
20.14_CD
Awards_NN
exercised_VBN
625_CD
189_CD
Awards_NN
canceled_VBD
109_CD
107_CD
At_PIN
31st_CD
December_NN
2003_CD
3,500_CD
2,479_CD
Awards_NN
granted_VBD [SUAV]
1,778_CD
7.25_CD
1,339_CD
$_$
23.89_CD
Awards_NN
exercised_VBN
409_CD
187_CD
Awards_NN
canceled_VBD
520_CD
276_CD
At_PIN
31st_CD
December_NN
2004_CD
4,349_CD
3,355_CD
Awards_NN
granted_VBD [SUAV]
130_CD
9.02_CD
88_CD
$_$
32.34_CD
Awards_NN
exercised_VBN
375_CD
199_CD
Awards_NN
canceled_VBD
477_CD
237_CD
At_PIN
31st_CD
December_NN
2005_CD
3,627_CD
3,007_CD
Restricted_NN
Share_NN
Plan_NN
The_NN
Group_NN
operates_VPRT
a_DT
Restricted_NN
Share_NN
Plan_NN
whereby_OSUB
awards_NN
are_VPRT [PASS]
granted_VBN [SUAV]
,_,
in_PIN
the_DT
form_NN
of_PIN
shares_NN
,_,
to_PIN
certain_JJ
employees_NN
at_PIN
no_SYNE
cost_NN
._.
The_DT
awards_NN
vest_NN
after_IN
three_CD
years_NN
._.
There_EX
are_VPRT
no_SYNE
performance_NN
criteria_NN
attached_VBN
._.
Shares_NN
Weighted_NN
ADSs_NN
Weighted_NN
Number_NN
of_PIN
shares_NN
and_PHC
ADSs_NN
issuable_JJ
Number_NN
000_CD
fair_JJ
value_NN
Number_NN
000_CD
fair_JJ
value_NN
At_PIN
1st_CD
January_NN
2004_CD
Awards_NN
granted_VBD [SUAV]
4,419_CD
10.07_CD
3,562_CD
$_$
38.14_CD
At_PIN
31st_CD
December_NN
2004_CD
4,419_CD
3,562_CD
Awards_NN
granted_VBD [SUAV]
403_CD
12.00_CD
511_CD
$_$
44.39_CD
Awards_NN
exercised_VBN
138_CD
143_CD
Awards_NN
canceled_VBD
170_CD
81_CD
At_PIN
31st_CD
December_NN
2005_CD
4,514_CD
3,849_CD
Employee_NN
Share_NN
Ownership_NN
Plan_NN
Trusts_NN
The_NN
Group_NN
sponsors_VPRT
Employee_NN
Share_NN
Ownership_NN
Plan_NN
ESOP_NN
Trusts_NN
to_TO
acquire_VB
and_PHC
hold_VB [PRIV]
shares_NN
in_PIN
GlaxoSmithKline_NN
plc_NN
to_TO
satisfy_VB
awards_NN
made_VBN
under_IN
employee_NN
incentive_NN
plans_NN
and_PHC
options_NOMZ
granted_VBN [SUAV]
under_IN
employee_NN
share_NN
option_NOMZ
schemes_NN
._.
The_DT
trustees_NN
of_PIN
the_DT
ESOP_NN
Trusts_NN
purchase_NN
shares_NN
on_PIN
the_DT
open_JJ
market_NN
with_PIN
finance_NN
provided_VBN [WZPAST]
by_PIN
the_DT
Group_NN
by_PIN
way_NN
of_PIN
loans_NN
or_CC
contributions_NOMZ
._.
Costs_NN
of_PIN
running_VBG
the_DT
ESOP_NN
Trusts_NN
are_VPRT [PASS]
charged_VBN
to_PIN
the_DT
income_NN
statement_NOMZ
._.
Shares_NN
held_VBN [PRIV] [WZPAST]
by_PIN
the_DT
ESOP_NN
Trusts_NN
are_VPRT [PASS]
deducted_VBN
from_PIN
other_JJ
reserves_NN
and_CC
held_VBN [PRIV]
at_PIN
the_DT
value_NN
of_PIN
proceeds_NN
receivable_JJ
from_PIN
employees_NN
on_PIN
exercise_NN
._.
If_COND
there_EX
is_VPRT [PASS]
deemed_VBN [PRIV]
to_TO
be_VB [BEMA]
a_DT
permanent_JJ
diminution_NOMZ
in_PIN
value_NN
this_DEMP
is_VPRT [BYPA]
reected_VBN
by_PIN
a_DT
transfer_NN
to_TO
retained_VBN
earnings_GER
._.
Shares_NN
held_VBD [PRIV]
for_PIN
share_NN
award_NN
schemes_NN
2005_CD
2004_CD
Number_NN
of_PIN
shares_NN
000_CD
22,169_CD
22,992_CD
m_NN
m_NN [BEMA]
Nominal_JJ
value_NN
6_CD
6_CD
Carrying_VBG
value_NN
116_CD
213_CD
Market_NN
value_NN
326_CD
281_CD
Shares_NN
held_VBN [PRIV] [WZPAST]
for_PIN
share_NN
option_NOMZ
schemes_NN
2005_CD
2004_CD
Number_NN
of_PIN
shares_NN
000_CD
145,267_CD
151,535_CD
m_NN
m_NN [BEMA]
Nominal_JJ
value_NN
36_CD
38_CD
Carrying_VBG
value_NN
2,197_CD
2,361_CD
Market_NN
value_NN
2,134_CD
1,852_CD
The_DT
Trusts_NN
also_RB
acquire_VB
and_PHC
hold_VB [PRIV]
shares_NN
to_TO
meet_VB
notional_JJ
dividends_NN
re-invested_VBD
on_PIN
deferred_VBN
awards_NN
under_IN
the_DT
SmithKline_NN
Beecham_NN
Mid-Term_NN
Incentive_NN
Plan_NN
._.
GSK_NN
Annual_JJ
Report_NN
2005_CD
134_CD
FINANCIAL_NN
STATEMENTS_NOMZ
Notes_NN
to_PIN
the_DT
financial_JJ
statements_NOMZ
continued_VBD
Like_IN
IFRS_NN
3_CD
,_,
SFAS_NN
142_CD
requires_VPRT [SUAV]
that_THVC
goodwill_NN
must_NEMD
not_XX0
be_VB [PASS]
amortised_VBN
38_CD
Reconciliation_NOMZ
to_PIN
US_FPP1
accounting_GER
principles_NN
and_CC
that_DEMO
annual_JJ
impairment_NOMZ
tests_NN
of_PIN
goodwill_NN
must_NEMD
be_VB [PASS]
undertaken_VBN
._.
The_DT
analyses_NN
and_PHC
reconciliations_NOMZ
presented_VBN [WZPAST]
in_PIN
this_DEMO
Note_NN
represent_VPRT
the_DT
The_DT
implementation_NOMZ
of_PIN
SFAS_NN
142_CD
in_PIN
2002_CD
,_,
a_DT
year_NN
earlier_TIME
than_PIN
the_DT
financial_JJ
information_NOMZ
prepared_VBN [WZPAST]
on_PIN
the_DT
basis_NN
of_PIN
US_FPP1
Generally_RB
Accepted_JJ
Groups_NN
transition_NOMZ
to_PIN
IFRS_NN
,_,
results_NN
in_PIN
goodwill_NN
balances_NN
acquired_VBD
Accounting_GER
Principles_NN
US_FPP1
GAAP_NN
rather_RB
than_PIN
IFRS_NN
._.
between_PIN
1998_CD
and_CC
2003_CD
reecting_VBG
one_CD
year_NN
less_JJ
of_PIN
amortisation_NOMZ
under_IN
US_FPP1
GAAP_NN
than_PIN
under_IN
IFRS_NN
._.
Summary_NN
of_PIN
material_NN
differences_NN
between_PIN
IFRS_NN
and_PHC
US_FPP1
GAAP_NN
Under_IN
IFRS_NN
,_,
costs_VPRT
to_TO
be_VB [PASS]
incurred_VBN
in_PIN
integrating_VBG
and_PHC
restructuring_VBG
the_DT
Acquisition_NOMZ
of_PIN
SmithKline_NN
Beecham_NN
Wellcome_NN
,_,
SmithKline_NN
Beecham_NN
and_PHC
Block_NN
Drug_NN
businesses_NOMZ
following_VBG [WZPRES]
The_DT
Group_NN
has_VPRT [PEAS]
exercised_VBN
the_DT
exemption_NOMZ
available_JJ
under_IN
IFRS_NN
1_CD
Firstthe_NN
acquisitions_NOMZ
in_PIN
1995_CD
,_,
2000_CD
and_CC
2001_CD
respectively_RB
were_VBD [PASS]
charged_VBN
time_NN
Adoption_NOMZ
of_PIN
IFRS_NN
not_XX0
to_TO
restate_VB
business_NOMZ
combinations_NOMZ
prior_RB
to_TO
to_PIN
the_DT
income_NN
statement_NOMZ
post_NN
acquisition_NOMZ
._.
Similarly_CONJ
,_,
integration_NOMZ
and_CC
the_DT
date_NN
of_PIN
transition_NOMZ
of_PIN
the_DT
Groups_NN
reporting_VBG [PUBV] [WZPRES]
GAAP_NN
from_PIN
UK_NN
restructuring_VBG [WZPRES]
costs_NN
arising_VBG [WZPRES]
in_PIN
respect_NN
of_PIN
the_DT
acquisitions_NOMZ
of_PIN
Corixa_NN
and_CC
Generally_RB
Accepted_JJ
Accounting_GER
Principles_NN
UKGAAP_NN
to_PIN
IFRS_NN
._.
ID_NN
Biomedical_NN
in_PIN
2005_CD
have_VPRT [PEAS]
been_VBN [PASS]
charged_VBN
to_PIN
the_DT
income_NN
statement_NOMZ
Therefore_CONJ
the_DT
combination_NOMZ
in_PIN
2000_CD
of_PIN
Glaxo_NN
Wellcome_NN
plc_NN
and_CC
under_IN
IFRS_NN
._.
Under_IN
US_FPP1
GAAP_NN
,_,
certain_JJ
of_PIN
these_DEMO
costs_NN
are_VPRT [PASS]
considered_VBN [PRIV]
in_PIN
SmithKline_NN
Beecham_NN
plc_NN
continues_VPRT
to_TO
be_VB [PASS]
accounted_VBN
for_PIN
as_IN
a_DT
merger_NN
the_DT
allocation_NOMZ
of_PIN
purchase_NN
consideration_NOMZ
thereby_RB
affecting_VBG
the_DT
pooling_VBG
of_PIN
interests_NN
in_PIN
accordance_NN
with_PIN
UK_NN
GAAP_NN
at_PIN
that_DEMO
time_NN
._.
Under_IN
goodwill_NN
arising_VBG [WZPRES]
on_PIN
acquisition_NOMZ
._.
US_FPP1
GAAP_NN
,_,
this_DEMO
business_NOMZ
combination_NOMZ
did_VBD
not_XX0
qualify_VB
for_PIN
pooling_VBG
of_PIN
In-process_JJ
research_NN
&_CC
development_NOMZ
IPR&D_NN
interests_NN
accounting_GER
and_PHC
Glaxo_NN
Wellcome_NN
was_VBD [PASS]
deemed_VBN [PRIV]
to_TO
be_VB [BEMA]
the_DT
Under_IN
IFRS_NN
,_,
IPR&D_NN
projects_NN
acquired_VBN [WZPAST]
in_PIN
a_DT
business_NOMZ
combination_NOMZ
are_VPRT
accounting_VBG
acquirer_NN
in_PIN
a_DT
purchase_NN
business_NOMZ
combination_NOMZ
._.
capitalized_JJ
and_CC
remain_VPRT
on_PIN
the_DT
balance_NN
sheet_NN
,_,
subject_JJ
to_PIN
any_QUAN
Accordingly_RB
the_DT
net_JJ
assets_NN
of_PIN
SmithKline_NN
Beecham_NN
were_VBD [PASS]
recognized_VBN [PRIV]
impairment_NOMZ
write-downs_NN
._.
Amortisation_NOMZ
is_VPRT [PASS]
charged_VBN
over_IN
the_DT
assets_NN
at_PIN
fair_JJ
value_NN
as_IN
at_PIN
the_DT
date_NN
of_PIN
acquisition_NOMZ
._.
As_CONJ
a_NULL
result_NULL
of_PIN
the_DT
fair_JJ
value_NN
estimated_VBN [PRIV]
useful_JJ
lives_NN
from_PIN
the_DT
point_NN
when_RB
the_DT
assets_NN
became_VBD
available_JJ
exercise_NN
,_,
increases_NN
in_PIN
the_DT
values_NN
of_PIN
SmithKline_NN
Beechams_NN
inventory_NN
,_,
for_PIN
use_NN
._.
Under_IN
US_FPP1
GAAP_NN
,_,
such_JJ
assets_NN
are_VPRT [PASS]
recognized_VBN [PRIV]
in_PIN
the_DT
opening_GER
property_NN
,_,
plant_NN
and_PHC
equipment_NOMZ
,_,
intangible_JJ
assets_NN
,_,
investments_NOMZ
and_PHC
balance_NN
sheet_NN
but_CC
are_VPRT [SPAU] [PASS]
then_RB
written_VBN [PUBV]
off_PIN
immediately_TIME
to_PIN
the_DT
income_NN
pension_NN
obligations_NOMZ
were_VBD [PASS]
recognized_VBN [PRIV]
and_CC
fair_JJ
market_NN
values_NN
statement_NOMZ
,_,
as_IN
the_DT
technological_JJ
feasibility_NOMZ
of_PIN
the_DT
IPR&D_NN
has_VPRT [PEAS]
not_XX0
yet_RB
attributed_VBN
to_PIN
its_PIT
internally-generated_JJ
intangible_JJ
assets_NN
,_,
mainly_RB
product_NN
been_VBN [PASS]
established_VBN [PRIV]
and_CC
it_PIT
has_VPRT
no_SYNE
alternative_JJ
future_JJ
use_NN
._.
Under_IN
IFRS_NN
,_,
rights_NN
inclusive_NN
of_PIN
patents_NN
and_PHC
trademarks_NN
and_CC
in-process_JJ
research_NN
deferred_VBN
tax_NN
is_VPRT [PASS]
provided_VBN
for_PIN
IPR&D_NN
assets_NN
acquired_VBN [WZPAST]
in_PIN
a_DT
business_NOMZ
and_PHC
development_NOMZ
,_,
together_RB
with_PIN
appropriate_JJ
deferred_VBN
taxation_NOMZ
combination_NOMZ
._.
US_FPP1
GAAP_NN
does_VPRT
not_XX0
provide_VB
for_PIN
deferred_JJ
tax_NN
on_PIN
these_DEMO
effects_NN
._.
The_DT
difference_NN
between_PIN
the_DT
cost_NN
of_PIN
acquisition_NOMZ
and_CC
the_DT
fair_JJ
assets_NN
,_,
resulting_VBG [PRESP]
in_PIN
a_DT
reconciling_GER
adjustment_NOMZ
to_TO
deferred_VBN
tax_NN
and_PHC
value_NN
of_PIN
the_DT
assets_NN
and_PHC
liabilities_NOMZ
of_PIN
SmithKline_NN
Beecham_NN
is_VPRT [PASS]
recorded_VBN
goodwill_NN
._.
IPR&D_NN
acquired_VBD
in_PIN
transactions_NOMZ
other_JJ
than_PIN
business_NOMZ
combinations_NOMZ
is_VPRT [PASS]
Capitalised_VBN
interest_NN
discussed_VBN
under_IN
Intangible_JJ
assets_NN
below_PLACE
._.
Under_IN
IFRS_NN
,_,
the_DT
Group_NN
does_VPRT
not_XX0
capitalize_VB
interest_NN
._.
US_FPP1
GAAP_NN
requires_VPRT [SUAV]
Intangible_JJ
assets_NN
interest_NN
incurred_VBN
as_IN
part_NN
of_PIN
the_DT
cost_NN
of_PIN
constructing_VBG
a_DT
xed_JJ
asset_NN
to_TO
be_VB
Under_IN
IFRS_NN
,_,
certain_JJ
intangible_JJ
assets_NN
related_VBN [WZPAST]
to_PIN
specic_JJ
compounds_NN
or_CC
capitalized_VBN
and_PHC
amortised_VBN
over_IN
the_DT
life_NN
of_PIN
the_DT
asset_NN
._.
products_NN
which_WDT [WHSUB]
are_VPRT [PASS]
purchased_VBN
from_PIN
a_DT
third_JJ
party_NN
and_CC
are_VPRT [PASS]
developed_VBN
Goodwill_NN
for_PIN
commercial_JJ
applications_NOMZ
are_VPRT [PASS]
capitalized_VBN
but_CC
not_XX0
subject_JJ
to_PIN
The_DT
Group_NN
has_VPRT [PEAS]
exercised_VBN
the_DT
exemption_NOMZ
available_JJ
under_IN
IFRS_NN
1_CD
not_XX0
to_PIN
amortisation_NOMZ
until_IN
regulatory_JJ
approval_NN
is_VPRT [PASS]
obtained_VBN
._.
Under_IN
US_FPP1
GAAP_NN
,_,
restate_VPRT
business_NOMZ
combinations_NOMZ
prior_RB
to_PIN
the_DT
date_NN
of_PIN
transition_NOMZ
of_PIN
the_DT
payments_NOMZ
made_VBN [WZPAST]
in_PIN
respect_NN
of_PIN
these_DEMO
compounds_NN
or_CC
products_NN
which_WDT [WHSUB]
are_VPRT
Groups_NN
reporting_VBG [PUBV] [WZPRES]
GAAP_NN
from_PIN
UK_NN
GAAP_NN
to_PIN
IFRS_NN
._.
Under_IN
UK_NN
GAAP_NN
,_,
still_RB
in_PIN
development_NOMZ
and_CC
have_VPRT [PEAS]
not_XX0
yet_RB
received_VBN
regulatory_JJ
approval_NN
are_VPRT
goodwill_NN
arising_VBG [WZPRES]
on_PIN
acquisitions_NOMZ
before_IN
1998_CD
accounted_VBD
for_PIN
under_IN
the_DT
charged_VBN
directly_RB
to_PIN
the_DT
income_NN
statement_NOMZ
._.
purchase_NN
method_NN
was_VBD [PASS]
eliminated_VBN
against_PIN
equity_NOMZ
,_,
and_ANDC
under_IN
IFRS_NN
,_,
on_PIN
Under_IN
IFRS_NN
,_,
intangible_JJ
assets_NN
are_VPRT [PASS]
amortised_VBN
over_IN
their_TPP3
estimated_VBN [PRIV]
useful_JJ
future_JJ
disposal_NN
or_CC
closure_NN
of_PIN
a_DT
business_NOMZ
,_,
any_QUAN
goodwill_NN
previously_TIME
taken_VBN
economic_JJ
life_NN
except_PIN
in_PIN
the_DT
case_NN
of_PIN
certain_JJ
acquired_VBN
brands_NN
where_RB
the_DT
directly_RB
to_PIN
equity_NOMZ
under_IN
a_DT
former_JJ
GAAP_NN
will_PRMD
not_XX0
be_VB [PASS]
charged_VBN
against_PIN
end_NN
of_PIN
the_DT
useful_JJ
economic_JJ
life_NN
of_PIN
the_DT
brand_NN
can_POMD
not_XX0
be_VB [PASS]
foreseen_VBN
._.
Under_IN
UK_NN
GAAP_NN
,_,
goodwill_NN
arising_VBG [WZPRES]
on_PIN
acquisitions_NOMZ
from_PIN
1998_CD
Under_IN
US_FPP1
GAAP_NN
,_,
until_IN
the_DT
implementation_NOMZ
of_PIN
SFAS_NN
142_CD
Goodwill_NN
and_CC
was_VBD [PASS]
capitalized_VBN
and_PHC
amortised_VBN
over_IN
a_DT
period_NN
not_XX0
exceeding_VBG
20_CD
years_NN
._.
Other_JJ
Intangible_NN
Assets_NN
in_PIN
2002_CD
,_,
all_QUAN
intangible_JJ
assets_NN
,_,
including_VBG [PRESP]
On_PIN
the_DT
date_NN
of_PIN
the_DT
Groups_NN
transition_NOMZ
to_PIN
IFRS_NN
,_,
1st_CD
January_NN
2003_CD
,_,
brands_NN
,_,
were_VBD [PASS]
amortised_VBN
over_IN
a_DT
nite_JJ
life_NN
._.
On_PIN
implementation_NOMZ
of_PIN
SFAS_NN
amortisation_NOMZ
ceased_VBD
in_PIN
accordance_NN
with_PIN
IFRS_NN
3_NN
Business_NOMZ
142_CD
in_PIN
2002_CD
,_,
intangible_JJ
assets_NN
deemed_VBD [PRIV]
to_TO
have_VB
indefinite_JJ
lives_NN
were_VBD
combinations_NOMZ
._.
The_DT
Group_NN
must_NEMD [SPAU]
instead_CONJ
identify_VB
and_PHC
value_VB
its_PIT
reporting_GER
no_RB
longer_RB
amortised_VBN
._.
As_CONJ
a_NULL
result_NULL
of_PIN
the_DT
difference_NN
in_PIN
accounting_VBG
units_NN
for_PIN
the_DT
purpose_NN
of_PIN
assessing_VBG
,_,
at_PIN
least_JJ
annually_RB
,_,
potential_JJ
treatment_NOMZ
prior_RB
to_PIN
the_DT
implementation_NOMZ
of_PIN
SFAS_NN
142_CD
,_,
the_DT
carrying_VBG
impairment_NOMZ
of_PIN
goodwill_NN
allocated_VBN [WZPAST]
to_PIN
each_QUAN
reporting_VBG [PUBV]
unit_NN
._.
As_IN
permitted_VBN
values_NN
of_PIN
indefinite_JJ
lived_VBD
brands_NN
are_VPRT [BYPA]
affected_VBN
by_PIN
amortisation_NOMZ
charged_VBN [WZPAST]
by_PIN
the_DT
business_NOMZ
combinations_NOMZ
exemption_NOMZ
available_JJ
under_IN
IFRS_NN
1_CD
,_,
before_IN
2002_CD
under_IN
US_FPP1
GAAP_NN
._.
amortisation_NOMZ
arising_VBG [WZPRES]
prior_RB
to_PIN
2003_CD
was_VBD [PASS]
not_XX0
reversed_VBN
._.
Under_IN
US_FPP1
GAAP_NN
,_,
goodwill_NN
arising_VBG [WZPRES]
on_PIN
acquisitions_NOMZ
prior_RB
to_PIN
30th_JJ
June_NN
2001_CD
was_VBD [PASS]
capitalized_VBN
and_PHC
amortised_VBN
over_IN
a_DT
period_NN
not_XX0
exceeding_VBG
40_CD
years_NN
._.
In_PIN
July_NN
2001_CD
,_,
the_DT
Financial_NN
Accounting_GER
Standards_NN
Board_NN
FASB_NN
issued_VBD
Statement_NOMZ
of_PIN
Financial_NN
Accounting_GER
Standard_NN
SFAS_NN
142_CD
,_,
Goodwill_NN
and_CC
Other_JJ
Intangible_NN
Assets_NN
._.
GSK_NN
Annual_JJ
Report_NN
2005_CD
135_CD
FINANCIAL_NN
STATEMENTS_NOMZ
Notes_NN
to_PIN
the_DT
financial_JJ
statements_NOMZ
continued_VBD
The_DT
proceeds_NN
from_PIN
sale_NN
of_PIN
marketable_JJ
securities_NOMZ
under_IN
US_FPP1
GAAP_NN
were_VBD [BEMA]
38_CD
Reconciliation_NOMZ
to_PIN
US_FPP1
accounting_GER
principles_NN
19,416_CD
million_CD
in_PIN
the_DT
year_NN
ended_VBD
31st_CD
December_NN
2005_CD
._.
The_DT
proceeds_NN
continued_VBD
include_VPRT
the_DT
roll-over_NN
of_PIN
liquid_JJ
funds_NN
on_PIN
short-term_JJ
deposit_NN
._.
The_DT
gross_JJ
Restructuring_GER
costs_VPRT
gains_NN
and_PHC
losses_NN
reected_VBD
in_PIN
the_DT
consolidated_JJ
income_NN
statement_NOMZ
in_PIN
Under_IN
IFRS_NN
,_,
restructuring_VBG
costs_NN
incurred_VBN
following_VBG
acquisitions_NOMZ
were_VBD
respect_NN
of_PIN
marketable_JJ
securities_NOMZ
were_VBD [BEMA]
7_CD
million_CD
and_CC
nil_NN
,_,
respectively_RB
._.
charged_VBN [PASTP]
to_PIN
the_DT
profit_NN
and_PHC
loss_NN
account_NN
post_NN
acquisition_NOMZ
._.
For_PIN
US_FPP1
GAAP_NN
purposes_NN
,_,
certain_JJ
of_PIN
these_DEMO
costs_NN
were_VBD [PASS]
recognized_VBN [PRIV]
as_IN
liabilities_NOMZ
upon_PIN
Pensions_NN
and_CC
other_JJ
post-retirement_JJ
benets_NN
acquisition_NOMZ
in_PIN
the_DT
opening_GER
balance_NN
sheet_NN
._.
The_DT
key_JJ
difference_NN
between_PIN
IFRS_NN
and_PHC
US_FPP1
GAAP_NN
is_VPRT [BEMA]
the_DT
method_NN
of_PIN
recognition_NOMZ
of_PIN
actuarial_JJ
gains_NN
and_PHC
losses_NN
._.
GSK_NN
has_VPRT [PEAS]
opted_VBN
under_IN
IFRS_NN
Other_JJ
restructuring_GER
costs_NN
are_VPRT [PASS]
recorded_VBN
as_IN
a_DT
provision_NN
under_IN
IFRS_NN
when_RB
to_TO
recognize_VB [PRIV]
actuarial_JJ
gains_NN
and_PHC
losses_NN
in_PIN
the_DT
statement_NOMZ
of_PIN
recognized_VBN [PRIV]
a_DT
restructuring_GER
plan_NN
has_VPRT [PEAS]
been_VBN [PASS]
announced_VBN [PUBV]
._.
Under_IN
US_FPP1
GAAP_NN
,_,
a_DT
provision_NN
income_NN
and_PHC
expense_NN
in_PIN
the_DT
year_NN
in_PIN
which_WDT [PIRE]
they_TPP3
arise_VPRT
._.
Under_IN
US_FPP1
GAAP_NN
may_POMD [SPAU]
only_DWNT
be_VB [PASS]
recognized_VBN [PRIV]
when_RB [WHCL]
further_JJ
criteria_NN
are_VPRT [PASS]
met_VBN
or_CC
the_DT
liability_NOMZ
actuarial_JJ
gains_NN
and_PHC
losses_NN
are_VPRT [PASS]
recognized_VBN [PRIV]
using_VBG
the_DT
10_CD
%_NN
corridor_NN
is_VPRT [PASS]
incurred_VBN
._.
Therefore_CONJ
adjustments_NOMZ
have_VPRT [PEAS]
been_VBN [PASS]
made_VBN
to_TO
eliminate_VB
approach_NN
and_CC
deferred_VBN
actuarial_JJ
gains_NN
and_PHC
losses_NN
are_VPRT [PASS]
amortised_VBN
._.
provisions_NN
for_PIN
restructuring_VBG
costs_NN
that_TSUB
do_VPRT
not_XX0
meet_VB
USGAAP_NN
Therefore_CONJ
the_DT
pension_NN
liability_NOMZ
recognized_VBN [PRIV]
under_IN
IFRS_NN
is_VPRT [BEMA]
greater_PRED
than_PIN
requirements_NOMZ
._.
Marketable_JJ
securities_NOMZ
Stock-based_JJ
compensation_NOMZ
Marketable_JJ
securities_NOMZ
consist_VPRT
primarily_RB
of_PIN
equity_NOMZ
securities_NOMZ
and_CC
certain_JJ
Under_IN
IFRS_NN
2_CD
Share-based_JJ
Payment_NOMZ
,_,
share_NN
options_NOMZ
are_VPRT [BEMA]
fair_PRED
valued_VBN
at_PIN
other_JJ
liquid_JJ
investments_NOMZ
,_,
principally_RB
government_NOMZ
bonds_NN
and_PHC
shorttheir_NN
grant_NN
dates_NN
and_CC
the_DT
cost_NN
is_VPRT [PASS]
charged_VBN
to_PIN
the_DT
income_NN
statement_NOMZ
term_NN
corporate_JJ
debt_NN
instruments_NOMZ
._.
Under_IN
SFAS_NN
115_CD
Accounting_GER
for_PIN
over_IN
the_DT
relevant_JJ
vesting_GER
periods_NN
._.
Under_IN
US_FPP1
GAAP_NN
,_,
the_DT
Group_NN
applies_VPRT
Certain_NN
Investments_NOMZ
in_PIN
Debt_NN
and_PHC
Equity_NOMZ
Securities_NOMZ
,_,
these_DEMO
securities_NOMZ
SFAS_NN
123_CD
Accounting_GER
for_PIN
Stock-Based_NN
Compensation_NOMZ
and_CC
related_VBN
are_VPRT [PASS]
considered_VBN [PRIV]
available_JJ
for_PIN
sale_NN
and_CC
are_VPRT [PASS]
carried_VBN
at_PIN
fair_JJ
value_NN
,_,
with_PIN
the_DT
accounting_GER
interpretations_NOMZ
in_PIN
accounting_GER
for_PIN
its_PIT
option_NOMZ
plans_NN
,_,
which_WDT [SERE]
unrealised_JJ
gains_NN
and_PHC
losses_NN
,_,
net_NN
of_PIN
tax_NN
,_,
recorded_VBN
as_IN
a_DT
separate_JJ
also_RB
require_VPRT [SUAV]
options_NOMZ
to_TO
be_VB [BEMA]
fair_PRED
valued_VBN
at_PIN
their_TPP3
grant_NN
date_NN
and_CC
included_VBD
component_NN
of_PIN
shareholders_NN
equity_NOMZ
._.
Under_IN
IFRS_NN
,_,
these_DEMP
are_VPRT [PASS]
accounted_VBN
in_PIN
the_DT
income_NN
statement_NOMZ
over_IN
the_DT
vesting_JJ
period_NN
of_PIN
the_DT
options_NOMZ
._.
for_PIN
as_IN
available-for-sale_JJ
financial_JJ
assets_NN
in_PIN
accordance_NN
with_PIN
IAS_NN
39_CD
Differences_NN
arise_VB
as_CONJ
a_NULL
result_NULL
of_PIN
the_DT
application_NOMZ
of_PIN
differing_VBG
Financial_NN
Instruments_NOMZ
:_:
Recognition_NOMZ
and_PHC
Measurement_NOMZ
._.
measurement_NOMZ
bases_NN
in_PIN
respect_NN
of_PIN
performance_NN
conditions_NOMZ
attaching_VBG [WZPRES]
The_DT
accounting_GER
treatment_NOMZ
for_PIN
marketable_JJ
securities_NOMZ
under_IN
US_FPP1
GAAP_NN
to_PIN
share-based_JJ
payments_NOMZ
and_CC
in_PIN
the_DT
treatment_NOMZ
of_PIN
lapsed_VBN
grants_NN
._.
However_CONJ
,_,
differences_NN
do_EMPH
arise_VB
,_,
principally_RB
as_CONJ
a_NULL
result_NULL
Derivative_JJ
instruments_NOMZ
of_PIN
the_DT
category_NN
of_PIN
marketable_JJ
securities_NOMZ
as_IN
dened_VBN
by_PIN
SFAS_NN
115_CD
being_VBG
SFAS_NN
133_CD
,_,
Accounting_GER
for_PIN
Derivative_NN
Instruments_NOMZ
and_PHC
Hedging_GER
smaller_JJ
than_PIN
the_DT
category_NN
of_PIN
available-for-sale_JJ
financial_JJ
assets_NN
as_IN
Activities_NOMZ
,_,
as_IN
amended_VBN
by_PIN
SFAS_NN
137_CD
and_CC
SFAS_NN
138_CD
and_CC
as_IN
interpreted_VBN
dened_VBN
by_PIN
IAS_NN
39_CD
._.
Investments_NOMZ
which_WDT [WHSUB]
are_VPRT [BEMA]
not_XX0
marketable_JJ
securities_NOMZ
by_PIN
the_DT
Derivatives_NN
Implementation_NOMZ
Group_NN
,_,
was_VBD [BYPA]
adopted_VBN
by_PIN
the_DT
Group_NN
under_IN
the_DT
SFAS_NN
115_CD
denition_NOMZ
are_VPRT [PASS]
accounted_VBN
for_PIN
at_PIN
cost_NN
less_RB
with_PIN
effect_NN
from_PIN
1st_CD
January_NN
2001_CD
._.
SFAS_NN
133_CD
establishes_VPRT [PRIV]
accounting_GER
impairments_NOMZ
under_IN
US_FPP1
GAAP_NN
rather_RB
than_PIN
at_PIN
fair_JJ
value_NN
._.
and_ANDC
reporting_VBG [PUBV]
standards_NN
for_PIN
derivative_JJ
instruments_NOMZ
,_,
including_VBG
certain_JJ
derivative_JJ
instruments_NOMZ
embedded_VBN [WZPAST]
in_PIN
other_JJ
contracts_NN
collectively_RB
,_,
The_DT
Group_NN
did_VBD
not_XX0
adopt_VB
IAS_NN
39_CD
until_IN
1st_CD
January_NN
2005_CD
,_,
and_ANDC
,_,
in_PIN
referred_VBN
to_PIN
as_IN
derivatives_NN
and_CC
for_PIN
hedging_VBG
activities_NOMZ
._.
SFAS_NN
133_CD
requires_VPRT [SUAV]
accordance_NN
with_PIN
the_DT
exemption_NOMZ
available_JJ
under_IN
IFRS_NN
1_CD
,_,
has_VPRT [PEAS]
presented_VBN
that_DEMO
an_DT
entity_NOMZ
recognize_VB [PRIV]
all_QUAN
derivatives_NN
as_IN
either_DT
assets_NN
or_CC
liabilities_NOMZ
in_PIN
financial_JJ
instruments_NOMZ
in_PIN
the_DT
comparative_JJ
periods_NN
in_PIN
accordance_NN
with_PIN
the_DT
consolidated_JJ
balance_NN
sheet_NN
and_CC
measure_VB
those_DEMO
instruments_NOMZ
at_PIN
fair_JJ
UK_NN
GAAP_NN
._.
Therefore_CONJ
in_PIN
2004_CD
these_DEMO
securities_NOMZ
are_VPRT [PASS]
stated_VBN [PUBV]
at_PIN
the_DT
lower_JJ
value_NN
._.
Changes_NN
in_PIN
fair_JJ
value_NN
over_IN
the_DT
period_NN
are_VPRT [PASS]
recorded_VBN
in_PIN
current_JJ
of_PIN
cost_NN
and_CC
net_JJ
realisable_JJ
value_NN
._.
earnings_GER
unless_COND
hedge_JJ
accounting_GER
is_VPRT [PASS]
obtained_VBN
._.
SFAS_NN
133_CD
prescribes_VPRT
Marketable_JJ
securities_NOMZ
are_VPRT [PASS]
reviewed_VBN
at_PIN
least_JJ
every_QUAN
six_CD
months_NN
for_PIN
other_JJ
requirements_NOMZ
for_PIN
designation_NOMZ
and_PHC
documentation_NOMZ
of_PIN
hedging_VBG
than_PIN
temporary_JJ
impairment_NOMZ
._.
For_PIN
equity_NOMZ
securities_NOMZ
,_,
the_DT
factors_NN
relationships_NN
and_CC
ongoing_JJ
assessments_NOMZ
of_PIN
effectiveness_NOMZ
in_PIN
order_NN
to_TO
considered_VBN [PRIV]
include_VPRT
:_:
qualify_VB
for_PIN
hedge_JJ
accounting_GER
._.
the_DT
investees_NN
current_JJ
financial_JJ
performance_NN
and_CC
future_JJ
prospects_NN
The_DT
Group_NN
also_RB
evaluates_VPRT
contracts_NN
for_PIN
embedded_VBN
derivatives_NN
._.
In_PIN
the_DT
general_JJ
market_NN
condition_NOMZ
of_PIN
the_DT
geographic_JJ
or_CC
industry_NN
area_NN
in_PIN
accordance_NN
with_PIN
SFAS_NN
133_CD
requirements_NOMZ
,_,
if_COND
embedded_VBN
derivatives_NN
are_VPRT
which_WDT
the_DT
investee_NN
operates_VPRT
not_XX0
clearly_RB
and_PHC
closely_RB
related_VBN
to_PIN
the_DT
host_NN
contract_NN
,_,
they_TPP3
are_VPRT [PASS]
accounted_VBN
the_DT
duration_NOMZ
and_PHC
extent_NN
to_PIN
which_WDT [PIRE]
the_DT
market_NN
value_NN
has_VPRT [PEAS]
been_VBN
below_PLACE
for_PIN
separately_RB
from_PIN
the_DT
host_NN
contract_NN
as_IN
derivatives_NN
._.
The_DT
key_JJ
differences_NN
between_PIN
IFRS_NN
under_IN
which_WDT
the_DT
Groups_NN
financial_JJ
Gross_NN
unrealised_JJ
gains_NN
and_PHC
losses_NN
on_PIN
marketable_JJ
securities_NOMZ
were_VBD [BEMA]
36_CD
statements_NOMZ
are_VPRT [BEMA]
prepared_PRED
and_CC
US_FPP1
GAAP_NN
,_,
and_ANDC
in_PIN
the_DT
Groups_NN
application_NOMZ
million_CD
and_CC
4_CD
million_CD
,_,
respectively_RB
,_,
at_PIN
31st_CD
December_NN
2005_CD
2004_CD
of_PIN
their_TPP3
respective_JJ
requirements_NOMZ
,_,
are_VPRT
:_:
60_CD
million_CD
and_CC
3_CD
million_CD
,_,
respectively_RB
._.
The_DT
fair_JJ
value_NN
of_PIN
marketable_JJ
securities_NOMZ
with_PIN
unrealised_JJ
losses_NN
at_PIN
31st_CD
December_NN
2005_CD
is_VPRT [BEMA]
62_CD
million_CD
certain_JJ
derivatives_NN
which_WDT [WHSUB]
are_VPRT [BYPA]
designated_VBN
by_PIN
the_DT
Group_NN
as_IN
hedging_VBG
2004_CD
21_CD
million_CD
._.
All_QUAN
of_PIN
these_DEMO
marketable_JJ
securities_NOMZ
have_VPRT [PEAS]
been_VBN [BEMA]
in_PIN
instruments_NOMZ
under_IN
IAS_NN
39_CD
are_VPRT [PASS]
not_XX0
designated_VBN
as_IN
hedging_VBG
a_DT
continuous_JJ
loss_NN
position_NOMZ
for_PIN
less_JJ
than_PIN
12_CD
months_NN
._.
Deferred_JJ
tax_NN
instruments_NOMZ
under_IN
SFAS_NN
133_CD
._.
Accordingly_RB
,_,
hedge_JJ
accounting_GER
is_VPRT [PASS]
not_XX0
provided_VBN
against_PIN
unrealised_JJ
gains_NN
and_PHC
losses_NN
at_PIN
31st_CD
December_NN
2005_CD
applied_VBN
under_IN
US_FPP1
GAAP_NN
in_PIN
respect_NN
of_PIN
these_DEMO
arrangements_NOMZ
was_VBD [BEMA]
4_CD
million_CD
2004_CD
16_CD
million_CD
._.
Gains_NN
of_PIN
7_CD
million_CD
were_VBD [PASS]
reclassied_VBN
out_PIN
of_PIN
accumulated_VBN
other_JJ
comprehensive_JJ
income_NN
into_PIN
the_DT
income_NN
statement_NOMZ
on_PIN
disposals_NN
of_PIN
equity_NOMZ
investments_NOMZ
during_PIN
the_DT
year_NN
._.
GSK_NN
Annual_JJ
Report_NN
2005_CD
136_CD
FINANCIAL_NN
STATEMENTS_NOMZ
Notes_NN
to_PIN
the_DT
financial_JJ
statements_NOMZ
continued_VBD
Other_JJ
38_CD
Reconciliation_NOMZ
to_PIN
US_FPP1
accounting_GER
principles_NN
The_DT
following_JJ
adjustments_NOMZ
are_VPRT [SPAU] [PASS]
also_RB
included_VBN
in_PIN
the_DT
reconciliations_NOMZ
:_:
continued_VBD
the_DT
denition_NOMZ
of_PIN
derivatives_NN
within_PIN
the_DT
scope_NN
of_PIN
SFAS_NN
133_CD
excludes_VPRT
computer_NN
software_NN
under_IN
IFRS_NN
,_,
the_DT
Group_NN
capitalises_VPRT
costs_NN
incurred_VBN
instruments_NOMZ
for_PIN
which_WDT [PIRE]
there_EX
is_VPRT
no_SYNE
liquid_JJ
market_NN
._.
This_DEMP
leads_VPRT
to_PIN
certain_JJ
in_PIN
acquiring_VBG
and_PHC
developing_VBG
computer_NN
software_NN
for_PIN
internal_JJ
use_NN
items_NN
not_XX0
being_VBG [PASS]
recognized_VBN [PRIV]
on_PIN
the_DT
balance_NN
sheet_NN
,_,
although_CONC
they_TPP3
are_VPRT
where_RB
the_DT
software_NN
supports_VPRT
a_DT
significant_JJ
business_NOMZ
system_NN
and_CC
the_DT
accounted_VBN
for_PIN
as_IN
derivatives_NN
under_IN
IFRS_NN
,_,
most_EMPH
notably_RB
the_DT
call_NN
option_NOMZ
expenditure_NN
leads_VPRT
to_PIN
the_DT
creation_NOMZ
of_PIN
a_DT
durable_JJ
asset_NN
._.
For_PIN
US_FPP1
GAAP_NN
,_,
over_IN
Theravance_NN
shares_NN
the_DT
Group_NN
applies_VPRT
SOP_NN
98-1_CD
,_,
Accounting_GER
for_PIN
the_DT
Costs_NN
of_PIN
Computer_NN
Software_NN
Developed_VBD
or_CC
Obtained_VBN
for_PIN
Internal_NN
Use_NN
,_,
which_WDT [SERE]
restricts_VPRT
IAS_NN
39_CD
has_VPRT
an_DT
exemption_NOMZ
from_PIN
the_DT
requirement_NOMZ
to_TO
recognize_VB [PRIV]
the_DT
categories_NN
of_PIN
costs_NN
which_WDT [WHSUB]
can_POMD
be_VB [PASS]
capitalized_VBN
._.
embedded_VBN
foreign_JJ
currency_NN
derivatives_NN
where_RB
the_DT
currency_NN
is_VPRT [SPAU] [PASS]
commonly_RB
used_VBN
in_PIN
the_DT
economic_JJ
environment_NOMZ
of_PIN
the_DT
host_NN
contract_NN
._.
guarantor_NN
obligations_NOMZ
under_IN
US_FPP1
GAAP_NN
,_,
the_DT
Group_NN
applies_VPRT
the_DT
SFAS_NN
133_CD
does_VPRT
not_XX0
grant_VB [SUAV]
a_DT
similar_JJ
exemption_NOMZ
and_CC
so_IN
the_DT
Group_NN
FASBs_NN
Financial_NN
Interpretation_NOMZ
No._NN
._.
45_CD
FIN45_CD
,_,
Guarantors_NN
identies_NN
and_CC
separately_RB
accounts_NN
for_PIN
more_EMPH
embedded_VBN
derivatives_NN
Accounting_GER
and_PHC
Disclosure_NN
Requirements_NOMZ
for_PIN
Guarantees_NN
,_,
Including_VBG
under_IN
US_FPP1
GAAP_NN
than_PIN
it_PIT
does_VPRT [PROD]
under_IN
IFRS_NN
._.
Indirect_JJ
Guarantees_NN
of_PIN
Indebtedness_NOMZ
of_PIN
Others_NN
._.
This_DEMP
requires_VPRT [SUAV]
that_THVC
the_DT
Group_NN
recognize_VPRT [PRIV] [THATD]
certain_JJ
guarantees_NN
issued_VBN
,_,
measured_VBN [PASTP]
at_PIN
fair_JJ
The_NN
Group_NN
has_VPRT [PEAS]
exercised_VBN
the_DT
exemption_NOMZ
available_JJ
under_IN
IFRS_NN
1_CD
to_PIN
value_NN
._.
Under_IN
IFRS_NN
,_,
such_JJ
guarantor_NN
obligations_NOMZ
are_VPRT [PASS]
recognized_VBN [PRIV]
when_RB [WHCL]
present_JJ
financial_JJ
instruments_NOMZ
in_PIN
the_DT
comparative_JJ
periods_NN
in_PIN
accordance_NN
further_JJ
additional_JJ
criteria_NN
are_VPRT [PASS]
met_VBN
or_CC
the_DT
liability_NOMZ
is_VPRT [PASS]
incurred_VBN
._.
Under_IN
UK_NN
GAAP_NN
,_,
some_QUAN
derivative_JJ
instruments_NOMZ
used_VBN [WZPAST]
for_PIN
hedges_NN
were_VBD [PASS]
not_XX0
recognized_VBN [PRIV]
on_PIN
the_DT
balance_NN
sheet_NN
and_CC
the_DT
matching_JJ
variable_JJ
interest_NN
entities_NOMZ
under_IN
the_DT
FASBs_NN
Interpretation_NOMZ
No._NN
._.
46_CD
principle_NN
was_VBD [PASS]
used_VBN
to_TO
match_VB
the_DT
gain_NN
or_CC
loss_NN
under_IN
these_DEMP
hedging_VBG
Revised_VBN
FIN_NN
46R_NN
,_,
Consolidation_NOMZ
of_PIN
Variable_JJ
Interest_NN
Entities_NOMZ
,_,
certain_JJ
contracts_NN
to_PIN
the_DT
foreign_JJ
currency_NN
transaction_NOMZ
or_CC
profits_NN
to_PIN
which_WDT [PIRE]
they_TPP3
entities_NOMZ
,_,
known_VBN [PRIV]
as_IN
Variable_JJ
Interest_NN
Entities_NOMZ
VIEs_NN
,_,
must_NEMD
be_VB [PASS]
related_VBN
._.
Gains_NN
and_PHC
losses_NN
related_VBN [WZPAST]
to_PIN
the_DT
fair_JJ
value_NN
adjustments_NOMZ
on_PIN
these_DEMP
consolidated_VBN
by_PIN
the_DT
primary_JJ
beneciary_NN
of_PIN
the_DT
entity_NOMZ
._.
The_DT
primary_JJ
derivative_NN
instruments_NOMZ
are_VPRT [SPAU]
therefore_CONJ
reconciling_VBG
items_NN
._.
As_IN
in_PIN
2005_CD
,_,
the_DT
beneciary_NN
is_VPRT [SPAU] [PASS]
generally_RB
dened_VBN
as_IN
having_VBG
the_DT
majority_NOMZ
of_PIN
the_DT
risks_NN
Group_NN
did_VBD
not_XX0
designate_VB
any_QUAN
of_PIN
its_PIT
derivatives_NN
as_IN
qualifying_VBG
hedge_NN
and_PHC
rewards_NN
arising_VBG [WZPRES]
from_PIN
the_DT
VIE_NN
._.
Additionally_RB
,_,
for_PIN
VIEs_NN
in_PIN
which_WDT [PIRE]
a_DT
instruments_NOMZ
under_IN
SFAS_NN
133_CD
._.
significant_JJ
,_,
but_CC
not_XX0
majority_NOMZ
,_,
variable_JJ
interest_NN
is_VPRT [PASS]
held_VBN [PRIV]
,_,
certain_JJ
disclosures_NN
are_VPRT [PASS]
required_VBN [SUAV]
._.
The_DT
Group_NN
has_VPRT [PEAS]
completed_VBN
a_DT
review_NN
of_PIN
The_DT
fair_JJ
value_NN
and_PHC
book_NN
value_NN
of_PIN
derivative_JJ
instruments_NOMZ
as_IN
at_PIN
31st_CD
potential_JJ
VIEs_NN
and_CC
,_,
as_CONJ
a_NULL
consequence_NULL
,_,
has_VPRT [PEAS]
consolidated_VBN
Theravance_NN
December_NN
2004_CD
is_VPRT [PASS]
disclosed_VBN [PUBV]
in_PIN
the_DT
Classication_NOMZ
and_CC
fair_JJ
value_NN
of_PIN
Inc._NN
from_PIN
May_POMD
2004_CD
see_VPRT [PRIV]
Note_NN
c_NN
on_PIN
page_NN
142_CD
._.
No_SYNE
other_JJ
VIEs_NN
of_PIN
financial_JJ
assets_NN
and_PHC
liabilities_NOMZ
table_NN
in_PIN
Note_NN
36_CD
._.
which_WDT [SERE]
the_DT
Group_NN
is_VPRT [BEMA]
the_DT
primary_JJ
beneciary_JJ
were_VBD [PASS]
identied_VBN
._.
Valuation_NOMZ
of_PIN
derivative_JJ
instruments_NOMZ
xed_VBD
asset_NN
and_PHC
inventory_NN
impairments_NOMZ
reversals_NN
of_PIN
impairments_NOMZ
The_DT
fair_JJ
value_NN
of_PIN
derivative_JJ
instruments_NOMZ
is_VPRT [BEMA]
sensitive_PRED
to_PIN
movements_NOMZ
in_PIN
previously_TIME
recorded_VBN
against_PIN
the_DT
carrying_VBG
value_NN
of_PIN
assets_NN
are_VPRT [PASS]
permitted_VBN
the_DT
underlying_VBG
market_NN
rates_NN
and_PHC
variables_NN
._.
The_DT
Group_NN
monitors_VPRT
the_DT
under_IN
IFRS_NN
in_PIN
certain_JJ
circumstances_NN
._.
US_FPP1
GAAP_NN
does_VPRT
not_XX0
permit_VB
fair_JJ
value_NN
of_PIN
derivative_JJ
instruments_NOMZ
on_PIN
at_PIN
least_JJ
a_DT
quarterly_JJ
basis_NN
._.
Derivatives_NN
,_,
including_VBG
interest_NN
rate_NN
swaps_NN
and_PHC
cross-currency_NN
swaps_NN
,_,
are_VPRT [PASS]
valued_VBN
using_VBG
standard_JJ
valuation_NOMZ
models_NN
,_,
counterparty_NN
valuations_NOMZ
,_,
various_JJ
other_JJ
small_JJ
adjustments_NOMZ
._.
Standard_NN
valuation_NOMZ
models_NN
used_VBN [WZPAST]
by_PIN
the_DT
Consolidated_NN
summary_NN
statement_NOMZ
of_PIN
cash_NN
ows_VPRT
Group_NN
consider_VB [PRIV]
relevant_JJ
discount_NN
rates_NN
,_,
the_DT
market_NN
yield_NN
curve_NN
on_PIN
the_DT
The_DT
US_FPP1
GAAP_NN
cash_NN
ow_NN
statement_NOMZ
reports_NN
three_CD
categories_NN
of_PIN
cash_NN
valuation_NOMZ
date_NN
,_,
forward_RB
currency_NN
exchange_NN
rates_NN
and_PHC
counterparty_NN
ows_NN
:_:
operating_VBG
activities_NOMZ
including_VBG [WZPRES]
tax_NN
and_PHC
interest_NN
:_:
investing_VBG
risk_NN
._.
All_QUAN
significant_JJ
rates_NN
and_PHC
variables_NN
are_VPRT [PASS]
obtained_VBN
from_PIN
market_NN
activities_NOMZ
including_VBG [WZPRES]
capital_NN
expenditure_NN
,_,
acquisitions_NOMZ
and_PHC
disposals_NN
sources_NN
._.
All_QUAN
valuations_NOMZ
are_VPRT [PASS]
based_VBN
on_PIN
the_DT
remaining_VBG
term_NN
to_PIN
maturity_NOMZ
together_RB
with_PIN
cash_NN
ows_NN
from_PIN
available-for-sale_JJ
current_JJ
asset_NN
of_PIN
the_DT
instrument_NOMZ
._.
investments_NOMZ
:_:
and_ANDC
nancing_VBG
activities_NOMZ
including_VBG [WZPRES]
dividends_NN
paid_VBN
._.
A_DT
Foreign_JJ
exchange_NN
contracts_NN
are_VPRT [PASS]
valued_VBN
using_VBG
forward_RB
rates_NN
observed_VBD [PRIV]
summary_NN
statement_NOMZ
of_PIN
cash_NN
ows_NN
is_VPRT [PASS]
presented_VBN
on_PIN
page_NN
140_CD
._.
from_PIN
quoted_VBN
prices_NN
in_PIN
the_DT
relevant_JJ
markets_NN
when_RB
possible_JJ
._.
The_DT
Group_NN
Comprehensive_NN
income_NN
statement_NOMZ
assumes_VPRT [PRIV]
parties_NN
to_PIN
long-term_JJ
contracts_NN
are_VPRT [BEMA]
economically_RB
viable_PRED
but_CC
The_DT
requirement_NOMZ
of_PIN
SFAS_NN
130_CD
,_,
Reporting_GER
comprehensive_JJ
income_NN
,_,
to_PIN
reserves_NN
the_DT
right_NN
to_TO
exercise_VB
early_TIME
termination_NOMZ
rights_NN
if_COND
economically_RB
provide_VB
a_DT
comprehensive_JJ
income_NN
statement_NOMZ
is_VPRT [PASS]
met_VBN
under_IN
IFRS_NN
by_PIN
the_DT
beneficial_JJ
when_RB
such_JJ
rights_NN
exist_VPRT
in_PIN
the_DT
contract_NN
._.
Statement_NOMZ
of_PIN
recognized_VBN [PRIV]
income_NN
and_PHC
expense_NN
page_NN
88_CD
._.
Dividends_NN
Under_IN
IFRS_NN
,_,
GSK_NN
plcs_NN
quarterly_JJ
dividends_NN
are_VPRT [PASS]
recognized_VBN [PRIV]
only_DWNT
on_PIN
payment_NOMZ
._.
Under_IN
US_FPP1
GAAP_NN
,_,
the_DT
dividends_NN
are_VPRT [PASS]
recognized_VBN [PRIV]
in_PIN
the_DT
financial_JJ
statements_NOMZ
when_RB
they_TPP3
are_VPRT [PASS]
declared_VBN [PUBV]
._.
GSK_NN
Annual_JJ
Report_NN
2005_CD
137_CD
FINANCIAL_NN
STATEMENTS_NOMZ
Notes_NN
to_PIN
the_DT
financial_JJ
statements_NOMZ
continued_VBD
Other_JJ
recent_JJ
FASB_NN
pronouncements_VPRT
38_CD
Reconciliation_NOMZ
to_PIN
US_FPP1
accounting_GER
principles_NN
In_PIN
November_NN
2004_CD
,_,
the_DT
FASB_NN
issued_VBD
SFAS_NN
151_CD
,_,
Inventory_NN
Costs_NN
an_DT
continued_JJ
amendment_NOMZ
of_PIN
ARB_NN
No._NN
._.
SFAS_NN
151_CD
claries_NN
that_TOBJ
Recent_JJ
Financial_NN
Accounting_GER
Standards_NN
Board_NN
FASB_NN
abnormal_JJ
amounts_NN
of_PIN
idle_JJ
facility_NOMZ
expense_NN
,_,
freight_NN
,_,
handling_VBG
costs_NN
,_,
pronouncements_NOMZ
and_CC
wasted_VBN
materials_NN
spoilage_VPRT
should_NEMD
be_VB [PASS]
recognized_VBN [PRIV]
as_IN
currentFSP_NN
FIN_NN
46_CD
R_NN
-5_CD
period_NN
charges_NN
and_CC
requires_VPRT [SUAV]
the_DT
allocation_NOMZ
of_PIN
xed_JJ
production_NOMZ
In_PIN
March_NN
2005_CD
,_,
the_DT
FASB_NN
issued_VBD
FASB_NN
Staff_NN
Position_NOMZ
FSP_NN
FIN_NN
46_CD
R_NN
-_:
overheads_NN
to_PIN
inventory_NN
based_VBN [WZPAST]
on_PIN
the_DT
normal_JJ
capacity_NOMZ
of_PIN
the_DT
5_CD
,_,
Implicit_NN
Variable_NN
Interests_NN
under_IN
FASB_NN
Interpretation_NOMZ
No._NN
._.
SFAS_NN
151_CD
is_VPRT [BEMA]
effective_PRED
for_PIN
scal_JJ
years_NN
beginning_VBG [WZPRES]
Consolidation_NOMZ
of_PIN
Variable_JJ
Interest_NN
Entities_NOMZ
._.
The_DT
FSP_NN
requires_VPRT [SUAV]
a_DT
reporting_GER
after_IN
15th_JJ
June_NN
2005_CD
._.
enterprise_NN
to_TO
consider_VB [PRIV]
whether_IN [WHCL]
it_PIT
holds_VPRT [PRIV]
an_DT
implicit_JJ
variable_JJ
interest_NN
in_PIN
the_DT
VIE_NN
or_CC
potential_JJ
VIE_NN
._.
The_DT
determination_NOMZ
of_PIN
whether_IN
an_DT
implicit_JJ
In_PIN
December_NN
2004_CD
,_,
the_DT
FASB_NN
issued_VBD
SFAS_NN
153_CD
,_,
Exchanges_NN
of_PIN
Nonvariable_JJ
interest_NN
exists_VPRT
involves_VPRT
determining_VBG [SUAV] [PRIV]
whether_IN [WHCL]
an_DT
enterprise_NN
monetary_JJ
Assets_NN
-_:
an_DT
amendment_NOMZ
of_PIN
APB_NN
Opinion_NN
29_CD
,_,
which_WDT [SERE]
amends_VPRT
may_POMD
be_VB [BEMA]
indirectly_RB
absorbing_PRED
or_CC
receiving_VBG
the_DT
variability_NOMZ
of_PIN
the_DT
entity_NOMZ
._.
APB_NN
Opinion_NN
29_CD
,_,
Accounting_GER
for_PIN
Non-monetary_JJ
Transactions_NOMZ
to_PIN
The_DT
FSP_NN
is_VPRT [BEMA]
effective_PRED
in_PIN
the_DT
first_JJ
reporting_GER
period_NN
beginning_VBG [WZPRES]
after_IN
3rd_CD
eliminate_VB
the_DT
exception_NOMZ
for_PIN
non-monetary_JJ
exchanges_NN
of_PIN
similar_JJ
March_NN
2005_CD
._.
The_DT
adoption_NOMZ
of_PIN
the_DT
FSP_NN
by_PIN
the_DT
Group_NN
has_VPRT [PEAS]
not_XX0
had_VBD
an_DT
productive_JJ
assets_NN
and_CC
replaces_VPRT
it_PIT
with_PIN
a_DT
general_JJ
exception_NOMZ
for_PIN
impact_NN
on_PIN
its_PIT
overall_JJ
results_NN
of_PIN
operations_NOMZ
or_CC
financial_JJ
position_NOMZ
under_IN
exchanges_NN
of_PIN
non-monetary_JJ
assets_NN
that_TSUB
do_VPRT
not_XX0
have_VB
commercial_JJ
US_FPP1
GAAP_NN
._.
SFAS_NN
153_CD
is_VPRT [BEMA]
effective_PRED
for_PIN
non-monetary_JJ
asset_NN
exchanges_NN
occurring_VBG [WZPRES]
in_PIN
scal_JJ
years_NN
beginning_VBG [WZPRES]
after_IN
15th_JJ
June_NN
2005_CD
._.
EITF_NN
05-06_CD
In_PIN
June_NN
2005_CD
the_DT
Emerging_VBG
Issues_NN
Task_NN
Force_NN
EITF_NN
reached_VBD
consensus_NN
In_PIN
March_NN
2005_CD
,_,
the_DT
FASB_NN
published_VBD
FASB_NN
Staff_NN
Position_NOMZ
FSP_NN
FIN_NN
47_CD
,_,
on_PIN
Issue_NN
05-6_CD
,_,
Determining_VBG [SUAV] [PRIV] [PRESP]
the_DT
Amortisation_NOMZ
Period_NN
for_PIN
Leasehold_NN
Accounting_GER
for_PIN
Conditional_NN
Asset_NN
Retirement_NOMZ
Obligations_NOMZ
an_DT
Improvements_NOMZ
Purchased_NN
after_IN
Lease_NN
Inception_NOMZ
or_CC
Acquired_VBN
in_PIN
a_DT
interpretation_NOMZ
of_PIN
FASB_NN
Statement_NOMZ
No._NN
._.
143_CD
which_WDT
claries_VPRT
the_DT
Business_NOMZ
Combination_NOMZ
._.
EITF_NN
05-6_CD
requires_VPRT [SUAV]
leasehold_NN
improvements_NOMZ
application_NOMZ
of_PIN
SFAS_NN
143_CD
Accounting_GER
for_PIN
Obligations_NOMZ
Associated_NN
with_PIN
acquired_VBN
in_PIN
a_DT
business_NOMZ
combination_NOMZ
to_TO
be_VB [PASS]
amortised_VBN
over_IN
the_DT
shorter_JJ
the_DT
Retirement_NOMZ
of_PIN
Long-Lived_NN
Assets_NN
in_PIN
respect_NN
of_PIN
conditional_JJ
asset_NN
of_PIN
the_DT
useful_JJ
life_NN
of_PIN
the_DT
assets_NN
or_CC
a_DT
term_NN
that_TSUB
includes_VPRT
required_VBN [SUAV]
lease_NN
retirement_NOMZ
obligations_NOMZ
._.
The_DT
FSP_NN
is_VPRT [BEMA]
effective_PRED
in_PIN
the_DT
first_JJ
period_NN
beginning_GER
periods_NN
and_PHC
renewals_NN
deemed_VBD [PRIV]
to_TO
be_VB [SPAU] [PASS]
reasonably_RB
assured_VBN
at_PIN
the_DT
date_NN
after_IN
15th_JJ
December_NN
2005_CD
._.
of_PIN
acquisition_NOMZ
._.
Additionally_RB
,_,
the_DT
Issue_NN
requires_VPRT [SUAV] [THATD]
improvements_NOMZ
placed_VBN [WZPAST]
in_PIN
In_PIN
November_NN
2005_CD
,_,
the_DT
FASB_NN
issued_VBD
FSP_NN
115-1_CD
and_CC
FSP_NN
124-1_CD
,_,
The_DT
service_NN
signicantly_RB
after_IN
and_CC
not_XX0
contemplated_VBN
at_PIN
or_CC
near_PLACE
the_DT
Meaning_GER
of_PIN
Other-Than-Temporary_NN
Impairment_NOMZ
and_CC
Its_PIT
Application_NOMZ
beginning_GER
of_PIN
the_DT
lease_NN
term_NN
to_TO
be_VB [PASS]
amortised_VBN
over_IN
the_DT
shorter_JJ
of_PIN
the_DT
to_PIN
Certain_NN
Investments_NOMZ
which_WDT [WHSUB]
nullify_VPRT
certain_JJ
requirements_NOMZ
of_PIN
EITF_NN
03_SYM
-_:
useful_JJ
life_NN
of_PIN
the_DT
assets_NN
or_CC
a_DT
term_NN
that_TSUB
includes_VPRT
required_VBN [SUAV]
lease_NN
periods_NN
1_CD
and_CC
supersede_VPRT
EITF_NN
D-44_NN
._.
The_DT
FSPs_NN
provide_VPRT
guidance_NN
for_PIN
identifying_VBG
and_CC
renewals_NN
deemed_VBD [PRIV]
to_TO
be_VB [SPAU] [PASS]
reasonably_RB
assured_VBN
at_PIN
the_DT
date_NN
the_DT
impaired_JJ
investments_NOMZ
and_CC
new_JJ
disclosure_NN
requirements_NOMZ
for_PIN
leasehold_NN
improvements_NOMZ
are_VPRT [PASS]
purchased_VBN
._.
investments_NOMZ
that_TSUB
are_VPRT [PASS]
deemed_VBN [PRIV]
to_TO
be_VB [SPAU] [PASS]
temporarily_RB
impaired_VBN
._.
The_DT
FSPs_NN
are_VPRT
EITF_NN
05-6_CD
is_VPRT [BEMA]
effective_JJ
immediately_TIME
._.
The_DT
adoption_NOMZ
of_PIN
EITF_NN
05-6_CD
has_VPRT
not_XX0
effective_JJ
for_PIN
scal_JJ
years_NN
beginning_VBG [WZPRES]
after_IN
15th_JJ
December_NN
2005_CD
._.
had_VBD
a_DT
material_NN
impact_NN
on_PIN
the_DT
Groups_NN
consolidated_JJ
financial_JJ
position_NOMZ
,_,
In_PIN
November_NN
2005_CD
,_,
the_DT
FASB_NN
issued_VBD
FSP_NN
FIN_NN
45-3_CD
to_TO
provide_VB
results_NN
of_PIN
operations_NOMZ
or_CC
cash_NN
ows_NN
under_IN
US_FPP1
GAAP_NN
._.
clarification_NOMZ
with_PIN
respect_NN
to_PIN
the_DT
application_NOMZ
of_PIN
FIN_NN
45_CD
,_,
Guarantors_NN
SFAS_NN
123R_NN
and_CC
related_VBN
FSPs_NN
Accounting_GER
and_PHC
Disclosure_NN
Requirements_NOMZ
for_PIN
Guarantees_NN
,_,
Including_VBG [PRESP]
In_PIN
December_NN
2004_CD
,_,
the_DT
FASB_NN
issued_VBD
SFAS_NN
123_CD
revised_VBN
2004_CD
,_,
ShareIndirect_NN
Guarantees_NN
of_PIN
Indebtedness_NOMZ
of_PIN
Others_NN
._.
FSP_NN
FIN_NN
45-3_JJ
includes_VPRT
Based_VBN
Payment_NOMZ
._.
SFAS_NN
123R_NN
replaces_VPRT
SFAS_NN
123_CD
and_CC
supersedes_VPRT
APB_NN
within_PIN
its_PIT
scope_NN
and_CC
provides_VPRT
guidance_NN
concerning_VBG [WZPRES]
the_DT
application_NOMZ
of_PIN
25_CD
._.
SFAS_NN
123R_NN
requires_VPRT [SUAV]
that_THVC
the_DT
cost_NN
resulting_VBG [WZPRES]
from_PIN
all_QUAN
share-based_JJ
FIN_NN
45_CD
to_PIN
a_DT
guarantee_NN
granted_VBN [SUAV] [WZPAST]
to_PIN
a_DT
business_NOMZ
or_CC
to_PIN
its_PIT
owners_NN
that_TOBJ
the_DT
payment_NOMZ
transactions_NOMZ
be_VB [PASS]
recognized_VBN [PRIV]
in_PIN
the_DT
financial_JJ
statements_NOMZ
at_PIN
fair_JJ
entitys_NN
revenue_NN
or_CC
the_DT
revenue_NN
of_PIN
a_DT
specified_VBN
portion_NOMZ
of_PIN
the_DT
entity_NOMZ
value_NN
and_CC
that_DEMO
excess_JJ
tax_NN
benets_NN
be_VB [PASS]
reported_VBN [PUBV]
as_IN
a_DT
nancing_GER
cash_NN
will_PRMD
meet_VB
a_DT
minimum_NN
amount_NN
referred_VBD
to_PIN
as_IN
a_DT
minimum_NN
revenue_NN
inow_NN
rather_RB
than_PIN
as_IN
a_DT
reduction_NOMZ
of_PIN
taxes_NN
paid_VBN
._.
for_PIN
the_DT
Group_NN
from_PIN
1st_CD
January_NN
2006_CD
._.
From_PIN
the_DT
effective_JJ
date_NN
,_,
The_DT
Group_NN
does_VPRT
not_XX0
expect_VB [PRIV]
the_DT
adoption_NOMZ
of_PIN
the_DT
above_PLACE
compensation_NOMZ
cost_NN
is_VPRT [PASS]
recognized_VBN [PRIV]
based_VBN
on_PIN
the_DT
requirements_NOMZ
of_PIN
SFAS_NN
pronouncements_NOMZ
to_TO
have_VB
a_DT
material_NN
impact_NN
on_PIN
its_PIT
consolidated_JJ
123R_NN
for_PIN
all_QUAN
new_JJ
share-based_JJ
awards_NN
and_CC
based_VBN
on_PIN
the_DT
requirements_NOMZ
financial_JJ
position_NOMZ
,_,
results_NN
of_PIN
operations_NOMZ
or_CC
cash_NN
ows_NN
under_IN
US_FPP1
GAAP_NN
._.
of_PIN
SFAS_NN
123_CD
for_PIN
all_QUAN
awards_NN
granted_VBN [SUAV] [WZPAST]
prior_RB
to_PIN
the_DT
effective_JJ
date_NN
of_PIN
SFAS_NN
123R_NN
that_TSUB
remain_VPRT
unvested_JJ
on_PIN
the_DT
effective_JJ
date_NN
._.
In_PIN
May_POMD
2005_CD
,_,
SFAS_NN
154_CD
,_,
Accounting_GER
Changes_NN
and_PHC
Error_NN
Corrections_NOMZ
replacement_NOMZ
of_PIN
APB_NN
Opinion_NN
20_CD
and_CC
SFAS_NN
3_CD
,_,
was_VBD [PASS]
issued_VBN
._.
SFAS_NN
154_CD
During_PIN
2005_CD
the_DT
FASB_NN
issued_VBD
FSP_NN
123R-1_NN
,_,
FSP_NN
123R-2_NN
and_PHC
FSP_NN
123Rchanges_VPRT
the_DT
accounting_GER
for_PIN
and_CC
reporting_VBG [PUBV]
of_PIN
a_DT
change_NN
in_PIN
accounting_GER
3_CD
._.
These_DEMO
FSPs_NN
detail_NN
with_PIN
various_JJ
aspects_NN
of_PIN
the_DT
implementation_NOMZ
of_PIN
principle_NN
by_PIN
requiring_VBG [SUAV]
retrospective_JJ
application_NOMZ
to_TO
prior_RB
periods_NN
SFAS_NN
123R_NN
._.
GSK_NN
is_VPRT [BEMA]
in_PIN
the_DT
process_NN
of_PIN
assessing_VBG
the_DT
impact_NN
of_PIN
the_DT
financial_JJ
statements_NOMZ
of_PIN
changes_NN
in_PIN
accounting_GER
principle_NN
unless_COND
adoption_NOMZ
of_PIN
SFAS_NN
123R_NN
on_PIN
the_DT
Groups_NN
consolidated_JJ
financial_JJ
position_NOMZ
,_,
impracticable_JJ
._.
SFAS_NN
154_CD
is_VPRT [BEMA]
effective_PRED
for_PIN
accounting_VBG
changes_NN
made_VBN [WZPAST]
in_PIN
results_NN
of_PIN
operations_NOMZ
and_PHC
cash_NN
ows_NN
under_IN
US_FPP1
GAAP_NN
._.
scal_JJ
years_NN
beginning_VBG [WZPRES]
after_IN
15th_JJ
December_NN
2005_CD
._.
The_DT
Group_NN
can_POMD
not_XX0
determine_VB [SUAV] [PRIV]
the_DT
impact_NN
of_PIN
SFAS_NN
154_CD
as_IN
it_PIT
depends_VPRT
in_PIN
part_NN
upon_PIN
future_JJ
changes_NN
to_PIN
US_FPP1
accounting_GER
principles_NN
._.
GSK_NN
Annual_JJ
Report_NN
2005_CD
138_CD
FINANCIAL_NN
STATEMENTS_NOMZ
Notes_NN
to_PIN
the_DT
financial_JJ
statements_NOMZ
continued_VBD
38_CD
Reconciliation_NOMZ
to_PIN
US_FPP1
accounting_GER
principles_NN
continued_VBD
The_DT
following_GER
is_VPRT [BEMA]
a_DT
summary_NN
of_PIN
the_DT
material_NN
adjustments_NOMZ
to_TO
profit_VB
and_CC
shareholders_NN
funds_NN
which_WDT [WHSUB]
would_PRMD
be_VB [PASS]
required_VBN [SUAV]
if_COND
US_FPP1
GAAP_NN
had_VBD [PEAS]
been_VBN [PASS]
applied_VBN
instead_CONJ
of_NULL
IFRS_NN
._.
2005 2004 2003_CD
profit_NN
Notes_NN
m_VPRT
m_FW
m_FW
profit_NN
after_IN
taxation_NOMZ
for_PIN
the_DT
year_NN
under_IN
IFRS_NN
4,816_CD
4,022_CD
4,308_CD
profit_NN
attributable_JJ
to_PIN
minority_NOMZ
interests_NN
127 114 107_CD
profit_NN
attributable_JJ
to_PIN
shareholders_NN
under_IN
IFRS_NN
4,689_CD
3,908_CD
4,201_CD
US_FPP1
GAAP_NN
adjustments_NOMZ
:_:
Amortisation_NOMZ
and_PHC
impairment_NOMZ
of_PIN
intangible_JJ
assets_NN
b_NN
1,584_CD
1,441_CD
2,303_CD
Acquisition_NOMZ
and_PHC
disposal_NN
of_PIN
product_NN
rights_NN
b_NN
72 210 105_CD
Write-off_PIN
of_PIN
in-process_JJ
R&D_NN
acquired_VBD
in_PIN
business_NOMZ
combinations_NOMZ
b_NN
26_CD
Capitalised_VBN
interest_NN
1_CD
17_CD
23_CD
Disposal_NN
of_PIN
interests_NN
in_PIN
associates_NN
and_PHC
subsidiaries_NN
97_CD
Investments_NOMZ
2_CD
30_CD
31_CD
Pensions_NN
and_CC
post-retirement_JJ
benets_NN
f_LS
127 126 130_CD
Stock-based_JJ
compensation_NOMZ
6_CD
13_CD
2_CD
Derivative_JJ
instruments_NOMZ
and_CC
hedging_VBG
30_CD
33_CD
41_CD
Fair_NN
value_NN
of_PIN
put_NN
option_NOMZ
granted_VBN [SUAV] [WZPAST]
to_PIN
minority_NOMZ
shareholders_NN
c_NN
17_CD
Restructuring_GER
1_CD
12_CD
98_CD
Tax_NN
benets_NN
on_PIN
exercise_NN
of_PIN
stock_NN
options_NOMZ
d_LS
47_CD
10_CD
13_CD
Deferred_JJ
taxation_NOMZ
d_SYM
585 757 740_CD
Other_JJ
56_CD
53_CD
17_CD
Net_JJ
income_NN
under_IN
US_FPP1
GAAP_NN
3,336_CD
2,732_CD
2,420_CD
2005 2004 2003_CD
Earnings_GER
per_PIN
share_NN
under_IN
US_FPP1
GAAP_NN
p_NN
pp_NN
Basic_JJ
net_JJ
income_NN
per_PIN
share_NN
58.8_CD
47.6_CD
41.7_CD
Diluted_NN
net_JJ
income_NN
per_PIN
share_NN
58.3_CD
47.5_CD
41.6_CD
2005 2004 2003_CD
Earnings_GER
per_PIN
ADS_NN
under_IN
US_FPP1
GAAP_NN
$_$
$_$
$_$
Basic_JJ
net_JJ
income_NN
per_PIN
ADS_NN
2.14_CD
1.74_CD
1.37_CD
Diluted_NN
net_JJ
income_NN
per_PIN
ADS_NN
2.12_CD
1.74_CD
1.36_CD
2005_CD
2004_CD
Equity_NOMZ
shareholders_NN
funds_NN
Notes_NN
m_FW
m_FW [BEMA]
Total_JJ
equity_NOMZ
under_IN
IFRS_NN
7,570_CD
5,937_CD
Minority_NOMZ
interests_NN
259_CD
213_CD
Shareholders_NN
equity_NOMZ
under_IN
IFRS_NN
7,311_CD
5,724_CD
US_FPP1
GAAP_NN
adjustments_NOMZ
:_:
Goodwill_NN
a_DT
17,976_CD
17,817_CD
Product_NN
rights_NN
b_NN
12,065_CD
13,756_CD
Pension_NN
intangible_JJ
asset_NN
f_SYM
86_CD
102_CD
Property_NN
,_,
plant_NN
and_PHC
equipment_NOMZ
33_CD
43_CD
Capitalised_VBN
interest_NN
179_CD
180_CD
Marketable_JJ
securities_NOMZ
49_CD
Other_JJ
investments_NOMZ
576_CD
532_CD
Pensions_NN
and_CC
other_JJ
post-retirement_JJ
benets_NN
f_LS
1,163_CD
1,128_CD
Restructuring_GER
costs_NN
65_CD
80_CD
Derivative_JJ
instruments_NOMZ
and_CC
hedging_VBG
33_CD
15_CD
Fair_NN
value_NN
of_PIN
put_NN
option_NOMZ
granted_VBN [SUAV] [WZPAST]
to_PIN
minority_NOMZ
shareholders_NN
c_NN
17_CD
Dividends_NN
568_CD
571_CD
Deferred_JJ
taxation_NOMZ
e_SYM
4,531_CD
4,840_CD
Other_JJ
40_CD
40_CD
Shareholders_NN
equity_NOMZ
under_IN
US_FPP1
GAAP_NN
34,282_CD
34,042_CD
GSK_NN
Annual_JJ
Report_NN
2005_CD
139_CD
FINANCIAL_NN
STATEMENTS_NOMZ
Notes_NN
to_PIN
the_DT
financial_JJ
statements_NOMZ
continued_VBD
38_CD
Reconciliation_NOMZ
to_PIN
US_FPP1
accounting_GER
principles_NN
continued_VBD
2005 2004 2003_CD
Consolidated_NN
statement_NOMZ
of_PIN
cash_NN
ows_NN
under_IN
US_FPP1
GAAP_NN
m_FW
m_FW
m_FW [BEMA]
Net_JJ
cash_NN
provided_VBN [WZPAST]
by_PIN
operating_VBG
activities_NOMZ
5,751_CD
4,618_CD
4,895_CD
Net_JJ
cash_NN
used_VBN [WZPAST]
in_PIN
investing_VBG
activities_NOMZ
1,843_CD
988_CD
904_CD
Net_JJ
cash_NN
used_VBN [WZPAST]
in_PIN
nancing_VBG
activities_NOMZ
2,409_CD
3,038_CD
3,051_CD
Net_JJ
increase_NN
in_PIN
cash_NN
and_PHC
cash_NN
equivalents_NN
1,499_CD
592_CD
940_CD
Exchange_NN
rate_NN
movements_NOMZ
237_CD
93_CD
36_CD
Cash_NN
and_PHC
cash_NN
equivalents_NN
at_PIN
beginning_GER
of_PIN
year_NN
2,485_CD
1,986_CD
1,082_CD
Cash_NN
and_PHC
cash_NN
equivalents_NN
at_PIN
end_NN
of_PIN
year_NN
4,221_CD
2,485_CD
1,986_CD
Notes_NN
to_PIN
the_DT
profit_NN
and_PHC
Equity_NOMZ
shareholders_NN
funds_NN
reconciliations_VPRT
a_DT
Goodwill_NN
The_NN
following_VBG [WZPRES]
tables_NN
set_VBN [WZPAST]
out_PIN
the_DT
IFRS_NN
to_PIN
US_FPP1
GAAP_NN
adjustments_NOMZ
required_VBN [SUAV] [WZPAST]
to_PIN
the_DT
IFRS_NN
balance_NN
sheet_NN
in_PIN
respect_NN
of_PIN
goodwill_NN
including_VBG [WZPRES]
goodwill_NN
in_PIN
respect_NN
of_PIN
associated_VBN
undertakings_GER
:_:
2005_CD
2004_CD
Balance_NN
sheet_NN
m_NN
m_NN
Goodwill_NN
under_IN
IFRS_NN
696_CD
304_CD
Goodwill_NN
under_IN
US_FPP1
GAAP_NN
18,672_CD
18,121_CD
IFRS_NN
to_PIN
US_FPP1
GAAP_NN
adjustments_NOMZ
17,976_CD
17,817_CD
Of_PIN
the_DT
18,672_CD
million_CD
2004_CD
18,121_CD
million_CD
US_FPP1
GAAP_NN
goodwill_NN
balance_NN
at_PIN
31st_CD
December_NN
2005_CD
,_,
15,875_CD
million_CD
2004_CD
15,875_CD
million_CD
is_VPRT [BEMA]
in_PIN
respect_NN
of_PIN
the_DT
goodwill_NN
arising_VBG [WZPRES]
on_PIN
the_DT
acquisition_NOMZ
of_PIN
SmithKline_NN
Beecham_NN
by_PIN
Glaxo_NN
Wellcome_NN
in_PIN
2000_CD
._.
The_DT
following_JJ
tables_NN
present_VPRT
the_DT
changes_NN
in_PIN
goodwill_NN
allocated_VBN [WZPAST]
to_PIN
the_DT
Groups_NN
reportable_JJ
segments_NOMZ
:_:
Consumer_NN
Pharmaceuticals_NN
Healthcare_NN
Total_NN
m_FW
m_FW
m_FW [BEMA]
At_PIN
1st_CD
January_NN
2004_CD
15,668_CD
2,461_CD
18,129_CD
Asset_NN
written_VBN [PUBV] [WZPAST]
off_PIN
1_CD
1_CD
Exchange_NN
adjustments_NOMZ
5_CD
12_CD
7_CD
At_PIN
31st_CD
December_NN
2004_CD
15,672_CD
2,449_CD
18,121_CD
Additions_NOMZ
528_CD
528_CD
Disposals_NN
1_CD
1_CD
Exchange_NN
adjustments_NOMZ
51924_CD
At_PIN
31st_CD
December_NN
2005_CD
16,204_CD
2,468_CD
18,672_CD
b_NN
Intangible_JJ
assets_NN
The_DT
following_JJ
tables_NN
set_VBN [WZPAST]
out_PIN
the_DT
IFRS_NN
to_PIN
US_FPP1
GAAP_NN
adjustments_NOMZ
required_VBN [SUAV] [WZPAST]
to_PIN
the_DT
IFRS_NN
income_NN
statement_NOMZ
and_PHC
balance_NN
sheet_NN
in_PIN
respect_NN
of_PIN
intangible_JJ
assets_NN
:_:
2005 2004 2003_CD
Income_NN
statement_NOMZ
m_NN
m_FW
m_FW
Amortisation_NOMZ
charge_NN
under_IN
IFRS_NN
109_CD
75_CD
58_CD
Amortisation_NOMZ
charge_NN
under_IN
US_FPP1
GAAP_NN
1,674_CD
1,516_CD
1,641_CD
IFRS_NN
to_PIN
US_FPP1
GAAP_NN
adjustment_NOMZ
for_PIN
amortisation_NOMZ
1,565_CD
1,441_CD
1,583_CD
Impairment_NOMZ
charge_NN
under_IN
IFRS_NN
99_CD
26_CD
46_CD
Impairment_NOMZ
charge_NN
under_IN
US_FPP1
GAAP_NN
118_CD
26_CD
766_CD
IFRS_NN
to_PIN
US_FPP1
GAAP_NN
adjustment_NOMZ
for_PIN
impairment_NOMZ
19_CD
720_CD
In_CONJ
addition_NULL
to_PIN
the_DT
above_PLACE
adjustments_NOMZ
for_PIN
amortisation_NOMZ
and_PHC
impairments_NOMZ
,_,
further_JJ
IFRS_NN
to_PIN
US_FPP1
GAAP_NN
adjustments_NOMZ
arose_VBD
during_PIN
the_DT
year_NN
of_PIN
98_CD
million_CD
2004_CD
173_CD
million_CD
:_:
2003_CD
105_CD
million_CD
in_PIN
respect_NN
of_PIN
the_DT
acquisition_NOMZ
and_PHC
disposal_NN
of_PIN
in-process_JJ
R&D_NN
,_,
licences_NN
,_,
patents_NN
etc._FW
._.
which_WDT [SERE]
are_VPRT [PASS]
capitalized_VBN
under_IN
IFRS_NN
but_CC
charged_VBD
directly_RB
to_PIN
research_NN
and_PHC
development_NOMZ
expense_NN
under_IN
US_FPP1
GAAP_NN
,_,
and_ANDC
nil_CD
million_CD
2004_CD
37_CD
million_CD
:_:
2003_CD
nil_NN
in_PIN
respect_NN
of_PIN
disposals_NN
of_PIN
product_NN
rights_NN
which_WDT [WHSUB]
have_VPRT
a_DT
higher_JJ
carrying_VBG
value_NN
under_IN
US_FPP1
GAAP_NN
than_PIN
under_IN
IFRS_NN
._.
GSK_NN
Annual_JJ
Report_NN
2005_CD
140_CD
FINANCIAL_NN
STATEMENTS_NOMZ
Notes_NN
to_PIN
the_DT
financial_JJ
statements_NOMZ
continued_VBD
38_CD
Reconciliation_NOMZ
to_PIN
US_FPP1
accounting_GER
principles_NN
continued_VBD
2005_CD
2004_CD
Balance_NN
sheet_NN
m_NN
m_NN
Product_NN
rights_NN
intangible_JJ
assets_NN
under_IN
IFRS_NN
3,120_CD
2,241_CD
Product_NN
rights_NN
intangible_JJ
assets_NN
under_IN
US_FPP1
GAAP_NN
15,185_CD
15,997_CD
Net_JJ
IFRS_NN
to_PIN
US_FPP1
GAAP_NN
product_NN
rights_NN
adjustments_NOMZ
12,065_CD
13,756_CD
Product_NN
rights_NN
intangible_JJ
assets_NN
under_IN
US_FPP1
GAAP_NN
are_VPRT [PASS]
analyzed_VBN
as_IN
follows_VPRT
:_:
Acquired_VBN
Licenses_NN
,_,
Brands_NN
subject_JJ
indefinite_JJ
products_NN
patents_NN
,_,
etc._FW
._.
to_PIN
amortisation_NOMZ
lived_VBD
brands_NN
Total_JJ
2005_CD
m_FW
m_FW
m_FW
m_FW
m_FW
Cost_NN
20,857_CD
512_CD
1,096_CD
4,722_CD
27,187_CD
Accumulated_VBN
amortisation_NOMZ
and_PHC
impairment_NOMZ
11,115_CD
72 185 630_CD
12,002_CD
Carrying_VBG
value_NN
9,742_CD
440_CD
911_CD
4,092_CD
15,185_CD
2004_CD
Cost_NN
20,061_CD
398_CD
1,096_CD
4,652_CD
26,207_CD
Accumulated_VBN
amortisation_NOMZ
and_PHC
impairment_NOMZ
9,472_CD
27 134 577_CD
10,210_CD
Carrying_VBG
value_NN
10,589_CD
371_CD
962_CD
4,075_CD
15,997_CD
The_DT
acquired_VBN
products_NN
are_VPRT [BEMA]
pharmaceutical_JJ
products_NN
,_,
principally_RB
arising_VBG
from_PIN
the_DT
acquisition_NOMZ
of_PIN
SmithKline_NN
Beecham_NN
plc_NN
,_,
with_PIN
book_NN
values_NN
net_NN
of_PIN
accumulated_VBN
amortisation_NOMZ
and_PHC
impairment_NOMZ
as_IN
follows_VPRT
:_:
2005_CD
2004_CD
m_NN
m_NN
Avandia_NN
3,841_CD
4,190_CD
Seroxat_NN
Paxil_NN
1,410_CD
1,879_CD
Augmentin_NN
1,142_CD
1,318_CD
Fluviral_NN
683_CD
Havrix_NN
363_CD
387_CD
Infanrix_NN
294_CD
314_CD
Coreg_NN
240_CD
320_CD
Twinrix_NN
235_CD
250_CD
Engerix-B_NN
224_CD
239_CD
Hycamtin_NN
212_CD
248_CD
Others_NN
827_CD
1,444_CD
Acquired_VBN
products_NN
intangible_JJ
assets_NN
under_IN
US_FPP1
GAAP_NN
9,471_CD
10,589_CD
The_DT
indefinite_JJ
lived_VBD
brands_NN
relate_VB
to_PIN
a_DT
large_JJ
number_NN
of_PIN
Consumer_NN
Healthcare_NN
products_NN
,_,
principally_RB
arising_VBG
from_PIN
the_DT
acquisitions_NOMZ
of_PIN
SmithKline_NN
Beecham_NN
plc_NN
including_VBG [WZPRES]
products_NN
previously_TIME
acquired_VBN
by_PIN
SmithKline_NN
Beecham_NN
from_PIN
Sterling_GER
Winthrop_NN
Inc._NN
and_CC
the_DT
Block_NN
Drug_NN
Company_NN
,_,
with_PIN
book_NN
values_NN
as_IN
follows_VPRT
:_:
2005_CD
2004_CD
m_NN
m_NN
Panadol_NN
730_CD
692_CD
Aquafresh_NN
347_CD
347_CD
Lucozade_NN
324_CD
324_CD
Horlicks_NN
319_CD
319_CD
Ribena_NN
309_CD
309_CD
Nicorette_NN
292_CD
292_CD
Odol_NN
228_CD
228_CD
Tums_NN
226_CD
226_CD
Sensodyne_NN
225_CD
221_CD
Nicoderm_NN
224_CD
224_CD
Others_NN
868_CD
893_CD
indefinite_JJ
lived_VBD
brands_NN
intangible_JJ
assets_NN
under_IN
US_FPP1
GAAP_NN
4,092_CD
4,075_CD
GSK_NN
Annual_JJ
Report_NN
2005_CD
141_CD
FINANCIAL_NN
STATEMENTS_NOMZ
Notes_NN
to_PIN
the_DT
financial_JJ
statements_NOMZ
continued_VBD
38_CD
Reconciliation_NOMZ
to_PIN
US_FPP1
accounting_GER
principles_NN
continued_VBD
Each_QUAN
of_PIN
these_DEMO
brands_NN
is_VPRT [PASS]
considered_VBN [PRIV]
to_TO
have_VB
an_DT
indefinite_JJ
life_NN
,_,
given_VBN
the_DT
strength_NN
and_PHC
durability_NOMZ
of_PIN
the_DT
brand_NN
and_CC
the_DT
level_NN
of_PIN
marketing_GER
support_NN
._.
Each_QUAN
brand_NN
is_VPRT [PASS]
tested_VBN
annually_RB
for_PIN
impairment_NOMZ
applying_VBG [WZPRES]
a_DT
fair_JJ
value_NN
less_RB
costs_NN
to_TO
sell_VB
methodology_NN
and_CC
using_VBG
five_CD
year_NN
post-tax_JJ
cash_NN
ow_NN
forecasts_NN
with_PIN
a_DT
terminal_NN
value_NN
calculation_NOMZ
and_CC
applying_VBG
a_DT
discount_NN
rate_NN
of_PIN
the_DT
Group_NN
post-tax_NN
weighted_VBN
average_JJ
cost_NN
of_PIN
capital_NN
of_PIN
8_CD
%_NN
._.
The_DT
carrying_VBG
values_NN
of_PIN
certain_JJ
intangibles_NN
subject_JJ
to_PIN
amortisation_NOMZ
were_VBD [PASS]
reviewed_VBN
and_CC
an_DT
impairment_NOMZ
of_PIN
68_CD
million_CD
2004_CD
26_CD
million_CD
has_VPRT [PEAS]
been_VBN [PASS]
recorded_VBN
._.
Of_PIN
this_DEMP
,_,
46_CD
million_CD
2004_CD
nil_NN
relates_VPRT
to_PIN
pharmaceutical_JJ
products_NN
and_CC
22_CD
million_CD
2004_CD
26_CD
million_CD
to_PIN
Consumer_NN
Healthcare_NN
products_NN
._.
An_DT
impairment_NOMZ
charge_NN
in_PIN
respect_NN
of_PIN
Consumer_NN
Healthcare_NN
intangible_JJ
assets_NN
not_XX0
subject_JJ
to_PIN
amortisation_NOMZ
of_PIN
50_CD
million_CD
was_VBD [PASS]
recognized_VBN [PRIV]
during_PIN
2005_CD
2004_CD
nil_NN
._.
As_IN
discussed_VBN
in_PIN
Note_NN
41_CD
Legal_NN
proceedings_GER
,_,
a_DT
number_NN
of_PIN
distributors_NN
of_PIN
generic_JJ
drugs_NN
have_VPRT [PEAS]
led_VBN
applications_NOMZ
to_PIN
market_NN
generic_JJ
versions_NN
of_PIN
a_DT
number_NN
of_PIN
the_DT
Groups_NN
products_NN
prior_RB
to_PIN
the_DT
expiration_NOMZ
of_PIN
the_DT
Groups_NN
patents_NN
._.
If_COND
generic_JJ
versions_NN
of_PIN
products_NN
are_VPRT [PASS]
launched_VBN
in_PIN
future_NN
periods_NN
at_PIN
earlier_TIME
dates_NN
than_PIN
the_DT
Group_NN
currently_RB
expects_VPRT [PRIV]
,_,
impairments_NOMZ
of_PIN
the_DT
carrying_VBG
value_NN
of_PIN
the_DT
products_NN
may_POMD
arise_VB
._.
The_DT
estimated_JJ
future_JJ
amortisation_NOMZ
expense_NN
for_PIN
the_DT
next_JJ
five_CD
years_NN
for_PIN
intangible_JJ
assets_NN
subject_JJ
to_PIN
amortisation_NOMZ
as_IN
of_PIN
31st_CD
December_NN
2005_CD
is_VPRT
as_IN
follows_VPRT
:_:
Year_NN
m_NN [BEMA]
2006_CD
1,447_CD
2007_CD
1,430_CD
2008_CD
1,430_CD
2009 774 2010 756_CD
Total_JJ
5,837_CD
In-process_JJ
R&D_NN
of_PIN
26_CD
million_CD
2004_CD
nil_NN
:_:
2003_CD
nil_NN
arising_VBG [WZPRES]
on_PIN
the_DT
acquisitions_NOMZ
of_PIN
ID_NN
Biomedical_NN
and_PHC
Corixa_NN
Corporation_NOMZ
has_VPRT [PEAS]
been_VBN
writtenoff_NN
._.
This_DEMP
has_VPRT [PEAS]
been_VBN [PASS]
valued_VBN
on_PIN
the_DT
same_JJ
basis_NN
as_IN
the_DT
other_JJ
intangible_JJ
assets_NN
acquired_VBN
and_PHC
relates_VPRT
to_PIN
various_JJ
development_NOMZ
projects_NN
in_PIN
the_DT
preapproval_JJ
stage_NN
where_RB
the_DT
technological_JJ
feasibility_NOMZ
of_PIN
the_DT
projects_NN
had_VBD [PEAS]
not_XX0
been_VBN [PASS]
established_VBN [PRIV]
at_PIN
the_DT
point_NN
of_PIN
acquisition_NOMZ
._.
c_NN
Theravance_NN
In_PIN
May_POMD
2004_CD
,_,
the_DT
Group_NN
formed_VBD
a_DT
strategic_JJ
alliance_NN
with_PIN
Theravance_NN
Inc._NN
to_TO
develop_VB
and_PHC
commercialise_VB
novel_JJ
medicines_NN
across_PLACE
a_DT
variety_NN
of_PIN
important_JJ
therapeutic_JJ
areas_NN
._.
Under_IN
the_DT
terms_NN
of_PIN
the_DT
alliance_NN
,_,
Theravance_NN
received_VBD
$_$
129_CD
million_CD
,_,
a_DT
significant_JJ
part_NN
of_PIN
which_WDT [PIRE]
related_VBN
to_PIN
the_DT
Groups_NN
purchase_NN
of_PIN
Theravance_NN
shares_NN
._.
The_DT
Group_NN
has_VPRT
a_DT
call_NN
option_NOMZ
in_PIN
2007_CD
to_PIN
further_JJ
increase_NN
its_PIT
ownership_NN
to_PIN
over_IN
50_CD
%_NN
at_PIN
a_DT
significant_JJ
premium_NN
to_PIN
the_DT
price_NN
paid_VBN [WZPAST]
in_PIN
the_DT
2004_CD
transaction_NOMZ
._.
Theravances_NN
shareholders_NN
have_VPRT
a_DT
put_NN
option_NOMZ
at_PIN
a_DT
lower_JJ
exercise_NN
price_NN
to_TO
cause_VB
GlaxoSmithKline_NN
to_TO
acquire_VB
up_RP
to_PIN
half_DT
of_PIN
their_TPP3
outstanding_JJ
stock_NN
in_PIN
2007_CD
._.
The_DT
Group_NN
has_VPRT
an_DT
exclusive_JJ
option_NOMZ
to_TO
license_VB
potential_JJ
new_JJ
medicines_NN
from_PIN
all_QUAN
of_PIN
Theravances_NN
programs_NN
until_IN
August_NN
2007_CD
._.
Upon_PIN
exercising_VBG
its_PIT
option_NOMZ
over_IN
a_DT
Theravance_NN
program_NN
,_,
the_DT
Group_NN
will_PRMD
be_VB [BEMA]
responsible_PRED
for_PIN
the_DT
relevant_JJ
development_NOMZ
,_,
manufacturing_GER
and_PHC
commercialisation_NOMZ
activities_NOMZ
._.
Depending_VBG [PRESP]
on_PIN
the_DT
success_NN
of_PIN
such_JJ
programs_NN
,_,
Theravance_NN
will_PRMD
receive_VB
clinical_JJ
,_,
regulatory_JJ
and_PHC
commercial_JJ
milestone_NN
payments_NOMZ
and_PHC
royalties_NN
on_PIN
the_DT
subsequent_JJ
sales_NN
of_PIN
medicines_NN
._.
Based_VBN [PASTP]
on_PIN
the_DT
assessment_NOMZ
performed_VBN
,_,
the_DT
Group_NN
was_VBD [BEMA]
the_DT
primary_JJ
beneciary_NN
of_PIN
Theravance_NN
,_,
as_IN
dened_VBN
by_PIN
FIN_NN
46R_NN
,_,
and_ANDC
as_CONJ
a_NULL
result_NULL
Theravance_NN
has_VPRT [PEAS]
been_VBN [PASS]
consolidated_VBN
into_PIN
the_DT
Groups_NN
US_FPP1
GAAP_NN
financial_JJ
statements_NOMZ
from_PIN
May_POMD
2004_CD
._.
The_DT
net_JJ
assets_NN
acquired_VBN [WZPAST]
were_VBD [PASS]
measured_VBN
at_PIN
fair_JJ
value_NN
._.
The_DT
principal_JJ
adjustment_NOMZ
to_PIN
the_DT
carrying_VBG
value_NN
of_PIN
the_DT
net_JJ
assets_NN
in_PIN
Theravances_NN
balance_NN
sheet_NN
prior_RB
to_PIN
the_DT
acquisition_NOMZ
was_VBD
recognition_NOMZ
of_PIN
in-process_JJ
research_NN
and_PHC
development_NOMZ
IPR&D_NN
at_PIN
a_DT
valuation_NOMZ
of_PIN
273_CD
million_CD
._.
The_DT
IPR&D_NN
was_VBD [PASS]
written_VBN [PUBV]
off_PIN
immediately_TIME
after_IN
the_DT
acquisition_NOMZ
in_PIN
accordance_NN
with_PIN
US_FPP1
GAAP_NN
purchase_NN
accounting_GER
._.
The_DT
effect_NN
of_PIN
consolidating_VBG
Theravance_NN
,_,
including_VBG
reversal_NN
of_PIN
fair_JJ
value_NN
gains_NN
recorded_VBN [WZPAST]
for_PIN
the_DT
investment_NOMZ
under_IN
IFRS_NN
,_,
has_VPRT [PEAS]
been_VBN
to_TO
decrease_VB
shareholders_NN
equity_NOMZ
by_PIN
10_CD
million_CD
2004_CD
60_CD
million_CD
and_CC
net_JJ
income_NN
by_PIN
16_CD
million_CD
2004_CD
60_CD
million_CD
._.
Additionally_RB
,_,
the_DT
Group_NN
has_VPRT [PEAS]
accounted_VBN
for_PIN
the_DT
Theravance_NN
put_VBD
option_NOMZ
discussed_VBN
above_PLACE
in_PIN
accordance_NN
with_PIN
SFAS_NN
150_CD
,_,
Accounting_GER
for_PIN
Certain_NN
Financial_NN
Instruments_NOMZ
with_PIN
Characteristics_NN
of_PIN
both_DT
Liabilities_NOMZ
and_PHC
Equity_NOMZ
,_,
which_WDT [SERE]
requires_VPRT [SUAV]
the_DT
Group_NN
to_TO
record_VB
the_DT
fair_JJ
value_NN
of_PIN
the_DT
put_NN
option_NOMZ
as_IN
a_DT
liability_NOMZ
._.
The_DT
fair_JJ
value_NN
of_PIN
the_DT
Theravance_NN
put_VBD
option_NOMZ
at_PIN
31st_CD
December_NN
2005_CD
is_VPRT [BEMA]
47_CD
million_CD
2004_CD
69_CD
million_CD
._.
In_PIN
accordance_NN
with_PIN
SFAS_NN
133_CD
Accounting_GER
for_PIN
Derivative_JJ
Instruments_NOMZ
and_PHC
Hedging_GER
Activities_NOMZ
the_DT
call_NN
option_NOMZ
is_VPRT [PASS]
not_XX0
recognized_VBN [PRIV]
in_PIN
the_DT
financial_JJ
statements_NOMZ
as_IN
it_PIT
is_VPRT
not_XX0
readily_RB
convertible_PRED
into_PIN
cash_NN
._.
GSK_NN
Annual_JJ
Report_NN
2005_CD
142_CD
FINANCIAL_NN
STATEMENTS_NOMZ
Notes_NN
to_PIN
the_DT
financial_JJ
statements_NOMZ
continued_VBD
38_CD
Reconciliation_NOMZ
to_PIN
US_FPP1
accounting_GER
principles_NN
continued_VBD
d_SYM
Taxation_NOMZ
2005 2004 2003_CD
Total_JJ
tax_NN
expense_NN
m_NN
m_FW
m_FW
IFRS_NN
:_:
Current_JJ
tax_NN
expense_NN
2,019_CD
1,667_CD
1,961_CD
Deferred_JJ
tax_NN
credit_NN
expense_NN
103_CD
90_CD
310_CD
Total_JJ
tax_NN
expense_NN
1,916_CD
1,757_CD
1,651_CD
US_FPP1
GAAP_NN
:_:
Current_JJ
tax_NN
expense_NN
2,103_CD
1,717_CD
2,014_CD
Deferred_JJ
tax_NN
credit_NN
688_CD
667_CD
1,050_CD
Total_JJ
tax_NN
expense_NN
1,415_CD
1,050_CD
964_CD
IFRS_NN
to_PIN
US_FPP1
GAAP_NN
adjustments_NOMZ
:_:
Current_JJ
tax_NN
expense_NN
84_CD
50_CD
53_CD
Deferred_JJ
tax_NN
credit_NN
585 757 740_CD
Total_JJ
tax_NN
expense_NN
501 707 687_CD
The_DT
IFRS_NN
to_PIN
US_FPP1
GAAP_NN
adjustment_NOMZ
in_PIN
respect_NN
of_PIN
current_JJ
tax_NN
expense_NN
includes_VPRT
37_CD
million_CD
2004_CD
40_CD
million_CD
:_:
2003_CD
40_CD
million_CD
for_PIN
the_DT
Groups_NN
share_NN
of_PIN
the_DT
tax_NN
expense_NN
of_PIN
associates_NN
._.
This_DEMP
is_VPRT [PASS]
recognized_VBN [PRIV]
in_PIN
the_DT
Taxation_NOMZ
charge_NN
in_PIN
the_DT
income_NN
statement_NOMZ
under_IN
US_FPP1
GAAP_NN
but_CC
recorded_VBN
in_PIN
Share_NN
of_PIN
after_IN
tax_NN
profits_NN
of_PIN
associates_NN
in_PIN
the_DT
income_NN
statement_NOMZ
presented_VBN [WZPAST]
in_PIN
accordance_NN
with_PIN
IFRS_NN
._.
e_LS
Deferred_VBN
taxation_NOMZ
under_IN
US_FPP1
GAAP_NN
Classication_NOMZ
of_PIN
GSKs_NN
deferred_VBD
taxation_NOMZ
liabilities_NOMZ
and_PHC
assets_NN
under_IN
US_FPP1
GAAP_NN
is_VPRT
as_IN
follows_VPRT
:_:
2005_CD
2004_CD
m_NN
m_NN
Liabilities_NOMZ
Stock_NN
valuation_NOMZ
adjustment_NOMZ
42_CD
52_CD
Other_JJ
timing_NN
differences_NN
63_CD
70_CD
Current_JJ
deferred_VBN
taxation_NOMZ
liabilities_NOMZ
21_CD
18_CD
Accelerated_VBN
capital_NN
allowances_NN
187_CD
621_CD
Product_NN
rights_NN
4,035_CD
4,264_CD
Product_NN
and_PHC
business_NOMZ
disposals_NN
13_CD
32_CD
Pensions_NN
and_CC
other_JJ
post-retirement_JJ
benets_NN
25_CD
294_CD
Other_JJ
timing_NN
differences_NN
25_CD
37_CD
Total_JJ
deferred_VBN
taxation_NOMZ
liabilities_NOMZ
4,138_CD
4,568_CD
Assets_NN
Intra-Group_JJ
profit_NN
619_CD
594_CD
Stock_NN
valuation_NOMZ
adjustment_NOMZ
72_CD
62_CD
Other_JJ
timing_NN
differences_NN
614_CD
523_CD
Current_JJ
deferred_VBN
taxation_NOMZ
assets_NN
1,161_CD
1,055_CD
Accelerated_VBN
capital_NN
allowances_NN
492_CD
54_CD
Product_NN
and_PHC
business_NOMZ
disposals_NN
9_CD
Pensions_NN
and_CC
other_JJ
post-retirement_JJ
benets_NN
43_CD
253_CD
Tax_NN
losses_NN
125_CD
61_CD
Restructuring_GER
53_CD
51_CD
Legal_NN
and_CC
other_JJ
disputes_NN
160_CD
149_CD
Share_NN
option_NOMZ
and_PHC
award_NN
schemes_NN
276_CD
179_CD
Other_JJ
timing_NN
differences_NN
3_CD
45_CD
Valuation_NOMZ
allowances_NN
62_CD
42_CD
Total_JJ
deferred_VBN
taxation_NOMZ
assets_NN
1,252_CD
1,191_CD
Net_JJ
deferred_VBN
taxation_NOMZ
under_IN
US_FPP1
GAAP_NN
2,886_CD
3,377_CD
Net_JJ
deferred_VBN
taxation_NOMZ
under_IN
IFRS_NN
1,645_CD
1,463_CD
IFRS_NN
to_PIN
US_FPP1
GAAP_NN
adjustment_NOMZ
4,531_CD
4,840_CD
GSK_NN
Annual_JJ
Report_NN
2005_CD
143_CD
FINANCIAL_NN
STATEMENTS_NOMZ
Notes_NN
to_PIN
the_DT
financial_JJ
statements_NOMZ
continued_VBD
38_CD
Reconciliation_NOMZ
to_PIN
US_FPP1
accounting_GER
principles_NN
continued_VBD
f_SYM
Pensions_NN
and_PHC
post-retirement_NOMZ
costs_NN
under_IN
US_FPP1
GAAP_NN
2005 2004 2003_CD
m_FW
m_FW
m_FW
UK_NN
pension_NN
schemes_NN
218 225 278_CD
US_FPP1
pension_NN
schemes_NN
55_CD
54_CD
79_CD
Other_JJ
overseas_PLACE
pension_NN
schemes_NN
87_CD
77_CD
83_CD
Unfunded_JJ
post-retirement_NOMZ
healthcare_NN
schemes_NN
114_CD
96_CD
118_CD
Post-employment_NOMZ
costs_NN
2_CD
18 24 476 470_CD
582_CD
Analysed_VBN
as_IN
:_:
Funded_VBN
dened_VBN
benefit_NN
hybrid_NN
schemes_NN
306 298 389_CD
Unfunded_JJ
dened_VBN
benefit_NN
schemes_NN
29_CD
37_CD
26_CD
Dened_VBN
contribution_NOMZ
schemes_NN
25_CD
21_CD
25_CD
Unfunded_JJ
post-retirement_NOMZ
healthcare_NN
schemes_NN
114_CD
96_CD
118_CD
Post-employment_NOMZ
costs_NN
2_CD
18 24 476 470_CD
582_CD
The_DT
disclosures_NN
below_PLACE
include_VPRT
the_DT
additional_JJ
information_NOMZ
required_VBN [SUAV] [WZPAST]
by_PIN
SFAS_NN
132R_NN
._.
The_DT
pension_NN
costs_NN
of_PIN
the_DT
UK_NN
,_,
US_FPP1
and_CC
major_JJ
overseas_PLACE
dened_VBN
benefit_NN
pension_NN
plans_NN
have_VPRT [PEAS]
been_VBN [PASS]
restated_VBN
in_PIN
the_DT
following_VBG
tables_NN
in_PIN
accordance_NN
with_PIN
US_FPP1
GAAP_NN
._.
Minor_NN
retirement_NOMZ
plans_NN
with_PIN
pension_NN
costs_NN
in_PIN
2005_CD
of_PIN
8_CD
million_CD
2004_CD
5_CD
million_CD
:_:
2003_CD
9_CD
million_CD
,_,
have_VPRT [PEAS]
not_XX0
been_VBN [PASS]
recalculated_VBN
in_PIN
accordance_NN
with_PIN
the_DT
requirements_NOMZ
of_PIN
SFAS_NN
87_CD
,_,
and_ANDC
have_VPRT [PEAS]
been_VBN [PASS]
excluded_VBN
._.
2005 2004 2003_CD
Net_JJ
periodic_JJ
pension_NN
cost_NN
for_PIN
the_DT
major_JJ
retirement_NOMZ
plans_NN
m_VPRT
m_FW
m_FW
Service_NN
cost_NN
223 213 211_CD
Interest_NN
cost_NN
408 400 392_CD
Expected_VBN [PRIV]
return_NN
on_PIN
plan_NN
assets_NN
444 431 408_CD
Amortisation_NOMZ
of_PIN
prior_JJ
service_NN
cost_NN
13_CD
14_CD
17_CD
Amortisation_NOMZ
of_PIN
transition_NOMZ
obligation_NOMZ
2_CD
23_CD
Amortisation_NOMZ
of_PIN
net_JJ
actuarial_JJ
loss_NN
107_CD
115_CD
79_CD
Net_JJ
periodic_JJ
pension_NN
cost_NN
under_IN
US_FPP1
GAAP_NN
309 313 294_CD
Termination_NOMZ
benets_NN
and_PHC
curtailment_NOMZ
costs_NN
19 13 112 2005_CD
2004_CD
2003_CD
Major_JJ
assumptions_NOMZ
used_VBN [WZPAST]
in_PIN
computing_VBG
pension_NN
costs_NN
%_NN
pa_CD
%_NN
pa_CD
%_NN
pa_NN
Rates_NN
of_PIN
future_JJ
pay_NN
increases_NN
4.00_CD
4.25_CD
4.25_CD
Discount_NN
rate_NN
4.75_CD
5.25_CD
5.50_CD
Expected_VBN [PRIV]
long-term_JJ
rates_NN
of_PIN
return_NN
on_PIN
plan_NN
assets_NN
6.75_CD
7.00_CD
7.50_CD
In_PIN
aggregate_JJ
,_,
average_JJ
international_JJ
plan_NN
assumptions_NOMZ
did_VBD
not_XX0
vary_VB
signicantly_RB
from_PIN
US_FPP1
assumptions_NOMZ
._.
Estimated_JJ
future_NN
benefit_NN
payments_NOMZ
m_VPRT [BEMA]
2006 339 2007 353_CD
2008 365 2009 381_CD
2010 400 20112015_CD
2,272_CD
GSK_NN
Annual_JJ
Report_NN
2005_CD
144_CD
FINANCIAL_NN
STATEMENTS_NOMZ
Notes_NN
to_PIN
the_DT
financial_JJ
statements_NOMZ
continued_VBD
38_CD
Reconciliation_NOMZ
to_PIN
US_FPP1
accounting_GER
principles_NN
continued_VBD
2005_CD
2004_CD
Change_NN
in_PIN
benefit_NN
obligation_NOMZ
m_NN
m_NN
benefit_NN
obligation_NOMZ
at_PIN
1st_CD
January_NN
8,171_CD
7,866_CD
Amendments_NOMZ
1_CD
2_CD
Service_NN
cost_NN
223_CD
213_CD
Interest_NN
cost_NN
408_CD
400_CD
Plan_NN
participants_NN
contributions_NOMZ
15_CD
15_CD
Actuarial_JJ
loss_NN
1,334_CD
137_CD
Benets_NN
paid_VBD
372_CD
345_CD
Termination_NOMZ
benets_NN
and_PHC
curtailment_NOMZ
costs_NN
15_CD
5_CD
Exchange_NN
adjustments_NOMZ
202_CD
122_CD
benefit_NN
obligation_NOMZ
at_PIN
31st_CD
December_NN
9,997_CD
8,171_CD
benefit_NN
obligation_NOMZ
at_PIN
31st_CD
December_NN
for_PIN
pension_NN
plans_NN
with_PIN
accumulated_VBN
benefit_NN
obligations_NOMZ
in_PIN
excess_NN
of_PIN
plan_NN
assets_NN
8,748_CD
5,554_CD
The_DT
accumulated_VBN
benefit_NN
obligation_NOMZ
at_PIN
31st_CD
December_NN
2005_CD
was_VBD [BEMA]
9,294_CD
million_CD
31st_JJ
December_NN
2004_CD
7,691_CD
million_CD
._.
2005_CD
2004_CD
Change_NN
in_PIN
plan_NN
assets_NN
m_VPRT
m_NN
Fair_NN
value_NN
of_PIN
plan_NN
assets_NN
at_PIN
1st_CD
January_NN
6,690_CD
5,968_CD
Actual_JJ
return_NN
on_PIN
plan_NN
assets_NN
1,113_CD
651_CD
Employer_NN
contributions_NOMZ
661_CD
465_CD
Plan_NN
participants_NN
contributions_NOMZ
15_CD
15_CD
Benets_NN
paid_VBD
372_CD
345_CD
Exchange_NN
adjustments_NOMZ
191_CD
64_CD
Fair_NN
value_NN
of_PIN
plan_NN
assets_NN
at_PIN
31st_CD
December_NN
8,298_CD
6,690_CD
Fair_NN
value_NN
of_PIN
plan_NN
assets_NN
at_PIN
end_NN
of_PIN
year_NN
for_PIN
pension_NN
plans_NN
with_PIN
accumulated_VBN
benefit_NN
obligations_NOMZ
in_PIN
excess_NN
of_PIN
plan_NN
assets_NN
7,735_CD
4,519_CD
Plan_NN
assets_NN
consist_VPRT
primarily_RB
of_PIN
investments_NOMZ
in_PIN
UK_NN
and_CC
overseas_PLACE
equities_NOMZ
,_,
xed_VBN
interest_NN
securities_NOMZ
,_,
index-linked_JJ
securities_NOMZ
and_PHC
property_NN
._.
At_PIN
31st_CD
December_NN
2005_CD
UK_NN
equities_NOMZ
included_VBD
1.9_CD
million_CD
GSK_NN
shares_NN
2004_CD
0.3_CD
million_CD
shares_NN
with_PIN
a_DT
market_NN
value_NN
of_PIN
28_CD
million_CD
2004_CD
4_CD
million_CD
._.
An_DT
analysis_NN
of_PIN
the_DT
percentage_NN
of_PIN
total_JJ
plan_NN
assets_NN
for_PIN
each_QUAN
major_JJ
category_NN
is_VPRT [PASS]
disclosed_VBN [PUBV]
in_PIN
Note_NN
26_CD
._.
This_DEMO
analysis_NN
includes_VPRT
assets_NN
valued_VBN [WZPAST]
at_PIN
101_CD
million_CD
in_PIN
minor_JJ
retirement_NOMZ
plans_NN
,_,
which_WDT [SERE]
have_VPRT [PEAS]
been_VBN [PASS]
excluded_VBN
from_PIN
these_DEMO
tables_NN
._.
2005_CD
2004_CD
Funded_VBN
status_NN
m_NN [PASS]
m_NN [PASS]
Funded_VBN
status_NN
1,699_CD
1,481_CD
Unrecognised_JJ
net_JJ
actuarial_JJ
loss_NN
2,499_CD
1,900_CD
Unrecognised_JJ
prior_JJ
service_NN
cost_NN
60_CD
75_CD
Unrecognised_JJ
transition_NOMZ
obligation_NOMZ
21_CD
24_CD
Net_JJ
amount_NN
recognized_VBN [PRIV] [THATD]
881 518 2005 2004_CD
Amounts_NN
recognized_VBN [PRIV] [WZPAST]
in_PIN
the_DT
statement_NOMZ
of_PIN
financial_JJ
position_NOMZ
m_NN
m_FW
Prepaid_FW
benefit_NN
cost_NN
8_CD
365_CD
Accrued_VBN
pension_NN
liability_NOMZ
1,027_CD
1,065_CD
Intangible_JJ
asset_NN
86_CD
102_CD
Accumulated_VBN
other_JJ
comprehensive_JJ
income_NN
1,814_CD
1,116_CD
Net_JJ
amount_NN
recognized_VBN [PRIV]
881_CD
518_CD
GSK_NN
Annual_JJ
Report_NN
2005_CD
145_CD
FINANCIAL_NN
STATEMENTS_NOMZ
Notes_NN
to_PIN
the_DT
financial_JJ
statements_NOMZ
continued_VBD
38_CD
Reconciliation_NOMZ
to_PIN
US_FPP1
accounting_GER
principles_NN
continued_VBD
Post-retirement_JJ
healthcare_NN
under_IN
US_FPP1
GAAP_NN
The_NN
post-retirement_JJ
healthcare_NN
costs_NN
of_PIN
the_DT
UK_NN
,_,
US_FPP1
and_CC
major_JJ
overseas_PLACE
post-retirement_NOMZ
healthcare_NN
schemes_NN
have_VPRT [PEAS]
been_VBN [PASS]
restated_VBN
in_PIN
the_DT
following_VBG
tables_NN
in_PIN
accordance_NN
with_PIN
US_FPP1
GAAP_NN
._.
Minor_NN
healthcare_NN
plans_NN
with_PIN
costs_NN
in_PIN
2005_CD
of_PIN
5_CD
million_CD
2004_CD
nil_NN
:_:
2003_CD
13_CD
million_CD
have_VPRT [PEAS]
not_XX0
been_VBN [PASS]
recalculated_VBN
and_PHC
have_VPRT [PEAS]
been_VBN [PASS]
excluded_VBN
._.
2005 2004 2003_CD
Net_JJ
healthcare_NN
cost_NN
m_FW
m_FW
m_FW
Service_NN
cost_NN
37_CD
32_CD
29_CD
Interest_NN
cost_NN
57_CD
55_CD
64_CD
Amortisation_NOMZ
of_PIN
prior_JJ
service_NN
cost_NN
2_CD
1_CD
2_CD
Amortisation_NOMZ
of_PIN
net_JJ
actuarial_JJ
loss_NN
15_CD
11_CD
14_CD
Net_JJ
healthcare_NN
cost_NN
107_CD
97_CD
105_CD
The_DT
major_JJ
assumptions_NOMZ
used_VBN [WZPAST]
in_PIN
calculating_VBG [PRIV]
the_DT
net_JJ
healthcare_NN
cost_NN
were_VBD
:_:
%_NN
pa_CD
%_NN
pa_CD
%_NN
pa_NN
Rate_NN
of_PIN
future_JJ
healthcare_NN
ination_NOMZ
10.0_CD
to_PIN
5.0_CD
9.0_CD
to_PIN
5.0_CD
10.0_CD
to_PIN
5.0_CD
Discount_NN
rate_NN
5.50_CD
5.75_CD
6.25_CD
The_DT
rate_NN
of_PIN
future_JJ
healthcare_NN
ination_NOMZ
reects_VPRT
the_DT
fact_NN
that_TOBJ
the_DT
benets_NN
of_PIN
certain_JJ
groups_NN
of_PIN
participants_NN
are_VPRT [PASS]
capped_VBN
._.
2005_CD
2004_CD
Change_NN
in_PIN
benefit_NN
obligation_NOMZ
m_NN
m_NN
benefit_NN
obligation_NOMZ
at_PIN
1st_CD
January_NN
965_CD
975_CD
Service_NN
cost_NN
37_CD
32_CD
Interest_NN
cost_NN
57_CD
55_CD
Plan_NN
participants_NN
contributions_NOMZ
8_CD
8_CD
Actuarial_JJ
loss_NN
82_CD
6_CD
Benets_NN
paid_VBD
43_CD
47_CD
Exchange_NN
105_CD
64_CD
benefit_NN
obligation_NOMZ
at_PIN
31st_CD
December_NN
1,211_CD
965_CD
Change_NN
in_PIN
plan_NN
assets_NN
Fair_NN
value_NN
of_PIN
plan_NN
assets_NN
at_PIN
1st_CD
January_NN
Employer_NN
and_PHC
plan_NN
participants_NN
contributions_NOMZ
43_CD
47_CD
Benets_NN
paid_VBD
43_CD
47_CD
Fair_NN
value_NN
of_PIN
plan_NN
assets_NN
at_PIN
31st_CD
December_NN
Funded_VBN
status_NN
Funded_VBN
status_NN
1,211_CD
965_CD
Unrecognised_JJ
net_JJ
actuarial_JJ
loss_NN
450_CD
340_CD
Unrecognised_JJ
prior_JJ
service_NN
cost_NN
14_CD
14_CD
Accrued_VBN
post-retirement_JJ
healthcare_NN
cost_NN
775_CD
639_CD
1_CD
%_NN
decrease_NN
1_CD
%_NN
increase_NN
Impact_NN
of_PIN
a_DT
1_CD
%_NN
variation_NOMZ
in_PIN
the_DT
rate_NN
of_PIN
future_JJ
healthcare_NN
ination_NOMZ
m_FW
m_FW
Effect_NN
on_PIN
total_JJ
service_NN
and_PHC
interest_NN
cost_NN
for_PIN
post-retirement_JJ
healthcare_NN
7_CD
10_CD
Effect_NN
on_PIN
obligation_NOMZ
for_PIN
post-retirement_JJ
healthcare_NN
81_CD
90_CD
Medicare_NN
Gross_NN
subsidy_NN
Net_NN
Estimated_VBN [PRIV]
future_JJ
benefit_NN
payments_NOMZ
m_VPRT
m_FW
m_FW [BEMA]
2006_CD
42_CD
3_CD
39_CD
2007_CD
46_CD
3_CD
43_CD
2008_CD
49_CD
4_CD
45_CD
2009_CD
53_CD
4_CD
49_CD
2010_CD
56_CD
4_CD
52 20112015_CD
317_CD
29_CD
288_CD
GSK_NN
Annual_JJ
Report_NN
2005_CD
146_CD
FINANCIAL_NN
STATEMENTS_NOMZ
Notes_NN
to_PIN
the_DT
financial_JJ
statements_NOMZ
continued_VBD
39_CD
Principal_NN
Group_NN
companies_NN
The_DT
following_JJ
represent_VPRT
the_DT
principal_JJ
subsidiary_NN
and_CC
associated_VBN
undertakings_GER
of_PIN
the_DT
GlaxoSmithKline_NN
Group_NN
at_PIN
31st_CD
December_NN
2005_CD
._.
Details_NN
are_VPRT [PASS]
given_VBN
of_PIN
the_DT
principal_JJ
country_NN
of_PIN
operation_NOMZ
,_,
the_DT
location_NOMZ
of_PIN
the_DT
headquarters_NN
,_,
the_DT
business_NOMZ
segment_NOMZ
and_CC
the_DT
business_NOMZ
activities_NOMZ
._.
The_DT
equity_NOMZ
share_NN
capital_NN
of_PIN
these_DEMO
undertakings_GER
is_VPRT [SPAU] [BYPA]
wholly_RB
owned_VBN
by_PIN
the_DT
Group_NN
except_PIN
where_RB
its_PIT
percentage_NN
interest_NN
is_VPRT [PASS]
shown_VBN [PRIV]
otherwise_CONJ
._.
All_QUAN
companies_NN
are_VPRT [PASS]
incorporated_VBN
in_PIN
their_TPP3
principal_JJ
country_NN
of_PIN
operation_NOMZ
except_PIN
where_RB
stated_VBN [PUBV]
._.
Europe_NN
Location_NOMZ
Subsidiary_NN
undertaking_VBG [WZPRES]
Segment_NOMZ
Activity_NOMZ
%_NN
England_NN
Brentford_NN
GlaxoSmithKline_NN
Holdings_GER
One_CD
Limited_NN
Ph_NN
,_,
CH_NN
h_NN
Brentford_NN
GlaxoSmithKline_NN
Services_NN
Unlimited_NN
Ph_NN
,_,
CH_NN
s_VPRT
Brentford_NN
GlaxoSmithKline_NN
Finance_NN
plc_NN
Ph_NN
,_,
CH_NN
f_LS
Brentford_NN
GlaxoSmithKline_NN
Capital_NN
plc_NN
Ph_NN
f_SYM
Brentford_NN
SmithKline_NN
Beecham_NN
p._FW
l._FW
c._FW
Ph_FW
,_,
CH_NN
d_LS
e_SYM
h_FW
m_FW
p_FW
r_NN
Brentford_NN
Wellcome_NN
Limited_NN
Ph_NN
,_,
CH_NN
h_NN
Greenford_NN
Glaxo_NN
Group_NN
Limited_NN
Ph_NN
h_VPRT
Greenford_NN
Glaxo_NN
Operations_NOMZ
UK_NN
Limited_NN
Ph_NN
p_VPRT
Brentford_NN
Glaxo_NN
Wellcome_NN
International_NN
B._NN
V._NN
i_FPP1
Ph_NN
,_,
CH_NN
h_NN
Brentford_NN
Glaxo_NN
Wellcome_NN
Investments_NOMZ
B._NN
V._NN
i_FPP1
Ph_NN
,_,
CH_NN
h_NN
Stockley_NN
Park_NN
Glaxo_NN
Wellcome_NN
UK_NN
Limited_NN
Ph_NN
h_VPRT
m_FW
p_FW
Brentford_NN
GlaxoSmithKline_NN
Export_NN
Limited_NN
Ph_NN
e_SYM
Brentford_NN
GlaxoSmithKline_NN
Research_NN
&_CC
Development_NOMZ
Limited_NN
Ph_NN
d_SYM
r_SYM
Brentford_NN
GlaxoSmithKline_NN
UK_NN
Limited_NN
Ph_NN
m_FW
p_FW
Brentford_NN
SmithKline_NN
Beecham_NN
Investments_NOMZ
Limited_NN
Ph_NN
,_,
CH_NN
f_LS
Brentford_NN
SmithKline_NN
Beecham_NN
SWG_NN
Limited_NN
CH_NN
e_LS
m_FW
Brentford_NN
SmithKline_NN
Beecham_NN
Research_NN
Limited_NN
Ph_NN
m_NN
Brentford_NN
Stafford-Miller_NN
Limited_NN
CH_NN
m_FW
p_FW
Greenford_NN
The_DT
Wellcome_NN
Foundation_NOMZ
Limited_NN
Ph_NN
p_VPRT
Austria_NN
Vienna_NN
GlaxoSmithKline_NN
Pharma_NN
G._NN
m._FW
b._FW
H_NN
Ph_NN
m_NN
Belgium_NN
Genval_NN
GlaxoSmithKline_NN
S._NN
A._NN
Ph_NN
m_NN
Rixensart_NN
GlaxoSmithKline_NN
Biologicals_NN
S._NN
A._NN
Ph_NN
d_SYM
e_SYM
m_FW
p_FW
r_NN
Rixensart_NN
GlaxoSmithKline_NN
Biologicals_NN
Manufacturing_GER
S._NN
A._NN
Ph_NN
h_VPRT
Guernsey_NN
St._NN
Peter_NN
Port_NN
SmithKline_NN
Beecham_NN
Limited_NN
Ph_NN
,_,
CH_NN
i_FPP1
Denmark_NN
Ballerup_NN
GlaxoSmithKline_NN
Consumer_NN
Healthcare_NN
A_NN
S_NN
CH_NN
m_FW
Brndby_NN
GlaxoSmithKline_NN
Pharma_NN
A_NN
S_NN
Ph_NN
m_VBD
Finland_NN
Espoo_NN
GlaxoSmithKline_NN
Oy_NN
Ph_NN
m_NN
France_NN
Marly_NN
le_FW
Roi_NN
Groupe_NN
GlaxoSmithKline_NN
S._NN
A._NN
S._NN
Ph_NN
h_VPRT
Marly_NN
le_FW
Roi_NN
Laboratoire_NN
GlaxoSmithKline_NN
S._NN
A._NN
S._NN
Ph_NN
m_NN
Marly_NN
le_FW
Roi_NN
Glaxo_NN
Wellcome_NN
Production_NOMZ
S._NN
A._NN
S._NN
Ph_NN
m_FW
p_FW
Marly_NN
le_FW
Roi_NN
GlaxoSmithKline_NN
Sante_NN
Grand_NN
Public_NN
S._NN
A._NN
S._NN
CH_NN
m_NN
Germany_NN
Buehl_NN
GlaxoSmithKline_NN
Consumer_NN
Healthcare_NN
GmbH_NN
&_CC
Co._NN
._.
KG_NN
CH_NN
d_LS
h_FW
m_FW
p_FW
r_NN
s_VPRT
Munich_NN
GlaxoSmithKline_NN
Pharma_NN
GmbH_NN
Ph_NN
h_VPRT
Greece_NN
Athens_NN
GlaxoSmithKline_NN
A._NN
E._NN
B._NN
E_NN
Ph_NN
,_,
CH_NN
h_FW
m_FW
Hungary_NN
Budapest_NN
GlaxoSmithKline_NN
Medicine_NN
and_PHC
Healthcare_NN
Products_NN
Limited_NN
Ph_NN
,_,
CH_NN
e_LS
m_FW
Italy_NN
Verona_NN
GlaxoSmithKline_NN
S._NN
p._NN
A._NN
Ph_NN
d_SYM
h_FW
m_FW
r_NN
Milan_NN
GlaxoSmithKline_NN
Consumer_NN
Healthcare_NN
S._NN
p_NN
A._NN
CH_NN
h_FW
m_FW
Luxembourg_NN
Mamer_NN
GlaxoSmithKline_NN
International_NN
Luxembourg_NN
S._NN
A._NN
Ph_NN
,_,
CH_NN
f_LS
h_FW
GSK_NN
Annual_JJ
Report_NN
2005_CD
147_CD
FINANCIAL_NN
STATEMENTS_NOMZ
Notes_NN
to_PIN
the_DT
financial_JJ
statements_NOMZ
continued_VBD
39_CD
Principal_NN
Group_NN
companies_NN
continued_VBD
Europe_NN
Location_NOMZ
Subsidiary_NN
undertaking_VBG [WZPRES]
Segment_NOMZ
Activity_NOMZ
%_NN
Netherlands_NN
Zeist_NN
GlaxoSmithKline_NN
B._NN
V._NN
Ph_NN
m_NN
Zeist_NN
GlaxoSmithKline_NN
Consumer_NN
Healthcare_NN
B._NN
V._NN
CH_NN
m_FW
Norway_NN
Oslo_NN
GlaxoSmithKline_NN
AS_NN
Ph_NN
m_NN
Poland_NN
Poznan_NN
GlaxoSmithKline_NN
Pharmaceuticals_NN
S._NN
A._NN
Ph_NN
m_NN
p_NN
97_CD
Warsaw_NN
GlaxoSmithKline_NN
Consumer_NN
Healthcare_NN
Sp_NN
._.
o._FW
CH_FW
m_FW
e_SYM
Portugal_NN
Lisbon_NN
Farmaceuticos_NN
,_,
Limitada_NN
Ph_NN
m_NN
Republic_NN
of_PIN
Dublin_NN
GlaxoSmithKline_NN
Consumer_NN
Healthcare_NN
Ireland_NN
Limited_NN
ii_FW
CH_NN
m_FW
Ireland_NN
Carrigaline_NN
SmithKline_NN
Beecham_NN
Cork_NN
Limited_NN
ii_FW
Ph_NN
p_FW
Carrigaline_NN
SmithKline_NN
Beecham_NN
Manufacturing_GER
Limited_NN
ii_FW
Ph_NN
p_NN
Spain_NN
Tres_NN
Cantos_NN
GlaxoSmithKline_NN
S._NN
A._NN
Ph_NN
m_FW
p_FW
Alcala_FW
fide_FW
Henares_NN
SmithKline_NN
Beecham_NN
S._NN
A._NN
Ph_NN
p_VPRT
Sweden_NN
Solna_NN
GlaxoSmithKline_NN
AB_NN
Ph_NN
m_NN
Switzerland_NN
Muenchenbuchsee_NN
GlaxoSmithKline_NN
Investments_NOMZ
Switzerland_NN
GmbH_NN
Ph_NN
,_,
CH_NN
h_NN
Muenchenbuchsee_NN
GlaxoSmithKline_NN
AG_NN
Ph_NN
m_NN
Zug_NN
Adechsa_NN
GmbH_NN
Ph_NN
e_SYM
USA_NN
USA_NN
Philadelphia_NN
SmithKline_NN
Beecham_NN
Corporation_NOMZ
Ph_NN
,_,
CH_NN
d_LS
e_SYM
h_FW
m_FW
p_FW
r_NN
s_VPRT
Pittsburgh_NN
GlaxoSmithKline_NN
Consumer_NN
Healthcare_NN
,_,
L._NN
P._NN
CH_NN
m_FW
p_FW
88_CD
Pittsburgh_NN
Block_NN
Drug_NN
Company_NN
,_,
Inc._NN
._.
CH_NN
h_FW
m_FW
p_FW
Wilmington_NN
GlaxoSmithKline_NN
Financial_NN
Inc._NN
._.
Ph_NN
f_SYM
Wilmington_NN
GlaxoSmithKline_NN
Holdings_GER
Americas_NN
Inc._NN
._.
Ph_NN
,_,
CH_NN
h_NN
Americas_NN
Bermuda_NN
Hamilton_NN
GlaxoSmithKline_NN
Insurance_NN
Ltd_NN
Ph_NN
,_,
CH_NN
i_FPP1
Canada_NN
Mississauga_NN
GlaxoSmithKline_NN
Inc._NN
._.
Ph_NN
,_,
CH_NN
m_FW
p_FW
r_NN
Vancouver_NN
ID_NN
Biomedical_NN
Corporation_NOMZ
Ph_NN
d_SYM
m_FW
p_FW
r_NN
Asia_NN
Pacific_NN
Australia_NN
Boronia_NN
Glaxo_NN
Wellcome_NN
Australia_NN
Pty_NN
Ltd_NN
Ph_NN
,_,
CH_NN
d_LS
e_SYM
m_FW
p_FW
r_NN
China_NN
Hong_NN
Kong_NN
GlaxoSmithKline_NN
Limited_NN
Ph_NN
,_,
CH_NN
m_NN
Tianjin_NN
Sino-American_NN
Tianjin_NN
Smith_NN
Kline_NN
&_CC
French_NN
Laboratories_NN
Ltd_NN
Ph_NN
d_SYM
m_FW
p_FW
r_NN
55_CD
India_NN
Mumbai_NN
GlaxoSmithKline_NN
Pharmaceuticals_NN
Limited_NN
Ph_NN
m_FW
p_FW
51_CD
Nabha_NN
GlaxoSmithKline_NN
Consumer_NN
Healthcare_NN
Limited_NN
iii_FW
CH_NN
m_FW
p_FW
43_CD
Malaysia_NN
Petaling_GER
Jaya_NN
GlaxoSmithKline_NN
Pharmaceutical_NN
Sdn_NN
Bhd_NN
Ph_NN
m_NN
New_NN
Zealand_NN
Auckland_NN
GlaxoSmithKline_NN
NZ_NN
Limited_NN
Ph_NN
,_,
CH_NN
m_NN
Pakistan_NN
Karachi_NN
GlaxoSmithKline_NN
Pakistan_NN
Limited_NN
Ph_NN
,_,
CH_NN
m_FW
p_FW
e_SYM
79_CD
Philippines_NN
Makati_NN
GlaxoSmithKline_NN
Philippines_NN
Inc_NN
Ph_NN
,_,
CH_NN
m_NN
Singapore_NN
Singapore_NN
Glaxo_NN
Wellcome_NN
Manufacturing_GER
Pte_NN
Ltd_NN
Ph_NN
p_VPRT
Singapore_NN
GlaxoSmithKline_NN
Pte_NN
Ltd_NN
Ph_NN
m_NN
South_NN
Korea_NN
Seoul_NN
GlaxoSmithKline_NN
Korea_NN
Ph_NN
m_FW
p_FW
Taiwan_NN
Taipei_NN
Glaxo_NN
Wellcome_NN
Taiwan_NN
Limited_NN
Ph_NN
m_FW
p_FW
GSK_NN
Annual_JJ
Report_NN
2005_CD
148_CD
FINANCIAL_NN
STATEMENTS_NOMZ
Notes_NN
to_PIN
the_DT
financial_JJ
statements_NOMZ
continued_VBD
39_CD
Principal_NN
Group_NN
companies_NN
continued_VBD
Japan_NN
Location_NOMZ
Subsidiary_NN
undertaking_VBG [WZPRES]
Segment_NOMZ
Activity_NOMZ
%_NN
Japan_NN
Tokyo_NN
GlaxoSmithKline_NN
K._NN
K._NN
Ph_NN
,_,
CH_NN
d_LS
m_FW
p_FW
r_NN
85_CD
Latin_NN
America_NN
Argentina_NN
Buenos_NN
Aires_NN
GlaxoSmithKline_NN
Argentina_NN
S._NN
A._NN
Ph_NN
,_,
CH_NN
m_FW
p_FW
Brazil_NN
Rio_NN
fide_VBD
Janeiro_NN
GlaxoSmithKline_NN
Brasil_NN
Ltda_NN
Ph_NN
,_,
CH_NN
m_FW
p_FW
Colombia_NN
Bogota_NN
GlaxoSmithKline_NN
Colombia_NN
S._NN
A._NN
Ph_NN
,_,
CH_NN
m_NN
Mexico_NN
Delegacion_NN
Tlalpan_NN
GlaxoSmithKline_NN
Mexico_NN
S._NN
A._NN
fide_NN
C._NN
V._NN
Ph_NN
,_,
CH_NN
e_LS
m_FW
p_FW
s_PRP
Puerto_NN
Rico_NN
Guaynabo_NN
GlaxoSmithKline_NN
Puerto_NN
Rico_NN
Inc._NN
._.
Ph_NN
m_FW
San_NN
Juan_NN
SB_NN
Pharmco_NN
Puerto_NN
Rico_NN
Inc._NN
._.
Ph_NN
p_NN
Venezuela_NN
Caracas_NN
GlaxoSmithKline_NN
Venezuela_NN
C._NN
A._NN
Ph_NN
,_,
CH_NN
m_NN
Middle_NN
East_NN
&_CC
Africa_NN
Egypt_NN
Cairo_NN
GlaxoSmithKline_NN
S._NN
A._NN
E_NN
Ph_NN
m_FW
p_FW
90_CD
South_NN
Africa_NN
Bryanston_NN
GlaxoSmithKline_NN
South_NN
Africa_NN
Pty_NN
Ltd_NN
Ph_NN
,_,
CH_NN
m_FW
p_FW
Turkey_NN
Istanbul_NN
GlaxoSmithKline_NN
Ilaclari_NN
Sanayi_NN
five_CD
Ticaret_NN
A._NN
S._NN
Ph_NN
m_NN
p_NN
USA_NN
Location_NOMZ
Associated_NN
undertaking_VBG [WZPRES]
Business_NOMZ
%_NN
USA_NN
Teterboro_NN
Quest_NN
Diagnostics_NN
Incorporated_NN
iv_NN
Clinical_NN
testing_GER
18_CD
i_FPP1
Incorporated_VBN
in_PIN
the_DT
Netherlands_NN
._.
ii_FW
Exempt_FW
from_PIN
the_DT
provisions_NN
of_PIN
Section_NOMZ
7_CD
of_PIN
the_DT
Companies_NN
Amendment_NOMZ
Act_NN
1986_CD
Ireland_NN
._.
iii_FW
Consolidated_NN
as_IN
a_DT
subsidiary_NN
undertaking_GER
in_PIN
accordance_NN
with_PIN
Section_NOMZ
258_CD
4_CD
a_DT
of_PIN
the_DT
Companies_NN
Act_NN
on_PIN
the_DT
grounds_NN
of_PIN
dominant_JJ
influence_NN
._.
iv_NN
Equity_NOMZ
accounted_VBD
on_PIN
the_DT
grounds_NN
of_PIN
significant_JJ
influence_NN
._.
Directly_RB
held_VBN [PRIV]
wholly_RB
owned_VBN
subsidiary_NN
of_PIN
GlaxoSmithKline_NN
plc._NN
._.
Key_NN
Business_NOMZ
segment_NOMZ
:_:
Ph_NN
Pharmaceuticals_NN
,_,
CH_NN
Consumer_NN
Healthcare_NN
Business_NOMZ
activity_NOMZ
:_:
d_LS
development_NOMZ
,_,
e_SYM
exporting_VBG
,_,
f_SYM
finance_NN
,_,
h_VPRT
holding_VBG [PRIV]
company_NN
,_,
i_FPP1
insurance_NN
,_,
m_NN
marketing_GER
,_,
p_NN
production_NOMZ
,_,
r_NN
research_NN
,_,
s_VPRT
service_NN
Full_NN
details_NN
of_PIN
all_QUAN
Group_NN
subsidiary_NN
and_CC
associated_VBN
undertakings_GER
will_PRMD
be_VB [PASS]
attached_VBN
to_PIN
the_DT
companys_NN
Annual_JJ
Return_NN
to_TO
be_VB [PASS]
filed_VBN
with_PIN
the_DT
Registrar_NN
of_PIN
Companies_NN
._.
GSK_NN
Annual_JJ
Report_NN
2005_CD
149_CD
FINANCIAL_NN
STATEMENTS_NOMZ
Notes_NN
to_PIN
the_DT
financial_JJ
statements_NOMZ
continued_VBD
40_CD
Transition_NOMZ
to_PIN
IFRS_NN
IFRS_NN
adjustments_NOMZ
A_DT
summary_NN
of_PIN
the_DT
principal_JJ
differences_NN
between_PIN
UK_NN
GAAP_NN
and_PHC
IFRS_NN
Background_NN
as_IN
they_TPP3
apply_VPRT
to_PIN
GSK_NN
is_VPRT [PASS]
set_VBN
out_PIN
below_PLACE
and_CC
the_DT
financial_JJ
effect_NN
is_VPRT [PASS]
shown_VBN [PRIV]
The_DT
IFRS_NN
project_NN
on_PIN
pages_NN
153_CD
to_PIN
156_CD
._.
In_PIN
June_NN
2002_CD
,_,
the_DT
Council_NN
of_PIN
the_DT
European_NN
Union_NN
adopted_VBD
a_DT
Customer_NN
allowances_NN
Regulation_NOMZ
requiring_VBG [SUAV] [WZPRES]
listed_VBN
companies_NN
in_PIN
its_PIT
Member_NN
States_NN
to_TO
prepare_VB
This_DEMO
adjustment_NOMZ
is_VPRT [BEMA]
a_DT
reclassification_NOMZ
between_PIN
turnover_NN
and_PHC
expenses_NN
their_TPP3
consolidated_JJ
financial_JJ
statements_NOMZ
in_PIN
accordance_NN
with_PIN
with_PIN
no_SYNE
profit_NN
or_CC
cash_NN
flow_NN
effect_NN
._.
IFRS_NN
has_VPRT
no_SYNE
detailed_JJ
rules_NN
in_PIN
relation_NOMZ
International_NN
Financial_NN
Reporting_GER
Standards_NN
IFRS_NN
from_PIN
2005_CD
._.
to_PIN
when_RB
certain_JJ
marketing_GER
and_CC
promotional_JJ
expenditure_NN
should_NEMD
be_VB [BEMA]
The_DT
GlaxoSmithKline_NN
Annual_JJ
Report_NN
for_PIN
the_DT
year_NN
ending_VBG [WZPRES]
31st_JJ
deducted_VBN
from_PIN
turnover_NN
rather_RB
than_PIN
recorded_VBN
as_IN
an_DT
expense_NN
._.
However_CONJ
,_,
December_NN
2005_CD
is_VPRT [BEMA]
the_DT
first_JJ
Annual_JJ
Report_NN
prepared_VBN
under_IN
IFRS_NN
._.
these_DEMO
rules_NN
do_EMPH
exist_VB
under_IN
US_FPP1
GAAP_NN
in_PIN
EITF_NN
01-09_CD
,_,
Accounting_GER
for_PIN
Consideration_NOMZ
Given_VBN [WZPAST]
by_PIN
a_DT
Vendor_NN
to_PIN
a_DT
Customer_NN
,_,
which_WDT [SERE]
requires_VPRT [SUAV]
most_EMPH
As_IN
2003_CD
is_VPRT [BEMA]
the_DT
earliest_JJ
year_NN
for_PIN
which_WDT [PIRE]
full_JJ
IFRS_NN
financial_JJ
statements_NOMZ
are_VPRT
marketing_VBG
,_,
advertising_GER
,_,
and_ANDC
promotion_NOMZ
payments_NOMZ
made_VBD
to_PIN
customers_NN
presented_VBN [WZPAST]
in_PIN
the_DT
Annual_JJ
Report_NN
2005_CD
,_,
the_DT
transition_NOMZ
date_NN
to_PIN
IFRS_NN
for_PIN
to_TO
be_VB [PASS]
deducted_VBN
from_PIN
turnover_NN
._.
This_DEMP
has_VPRT
the_DT
most_EMPH
significant_JJ
impact_NN
in_PIN
GlaxoSmithKline_NN
is_VPRT [BEMA]
1st_CD
January_NN
2003_CD
._.
Normally_RB
,_,
accounting_VBG
changes_NN
the_DT
Consumer_NN
Healthcare_NN
business_NOMZ
where_RB
payments_NOMZ
to_PIN
large_JJ
retailers_NN
of_PIN
this_DEMO
nature_NN
would_PRMD
require_VB [SUAV]
full_JJ
retrospective_NN
application_NOMZ
,_,
but_CC
GSK_NN
has_VPRT
for_PIN
in-store_JJ
advertising_GER
,_,
preferential_JJ
shelf-space_NN
,_,
product_NN
listings_GER
etc._FW
._.
taken_VBN
advantage_NN
of_PIN
exemptions_NOMZ
available_JJ
under_IN
the_DT
IFRS_NN
transitional_JJ
are_VPRT [BEMA]
commonplace_PRED
._.
rules_NN
to_TO
apply_VB
certain_JJ
requirements_NOMZ
only_DWNT
with_PIN
effect_NN
from_PIN
the_DT
transition_NOMZ
date_NN
of_PIN
1st_CD
January_NN
2003_CD
or_CC
,_,
in_PIN
the_DT
case_NN
of_PIN
financial_JJ
instruments_NOMZ
,_,
from_PIN
GSK_NN
believes_VPRT [PRIV] [THATD]
that_DEMP
this_DEMP
reflects_VPRT [PRIV]
best_JJ
practice_NN
in_PIN
revenue_NN
recognition_NOMZ
1st_CD
January_NN
2005_CD
._.
and_ANDC
hence_CONJ
,_,
in_PIN
the_DT
absence_NN
of_PIN
detailed_JJ
guidance_NN
under_IN
IFRS_NN
,_,
has_VPRT [PEAS]
decided_VBN [SUAV] [PRIV]
to_TO
adopt_VB
a_DT
revenue_NN
recognition_NOMZ
policy_NN
under_IN
IFRS_NN
in_PIN
line_NN
with_PIN
Financial_NN
instruments_NOMZ
EITF_NN
01-09_CD
._.
Therefore_CONJ
there_EX
is_VPRT [PASS]
not_XX0
expected_VBN [PRIV]
to_TO
be_VB [BEMA]
any_QUAN
difference_NN
GSK_NN
has_VPRT [PEAS]
adopted_VBN
IAS_NN
39_CD
as_IN
endorsed_VBN
by_PIN
the_DT
European_NN
Union_NN
._.
between_PIN
turnover_NN
reported_VBN [PUBV]
under_IN
IFRS_NN
and_PHC
turnover_NN
reported_VBN [PUBV]
under_IN
However_CONJ
,_,
one_CD
of_PIN
the_DT
exemptions_NOMZ
available_JJ
under_IN
IFRS_NN
1_CD
relaxes_VPRT
the_DT
US_FPP1
GAAP_NN
._.
This_DEMO
adjustment_NOMZ
has_VPRT
no_SYNE
impact_NN
on_PIN
profit_NN
before_IN
tax_NN
or_CC
EPS_NN
._.
requirement_NOMZ
for_PIN
comparative_JJ
information_NOMZ
presented_VBN [WZPAST]
in_PIN
the_DT
Annual_JJ
Report_NN
2005_CD
to_TO
comply_VB
with_PIN
IAS_NN
32_CD
and_CC
IAS_NN
39_CD
._.
GlaxoSmithKline_NN
has_VPRT
Share-based_JJ
payments_NOMZ
taken_VBN
advantage_NN
of_PIN
this_DEMO
exemption_NOMZ
,_,
and_ANDC
so_RB
,_,
in_PIN
2003_CD
and_CC
2004_CD
,_,
financial_JJ
The_DT
previous_JJ
UK_NN
GAAP_NN
approach_NN
to_PIN
share-based_JJ
payments_NOMZ
was_VBD [BEMA]
to_PIN
instruments_NOMZ
are_VPRT [PASS]
accounted_VBN
for_PIN
and_CC
presented_VBN
on_PIN
a_DT
UK_NN
GAAP_NN
basis_NN
._.
record_NN
any_QUAN
intrinsic_JJ
loss_NN
on_PIN
grant_NN
suffered_VBN [WZPAST]
by_PIN
the_DT
company_NN
._.
This_DEMP
means_VPRT [PRIV]
that_THVC
for_PIN
share_NN
options_NOMZ
granted_VBN [SUAV] [WZPAST]
at_PIN
the_DT
market_NN
price_NN
,_,
there_EX
was_VBD
no_DT
On_PIN
1st_CD
January_NN
2005_CD
there_EX
was_VBD
an_DT
adjustment_NOMZ
of_PIN
12_CD
million_CD
to_PIN
the_DT
charge_NN
to_PIN
the_DT
income_NN
statement_NOMZ
._.
Where_RB
shares_NN
or_CC
options_NOMZ
were_VBD
opening_VBG
balance_NN
sheet_NN
to_TO
reflect_VB [PRIV]
the_DT
movements_NOMZ
from_PIN
the_DT
UK_NN
GAAP_NN
granted_VBD [SUAV]
at_PIN
no_SYNE
cost_NN
to_PIN
the_DT
employee_NN
e._FW
g._FW
under_IN
long-term_JJ
incentive_NN
carrying_VBG [WZPRES]
values_NN
to_PIN
the_DT
IAS_NN
39_CD
values_NN
,_,
which_WDT [SERE]
for_PIN
many_QUAN
financial_JJ
plans_NN
the_DT
income_NN
statement_NOMZ
was_VBD [PASS]
charged_VBN
with_PIN
an_DT
amount_NN
equal_JJ
to_PIN
instruments_NOMZ
will_PRMD
be_VB [BEMA]
fair_JJ
value_NN
._.
the_DT
market_NN
price_NN
on_PIN
the_DT
date_NN
of_PIN
the_DT
award_NN
,_,
spread_VBN
over_IN
the_DT
The_DT
financial_JJ
instruments_NOMZ
concerned_VBN [WZPAST]
are_VPRT
:_:
performance_NN
period_NN
usually_RB
three_CD
years_NN
._.
Held_VBN [PRIV] [PASTP]
at_PIN
fair_JJ
value_NN
under_IN
IFRS_NN
with_PIN
movements_NOMZ
recorded_VBN [WZPAST]
in_PIN
equity_NOMZ
:_:
IFRS_NN
2_CD
,_,
Share-based_JJ
Payment_NOMZ
,_,
and_ANDC
its_PIT
UK_NN
GAAP_NN
equivalent_JJ
FRS_NN
20_CD
,_,
Equity_NOMZ
investments_NOMZ
Share-based_JJ
Payment_NOMZ
,_,
both_DT
of_PIN
which_WDT [PIRE]
came_VBD
into_PIN
force_NN
in_PIN
2005_CD
,_,
Liquid_NN
investments_NOMZ
require_VPRT [SUAV]
the_DT
fair_JJ
value_NN
of_PIN
the_DT
equity_NOMZ
instruments_NOMZ
issued_VBN
to_TO
be_VB [PASS]
charged_VBN
Derivatives_NN
classified_VBN
as_IN
cash_NN
flow_NN
hedging_VBG [WZPRES]
instruments_NOMZ
to_PIN
the_DT
income_NN
statement_NOMZ
._.
The_DT
Group_NN
has_VPRT [PEAS]
chosen_VBN
to_TO
recognize_VB [PRIV]
all_QUAN
unvested_JJ
options_NOMZ
and_PHC
awards_NN
retrospectively_RB
._.
Held_VBN [PRIV] [PASTP]
at_PIN
fair_JJ
value_NN
under_IN
IFRS_NN
with_PIN
movements_NOMZ
recorded_VBN [WZPAST]
in_PIN
the_DT
income_NN
statement_NOMZ
:_:
GSK_NN
receives_VPRT
a_DT
tax_NN
credit_NN
,_,
as_IN
appropriate_JJ
,_,
which_WDT [SERE]
relates_VPRT
to_TO
share_VB
Equity_NOMZ
collar_NN
linked_VBN [WZPAST]
to_PIN
the_DT
Groups_NN
investment_NOMZ
in_PIN
Quest_NN
Diagnostics_NN
options_NOMZ
and_PHC
awards_NN
when_RB
exercised_VBN
,_,
based_VBN [PASTP]
on_PIN
the_DT
gains_NN
the_DT
holders_NN
Inc._NN
make_VB
and_CC
dependent_JJ
on_PIN
the_DT
tax_NN
rules_NN
in_PIN
the_DT
country_NN
in_PIN
which_WDT [PIRE]
the_DT
Put_NN
and_PHC
call_NN
options_NOMZ
linked_VBN [WZPAST]
to_PIN
the_DT
Groups_NN
strategic_JJ
alliance_NN
with_PIN
deduction_NOMZ
is_VPRT [PASS]
claimed_VBN [PUBV]
._.
The_DT
deferred_JJ
tax_NN
asset_NN
represents_VPRT
an_DT
estimate_NN
Theravance_NN
Inc._NN
of_PIN
future_JJ
tax_NN
relief_NN
for_PIN
this_DEMO
gain_NN
and_CC
is_VPRT [PASS]
based_VBN
on_PIN
the_DT
potential_JJ
gains_NN
Other_JJ
derivatives_NN
not_XX0
classified_VBN
as_IN
hedging_VBG
instruments_NOMZ
,_,
including_VBG
available_JJ
to_PIN
the_DT
option_NOMZ
or_CC
award_NN
holders_NN
at_PIN
the_DT
balance_NN
sheet_NN
date_NN
._.
embedded_VBN
derivatives_NN
The_DT
movement_NOMZ
in_PIN
deferred_JJ
tax_NN
asset_NN
from_PIN
one_CD
balance_NN
sheet_NN
to_PIN
the_DT
Derivatives_NN
classified_VBN
as_IN
fair_JJ
value_NN
hedges_NN
together_RB
with_PIN
the_DT
next_JJ
may_POMD
result_VB
in_PIN
either_CC
a_DT
tax_NN
credit_NN
or_CC
a_DT
tax_NN
charge_NN
recorded_VBN [WZPAST]
in_PIN
the_DT
hedged_VBN
element_NOMZ
of_PIN
the_DT
relevant_JJ
asset_NN
or_CC
liability_NOMZ
income_NN
statement_NOMZ
._.
The_DT
amount_NN
of_PIN
any_QUAN
tax_NN
credit_NN
recognized_VBN [PRIV] [WZPAST]
in_PIN
the_DT
income_NN
statement_NOMZ
is_VPRT [PASS]
capped_VBN
at_PIN
the_DT
cumulative_JJ
amount_NN
of_PIN
the_DT
tax_NN
Presentation_NOMZ
differences_NN
only_DWNT
:_:
effect_NN
of_PIN
the_DT
share-based_JJ
payment_NOMZ
charge_NN
._.
Any_QUAN
excess_JJ
credit_NN
is_VPRT [PASS]
taken_VBN
Non-equity_JJ
minority_NOMZ
interests_NN
repaid_VBN [WZPAST]
during_PIN
2004_CD
._.
to_PIN
equity_NOMZ
._.
If_COND
the_DT
IAS_NN
39_CD
valuation_NOMZ
rules_NN
had_VBD [PEAS]
been_VBN [PASS]
applied_VBN
in_PIN
2004_CD
there_EX
would_PRMD
This_DEMO
adjustment_NOMZ
reduced_VBD
profit_NN
before_IN
tax_NN
in_PIN
2004_CD
by_PIN
309_CD
million_CD
have_VPRT [PEAS]
been_VBN [BEMA]
a_DT
charge_NN
to_PIN
profit_NN
before_IN
tax_NN
,_,
the_DT
largest_JJ
elements_NOMZ
of_PIN
which_WDT [PIRE]
2003_CD
368_CD
million_CD
,_,
earnings_GER
by_PIN
314_CD
million_CD
2003_CD
344_CD
million_CD
arise_VB
from_PIN
the_DT
Quest_NN
collar_NN
42_CD
million_CD
:_:
2003_CD
42_CD
million_CD
and_CC
the_DT
and_CC
EPS_NN
by_PIN
5.5_CD
pence_NN
2003_CD
5.9_CD
pence_NN
._.
Theravance_NN
put_VBD
and_PHC
call_VB
options_NOMZ
53_CD
million_CD
:_:
2003_CD
nil_NN
._.
Valuations_NOMZ
are_VPRT [BEMA]
inherently_RB
unpredictable_PRED
and_CC
changes_NN
in_PIN
the_DT
fair_JJ
values_NN
of_PIN
financial_JJ
instruments_NOMZ
could_POMD
have_VB
a_DT
material_NN
impact_NN
on_PIN
the_DT
future_JJ
results_NN
and_CC
financial_JJ
position_NOMZ
of_PIN
GSK_NN
._.
GSK_NN
Annual_JJ
Report_NN
2005_CD
150_CD
FINANCIAL_NN
STATEMENTS_NOMZ
Notes_NN
to_PIN
the_DT
financial_JJ
statements_NOMZ
continued_VBD
Pensions_NN
and_CC
other_JJ
post-employment_NOMZ
benefits_NN
40_CD
Transition_NOMZ
to_PIN
IFRS_NN
continued_VBD
GlaxoSmithKline_NN
accounted_VBD
under_IN
UK_NN
GAAP_NN
for_PIN
pensions_NN
and_CC
other_JJ
IFRS_NN
adjustments_NOMZ
post-employment_JJ
benefits_NN
OPEBs_NN
in_PIN
accordance_NN
with_PIN
SSAP_NN
24_CD
,_,
which_WDT [SERE]
The_DT
share-based_JJ
payments_NOMZ
charge_VPRT
reduced_VBN
to_PIN
a_DT
more_EMPH
normal_JJ
level_NN
of_PIN
spread_NN
the_DT
costs_NN
of_PIN
providing_VBG
the_DT
benefits_NN
over_IN
the_DT
estimated_VBN [PRIV]
average_JJ
236_CD
million_CD
in_PIN
2005_CD
._.
The_DT
considerably_RB
higher_JJ
charge_NN
in_PIN
2004_CD
and_CC
service_NN
lives_NN
of_PIN
the_DT
employees_NN
._.
2003_CD
arises_VPRT
from_PIN
two_CD
main_JJ
factors_NN
._.
Relatively_RB
few_QUAN
share_NN
options_NOMZ
were_VBD [PASS]
granted_VBN [SUAV]
during_PIN
2000_CD
when_RB
the_DT
GW_NN
SB_NN
merger_NN
was_VBD
being_VBG [PASS]
finalized_VBN
,_,
IAS_NN
19_CD
,_,
Employee_NN
Benefits_NN
,_,
recognizes_VPRT [PRIV]
surpluses_NN
and_PHC
deficits_NN
in_PIN
the_DT
but_CC
then_RB
in_PIN
2001_CD
there_EX
was_VBD
a_DT
full_JJ
catch-up_NN
grant_NN
early_TIME
in_PIN
the_DT
year_NN
accounts_NN
,_,
and_ANDC
in_PIN
accordance_NN
with_PIN
the_DT
transitional_JJ
provisions_NN
of_PIN
IFRS_NN
1_CD
,_,
followed_VBN [PASTP]
by_PIN
the_DT
normal_JJ
annual_JJ
grant_NN
in_PIN
November_NN
2001_CD
._.
In_CONJ
addition_NULL
,_,
the_DT
surpluses_NN
and_PHC
deficits_NN
have_VPRT [PEAS]
been_VBN [PASS]
recognized_VBN [PRIV]
in_PIN
full_JJ
on_PIN
the_DT
balance_NN
the_DT
grants_NN
in_PIN
2001_CD
were_VBD [PASS]
made_VBN
at_PIN
an_DT
average_JJ
share_NN
price_NN
in_PIN
excess_NN
of_PIN
sheet_NN
at_PIN
the_DT
transition_NOMZ
date_NN
of_PIN
1st_CD
January_NN
2003_CD
._.
These_DEMO
share_NN
options_NOMZ
became_VBD
exercisable_JJ
in_PIN
2004_CD
and_ANDC
therefore_CONJ
an_DT
amendment_NOMZ
to_PIN
IAS_NN
19_CD
issued_VBN
by_PIN
the_DT
IASB_NN
in_PIN
December_NN
2004_CD
,_,
it_PIT
is_VPRT [PASS]
fell_VBD
out_PIN
of_PIN
the_DT
charge_NN
in_PIN
2005_CD
,_,
which_WDT [SERE]
now_TIME
reflects_VPRT [PRIV]
more_EMPH
current_JJ
share_NN
permitted_VBN
to_TO
recognize_VB [PRIV]
any_QUAN
movements_NOMZ
in_PIN
the_DT
surpluses_NN
or_CC
deficits_NN
prices_NN
and_CC
more_EMPH
normal_JJ
grant_NN
levels_NN
._.
immediately_TIME
in_PIN
the_DT
balance_NN
sheet_NN
,_,
but_CC
outside_PLACE
the_DT
income_NN
statement_NOMZ
,_,
in_PIN
the_DT
Statement_NOMZ
of_PIN
recognized_VBN [PRIV]
income_NN
and_PHC
expense_NN
._.
This_DEMP
means_VPRT [PRIV] [THATD]
that_DEMP
,_,
Coreg_NN
capitalization_NOMZ
and_PHC
amortisation_NOMZ
in_PIN
most_EMPH
cases_NN
,_,
the_DT
balance_NN
sheet_NN
reflects_VPRT [PRIV]
the_DT
full_JJ
surplus_NN
or_CC
deficit_NN
The_DT
North_PLACE
American_JJ
rights_NN
to_PIN
Coreg_NN
were_VBD [PASS]
acquired_VBN
at_PIN
the_DT
time_NN
of_PIN
the_DT
positions_NOMZ
of_PIN
the_DT
funds_NN
._.
GW_NN
SB_NN
merger_NN
as_IN
partial_JJ
consideration_NOMZ
for_PIN
the_DT
required_VBN [SUAV]
disposal_NN
of_PIN
The_DT
Groups_NN
policy_NN
is_VPRT
to_TO
charge_VB
out_PIN
to_PIN
the_DT
operating_GER
businesses_NOMZ
the_DT
Kytril_NN
to_PIN
Roche_NN
._.
Under_IN
UK_NN
GAAP_NN
this_DEMP
was_VBD [PASS]
accounted_VBN
for_PIN
as_IN
an_DT
service_NN
cost_NN
element_NOMZ
of_PIN
the_DT
pension_NN
charge_NN
,_,
which_WDT [SERE]
then_RB
gets_VPRT
reported_VBN [PUBV]
exchange_NN
of_PIN
assets_NN
with_PIN
no_SYNE
value_NN
being_VBG [WZPRES] [PASS]
attributed_VBN
to_PIN
Coreg_NN
on_PIN
the_DT
within_PIN
cost_NN
of_PIN
sales_NN
,_,
selling_GER
,_,
general_JJ
and_PHC
administrative_JJ
expenditure_NN
or_CC
balance_NN
sheet_NN
._.
IFRS_NN
,_,
however_CONJ
,_,
requires_VPRT [SUAV]
the_DT
acquired_VBN
rights_NN
to_PIN
Coreg_NN
to_PIN
research_NN
and_PHC
development_NOMZ
as_IN
appropriate_JJ
,_,
but_CC
not_XX0
to_TO
charge_VB
out_PIN
the_DT
be_VB [PASS]
added_VBN [PUBV]
to_PIN
intangible_JJ
assets_NN
at_PIN
their_TPP3
fair_JJ
value_NN
on_PIN
the_DT
date_NN
of_PIN
element_NOMZ
related_VBN [WZPAST]
to_PIN
the_DT
funding_GER
deficit_NN
,_,
which_WDT [SERE]
is_VPRT [BEMA]
all_QUAN
reported_VBN [PUBV]
in_PIN
selling_GER
,_,
acquisition_NOMZ
of_PIN
$_$
400_CD
million_CD
,_,
and_ANDC
then_RB
amortised_VBN
over_IN
their_TPP3
remaining_VBG
general_JJ
and_PHC
administrative_JJ
expenditure_NN
._.
Under_IN
IAS_NN
19_CD
,_,
the_DT
service_NN
useful_JJ
life_NN
of_PIN
eight_CD
years_NN
._.
This_DEMO
adjustment_NOMZ
reduces_VPRT
2004_CD
profit_NN
before_IN
cost_NN
element_NOMZ
of_PIN
the_DT
total_JJ
charge_NN
is_VPRT [BEMA]
considerably_RB
higher_PRED
than_PIN
under_IN
tax_NN
by_PIN
27_CD
million_CD
2003_CD
31_CD
million_CD
and_CC
EPS_NN
by_PIN
0.3_CD
pence_NN
2003_CD
SSAP_NN
24_CD
and_CC
the_DT
funding_GER
deficit_NN
element_NOMZ
lower_JJ
._.
additional_JJ
reclassification_NOMZ
adjustment_NOMZ
between_PIN
the_DT
income_NN
statement_NOMZ
Other_JJ
intangible_JJ
assets_NN
amortisation_NOMZ
expense_NN
headings_GER
._.
Under_IN
UK_NN
GAAP_NN
,_,
GSK_NN
amortised_VBD
intangible_JJ
assets_NN
over_IN
their_TPP3
estimated_VBN [PRIV]
expected_VBN [PRIV]
useful_JJ
lives_NN
from_PIN
acquisition_NOMZ
,_,
which_WDT [SERE]
was_VBD [BEMA]
up_RB
to_PIN
a_DT
maximum_NN
The_DT
overall_JJ
impact_NN
of_PIN
the_DT
adjustments_NOMZ
to_PIN
pensions_NN
and_PHC
OPEBs_NN
in_PIN
2004_CD
of_PIN
15_CD
years_NN
._.
IFRS_NN
only_DWNT
permits_VPRT
amortisation_NOMZ
to_PIN
commence_NN
when_RB
the_DT
was_VBD [BEMA]
a_DT
decrease_NN
in_PIN
profit_NN
before_IN
tax_NN
of_PIN
36_CD
million_CD
2003_CD
increase_NN
of_PIN
asset_NN
becomes_VPRT
available_JJ
for_PIN
use_NN
,_,
with_PIN
annual_JJ
impairment_NOMZ
testing_GER
11_CD
million_CD
and_CC
a_DT
decrease_NN
in_PIN
EPS_NN
of_PIN
0.4_CD
pence_NN
2003_CD
nil_NN
._.
GSK_NN
has_VPRT [PEAS]
determined_VBN [SUAV] [PRIV]
that_THVC
the_DT
point_NN
at_PIN
which_WDT [PIRE]
Share_NN
of_PIN
profits_NN
of_PIN
associates_NN
amortisation_NOMZ
of_PIN
product-related_JJ
assets_NN
commences_NN
under_IN
IFRS_NN
will_PRMD
Under_IN
UK_NN
GAAP_NN
the_DT
share_NN
of_PIN
profits_NN
of_PIN
associates_NN
was_VBD [PASS]
reported_VBN [PUBV]
within_PIN
normally_RB
be_VB [BEMA]
regulatory_JJ
approval_NN
._.
The_DT
majority_NOMZ
of_PIN
the_DT
Groups_NN
profit_NN
before_IN
tax_NN
for_PIN
the_DT
Group_NN
._.
However_CONJ
,_,
IFRS_NN
requires_VPRT [SUAV]
this_DEMO
share_NN
of_PIN
intangible_JJ
assets_NN
relates_VPRT
to_PIN
the_DT
acquisition_NOMZ
of_PIN
rights_NN
to_PIN
compounds_NN
in_PIN
profits_NN
to_TO
be_VB [BEMA]
the_DT
net_JJ
profit_NN
attributable_JJ
to_PIN
the_DT
Group_NN
,_,
i._FW
e._FW
after_IN
interest_NN
,_,
development_NOMZ
and_CC
so_RB
has_VPRT [PEAS]
not_XX0
reached_VBN
the_DT
point_NN
at_PIN
which_WDT [PIRE]
amortisation_NOMZ
tax_NN
and_PHC
minority_NOMZ
interests_NN
of_PIN
the_DT
associate_NN
._.
This_DEMP
has_VPRT [PEAS]
led_VBN
to_PIN
a_DT
commences_NN
._.
This_DEMP
has_VPRT [PEAS]
led_VBN
to_PIN
a_DT
reduction_NOMZ
in_PIN
the_DT
amortisation_NOMZ
charge_NN
,_,
reclassification_NOMZ
adjustment_NOMZ
removing_VBG [WZPRES]
the_DT
share_NN
of_PIN
the_DT
associates_NN
which_WDT [WHSUB]
is_VPRT [BEMA]
likely_PRED
to_TO
reverse_VB
in_PIN
the_DT
future_NN
as_IN
these_DEMO
compounds_NN
reach_VPRT
interest_NN
,_,
tax_NN
and_PHC
minority_NOMZ
interests_NN
from_PIN
those_DEMO
lines_NN
in_PIN
the_DT
income_NN
regulatory_JJ
approval_NN
and_PHC
amortisation_NOMZ
is_VPRT [SPAU] [PASS]
then_RB
charged_VBN
over_IN
a_DT
shorter_JJ
statement_NOMZ
and_CC
netting_VBG
them_TPP3
all_QUAN
together_RB
in_PIN
the_DT
share_NN
of_PIN
profits_NN
of_PIN
period_NN
._.
Profit_NN
before_IN
tax_NN
in_PIN
2004_CD
increased_VBN
by_PIN
43_CD
million_CD
2003_CD
43_CD
associates_NN
line_NN
._.
This_DEMO
adjustment_NOMZ
reduced_VBD
2004_CD
profit_NN
before_IN
tax_NN
by_PIN
million_CD
and_CC
EPS_NN
by_PIN
0.5_CD
pence_NN
2003_CD
0.5_CD
pence_NN
._.
42_CD
million_CD
2003_CD
42_CD
million_CD
but_CC
did_VBD
not_XX0
affect_VB
EPS_NN
._.
Goodwill_NN
amortisation_NOMZ
Deferred_JJ
tax_NN
on_PIN
intercompany_NN
profit_NN
UK_NN
GAAP_NN
required_VBD [SUAV]
goodwill_NN
to_TO
be_VB [PASS]
amortised_VBN
over_IN
its_PIT
estimated_VBN [PRIV]
Under_IN
UK_NN
GAAP_NN
,_,
deferred_VBN
tax_NN
on_PIN
the_DT
provision_NN
for_PIN
intercompany_NN
profit_NN
expected_VBN [PRIV]
useful_JJ
life_NN
,_,
which_WDT [SERE]
GSK_NN
had_VBD [PEAS]
determined_VBN [SUAV] [PRIV]
to_TO
be_VB [BEMA]
normally_RB
no_DT
held_VBN [PRIV]
in_PIN
inventory_NN
is_VPRT [PASS]
calculated_VBN [PRIV]
at_PIN
the_DT
supplying_VBG
companys_NN
effective_JJ
tax_NN
longer_RB
than_PIN
20_CD
years_NN
._.
Under_IN
IFRS_NN
,_,
however_CONJ
,_,
goodwill_NN
is_VPRT [PASS]
considered_VBN [PRIV]
to_PIN
rate_NN
._.
IFRS_NN
,_,
however_CONJ
,_,
takes_VPRT
a_DT
balance_NN
sheet_NN
approach_NN
to_PIN
the_DT
recognition_NOMZ
have_VPRT
an_DT
indefinite_JJ
life_NN
and_CC
so_RB
is_VPRT [PASS]
not_XX0
amortised_VBN
,_,
but_CC
is_VPRT [BEMA]
subject_PRED
to_PIN
annual_JJ
of_PIN
deferred_JJ
tax_NN
which_WDT [WHOBJ]
results_NN
in_PIN
the_DT
tax_NN
rate_NN
of_PIN
the_DT
company_NN
holding_VBG [PRIV] [WZPRES]
impairment_NOMZ
testing_GER
._.
This_DEMO
adjustment_NOMZ
therefore_CONJ
reverses_VPRT
the_DT
goodwill_NN
the_DT
inventory_NN
at_PIN
the_DT
balance_NN
sheet_NN
date_NN
being_VBG [WZPRES] [PASS]
applied_VBN
to_PIN
the_DT
provision_NN
._.
amortisation_NOMZ
charged_VBN
under_IN
UK_NN
GAAP_NN
,_,
including_VBG
that_DEMP
recorded_VBN
in_PIN
the_DT
If_COND
the_DT
proportions_NOMZ
of_PIN
the_DT
Groups_NN
inventory_NN
held_VBN [PRIV] [WZPAST]
in_PIN
specific_JJ
locations_NOMZ
profit_NN
on_PIN
share_NN
of_PIN
associates_NN
line_NN
relating_VBG [WZPRES]
to_PIN
the_DT
acquisition_NOMZ
of_PIN
the_DT
change_NN
significantly_RB
from_PIN
one_CD
balance_NN
sheet_NN
date_NN
to_PIN
the_DT
next_JJ
there_EX
Groups_NN
interest_NN
in_PIN
Quest_NN
Diagnostics_NN
Inc._NN
._.
Under_IN
the_DT
business_NOMZ
could_POMD
be_VB [BEMA]
a_DT
significant_JJ
change_NN
in_PIN
the_DT
value_NN
of_PIN
the_DT
deferred_JJ
tax_NN
asset_NN
,_,
combinations_NOMZ
exemption_NOMZ
of_PIN
IFRS_NN
1_CD
,_,
goodwill_NN
previously_TIME
written_VBN [PUBV]
off_PIN
which_WDT [PIRE]
is_VPRT [PASS]
reflected_VBN [PRIV]
through_PIN
the_DT
tax_NN
charge_NN
for_PIN
the_DT
year_NN
._.
direct_JJ
to_PIN
reserves_NN
under_IN
UK_NN
GAAP_NN
is_VPRT [PASS]
not_XX0
recycled_VBN
to_PIN
the_DT
income_NN
statement_NOMZ
on_PIN
the_DT
disposal_NN
or_CC
part-disposal_NN
of_PIN
the_DT
subsidiary_NN
or_CC
associate_NN
,_,
as_IN
it_PIT
would_PRMD
be_VB
under_IN
UK_NN
GAAP_NN
._.
The_DT
adjustment_NOMZ
increases_VPRT
2004_CD
profit_NN
before_IN
tax_NN
by_PIN
37_CD
million_CD
2003_CD
26_CD
million_CD
and_CC
EPS_NN
by_PIN
0.7_CD
pence_NN
2003_CD
0.4_CD
pence_NN
._.
GSK_NN
Annual_JJ
Report_NN
2005_CD
151_CD
FINANCIAL_NN
STATEMENTS_NOMZ
Notes_NN
to_PIN
the_DT
financial_JJ
statements_NOMZ
continued_VBD
Amortisation_NOMZ
of_PIN
goodwill_NN
under_IN
UK_NN
GAAP_NN
prior_RB
to_PIN
the_DT
date_NN
of_PIN
40_CD
Transition_NOMZ
to_PIN
IFRS_NN
continued_VBD
transition_NOMZ
to_PIN
IFRS_NN
,_,
1st_CD
January_NN
2003_CD
,_,
has_VPRT [PEAS]
not_XX0
been_VBN [PASS]
reversed_VBN
._.
Other_JJ
adjustments_NOMZ
Accordingly_RB
,_,
goodwill_NN
recognized_VBN [PRIV] [WZPAST]
on_PIN
the_DT
IFRS_NN
balance_NN
sheet_NN
is_VPRT [BEMA]
lower_PRED
There_EX
are_VPRT
a_DT
number_NN
of_PIN
other_JJ
minor_JJ
adjustments_NOMZ
and_PHC
reclassifications_NOMZ
,_,
in_PIN
this_DEMO
respect_NN
than_PIN
it_PIT
would_PRMD
have_VB [PEAS]
been_VBN
if_COND
GSK_NN
had_VBD [PEAS]
not_XX0
taken_VBN
including_VBG
:_:
advantage_NN
of_PIN
the_DT
business_NOMZ
combinations_NOMZ
exemption_NOMZ
Computer_NN
software_NN
,_,
which_WDT [SERE]
is_VPRT [PASS]
recorded_VBN
as_IN
an_DT
intangible_JJ
asset_NN
unless_COND
Share-based_JJ
payments_NOMZ
:_:
IFRS_NN
2_CD
,_,
Share-based_JJ
Payment_NOMZ
,_,
applies_VPRT
to_PIN
it_PIT
forms_VPRT
an_DT
integral_JJ
part_NN
of_PIN
the_DT
operating_GER
system_NN
of_PIN
a_DT
tangible_JJ
fixed_VBN
equity_NOMZ
instruments_NOMZ
,_,
such_JJ
as_IN
share_NN
options_NOMZ
granted_VBN [SUAV]
since_OSUB
7th_JJ
asset_NN
November_NN
2002_CD
,_,
but_CC
GlaxoSmithKline_NN
has_VPRT [PEAS]
elected_VBN
to_TO
adopt_VB
full_JJ
Deferred_JJ
tax_NN
on_PIN
brands_NN
acquired_VBN [WZPAST]
with_PIN
a_DT
company_NN
,_,
where_RB
if_COND
there_EX
is_VPRT
retrospective_JJ
application_NOMZ
of_PIN
the_DT
standard_NN
a_DT
difference_NN
between_PIN
the_DT
fair_JJ
value_NN
of_PIN
the_DT
brands_NN
on_PIN
acquisition_NOMZ
and_CC
Financial_JJ
instruments_NOMZ
:_:
Financial_NN
instruments_NOMZ
in_PIN
the_DT
comparative_JJ
the_DT
tax_NN
value_NN
,_,
a_DT
taxable_JJ
temporary_JJ
difference_NN
arises_VPRT
periods_NN
presented_VBN [WZPAST]
in_PIN
the_DT
Annual_JJ
Report_NN
2005_CD
i._FW
e._FW
2004_CD
and_CC
2003_CD
are_VPRT [PASS]
recognized_VBN [PRIV]
and_PHC
measured_VBN
on_PIN
the_DT
UK_NN
GAAP_NN
basis_NN
applicable_JJ
in_PIN
Cash_NN
equivalents_NN
reclassification_NOMZ
,_,
where_RB
liquid_JJ
investments_NOMZ
with_PIN
those_DEMO
years_NN
,_,
rather_CONJ
than_PIN
in_PIN
accordance_NN
with_PIN
IAS_NN
39_CD
Financial_NN
maturities_NOMZ
of_PIN
less_JJ
than_PIN
three_CD
months_NN
at_PIN
acquisition_NOMZ
are_VPRT [PASS]
included_VBN
Instruments_NOMZ
:_:
Recognition_NOMZ
and_PHC
Measurement_NOMZ
._.
As_CONJ
a_NULL
result_NULL
,_,
certain_JJ
within_PIN
cash_NN
and_PHC
cash_NN
equivalents_NN
derivative_JJ
instruments_NOMZ
,_,
are_VPRT [PASS]
not_XX0
recognized_VBN [PRIV]
in_PIN
the_DT
comparative_JJ
Provisions_NN
reclassification_NOMZ
,_,
where_RB
the_DT
elements_NOMZ
of_PIN
provisions_NN
expected_VBN [PRIV]
periods_NN
._.
IFRS_NN
hedge_VPRT
accounting_GER
is_VPRT [PASS]
not_XX0
applied_VBN
in_PIN
the_DT
comparative_JJ
to_TO
be_VB [PASS]
paid_VBN
within_PIN
one_CD
year_NN
of_PIN
the_DT
balance_NN
sheet_NN
date_NN
,_,
with_PIN
the_DT
periods_NN
so_EMPH
hedged_JJ
borrowings_GER
are_VPRT [PASS]
recorded_VBN
at_PIN
amortised_JJ
cost_NN
rather_RB
exception_NOMZ
of_PIN
pensions_NN
and_PHC
OPEBs_NN
,_,
are_VPRT [PASS]
presented_VBN
within_PIN
current_JJ
than_PIN
at_PIN
fair_JJ
value_NN
._.
Also_RB
,_,
available-for-sale_JJ
financial_JJ
assets_NN
such_JJ
as_IN
liabilities_NOMZ
._.
equity_NOMZ
investments_NOMZ
and_CC
liquid_JJ
investments_NOMZ
are_VPRT [PASS]
recorded_VBN
at_PIN
cost_NN
less_JJ
impairments_NOMZ
rather_RB
than_PIN
at_PIN
fair_JJ
value_NN
._.
Cash_NN
flow_NN
statement_NOMZ
The_DT
move_NN
from_PIN
UK_NN
GAAP_NN
to_PIN
IFRS_NN
does_VPRT
not_XX0
change_VB
any_QUAN
of_PIN
the_DT
cash_NN
flows_VPRT
of_PIN
the_DT
Group_NN
._.
The_DT
IFRS_NN
cash_NN
flow_NN
format_NN
is_VPRT [BEMA]
similar_PRED
to_PIN
UK_NN
GAAP_NN
but_CC
presents_VPRT
various_JJ
cash_NN
flows_NN
in_PIN
different_JJ
categories_NN
and_CC
in_PIN
a_DT
different_JJ
order_NN
from_PIN
the_DT
UK_NN
GAAP_NN
cash_NN
flow_NN
statement_NOMZ
._.
All_QUAN
of_PIN
the_DT
IFRS_NN
accounting_GER
adjustments_NOMZ
net_JJ
out_PIN
within_PIN
cash_NN
generated_VBD
from_PIN
operations_NOMZ
except_PIN
for_PIN
the_DT
intangible_JJ
assets_NN
reclassification_NOMZ
and_CC
the_DT
inclusion_NN
of_PIN
liquid_JJ
investments_NOMZ
with_PIN
a_DT
maturity_NOMZ
of_PIN
less_JJ
than_PIN
three_CD
months_NN
on_PIN
acquisition_NOMZ
,_,
together_RB
with_PIN
related_JJ
exchange_NN
adjustments_NOMZ
,_,
within_PIN
cash_NN
and_PHC
cash_NN
equivalents_NN
under_IN
IFRS_NN
._.
IFRS_NN
1_CD
exemptions_NOMZ
and_PHC
elections_NOMZ
IFRS_VPRT
1_CD
,_,
First-Time_NN
Adoption_NOMZ
of_PIN
International_NN
Financial_NN
Reporting_GER
Standards_NN
,_,
permits_VPRT
those_DEMO
companies_NN
adopting_VBG [WZPRES]
IFRS_NN
for_PIN
the_DT
first_JJ
time_NN
to_TO
take_VB
some_QUAN
exemptions_NOMZ
from_PIN
the_DT
full_JJ
requirements_NOMZ
of_PIN
IFRS_NN
in_PIN
the_DT
transition_NOMZ
period_NN
or_CC
to_TO
make_VB
elections_NOMZ
to_TO
apply_VB
IFRS_NN
with_PIN
full_JJ
retrospective_JJ
effect_NN
where_RB
not_XX0
required_VBN [SUAV]
to_TO
do_VB
so_RB
._.
GSK_NN
has_VPRT [PEAS]
adopted_VBN
the_DT
following_VBG
key_JJ
exemptions_NOMZ
and_PHC
elections_NOMZ
:_:
Business_NOMZ
combinations_NOMZ
:_:
Business_NOMZ
combinations_NOMZ
prior_RB
to_PIN
the_DT
transition_NOMZ
date_NN
1st_CD
January_NN
2003_CD
have_VPRT [PEAS]
not_XX0
been_VBN [PASS]
restated_VBN
onto_PIN
an_DT
IFRS_NN
basis_NN
._.
If_COND
the_DT
merger_NN
of_PIN
Glaxo_NN
Wellcome_NN
and_PHC
SmithKline_NN
Beecham_NN
in_PIN
2000_CD
had_VBD [PEAS]
been_VBN [PASS]
restated_VBN
onto_PIN
an_DT
IFRS_NN
basis_NN
it_PIT
would_PRMD
have_VB [PEAS]
been_VBN [PASS]
accounted_VBN
for_PIN
as_IN
an_DT
acquisition_NOMZ
._.
Fair_NN
value_NN
adjustments_NOMZ
to_PIN
the_DT
net_JJ
assets_NN
of_PIN
the_DT
acquired_VBN
company_NN
would_PRMD
have_VB [PEAS]
been_VBN [PASS]
required_VBN [SUAV]
,_,
including_VBG [PRESP]
the_DT
recognition_NOMZ
of_PIN
significant_JJ
intangible_JJ
asset_NN
balances_NN
for_PIN
product_NN
rights_NN
relating_VBG [WZPRES]
to_PIN
both_DT
marketed_VBN
products_NN
and_CC
in-process_JJ
R&D_NN
,_,
which_WDT [SERE]
were_VBD [PASS]
not_XX0
recognized_VBN [PRIV]
under_IN
merger_NN
accounting_GER
._.
A_DT
significant_JJ
goodwill_NN
balance_NN
would_PRMD [SPAU]
also_RB
have_VB [PEAS]
been_VBN [PASS]
recorded_VBN
Goodwill_NN
written_VBN [PUBV] [WZPAST]
off_PIN
to_PIN
reserves_NN
prior_RB
to_PIN
1998_CD
under_IN
old_JJ
UK_NN
GAAP_NN
is_VPRT [PASS]
not_XX0
written_VBN [PUBV]
back_RB
to_PIN
goodwill_NN
._.
If_COND
the_DT
business_NOMZ
combinations_NOMZ
exemption_NOMZ
had_VBD [PEAS]
not_XX0
been_VBN [PASS]
taken_VBN
,_,
additional_JJ
goodwill_NN
balances_NN
relating_VBG [WZPRES]
to_PIN
acquisitions_NOMZ
prior_RB
to_PIN
1998_CD
would_PRMD
have_VB [PEAS]
been_VBN [PASS]
recognized_VBN [PRIV]
on_PIN
the_DT
IFRS_NN
balance_NN
sheet_NN
GSK_NN
Annual_JJ
Report_NN
2005_CD
152_CD
FINANCIAL_NN
STATEMENTS_NOMZ
Notes_NN
to_PIN
the_DT
financial_JJ
statements_NOMZ
continued_VBD
40_CD
Transition_NOMZ
to_PIN
IFRS_NN
continued_VBD
IFRS_NN
Consolidated_NN
income_NN
statement_NOMZ
12_CD
months_NN
2004_CD
12_CD
months_NN
2003_CD
UK_NN
GAAP_NN
Adjustments_NOMZ
IFRS_NN
UK_NN
GAAP_NN
Adjustments_NOMZ
IFRS_NN
m_FW
m_FW
m_FW
m_FW
m_FW
m_FW
Turnover_NN
20,359_CD
373_CD
19,986_CD
21,441_CD
371_CD
21,070_CD
Cost_NN
of_PIN
sales_NN
4,309_CD
51_CD
4,360_CD
4,544_CD
33_CD
4,577_CD
Gross_NN
profit_NN
16,050_CD
424_CD
15,626_CD
16,897_CD
404_CD
16,493_CD
Selling_GER
,_,
general_JJ
and_CC
administration_NOMZ
7,061_CD
140_CD
7,201_CD
7,597_CD
291_CD
7,888_CD
Research_NN
and_PHC
development_NOMZ
2,839_CD
65_CD
2,904_CD
2,791_CD
74_CD
2,865_CD
Other_JJ
operating_GER
income_NN
60 295 235 133_CD
443_CD
310_CD
Operating_GER
profit_NN
6,090_CD
334_CD
5,756_CD
6,376_CD
326_CD
6,050_CD
Finance_NN
income_NN
102_CD
74_CD
176_CD
61_CD
40_CD
101_CD
Finance_NN
costs_NN
305 57 362 222_CD
32_CD
254_CD
Share_NN
of_PIN
profits_NN
losses_NN
of_PIN
associates_NN
and_CC
joint_JJ
ventures_NN
95_CD
35_CD
60_CD
93_CD
36_CD
57_CD
Profit_NN
on_PIN
disposal_NN
of_PIN
interests_NN
in_PIN
associates_NN
138_CD
11_CD
149_CD
Profit_NN
before_IN
taxation_NOMZ
6,120_CD
341_CD
5,779_CD
6,308_CD
354_CD
5,954_CD
Taxation_NOMZ
1,701_CD
56_CD
1,757_CD
1,729_CD
78_CD
1,651_CD
Loss_NN
profit_NN
on_PIN
disposal_NN
of_PIN
businesses_NOMZ
1_CD
1_CD
5_CD
5_CD
Profit_NN
after_IN
taxation_NOMZ
for_PIN
the_DT
year_NN
4,418_CD
396_CD
4,022_CD
4,584_CD
276_CD
4,308_CD
Profit_NN
attributable_JJ
to_PIN
minority_NOMZ
interests_NN
116_CD
2_CD
114_CD
106_CD
1_CD
107_CD
Profit_NN
attributable_JJ
to_PIN
shareholders_NN
4,302_CD
394_CD
3,908_CD
4,478_CD
277_CD
4,201_CD
Earnings_GER
per_PIN
share_NN
pence_NN
75.0_CD
p_VPRT
6.9_CD
p_JJ
68.1_CD
p_NN
77.1_CD
p_NN
4.8_CD
p_VPRT
72.3_CD
p_JJ
Diluted_JJ
earnings_GER
per_PIN
share_NN
pence_NN
74.8_CD
p_NN
6.8_CD
p_VPRT
68.0_CD
p_JJ
76.9_CD
p_NN
4.8_CD
p_VPRT
72.1_CD
p_JJ
IFRS_NN
Consolidated_NN
statement_NOMZ
of_PIN
recognized_VBN [PRIV]
income_NN
and_PHC
expense_NN
31st_CD
December_NN
2004_CD
31st_CD
December_NN
2003_CD
UK_NN
GAAP_NN
Adjustments_NOMZ
IFRS_NN
UK_NN
GAAP_NN
Adjustments_NOMZ
IFRS_NN
m_FW
m_FW
m_FW
m_FW
m_FW
m_FW
Exchange_NN
movements_NOMZ
on_PIN
overseas_PLACE
net_JJ
assets_NN
54_CD
7_CD
47_CD
113_CD
60_CD
53_CD
Tax_NN
on_PIN
exchange_NN
movements_NOMZ
and_CC
unrealised_JJ
gains_NN
73_CD
73_CD
92_CD
2_CD
90_CD
Goodwill_NN
written_VBN [PUBV] [WZPAST]
back_RB
20_CD
20_CD
Revaluation_NOMZ
of_PIN
goodwill_NN
due_JJ
to_TO
exchange_VB
6_CD
6_CD
7_CD
7_CD
Unrealised_JJ
loss_NN
profit_NN
on_PIN
disposal_NN
of_PIN
intellectual_JJ
property_NN
1_CD
1_CD
7_CD
7_CD
Actuarial_JJ
gains_NN
losses_NN
on_PIN
defined_VBN
benefit_NN
plans_NN
108 108 432 432_CD
Deferred_JJ
tax_NN
on_PIN
actuarial_JJ
movements_NOMZ
on_PIN
defined_VBN
benefit_NN
plans_NN
17 17 121 121_CD
Net_JJ
losses_NN
gains_NN
recognized_VBN [PRIV] [WZPAST]
directly_RB
in_PIN
equity_NOMZ
102_CD
79_CD
23 21 376 355_CD
Profit_NN
for_PIN
the_DT
year_NN
4,418_CD
396_CD
4,022_CD
4,584_CD
276_CD
4,308_CD
Total_JJ
recognized_VBN [PRIV]
income_NN
and_PHC
expense_NN
for_PIN
the_DT
year_NN
4,316_CD
317_CD
3,999_CD
4,605_CD
652_CD
3,953_CD
GSK_NN
Annual_JJ
Report_NN
2005_CD
153_CD
FINANCIAL_NN
STATEMENTS_NOMZ
Notes_NN
to_PIN
the_DT
financial_JJ
statements_NOMZ
continued_VBD
40_CD
Transition_NOMZ
to_PIN
IFRS_NN
continued_VBD
IFRS_NN
Consolidated_NN
balance_NN
sheet_NN
31st_CD
December_NN
2004_CD
31st_CD
December_NN
2003_CD
UK_NN
GAAP_NN
Adjustments_NOMZ
IFRS_NN
UK_NN
GAAP_NN
Adjustments_NOMZ
IFRS_NN
m_FW
m_FW
m_FW
m_FW
m_FW
m_FW [BEMA]
Non-current_JJ
assets_NN
Property_NN
,_,
plant_NN
and_PHC
equipment_NOMZ
6,471_CD
274_CD
6,197_CD
6,441_CD
285_CD
6,156_CD
Goodwill_NN
139 165 304 143_CD
151_CD
294_CD
Other_JJ
intangible_JJ
assets_NN
2,003_CD
510_CD
2,513_CD
1,697_CD
533_CD
2,230_CD
Investments_NOMZ
in_PIN
associates_NN
and_CC
joint_JJ
ventures_NN
187 22 209 196_CD
14_CD
210_CD
Other_JJ
investments_NOMZ
298 298 262 262_CD
Deferred_JJ
tax_NN
assets_NN
1,537_CD
495_CD
2,032_CD
1,441_CD
498_CD
1,939_CD
Other_JJ
non-current_JJ
assets_NN
597 14 611 522_CD
9_CD
531_CD
Total_JJ
non-current_JJ
assets_NN
11,232_CD
932_CD
12,164_CD
10,702_CD
920_CD
11,622_CD
Current_JJ
assets_NN
Inventories_NN
2,192_CD
1_CD
2,193_CD
2,109_CD
2,109_CD
Current_JJ
tax_NN
recoverable_JJ
155 155 239 239_CD
Trade_NN
and_CC
other_JJ
receivables_NN
5,175_CD
724_CD
4,451_CD
4,934_CD
439_CD
4,495_CD
Liquid_NN
investments_NOMZ
2,818_CD
1,306_CD
1,512_CD
2,493_CD
1,024_CD
1,469_CD
Cash_NN
and_PHC
cash_NN
equivalents_NN
1,161_CD
1,306_CD
2,467_CD
962_CD
1,024_CD
1,986_CD
Assets_NN
held_VBN [PRIV] [WZPAST]
for_PIN
sale_NN
2_CD
2_CD
Total_JJ
current_JJ
assets_NN
11,346_CD
566_CD
10,780_CD
10,498_CD
200_CD
10,298_CD
Total_JJ
assets_NN
22,578_CD
366_CD
22,944_CD
21,200_CD
720_CD
21,920_CD
Current_JJ
liabilities_NOMZ
Short-term_JJ
borrowings_GER
1,582_CD
1,582_CD
1,452_CD
1,452_CD
Trade_NN
and_CC
other_JJ
payables_NN
5,542_CD
1,275_CD
4,267_CD
5,561_CD
1,364_CD
4,197_CD
Current_JJ
tax_NN
payable_JJ
1,598_CD
155_CD
1,753_CD
1,458_CD
239_CD
1,697_CD
Short-term_JJ
provisions_NN
962 962 968 968_CD
Total_JJ
current_JJ
liabilities_NOMZ
8,722_CD
158_CD
8,564_CD
8,471_CD
157_CD
8,314_CD
Non-current_JJ
liabilities_NOMZ
Long-term_JJ
borrowings_GER
4,381_CD
4,381_CD
3,651_CD
3,651_CD
Deferred_JJ
tax_NN
provision_NN
710 141 569 618_CD
253_CD
365_CD
Pensions_NN
and_CC
other_JJ
post-employment_NOMZ
benefits_NN
785_CD
1,734_CD
2,519_CD
807_CD
2,137_CD
2,944_CD
Other_JJ
provisions_NN
1,534_CD
965_CD
569_CD
1,617_CD
962_CD
655_CD
Other_JJ
non-current_JJ
liabilities_NOMZ
244 161 405 232_CD
161_CD
393_CD
Total_JJ
non-current_JJ
liabilities_NOMZ
7,654_CD
789_CD
8,443_CD
6,925_CD
1,083_CD
8,008_CD
Total_JJ
liabilities_NOMZ
16,376_CD
631_CD
17,007_CD
15,396_CD
926_CD
16,322_CD
Net_JJ
assets_NN
6,202_CD
265_CD
5,937_CD
5,804_CD
206_CD
5,598_CD
Equity_NOMZ
Share_NN
capital_NN
1,484_CD
1,484_CD
1,487_CD
1,487_CD
Share_NN
premium_NN
account_NN
304 304 264 264_CD
Retained_VBN
earnings_GER
4,781_CD
239_CD
4,542_CD
4,112_CD
153_CD
3,959_CD
Other_JJ
reserves_NN
644 38 606 804_CD
11_CD
793_CD
Shareholders_NN
equity_NOMZ
5,925_CD
201_CD
5,724_CD
5,059_CD
142_CD
4,917_CD
Minority_NOMZ
interests_NN
277 64 213 745_CD
64_CD
681_CD
Total_JJ
equity_NOMZ
6,202_CD
265_CD
5,937_CD
5,804_CD
206_CD
5,598_CD
GSK_NN
Annual_JJ
Report_NN
2005_CD
154_CD
FINANCIAL_NN
STATEMENTS_NOMZ
Notes_NN
to_PIN
the_DT
financial_JJ
statements_NOMZ
continued_VBD
40_CD
Transition_NOMZ
to_PIN
IFRS_NN
continued_VBD
Analysis_NN
of_PIN
IFRS_NN
adjustments_NOMZ
to_PIN
the_DT
Income_NN
Statement_NOMZ
Year_NN
ended_VBD
31st_CD
December_NN
2004_CD
Other_JJ
Shareintangible_NN
Share_NN
of_PIN
Customer_NN
based_VBN
Coreg_NN
assets_NN
Goodwill_NN
Pensions_NN
profits_NN
of_PIN
IFRS_NN
allowances_NN
payments_NOMZ
amortisation_NOMZ
amortisation_NOMZ
amortisation_NOMZ
and_PHC
OPEBS_NN
associates_NN
Other_JJ
adjustments_NOMZ
m_VPRT
m_FW
m_FW
m_FW
m_FW
m_FW
m_FW
m_FW
m_FW
Turnover_NN
373_CD
373_CD
Cost_NN
of_PIN
sales_NN
14_CD
36_CD
16_CD
13_CD
51_CD
Gross_NN
profit_NN
359_CD
36_CD
16_CD
13_CD
424_CD
Selling_GER
,_,
general_JJ
and_CC
administration_NOMZ
359_CD
182_CD
27_CD
12_CD
3_CD
299_CD
140_CD
Research_NN
and_PHC
development_NOMZ
91_CD
43_CD
17_CD
65_CD
Other_JJ
operating_GER
income_NN
295_CD
295_CD
Operating_GER
profit_NN
309_CD
27_CD
43_CD
12_CD
36_CD
17_CD
334_CD
Finance_NN
income_NN
74_CD
74_CD
Finance_NN
costs_NN
7_CD
64_CD
57_CD
Share_NN
of_PIN
profits_NN
losses_NN
of_PIN
associates_NN
and_CC
joint_JJ
ventures_NN
14_CD
49_CD
35_CD
Profit_NN
on_PIN
disposal_NN
of_PIN
interests_NN
in_PIN
associates_NN
11_CD
11_CD
Profit_NN
before_IN
taxation_NOMZ
309_CD
27_CD
43_CD
37_CD
36_CD
42_CD
7_CD
341_CD
Taxation_NOMZ
5_CD
9_CD
12_CD
13_CD
40_CD
101_CD
56_CD
Profit_NN
on_PIN
disposal_NN
of_PIN
businesses_NOMZ
1_CD
1_CD
Profit_NN
after_IN
taxation_NOMZ
for_PIN
the_DT
year_NN
314_CD
18_CD
31_CD
38_CD
23_CD
2_CD
108_CD
396_CD
Profit_NN
attributable_JJ
to_PIN
minority_NOMZ
interests_NN
2_CD
2_CD
Profit_NN
attributable_JJ
to_PIN
shareholders_NN
314_CD
18_CD
31_CD
38 23 108 394_CD
Earnings_GER
per_PIN
share_NN
pence_NN
5.5_CD
p_NN
0.3_CD
p_VPRT
0.5_CD
p_JJ
0.7_CD
p_NN
0.4_CD
p_NN
1.9_CD
p_VPRT
6.9_CD
p_JJ
Reconciliation_NOMZ
of_PIN
opening_VBG
equity_NOMZ
by_PIN
component_NN
of_PIN
equity_NOMZ
At_PIN
1st_CD
January_NN
2003_CD
Share_NN
Total_JJ
Share_NN
premium_NN
Other_JJ
Retained_VBN
shareholders_NN
Minority_NOMZ
Total_JJ
capital_NN
account_NN
reserves_NN
earnings_GER
equity_NOMZ
interests_NN
equity_NOMZ
m_NN
m_FW
m_FW
m_FW
m_FW
m_FW
m_FW
UK_NN
GAAP_NN
1,506_CD
224_CD
921_CD
3,031_CD
3,840_CD
807_CD
4,647_CD
IFRS_NN
adjustments_NOMZ
net_NN
of_PIN
tax_NN
:_:
Pensions_NN
1,456_CD
1,456_CD
1,456_CD
Deferred_JJ
profit_NN
on_PIN
stock_NN
249 249 249_CD
Dividends_NN
1,287_CD
1,287_CD
1,287_CD
Deferred_JJ
tax_NN
on_PIN
indefinite_JJ
life_NN
assets_NN
300 300 300_CD
Coreg_NN
126 126 126_CD
Other_JJ
intangible_JJ
assets_NN
45_CD
45_CD
45_CD
Share-based_JJ
payments_NOMZ
5_CD
5_CD
Tax_NN
on_PIN
share-based_JJ
payments_NOMZ
48_CD
48_CD
48_CD
Other_JJ
30_CD
30_CD
64_CD
34_CD
Total_JJ
IFRS_NN
adjustments_NOMZ
5_CD
34_CD
29_CD
64_CD
35_CD
IFRS_NN
1,506_CD
224_CD
926_CD
3,065_CD
3,869_CD
743_CD
4,612_CD
GSK_NN
Annual_JJ
Report_NN
2005_CD
155_CD
FINANCIAL_NN
STATEMENTS_NOMZ
Notes_NN
to_PIN
the_DT
financial_JJ
statements_NOMZ
continued_VBD
40_CD
Transition_NOMZ
to_PIN
IFRS_NN
continued_VBD
Analysis_NN
of_PIN
IFRS_NN
balance_NN
sheet_NN
adjustments_NOMZ
At_PIN
31st_CD
December_NN
2004_CD
Coreg_NN
Other_JJ
capitalization_NOMZ
intangible_JJ
Goodwill_NN
Dividend_NN
Share-based_JJ
and_PHC
amortisation_JJ
assets_NN
Pensions_NN
IFRS_NN
deferred_VBD
payments_NOMZ
amortisation_NOMZ
amortisation_NOMZ
reversal_NN
and_PHC
OPEBS_NN
Other_JJ
adjustments_NOMZ
m_VPRT
m_FW
m_FW
m_FW
m_FW
m_FW
m_FW
m_FW [BEMA]
Non-current_JJ
assets_NN
Property_NN
,_,
plant_NN
and_PHC
equipment_NOMZ
274_CD
274_CD
Goodwill_NN
26 139 165_CD
Other_JJ
intangible_JJ
assets_NN
104 148 258 510_CD
Investments_NOMZ
in_PIN
associates_NN
and_CC
joint_JJ
ventures_NN
22_CD
22_CD
Other_JJ
investments_NOMZ
Deferred_VBN
tax_NN
assets_NN
67_CD
34 29 324 167_CD
495_CD
Other_JJ
non-current_JJ
assets_NN
14_CD
14_CD
Total_JJ
non-current_JJ
assets_NN
67_CD
70_CD
119 48 338 290_CD
932_CD
Current_JJ
assets_NN
Inventories_NN
1_CD
1_CD
Current_JJ
tax_NN
recoverable_JJ
155_CD
155_CD
Trade_NN
and_CC
other_JJ
receivables_NN
724_CD
724_CD
Liquid_NN
investments_NOMZ
1,306_CD
1,306_CD
Cash_NN
and_PHC
cash_NN
equivalents_NN
1,306_CD
1,306_CD
Assets_NN
held_VBN [PRIV] [WZPAST]
for_PIN
sale_NN
2_CD
2_CD
Total_JJ
current_JJ
assets_NN
724 158 566_CD
Total_JJ
assets_NN
67_CD
70_CD
119 48 386 448_CD
366_CD
Current_JJ
liabilities_NOMZ
Short-term_JJ
borrowings_GER
Trade_NN
and_CC
other_JJ
payables_NN
1,254_CD
21_CD
1,275_CD
Current_JJ
tax_NN
payable_JJ
155_CD
155_CD
Short-term_JJ
provisions_NN
962_CD
962_CD
Total_JJ
current_JJ
liabilities_NOMZ
1,254_CD
21_CD
1,117_CD
158_CD
Non-current_JJ
liabilities_NOMZ
Long-term_JJ
borrowings_GER
Deferred_VBN
tax_NN
provision_NN
27 472 304 141_CD
Pensions_NN
and_CC
other_JJ
post-employment_NOMZ
benefits_NN
1,734_CD
1,734_CD
Other_JJ
provisions_NN
3_CD
962_CD
965_CD
Other_JJ
non-current_JJ
liabilities_NOMZ
161_CD
161_CD
Total_JJ
non-current_JJ
liabilities_NOMZ
27_CD
1,259_CD
497_CD
789_CD
Total_JJ
liabilities_NOMZ
1,254_CD
27_CD
1,238_CD
620_CD
631_CD
Net_JJ
assets_NN
1,254_CD
67_CD
70_CD
92_CD
48_CD
1,624_CD
172_CD
265_CD
Equity_NOMZ
Share_NN
capital_NN
Share_NN
premium_NN
account_NN
Retained_VBN
earnings_GER
1,254_CD
29_CD
70_CD
92_CD
48_CD
1,619_CD
113_CD
239_CD
Other_JJ
reserves_NN
38_CD
38_CD
Shareholders_NN
equity_NOMZ
1,254_CD
67_CD
70_CD
92_CD
48_CD
1,619_CD
113_CD
201_CD
Minority_NOMZ
interests_NN
5_CD
59_CD
64_CD
Total_JJ
equity_NOMZ
1,254_CD
67_CD
70_CD
92_CD
48_CD
1,624_CD
172_CD
265_CD
GSK_NN
Annual_JJ
Report_NN
2005_CD
156_CD
FINANCIAL_NN
STATEMENTS_NOMZ
Notes_NN
to_PIN
the_DT
financial_JJ
statements_NOMZ
continued_VBD
The_DT
Group_NN
holds_VPRT [PRIV]
other_JJ
US_FPP1
patents_NN
relating_VBG [WZPRES]
to_PIN
Advair_NN
which_WDT [WHSUB]
are_VPRT [BEMA]
not_XX0
41_CD
Legal_JJ
proceedings_GER
affected_VBN [WZPAST]
by_PIN
the_DT
re-issue_JJ
application_NOMZ
,_,
including_VBG [PRESP]
the_DT
compound_NN
patent_NN
The_DT
Group_NN
is_VPRT [PASS]
involved_VBN
in_PIN
significant_JJ
legal_JJ
and_PHC
administrative_JJ
related_VBN
to_PIN
the_DT
active_JJ
ingredient_NN
salmeterol_NN
which_WDT [WHSUB]
affords_VPRT
protection_NOMZ
proceedings_GER
,_,
principally_RB
product_NN
liability_NOMZ
,_,
intellectual_JJ
property_NN
,_,
tax_NN
,_,
antithrough_JJ
August_NN
2008_CD
after_IN
giving_VBG
effect_NN
to_PIN
an_DT
expected_VBN [PRIV]
grant_NN
of_PIN
trust_NN
and_CC
governmental_JJ
investigations_NOMZ
and_CC
related_JJ
private_JJ
litigation_NOMZ
._.
paediatric_JJ
exclusivity_NOMZ
by_PIN
the_DT
FDA_NN
and_CC
various_JJ
patents_NN
relating_VBG [WZPRES]
to_PIN
the_DT
The_NN
Group_NN
makes_VPRT
provision_NN
for_PIN
these_DEMO
proceedings_GER
on_PIN
a_DT
regular_JJ
basis_NN
Diskus_NN
device_NN
which_WDT [WHSUB]
expire_VPRT
over_IN
a_DT
period_NN
from_PIN
2011_CD
to_PIN
2016_CD
._.
as_IN
summarised_VBN
in_PIN
Notes_NN
2_CD
and_CC
27_CD
._.
The_DT
Group_NN
may_POMD
make_VB
additional_JJ
significant_JJ
provisions_NN
for_PIN
such_JJ
legal_JJ
proceedings_GER
as_IN
required_VBN [SUAV]
in_PIN
the_DT
Avandia_NN
and_PHC
Avandamet_NN
event_NN
of_PIN
further_JJ
developments_NOMZ
in_PIN
these_DEMO
matters_NN
,_,
consistent_JJ
with_PIN
In_PIN
August_NN
2003_CD
,_,
the_DT
Group_NN
filed_VBD
an_DT
action_NOMZ
in_PIN
the_DT
US_FPP1
District_NN
Court_NN
for_PIN
generally_RB
accepted_VBN [PRIV]
accounting_GER
principles_NN
._.
Litigation_NOMZ
,_,
particularly_RB
in_PIN
the_DT
the_DT
District_NN
of_PIN
New_NN
Jersey_NN
against_PIN
Teva_NN
Pharmaceuticals_NN
USA_NN
Inc._NN
for_PIN
USA_NN
,_,
is_VPRT [BEMA]
inherently_RB
unpredictable_PRED
and_PHC
excessive_PRED
awards_NN
that_TSUB
may_POMD
not_XX0
infringement_NOMZ
of_PIN
the_DT
Groups_NN
patent_NN
relating_VBG [WZPRES]
to_PIN
the_DT
maleate_NN
salt_NN
form_NN
be_VB [BYPA]
justified_VBN
by_PIN
the_DT
evidence_NN
may_POMD
occur_VB
._.
The_DT
Group_NN
could_POMD
in_PIN
the_DT
future_NN
of_PIN
rosiglitazone_NN
,_,
the_DT
active_JJ
ingredient_NN
in_PIN
Avandia_NN
,_,
which_WDT [SERE]
expires_VPRT
in_PIN
incur_VPRT
judgments_NOMZ
or_CC
enter_VPRT
into_PIN
settlements_NOMZ
of_PIN
claims_NN
that_TSUB
could_POMD
result_VB
2015_CD
._.
In_PIN
September_NN
2003_CD
,_,
the_DT
Group_NN
filed_VBD
a_DT
comparable_JJ
action_NOMZ
in_PIN
in_PIN
payments_NOMZ
that_TSUB
exceed_VPRT
its_PIT
current_JJ
provisions_NN
by_PIN
an_DT
amount_NN
that_TOBJ
the_DT
same_JJ
court_NN
against_PIN
Dr_NN
Reddys_NN
Laboratories_NN
,_,
alleging_VBG [PUBV]
infringement_NOMZ
of_PIN
the_DT
same_JJ
patent_NN
._.
Those_DEMO
actions_NOMZ
were_VBD [PASS]
filed_VBN
in_PIN
response_NN
to_TO
would_PRMD
have_VB
a_DT
material_NN
adverse_JJ
effect_NN
on_PIN
the_DT
Groups_NN
financial_JJ
Abbreviated_NN
New_NN
Drug_NN
Application_NOMZ
ANDA_NN
filings_GER
with_PIN
the_DT
FDA_NN
by_PIN
Dr_NN
condition_NOMZ
,_,
results_NN
of_PIN
operations_NOMZ
and_CC
or_CC
cash_NN
flows_NN
._.
Reddys_NN
Laboratories_NN
and_PHC
Teva_NN
with_PIN
certifications_NOMZ
that_TOBJ
the_DT
Groups_NN
Intellectual_NN
property_NN
claims_NN
include_VPRT
challenges_NN
to_PIN
the_DT
validity_NOMZ
of_PIN
the_DT
maleate_NN
salt_NN
patent_NN
is_VPRT [BEMA]
invalid_PRED
._.
FDA_NN
approval_NN
of_PIN
those_DEMO
ANDAs_NN
is_VPRT [PASS]
stayed_VBN
Groups_NN
patents_NN
on_PIN
various_JJ
products_NN
or_CC
processes_NN
and_PHC
assertions_NOMZ
of_PIN
until_IN
the_DT
earlier_TIME
of_PIN
November_NN
2006_CD
or_CC
resolution_NOMZ
of_PIN
the_DT
respective_JJ
non-infringement_NOMZ
of_PIN
those_DEMO
patents_NN
._.
A_DT
loss_NN
in_PIN
any_QUAN
of_PIN
these_DEMO
cases_NN
could_POMD
patent_NN
infringement_NOMZ
actions_NOMZ
._.
result_NN
in_PIN
loss_NN
of_PIN
patent_NN
protection_NOMZ
for_PIN
the_DT
product_NN
at_PIN
issue_NN
._.
The_DT
Teva_NN
subsequently_TIME
filed_VBD
an_DT
additional_JJ
certification_NOMZ
challenging_VBG [WZPRES]
the_DT
consequences_NN
of_PIN
any_QUAN
such_JJ
loss_NN
could_POMD
be_VB [BEMA]
a_DT
significant_JJ
decrease_NN
in_PIN
sales_NN
validity_NOMZ
of_PIN
the_DT
Groups_NN
basic_JJ
compound_NN
patent_NN
for_PIN
rosiglitazone_NN
,_,
and_ANDC
of_PIN
that_DEMO
product_NN
and_CC
could_POMD [SPAU]
materially_RB
affect_VB
future_JJ
results_NN
of_PIN
operations_NOMZ
in_PIN
January_NN
2004_CD
the_DT
Group_NN
commenced_VBD
an_DT
action_NOMZ
against_PIN
Teva_NN
in_PIN
the_DT
for_PIN
the_DT
Group_NN
._.
same_JJ
court_NN
for_PIN
infringement_NOMZ
of_PIN
that_DEMO
patent_NN
._.
The_DT
basic_JJ
compound_NN
Legal_NN
expenses_NN
incurred_VBN
and_CC
provisions_NN
related_VBN [WZPAST]
to_PIN
legal_JJ
claims_NN
are_VPRT
patent_NN
currently_RB
expires_VPRT
in_PIN
2012_CD
after_IN
giving_VBG
effect_NN
to_PIN
patent_NN
term_NN
charged_VBN
to_TO
selling_VBG
,_,
general_JJ
and_CC
administration_NOMZ
costs_NN
._.
Provisions_NN
are_VPRT
restoration_NOMZ
and_CC
paediatric_JJ
exclusivity_NOMZ
._.
made_VBN
,_,
after_IN
taking_VBG
appropriate_JJ
legal_JJ
advice_NN
,_,
when_RB
a_DT
reasonable_JJ
In_PIN
January_NN
2005_CD
,_,
the_DT
Group_NN
filed_VBD
an_DT
action_NOMZ
in_PIN
the_DT
US_FPP1
District_NN
Court_NN
for_PIN
estimate_NN
can_POMD
be_VB [PASS]
made_VBN
of_PIN
the_DT
likely_JJ
outcome_NN
of_PIN
the_DT
dispute_NN
._.
In_PIN
2004_CD
the_DT
District_NN
of_PIN
New_NN
Jersey_NN
against_PIN
Teva_NN
for_PIN
infringement_NOMZ
of_PIN
the_DT
same_JJ
the_DT
Group_NN
established_VBD [PRIV]
an_DT
actuarially_RB
determined_VBN [SUAV] [PRIV]
provision_NN
for_PIN
product_NN
two_CD
patents_NN
the_DT
basic_JJ
compound_NN
and_CC
maleate_VB
salt_NN
patents_NN
for_PIN
liability_NOMZ
claims_NN
incurred_VBN
but_CC
not_XX0
yet_RB
reported_VBN [PUBV]
as_IN
described_VBN
in_PIN
Note_NN
27_CD
._.
rosiglitazone_NN
._.
Teva_NN
had_VBD [PEAS]
filed_VBN
an_DT
ANDA_NN
with_PIN
the_DT
FDA_NN
for_PIN
a_DT
generic_JJ
At_PIN
31st_CD
December_NN
2005_CD
the_DT
Groups_NN
aggregate_JJ
provision_NN
for_PIN
legal_JJ
version_NN
of_PIN
Avandamet_NN
with_PIN
a_DT
certification_NOMZ
that_TOBJ
those_DEMO
patents_NN
are_VPRT [BEMA]
invalid_PRED
and_PHC
other_PRED
disputes_NN
not_XX0
including_VBG
tax_NN
matters_NN
described_VBN
under_IN
or_CC
not_XX0
infringed_VBN
._.
FDA_NN
approval_NN
of_PIN
that_DEMO
ANDA_NN
is_VPRT [PASS]
stayed_VBN
until_IN
the_DT
earlier_TIME
Taxation_NOMZ
in_PIN
Note_NN
12_CD
was_VBD
over_IN
1.1_CD
billion_CD
._.
The_DT
ultimate_JJ
liability_NOMZ
for_PIN
of_PIN
June_NN
2007_CD
or_CC
resolution_NOMZ
of_PIN
the_DT
patent_NN
infringement_NOMZ
action_NOMZ
._.
Since_OSUB
legal_JJ
claims_NN
may_POMD
vary_VB
from_PIN
the_DT
amounts_NN
provided_VBN
and_PHC
is_VPRT [BEMA]
dependent_JJ
Avandamet_NN
is_VPRT [BYPA]
protected_VBN
by_PIN
the_DT
same_JJ
patents_NN
as_IN
Avandia_NN
,_,
any_QUAN
earlier_TIME
upon_PIN
the_DT
outcome_NN
of_PIN
litigation_NOMZ
proceedings_GER
,_,
investigations_NOMZ
and_PHC
holding_GER
of_PIN
invalidity_NOMZ
in_PIN
the_DT
Avandia_NN
cases_NN
would_PRMD
be_VB [BEMA]
dispositive_PRED
for_PIN
possible_JJ
settlement_NOMZ
negotiations_NOMZ
._.
The_DT
most_EMPH
significant_JJ
of_PIN
those_DEMO
matters_NN
are_VPRT [PASS]
described_VBN
below_PLACE
._.
Imitrex_NN
Intellectual_NN
property_NN
In_PIN
December_NN
2003_CD
,_,
the_DT
Group_NN
commenced_VBD
an_DT
action_NOMZ
in_PIN
the_DT
US_FPP1
District_NN
Court_NN
for_PIN
the_DT
Southern_NN
District_NN
of_PIN
New_NN
York_NN
against_PIN
Dr_NN
Reddys_NN
Advair_NN
Laboratories_NN
,_,
alleging_VBG [PUBV]
infringement_NOMZ
of_PIN
one_CD
of_PIN
the_DT
two_CD
primary_JJ
In_PIN
September_NN
2004_CD
,_,
the_DT
Group_NN
applied_VBD
to_PIN
the_DT
US_FPP1
Patent_NN
and_CC
compound_JJ
patents_NN
for_PIN
sumatriptan_NN
,_,
the_DT
active_JJ
ingredient_NN
in_PIN
Imitrex_NN
._.
Trademark_NN
Office_NN
USPTO_NN
for_PIN
re-issue_NN
of_PIN
its_PIT
combination_NOMZ
patent_NN
for_PIN
The_DT
patent_NN
at_PIN
issue_NN
affords_NN
protection_NOMZ
through_PIN
February_NN
2009_CD
after_IN
Advair_NN
,_,
an_DT
inhaled_JJ
combination_NOMZ
of_PIN
salmeterol_NN
and_PHC
fluticasone_NN
giving_VBG [WZPRES]
effect_NN
to_PIN
a_DT
grant_NN
of_PIN
paediatric_JJ
exclusivity_NOMZ
by_PIN
the_DT
FDA_NN
._.
The_DT
propionate_NN
,_,
which_WDT [SERE]
expires_VPRT
in_PIN
September_NN
2010_CD
._.
This_DEMP
followed_VBD
an_DT
defendant_NN
had_VBD [PEAS]
filed_VBN
an_DT
ANDA_NN
with_PIN
the_DT
FDA_NN
for_PIN
sumatriptan_JJ
oral_JJ
internal_JJ
review_NN
which_WDT [WHSUB]
concluded_VBD [PRIV]
that_THVC
the_DT
language_NN
in_PIN
the_DT
patent_NN
may_POMD
tablets_NN
with_PIN
a_DT
certification_NOMZ
of_PIN
invalidity_NOMZ
of_PIN
that_DEMO
compound_NN
patent_NN
but_CC
not_XX0
accurately_RB
describe_VB
all_QUAN
of_PIN
the_DT
circumstances_NN
of_PIN
the_DT
invention_NOMZ
and_CC
did_VBD
not_XX0
certify_VB [PUBV]
invalidity_NOMZ
or_CC
non-infringement_NOMZ
of_PIN
the_DT
other_JJ
compound_NN
may_POMD
not_XX0
claim_VB [PUBV]
the_DT
invention_NOMZ
as_IN
precisely_RB
as_IN
it_PIT
could_POMD
._.
The_DT
objective_NN
of_PIN
patent_NN
that_TSUB
expires_VPRT
in_PIN
June_NN
2007_CD
after_IN
giving_VBG
effect_NN
to_PIN
paediatric_NN
seeking_VBG [WZPRES]
re-issuance_NN
is_VPRT
to_TO
strengthen_VB
the_DT
protection_NOMZ
afforded_VBN [WZPAST]
by_PIN
the_DT
exclusivity_NOMZ
._.
In_PIN
January_NN
2006_CD
,_,
the_DT
USPTO_NN
issued_VBD
a_DT
final_JJ
office_NN
action_NOMZ
rejecting_VBG [WZPRES]
that_DEMO
application_NOMZ
._.
The_DT
Group_NN
will_PRMD
seek_VB
reconsideration_NOMZ
of_PIN
the_DT
In_PIN
March_NN
2004_CD
,_,
the_DT
Group_NN
commenced_VBD
an_DT
infringement_NOMZ
action_NOMZ
rejection_NOMZ
,_,
and_ANDC
a_DT
response_NN
to_PIN
the_DT
USPTO_NN
is_VPRT [PASS]
expected_VBN [PRIV]
in_PIN
the_DT
first_JJ
half_NN
of_PIN
against_PIN
Cobalt_NN
Pharmaceuticals_NN
which_WDT [WHSUB]
was_VBD [PASS]
transferred_VBN
to_PIN
the_DT
US_FPP1
the_DT
year_NN
._.
While_OSUB
the_DT
application_NOMZ
for_PIN
re-issue_NN
remains_VPRT
pending_VBG
,_,
the_DT
District_NN
Court_NN
for_PIN
the_DT
Southern_NN
District_NN
of_PIN
New_NN
York_NN
._.
The_DT
defendant_NN
patent_NN
remains_VPRT
in_PIN
force_NN
and_CC
is_VPRT [PASS]
listed_VBN
in_PIN
the_DT
register_NN
of_PIN
pharmaceutical_JJ
had_VBD [PEAS]
filed_VBN
an_DT
ANDA_NN
for_PIN
sumatripan_JJ
oral_JJ
tablets_NN
with_PIN
a_DT
certification_NOMZ
of_PIN
patents_NN
maintained_VBN [PUBV] [WZPAST]
by_PIN
the_DT
US_FPP1
Food_NN
and_PHC
Drug_NN
Administration_NOMZ
FDA_NN
invalidity_NOMZ
or_CC
non-infringement_NOMZ
of_PIN
the_DT
same_JJ
compound_NN
patent_NN
at_PIN
issue_NN
the_DT
Orange_NN
Book_NN
._.
Final_JJ
pre-trial_JJ
conference_NN
in_PIN
the_DT
consolidated_JJ
Dr_NN
Reddys_NN
and_PHC
Cobalt_NN
case_NN
is_VPRT [PASS]
scheduled_VBN
for_PIN
May_POMD
2006_CD
._.
GSK_NN
Annual_JJ
Report_NN
2005_CD
157_CD
FINANCIAL_NN
STATEMENTS_NOMZ
Notes_NN
to_PIN
the_DT
financial_JJ
statements_NOMZ
continued_VBD
Between_PIN
1999_CD
and_CC
2001_CD
,_,
the_DT
Group_NN
filed_VBD
further_JJ
actions_NOMZ
against_PIN
41_CD
Legal_JJ
proceedings_GER
continued_VBD
Apotex_NN
in_PIN
the_DT
US_FPP1
District_NN
Court_NN
for_PIN
the_DT
Eastern_NN
District_NN
of_PIN
Pennsylvania_NN
for_PIN
infringement_NOMZ
of_PIN
additional_JJ
of_PIN
the_DT
Groups_NN
patents_NN
._.
In_PIN
December_NN
In_PIN
February_NN
2005_CD
,_,
the_DT
Group_NN
commenced_VBD
an_DT
infringement_NOMZ
action_NOMZ
in_PIN
2002_CD
,_,
the_DT
judge_NN
granted_VBN [SUAV] [WZPAST]
in_PIN
part_NN
and_CC
denied_VBN [PUBV]
in_PIN
part_NN
summary_NN
the_DT
US_FPP1
District_NN
Court_NN
for_PIN
the_DT
District_NN
of_PIN
Delaware_NN
against_PIN
Spectrum_NN
judgment_NOMZ
motions_NOMZ
filed_VBN [WZPAST]
by_PIN
Apotex_NN
with_PIN
the_DT
result_NN
that_TOBJ
issues_NN
of_PIN
validity_NOMZ
Pharmaceuticals_NN
._.
The_DT
defendant_NN
had_VBD [PEAS]
filed_VBN
an_DT
ANDA_NN
for_PIN
injectable_JJ
and_CC
infringement_NOMZ
of_PIN
three_CD
of_PIN
the_DT
four_CD
additional_JJ
patents_NN
remained_VBD
sumatriptan_JJ
with_PIN
a_DT
certification_NOMZ
of_PIN
invalidity_NOMZ
or_CC
non-infringement_NOMZ
of_PIN
for_PIN
trial_NN
._.
In_PIN
July_NN
2004_CD
,_,
the_DT
judge_NN
certified_VBD [PUBV]
the_DT
patent_NN
that_TSUB
had_VBD [PEAS]
been_VBN [BEMA]
the_DT
same_JJ
compound_NN
patent_NN
at_PIN
issue_NN
in_PIN
the_DT
Dr_NN
Reddys_NN
and_PHC
Cobalt_NN
held_VBD [PRIV]
invalid_JJ
for_PIN
appeal_NN
to_PIN
the_DT
CAFC_NN
._.
In_PIN
February_NN
2006_CD
,_,
the_DT
CAFC_NN
cases_NN
._.
Trial_NN
date_NN
in_PIN
this_DEMO
case_NN
is_VPRT [PASS]
set_VBN
at_PIN
November_NN
2006_CD
._.
affirmed_VBD [PUBV]
the_DT
judges_NN
ruling_NN
of_PIN
invalidity_NOMZ
of_PIN
that_DEMO
patent_NN
._.
Lamictal_JJ
In_PIN
August_NN
2002_CD
,_,
the_DT
Group_NN
commenced_VBD
an_DT
action_NOMZ
in_PIN
the_DT
US_FPP1
District_NN
The_NN
Group_NN
also_RB
commenced_VBD
actions_NOMZ
in_PIN
the_DT
US_FPP1
District_NN
Court_NN
for_PIN
the_DT
Eastern_NN
District_NN
of_PIN
Pennsylvania_NN
against_PIN
Geneva_NN
,_,
Alphapharm_NN
,_,
Andrx_NN
Court_NN
for_PIN
the_DT
District_NN
of_PIN
New_NN
Jersey_NN
against_PIN
Teva_NN
Pharmaceuticals_NN
USA_NN
Pharmaceuticals_NN
,_,
Zenith_NN
and_PHC
Teva_NN
Pharmaceuticals_NN
in_PIN
connection_NOMZ
with_PIN
Inc._NN
alleging_VBG [PUBV] [WZPRES]
infringement_NOMZ
of_PIN
the_DT
Groups_NN
compound_VPRT
patent_NN
for_PIN
their_TPP3
ANDA_NN
filings_GER
for_PIN
Paxil_NN
and_PHC
BASF_NN
and_PHC
Sumika_NN
Fine_NN
Chemicals_NN
in_PIN
lamotrigine_NN
,_,
the_DT
active_JJ
ingredient_NN
in_PIN
Lamictal_JJ
oral_JJ
tablets_NN
._.
That_DEMO
patent_NN
connection_NOMZ
with_PIN
their_TPP3
supply_NN
of_PIN
paroxetine_JJ
hydrochloride_NN
for_PIN
use_NN
in_PIN
affords_NN
protection_NOMZ
through_PIN
January_NN
2009_CD
after_IN
giving_VBG
effect_NN
to_PIN
a_DT
grant_NN
ANDAs_NN
._.
Those_DEMO
lawsuits_NN
have_VPRT [PEAS]
been_VBN [PASS]
settled_VBN
or_CC
stayed_VBN
pending_JJ
resolution_NOMZ
of_PIN
paediatric_JJ
exclusivity_NOMZ
by_PIN
the_DT
FDA_NN
._.
Teva_NN
had_VBD [PEAS]
filed_VBN
an_DT
ANDA_NN
with_PIN
the_DT
of_PIN
the_DT
appeals_NN
in_PIN
the_DT
Apotex_NN
case_NN
._.
Apotex_NN
launched_VBD
its_PIT
generic_JJ
product_NN
FDA_NN
with_PIN
a_DT
certification_NOMZ
of_PIN
invalidity_NOMZ
of_PIN
the_DT
Groups_NN
patent_NN
._.
The_DT
parties_NN
in_PIN
the_DT
USA_NN
in_PIN
September_NN
2003_CD
._.
Additional_JJ
generic_JJ
products_NN
were_VBD [PASS]
reached_VBN
a_DT
settlement_NOMZ
agreement_NOMZ
pursuant_JJ
to_PIN
which_WDT [PIRE]
the_DT
Group_NN
has_VPRT [PEAS]
launched_VBN
by_PIN
other_JJ
defendants_NN
after_IN
March_NN
2004_CD
._.
granted_VBN [SUAV]
Teva_NN
an_DT
exclusive_JJ
royalty-bearing_GER
license_NN
to_TO
distribute_VB
in_PIN
the_DT
USA_NN
a_DT
generic_JJ
version_NN
of_PIN
lamotrigine_NN
chewable_JJ
tablets_NN
._.
In_CONJ
addition_NULL
,_,
The_DT
Groups_NN
US_FPP1
patent_NN
litigation_NOMZ
with_PIN
Synthon_NN
BV_NN
was_VBD [PASS]
settled_VBN
in_PIN
Teva_NN
was_VBD [PASS]
granted_VBN [SUAV]
the_DT
exclusive_JJ
right_NN
to_TO
manufacture_VB
and_PHC
sell_VB
Tevas_NN
December_NN
2003_CD
enabling_VBG
US_FPP1
marketing_GER
of_PIN
Synthons_NN
paroxetine_JJ
own_JJ
generic_JJ
version_NN
of_PIN
lamotrigine_NN
tablets_NN
in_PIN
the_DT
USA_NN
with_PIN
an_DT
mesylate_JJ
product_NN
._.
This_DEMP
was_VBD [PASS]
followed_VBN
with_PIN
settlement_NOMZ
in_PIN
August_NN
2004_CD
expected_VBD [PRIV]
launch_NN
date_NN
in_PIN
2008_CD
._.
of_PIN
most_EMPH
of_PIN
the_DT
Groups_NN
non-US_FPP1
patent_NN
litigation_NOMZ
with_PIN
Synthon_NN
as_CONJ
a_NULL
consequence_NULL
of_PIN
which_WDT [PIRE]
Synthon_NN
is_VPRT [BEMA]
free_PRED
to_TO
market_VB
its_PIT
paroxetine_JJ
Paxil_NN
Seroxat_NN
mesylate_VB
product_NN
in_PIN
many_QUAN
markets_NN
globally_RB
where_RB
it_PIT
has_VPRT [PEAS]
obtained_VBN
In_PIN
the_DT
USA_NN
a_DT
number_NN
of_PIN
distributors_NN
of_PIN
generic_JJ
drugs_NN
filed_VBD
applications_NOMZ
marketing_VBG [WZPRES]
authorisations_NOMZ
._.
Resolution_NOMZ
of_PIN
damages_NN
in_PIN
respect_NN
of_PIN
several_QUAN
with_PIN
the_DT
FDA_NN
to_TO
market_VB
generic_JJ
versions_NN
of_PIN
Paxil_NN
Seroxat_NN
paroxetine_JJ
country_NN
markets_NN
remains_VPRT
outstanding_JJ
._.
Paroxetine_JJ
mesylate_NN
is_VPRT [BEMA]
a_DT
hydrochloride_NN
prior_RB
to_PIN
the_DT
expiration_NOMZ
in_PIN
2007_CD
after_IN
giving_VBG
effect_NN
to_PIN
a_DT
different_JJ
salt_NN
form_NN
of_PIN
paroxetine_NN
than_PIN
that_DEMP
used_VBN
in_PIN
the_DT
marketed_VBN
form_NN
grant_NN
of_PIN
paediatric_JJ
exclusivity_NOMZ
by_PIN
the_DT
FDA_NN
of_PIN
the_DT
Groups_NN
patent_NN
on_PIN
of_PIN
Seroxat_NN
Paxil_NN
._.
In_PIN
certain_JJ
markets_NN
litigation_NOMZ
with_PIN
Synthon_NN
is_VPRT [BEMA]
ongoing_JJ
paroxetine_JJ
hyrdrochloride_NN
hemihydrate_NN
._.
These_DEMO
distributors_NN
sought_VBD
to_TO
and_CC
Synthon_NN
is_VPRT
asserting_VBG [PUBV]
counterclaims_NN
for_PIN
unfair_JJ
competition_NOMZ
against_PIN
bring_VB
to_PIN
market_NN
anhydrate_NN
or_CC
other_JJ
versions_NN
of_PIN
paroxetine_NN
the_DT
Group_NN
._.
hydrochloride_NN
and_CC
in_PIN
one_CD
case_NN
paroxetine_JJ
mesylate_NN
._.
In_PIN
response_NN
the_DT
Group_NN
filed_VBD
actions_NOMZ
against_PIN
all_QUAN
those_DEMO
distributors_NN
for_PIN
infringement_NOMZ
of_PIN
Generic_JJ
products_NN
containing_VBG [WZPRES]
the_DT
anhydrate_JJ
form_NN
of_PIN
paroxetine_JJ
various_JJ
of_PIN
the_DT
Groups_NN
patents_NN
on_PIN
the_DT
basis_NN
that_TOBJ
the_DT
generic_JJ
anhydrate_NN
hydrochloride_NN
are_VPRT [BEMA]
now_TIME
on_PIN
the_DT
market_NN
in_PIN
most_EMPH
European_JJ
countries_NN
._.
and_ANDC
other_JJ
versions_NN
infringe_VPRT
because_CAUS
they_TPP3
contain_VPRT
and_CC
or_CC
convert_VB
to_PIN
the_DT
Whilst_OSUB
some_QUAN
of_PIN
these_DEMO
products_NN
are_VPRT [BEMA]
the_DT
subject_NN
of_PIN
continuing_VBG
litigation_NOMZ
,_,
hemihydrate_JJ
form_NN
and_CC
or_CC
infringe_VB
other_JJ
Group_NN
patents_NN
._.
most_EMPH
actions_NOMZ
have_VPRT [SPAU] [PEAS]
now_TIME
been_VBN [PASS]
settled_VBN
and_CC
it_PIT
is_VPRT [PASS]
expected_VBN [PRIV]
that_THVC
more_EMPH
will_PRMD
be_VB [PASS]
settled_VBN
in_PIN
the_DT
future_NN
._.
In_PIN
the_DT
UK_NN
,_,
litigation_NOMZ
of_PIN
several_QUAN
years_NN
standing_VBG [WZPRES]
In_PIN
July_NN
1998_CD
,_,
GSK_NN
filed_VBD
an_DT
action_NOMZ
against_PIN
Apotex_NN
in_PIN
the_DT
US_FPP1
District_NN
between_PIN
the_DT
Group_NN
and_PHC
Apotex_NN
culminated_VBD
in_PIN
an_DT
Appeal_NN
Court_NN
Court_NN
for_PIN
the_DT
Northern_NN
District_NN
of_PIN
Illinois_NN
for_PIN
infringement_NOMZ
of_PIN
the_DT
decision_NN
that_TOBJ
the_DT
Groups_NN
anhydrate_JJ
process_NN
patent_NN
was_VBD [BEMA]
valid_PRED
but_CC
not_XX0
Groups_NN
patent_NN
for_PIN
paroxetine_JJ
hydrochloride_NN
hemihydrate_NN
._.
As_CONJ
a_NULL
result_NULL
of_PIN
the_DT
litigation_NOMZ
,_,
Apotex_NN
was_VBD [PASS]
enjoined_VBN [SUAV]
from_PIN
filed_VBN
an_DT
ANDA_NN
with_PIN
the_DT
FDA_NN
seeking_VBG [WZPRES]
approval_NN
to_TO
introduce_VB
a_DT
generic_JJ
launching_VBG
a_DT
product_NN
for_PIN
about_IN
one_CD
year_NN
but_CC
is_VPRT [BEMA]
now_TIME
on_PIN
the_DT
market_NN
._.
Following_VBG [PRESP]
a_DT
trial_NN
in_PIN
February_NN
2003_CD
the_DT
judge_NN
ruled_VBD [SUAV]
GSKs_NN
damages_NN
enquiry_JJ
relating_VBG
to_PIN
the_DT
injunction_NOMZ
is_VPRT [BEMA]
ongoing_PRED
._.
A_DT
settlement_NOMZ
patent_NN
valid_JJ
but_CC
not_XX0
infringed_VBN
by_PIN
Apotexs_NN
product_NN
._.
On_PIN
the_DT
Groups_NN
of_PIN
damages_NN
claim_VPRT [PUBV]
has_VPRT [PEAS]
been_VBN [PASS]
reached_VBN
with_PIN
one_CD
of_PIN
Apotexs_NN
local_JJ
appeal_NN
the_DT
US_FPP1
Court_NN
of_PIN
Appeals_NN
for_PIN
the_DT
Federal_NN
Circuit_NN
CAFC_NN
,_,
which_WDT [SERE]
distributors_NN
._.
hears_VPRT [PRIV]
all_QUAN
appeals_NN
from_PIN
US_FPP1
District_NN
Courts_NN
on_PIN
patent_NN
matters_NN
,_,
ruled_VBD [SUAV]
that_THVC
the_DT
Groups_NN
patent_NN
was_VBD [PASS]
infringed_VBN
but_CC
invalid_JJ
based_VBN
upon_PIN
public_JJ
use_NN
Paxil_NN
CR_NN
in_PIN
clinical_JJ
trials_NN
prior_RB
to_PIN
the_DT
filing_NN
date_NN
in_PIN
the_DT
USA_NN
._.
The_DT
Group_NN
filed_VBD
a_DT
In_PIN
November_NN
2005_CD
,_,
Mylan_NN
Pharmaceuticals_NN
filed_VBD
an_DT
ANDA_NN
for_PIN
Paxil_NN
CR_NN
petition_NOMZ
to_PIN
the_DT
CAFC_NN
for_PIN
rehearing_GER
on_PIN
its_PIT
appeal_NN
by_PIN
the_DT
full_JJ
court_NN
and_CC
paroxetine_JJ
hydrochloride_NN
controlled_VBN
release_NN
formulation_NOMZ
with_PIN
a_DT
in_PIN
April_NN
2005_CD
the_DT
full_JJ
CAFC_NN
vacated_VBD
that_DEMO
judgment_NOMZ
and_CC
remanded_VBD
the_DT
certification_NOMZ
of_PIN
invalidity_NOMZ
and_PHC
non-infringement_NOMZ
of_PIN
several_QUAN
patents_NN
listed_VBN
matter_NN
to_PIN
the_DT
same_JJ
panel_NN
._.
Concurrently_RB
with_PIN
entry_NN
of_PIN
that_DEMO
decision_NN
,_,
in_PIN
the_DT
FDA_NN
Orange_NN
Book_NN
._.
There_EX
was_VBD
no_SYNE
certification_NOMZ
of_PIN
invalidity_NOMZ
or_CC
the_DT
panel_NN
issued_VBD
a_DT
new_JJ
opinion_NN
ruling_VBG [SUAV] [WZPRES]
the_DT
same_JJ
patent_NN
invalid_JJ
under_IN
non-infringement_NOMZ
of_PIN
the_DT
patent_NN
covering_VBG [WZPRES]
paroxetine_JJ
hydrochloride_NN
an_DT
alternative_JJ
theory_NN
._.
The_DT
Groups_NN
request_NN
for_PIN
a_DT
rehearing_GER
by_PIN
the_DT
full_JJ
hemihydrate_NN
,_,
which_WDT [SERE]
Mylan_NN
admitted_VBD [PUBV]
is_VPRT [BEMA]
the_DT
active_JJ
ingredient_NN
in_PIN
its_PIT
court_NN
of_PIN
the_DT
panels_NN
new_JJ
decision_NN
was_VBD [PASS]
denied_VBN [PUBV]
and_CC
the_DT
Group_NN
has_VPRT [PEAS]
filed_VBN
product_NN
._.
That_DEMO
patent_NN
expires_VPRT
in_PIN
June_NN
2007_CD
after_IN
giving_VBG
effect_NN
to_PIN
a_DT
grant_NN
a_DT
petition_NOMZ
for_PIN
review_NN
by_PIN
the_DT
US_FPP1
Supreme_NN
Court_NN
._.
of_PIN
paediatric_JJ
exclusivity_NOMZ
by_PIN
the_DT
FDA_NN
._.
As_IN
the_DT
Group_NN
did_VBD
not_XX0
file_VB
a_DT
patent_NN
infringement_NOMZ
action_NOMZ
against_PIN
Mylan_NN
within_PIN
the_DT
45-day_JJ
period_NN
provided_VBN
under_IN
Hatch-Waxman_NN
,_,
there_EX
will_PRMD
be_VB
no_SYNE
30-month_JJ
stay_NN
against_PIN
FDA_NN
approval_NN
of_PIN
the_DT
Mylan_NN
ANDA_NN
to_TO
conduct_VB
patent_NN
litigation_NOMZ
._.
GSK_NN
Annual_JJ
Report_NN
2005_CD
158_CD
FINANCIAL_NN
STATEMENTS_NOMZ
Notes_NN
to_PIN
the_DT
financial_JJ
statements_NOMZ
continued_VBD
Zofran_NN
41_CD
Legal_NN
proceedings_GER
continued_VBD
In_PIN
August_NN
2001_CD
,_,
the_DT
Group_NN
commenced_VBD
an_DT
action_NOMZ
in_PIN
the_DT
US_FPP1
District_NN
Requip_NN
Court_NN
for_PIN
the_DT
District_NN
of_PIN
New_NN
Jersey_NN
against_PIN
Reddy-Cheminor_NN
and_PHC
Dr_NN
In_PIN
April_NN
2005_CD
,_,
the_DT
Group_NN
commenced_VBD
an_DT
action_NOMZ
in_PIN
the_DT
US_FPP1
District_NN
Reddys_NN
Laboratories_NN
._.
Dr_NN
Reddy_NN
had_VBD [PEAS]
certified_VBN [PUBV]
invalidity_NOMZ
of_PIN
three_CD
patents_NN
Court_NN
for_PIN
the_DT
District_NN
of_PIN
Delaware_NN
against_PIN
Teva_NN
Pharmaceutical_NN
USA_NN
for_PIN
ondansetron_NN
,_,
the_DT
active_JJ
ingredient_NN
in_PIN
Zofran_NN
tablets_NN
,_,
including_VBG [PRESP]
the_DT
Inc._NN
alleging_VBG [PUBV] [WZPRES]
infringement_NOMZ
of_PIN
the_DT
Groups_NN
compound_VPRT
patent_NN
for_PIN
compound_NN
patent_NN
that_TSUB
expired_VBD
in_PIN
July_NN
2005_CD
and_CC
two_CD
method_NN
of_PIN
use_NN
ropinirole_NN
hydrochloride_NN
the_DT
active_JJ
ingredient_NN
in_PIN
Requip_NN
and_CC
a_DT
patents_NN
,_,
the_DT
later_TIME
of_PIN
which_WDT [PIRE]
expires_VPRT
in_PIN
December_NN
2006_CD
,_,
in_PIN
both_DT
method_NN
of_PIN
use_NN
patent_NN
for_PIN
treatment_NOMZ
of_PIN
Parkinsons_NN
disease_NN
,_,
both_DT
of_PIN
instances_NN
taking_VBG [WZPRES]
into_PIN
account_NN
the_DT
extension_NN
for_PIN
paediatric_JJ
exclusivity_NOMZ
._.
which_WDT [SERE]
are_VPRT [PASS]
listed_VBN
in_PIN
the_DT
FDA_NN
Orange_NN
Book_NN
._.
The_DT
compound_NN
patent_NN
In_PIN
July_NN
2003_CD
,_,
the_DT
Group_NN
filed_VBD
an_DT
action_NOMZ
against_PIN
Dr_NN
Reddys_NN
Laboratories_NN
expires_VPRT
in_PIN
December_NN
2007_CD
and_CC
the_DT
method_NN
of_PIN
use_NN
patent_NN
in_PIN
May_POMD
in_PIN
the_DT
same_JJ
district_NN
court_NN
for_PIN
infringement_NOMZ
of_PIN
the_DT
Groups_NN
patents_NN
2008_CD
._.
The_DT
defendant_NN
filed_VBD
an_DT
ANDA_NN
with_PIN
the_DT
FDA_NN
with_PIN
a_DT
certification_NOMZ
related_VBN [WZPAST]
to_PIN
the_DT
orally_RB
disintegrating_VBG
tablet_NN
presentation_NOMZ
of_PIN
Zofran_NN
._.
In_PIN
of_PIN
invalidity_NOMZ
and_PHC
non-infringement_NOMZ
of_PIN
those_DEMO
patents_NN
._.
FDA_NN
approval_NN
of_PIN
October_NN
2003_CD
,_,
the_DT
Group_NN
filed_VBD
an_DT
action_NOMZ
against_PIN
West-ward_JJ
that_THAC
ANDA_NN
is_VPRT [PASS]
stayed_VBN
until_IN
the_DT
earlier_TIME
of_PIN
August_NN
2007_CD
or_CC
resolution_NOMZ
of_PIN
Pharmaceuticals_NN
,_,
Inc._NN
in_PIN
the_DT
same_JJ
district_NN
court_NN
for_PIN
infringement_NOMZ
of_PIN
the_DT
patent_NN
infringement_NOMZ
action_NOMZ
._.
The_DT
case_NN
is_VPRT
progressing_VBG
through_PIN
the_DT
the_DT
Groups_NN
patents_NN
related_VBN [WZPAST]
to_PIN
an_DT
injectable_JJ
presentation_NOMZ
of_PIN
Zofran_NN
._.
Both_DT
the_DT
Dr_NN
Reddy_NN
disintegrating_VBG [WZPRES]
tablet_NN
case_NN
and_CC
the_DT
West-ward_JJ
case_NN
were_VBD [PASS]
consolidated_VBN
with_PIN
the_DT
earlier_TIME
Dr_NN
Reddy_NN
case_NN
._.
Valtrex_NN
In_PIN
May_POMD
2003_CD
,_,
the_DT
Group_NN
commenced_VBD
an_DT
action_NOMZ
in_PIN
the_DT
US_FPP1
District_NN
Prior_RB
to_PIN
the_DT
trial_NN
both_DT
Reddy-Cheminor_NN
and_CC
West-ward_JJ
withdrew_VBD
their_TPP3
Court_NN
for_PIN
the_DT
District_NN
of_PIN
New_NN
Jersey_NN
against_PIN
Ranbaxy_NN
Laboratories_NN
,_,
challenge_NN
to_PIN
the_DT
compound_NN
patent_NN
._.
The_DT
trial_NN
over_IN
infringement_NOMZ
and_CC
alleging_VBG [PUBV]
infringement_NOMZ
of_PIN
the_DT
Groups_NN
compound_VPRT
patent_NN
for_PIN
valaciclovir_NN
,_,
validity_NOMZ
of_PIN
the_DT
Groups_NN
method_NN
of_PIN
use_NN
and_PHC
process_NN
patents_NN
was_VBD [BEMA]
the_DT
active_JJ
ingredient_NN
in_PIN
Valtrex_NN
._.
The_DT
completed_VBN
in_PIN
June_NN
2004_CD
and_CC
closing_VBG
arguments_NOMZ
were_VBD [PASS]
heard_VBN [PRIV]
in_PIN
May_POMD
defendant_NN
has_VPRT [PEAS]
filed_VBN
an_DT
ANDA_NN
with_PIN
the_DT
FDA_NN
with_PIN
a_DT
certification_NOMZ
the_DT
2005_CD
but_CC
as_IN
of_PIN
the_DT
date_NN
of_PIN
this_DEMO
report_NN
no_SYNE
decision_NN
has_VPRT [PEAS]
been_VBN
Groups_NN
compound_VPRT
patent_NN
was_VBD [BEMA]
invalid_PRED
or_CC
not_XX0
infringed_VBN
._.
2004_CD
,_,
Ranbaxy_NN
filed_VBD
a_DT
motion_NOMZ
for_PIN
partial_JJ
summary_NN
judgment_NOMZ
on_PIN
In_PIN
March_NN
2002_CD
,_,
the_DT
Group_NN
filed_VBD
a_DT
similar_JJ
action_NOMZ
against_PIN
Teva_NN
grounds_NN
that_TOBJ
the_DT
patent_NN
was_VBD [BEMA]
invalid_PRED
for_PIN
being_VBG [BEMA]
in_PIN
public_JJ
use_NN
more_EMPH
Pharmaceuticals_NN
USA_NN
Inc._NN
in_PIN
the_DT
US_FPP1
District_NN
Court_NN
for_PIN
the_DT
District_NN
of_PIN
than_PIN
one_CD
year_NN
before_IN
the_DT
filing_NN
of_PIN
the_DT
patent_NN
application_NOMZ
and_CC
the_DT
Delaware_NN
alleging_VBG [PUBV] [WZPRES]
infringement_NOMZ
of_PIN
the_DT
two_CD
method_NN
of_PIN
use_NN
patents_NN
for_PIN
Group_NN
filed_VBD
a_DT
motion_NOMZ
that_TOBJ
the_DT
patent_NN
was_VBD [BEMA]
not_XX0
invalid_PRED
on_PIN
those_DEMO
ondansetron_NN
._.
Teva_NN
had_VBD [PEAS]
certified_VBN [PUBV]
invalidity_NOMZ
or_CC
non-infringement_NOMZ
of_PIN
the_DT
grounds_NN
._.
In_PIN
March_NN
2005_CD
,_,
the_DT
court_NN
ruled_VBD [SUAV]
in_PIN
the_DT
Groups_NN
favor_VPRT
that_DEMO
two_CD
method_NN
of_PIN
use_NN
patents_NN
._.
Teva_NN
did_VBD
not_XX0
challenge_VB
the_DT
compound_NN
the_DT
patent_NN
was_VBD [BEMA]
not_XX0
invalid_PRED
on_PIN
those_DEMO
grounds_NN
._.
The_DT
trial_NN
judge_NN
ruled_VBD [SUAV]
in_PIN
the_DT
Groups_NN
favor_VPRT
,_,
upholding_VBG [PRESP]
the_DT
completed_VBN
._.
validity_NOMZ
of_PIN
the_DT
method_NN
of_PIN
use_NN
patents_NN
._.
Following_VBG [PRESP]
an_DT
appeal_NN
by_PIN
Teva_NN
to_PIN
Wellbutrin_NN
XL_NN
the_DT
CAFC_NN
,_,
the_DT
parties_NN
reached_VBD
a_DT
settlement_NOMZ
agreement_NOMZ
,_,
the_DT
terms_NN
of_PIN
In_PIN
December_NN
2004_CD
,_,
Biovail_NN
commenced_VBD
actions_NOMZ
in_PIN
the_DT
US_FPP1
District_NN
Court_NN
which_WDT [WHSUB]
are_VPRT [BEMA]
confidential_PRED
._.
for_PIN
the_DT
Central_NN
District_NN
of_PIN
California_NN
against_PIN
Anchen_NN
Pharmaceuticals_NN
and_CC
in_PIN
the_DT
US_FPP1
District_NN
Court_NN
for_PIN
the_DT
Southern_NN
District_NN
of_PIN
Florida_NN
against_PIN
In_PIN
January_NN
2003_CD
,_,
the_DT
Group_NN
commenced_VBD
an_DT
action_NOMZ
against_PIN
Kali_NN
Abrika_NN
Pharmaceuticals_NN
,_,
in_PIN
each_QUAN
case_NN
alleging_VBG [PUBV] [WZPRES]
infringement_NOMZ
of_PIN
Biovail_NN
Laboratories_NN
now_TIME
Par_NN
Pharmaceutical_NN
Company_NN
in_PIN
the_DT
US_FPP1
District_NN
formulation_NOMZ
patents_NN
for_PIN
Wellbutrin_NN
XL_NN
._.
In_PIN
April_NN
2005_CD
,_,
Biovail_NN
filed_VBD
an_DT
Court_NN
for_PIN
the_DT
District_NN
of_PIN
New_NN
Jersey_NN
involving_VBG [WZPRES]
orally_RB
disintegrating_VBG
action_NOMZ
in_PIN
the_DT
US_FPP1
District_NN
Court_NN
for_PIN
the_DT
Eastern_NN
District_NN
of_PIN
Pennsylvania_NN
Zofran_NN
tablets_NN
._.
The_DT
trial_NN
judge_NN
denied_VBD [PUBV]
Kalis_NN
summary_NN
judgment_NOMZ
motion_NOMZ
against_PIN
Impax_NN
Laboratories_NN
for_PIN
infringement_NOMZ
of_PIN
the_DT
same_JJ
patents_NN
._.
and_ANDC
granted_VBN [SUAV]
the_DT
Groups_NN
summary_NN
judgment_NOMZ
motions_NOMZ
in_PIN
June_NN
2005_CD
Those_DEMO
patents_NN
expire_VPRT
in_PIN
2018_CD
._.
Each_QUAN
of_PIN
Anchen_NN
,_,
Abrika_NN
and_PHC
Impax_NN
had_VBD
and_CC
July_NN
2005_CD
,_,
affirming_VBG [PUBV] [PRESP]
the_DT
validity_NOMZ
of_PIN
the_DT
Groups_NN
method_NN
of_PIN
use_NN
filed_VBD
an_DT
ANDA_NN
with_PIN
the_DT
FDA_NN
with_PIN
a_DT
certification_NOMZ
of_PIN
invalidity_NOMZ
or_CC
nonpatents_NN
and_CC
holding_VBG [PRIV] [THATD]
that_DEMP
Kalis_NN
proposed_VBD [SUAV] [THATD]
generic_JJ
product_NN
would_PRMD
infringement_NOMZ
of_PIN
the_DT
Biovail_NN
patents_NN
._.
The_DT
Group_NN
is_VPRT [BEMA]
the_DT
licensee_NN
under_IN
infringe_VB
those_DEMO
patents_NN
._.
Kali_NN
has_VPRT [PEAS]
filed_VBN
a_DT
notice_NN
of_PIN
appeal_NN
with_PIN
the_DT
CAFC_NN
those_DEMO
patents_NN
._.
A_DT
hearing_GER
on_PIN
Abrikas_NN
motion_NOMZ
for_PIN
summary_NN
judgment_NOMZ
from_PIN
that_DEMO
ruling_NN
._.
As_IN
of_PIN
the_DT
date_NN
of_PIN
this_DEMO
report_NN
no_SYNE
hearing_GER
date_NN
for_PIN
that_DEMP
was_VBD [PASS]
heard_VBN [PRIV]
in_PIN
November_NN
2005_CD
but_CC
as_IN
of_PIN
the_DT
date_NN
of_PIN
this_DEMO
report_NN
no_SYNE
appeal_NN
has_VPRT [PEAS]
been_VBN [PASS]
announced_VBN [PUBV]
._.
A_DT
trial_NN
date_NN
for_PIN
Biovails_NN
action_NOMZ
against_PIN
In_PIN
June_NN
2003_CD
,_,
the_DT
Group_NN
commenced_VBD
an_DT
action_NOMZ
in_PIN
the_DT
US_FPP1
District_NN
Anchen_NN
has_VPRT [PEAS]
been_VBN [PASS]
set_VBN
for_PIN
12th_JJ
September_NN
2006_CD
._.
The_DT
Group_NN
is_VPRT [BEMA]
not_XX0
a_DT
Court_NN
for_PIN
the_DT
District_NN
of_PIN
New_NN
Jersey_NN
against_PIN
the_DT
Faulding_GER
party_NN
to_PIN
any_QUAN
of_PIN
those_DEMO
actions_NOMZ
._.
In_PIN
September_NN
2005_CD
,_,
Biovail_NN
commenced_VBD
Pharmaceutical_NN
Company_NN
now_TIME
Mayne_NN
Pharma_NN
Inc._NN
alleging_VBG [PUBV] [WZPRES]
actions_NOMZ
in_PIN
the_DT
US_FPP1
District_NN
Court_NN
for_PIN
the_DT
Southern_NN
District_NN
of_PIN
New_NN
York_NN
infringement_NOMZ
of_PIN
the_DT
two_CD
method_NN
of_PIN
use_NN
patents_NN
for_PIN
ondansetron_NN
._.
against_PIN
Watson_NN
Laboratories_NN
alleging_VBG [PUBV] [WZPRES]
infringement_NOMZ
of_PIN
the_DT
Biovail_NN
Faulding_GER
did_VBD
not_XX0
challenge_VB
the_DT
compound_NN
patent_NN
._.
That_DEMO
case_NN
,_,
as_IN
of_PIN
the_DT
formulation_NOMZ
patents_NN
._.
The_DT
Group_NN
remains_VPRT
a_DT
third_JJ
party_NN
counterclaim_NN
date_NN
of_PIN
this_DEMO
report_NN
,_,
has_VPRT [PEAS]
been_VBN [PASS]
stayed_VBN
pending_VBG
decisions_NN
in_PIN
the_DT
defendant_NN
based_VBN [WZPAST]
on_PIN
listing_GER
activities_NOMZ
associated_VBN [WZPAST]
with_PIN
the_DT
FDA_NN
Orange_NN
Reddy_NN
West-ward_JJ
case_NN
._.
Additional_JJ
actions_NOMZ
remain_VPRT
pending_VBG
against_PIN
generic_JJ
distributors_NN
which_WDT [WHOBJ]
In_PIN
December_NN
2005_CD
,_,
Andrx_NN
Pharmaceuticals_NN
filed_VBD
an_DT
action_NOMZ
against_PIN
the_DT
are_VPRT
asserting_VBG [PUBV]
that_THVC
their_TPP3
products_NN
do_VPRT
not_XX0
infringe_VB
the_DT
Groups_NN
patent_NN
Group_NN
in_PIN
the_DT
US_FPP1
District_NN
Court_NN
for_PIN
the_DT
Southern_NN
District_NN
of_PIN
Florida_NN
,_,
for_PIN
a_DT
reduced_VBN
crystal_NN
size_NN
of_PIN
ondansetron_NN
,_,
which_WDT [SERE]
expires_VPRT
in_PIN
March_NN
alleging_VBG [PUBV] [WZPRES]
that_THVC
the_DT
manufacture_NN
,_,
importation_NOMZ
and_PHC
sale_NN
of_PIN
the_DT
150_CD
mg_NN
2012_CD
taking_VBG
into_PIN
account_NN
the_DT
extension_NN
for_PIN
paediatric_JJ
exclusivity_NOMZ
,_,
but_CC
Wellbutrin_NN
XL_NN
product_NN
infringes_VPRT
a_DT
patent_NN
issued_VBN [WZPAST]
to_PIN
Andrx_NN
in_PIN
June_NN
2005_CD
which_WDT
are_VPRT
not_XX0
asserting_VBG [PUBV]
invalidity_NOMZ
or_CC
non-infringement_NOMZ
of_PIN
the_DT
Groups_NN
and_CC
asking_VBG [SUAV]
for_PIN
treble_JJ
damages_NN
,_,
attorneys_NN
fees_NN
and_CC
that_THVC
the_DT
Group_NN
and_CC
compound_JJ
patents_NN
or_CC
emesis_NN
use_NN
patent_NN
._.
others_NN
acting_VBG [WZPRES]
in_PIN
concert_NN
with_PIN
it_PIT
be_VB [PASS]
enjoined_VBN [SUAV]
._.
The_DT
case_NN
is_VPRT [BEMA]
in_PIN
its_PIT
early_TIME
stages_NN
._.
GSK_NN
Annual_JJ
Report_NN
2005_CD
159_CD
FINANCIAL_NN
STATEMENTS_NOMZ
Notes_NN
to_PIN
the_DT
financial_JJ
statements_NOMZ
continued_VBD
The_DT
federal_JJ
cases_NN
have_VPRT [PEAS]
been_VBN [PASS]
consolidated_VBN
in_PIN
a_DT
multidistrict_JJ
litigation_NOMZ
41_CD
Legal_NN
proceedings_GER
continued_VBD
proceeding_VBG
in_PIN
the_DT
US_FPP1
District_NN
Court_NN
for_PIN
the_DT
District_NN
of_PIN
Washington_NN
._.
The_DT
Product_NN
liability_NOMZ
judge_NN
responsible_JJ
for_PIN
those_DEMO
proceedings_GER
has_VPRT [PEAS]
denied_VBN [PUBV]
class_NN
certification_NOMZ
and_CC
struck_VBD
all_QUAN
class_NN
allegations_NOMZ
in_PIN
the_DT
federal_JJ
personal_JJ
injury_NN
and_PHC
Paxil_NN
consumer_NN
refund_NN
class_NN
actions_NOMZ
._.
Class_NN
certification_NOMZ
has_VPRT [PEAS]
been_VBN [PASS]
denied_VBN [PUBV]
in_PIN
The_DT
Group_NN
has_VPRT [PEAS]
received_VBN
lawsuits_NN
and_PHC
claims_NN
filed_VBN [WZPAST]
on_PIN
behalf_NN
of_PIN
patients_NN
California_NN
state_NN
court_NN
and_CC
a_DT
Pennsylvania_NN
state_NN
court_NN
putative_JJ
class_NN
alleging_VBG [PUBV] [WZPRES]
that_THVC
they_TPP3
have_VPRT [PEAS]
suffered_VBN
symptoms_NN
on_PIN
discontinuing_VBG
treatment_NOMZ
action_NOMZ
has_VPRT [PEAS]
been_VBN [PASS]
dismissed_VBN
,_,
leaving_VBG [PRESP]
no_SYNE
putative_JJ
class_NN
actions_NOMZ
pending_VBG [WZPRES]
with_PIN
Paxil_NN
paroxetine_NN
._.
Separately_RB
,_,
the_DT
Group_NN
has_VPRT [PEAS]
received_VBN
lawsuits_NN
and_CC
against_PIN
the_DT
Group_NN
in_PIN
this_DEMO
litigation_NOMZ
._.
A_DT
substantial_JJ
number_NN
of_PIN
cases_NN
in_PIN
claims_NN
that_TOBJ
patients_NN
who_WP [WHSUB]
had_VBD [PEAS]
commenced_VBN
Paxil_NN
treatment_NOMZ
committed_VBN
which_WDT
the_DT
Group_NN
or_CC
other_JJ
manufacturers_NN
are_VPRT
defendants_NN
have_VPRT [PEAS]
reached_VBN
or_CC
attempted_VBN
to_TO
commit_VB
suicide_NN
and_CC
or_CC
acts_NN
of_PIN
violence_NN
._.
There_EX
are_VPRT
also_RB
trial_NN
in_PIN
state_NN
and_CC
federal_JJ
courts_NN
._.
Manufacturers_NN
have_VPRT
for_PIN
the_DT
most_EMPH
part_NN
private_JJ
consumer_NN
lawsuits_NN
alleging_VBG [PUBV] [WZPRES]
that_THVC
the_DT
Group_NN
concealed_VBD
and_PHC
received_VBD
favourable_JJ
outcomes_NN
at_PIN
trial_NN
._.
misrepresented_VBN
data_NN
from_PIN
paediatric_JJ
clinical_JJ
trials_NN
of_PIN
Paxil_NN
._.
The_DT
Group_NN
has_VPRT [PEAS]
received_VBN
lawsuits_NN
filed_VBN [WZPAST]
in_PIN
state_NN
and_CC
federal_JJ
courts_NN
in_PIN
the_DT
Baycol_NN
In_PIN
August_NN
2001_CD
,_,
Bayer_NN
AG_NN
withdrew_VBD
Baycol_NN
cerivastatin_NN
sodium_NN
USA_NN
and_PHC
Canada_NN
on_PIN
behalf_NN
of_PIN
thousands_NN
of_PIN
plaintiffs_NN
,_,
including_VBG
worldwide_NN
in_PIN
light_NN
of_PIN
reports_NN
of_PIN
adverse_JJ
events_NN
,_,
including_VBG
deaths_NN
,_,
purported_JJ
class_NN
actions_NOMZ
,_,
alleging_VBG [PUBV]
that_THVC
paroxetine_JJ
the_DT
active_JJ
ingredient_NN
involving_VBG [WZPRES]
rhabdomyolosis_NN
._.
GSK_NN
had_VBD [PEAS]
participated_VBN
in_PIN
the_DT
marketing_GER
of_PIN
in_PIN
Paxil_NN
is_VPRT [BEMA]
addictive_PRED
and_CC
causes_VPRT
dependency_NN
and_PHC
withdrawal_NN
reactions_NOMZ
._.
Baycol_NN
in_PIN
the_DT
USA_NN
pursuant_JJ
to_PIN
a_DT
co-promotion_NOMZ
agreement_NOMZ
with_PIN
Bayer_NN
Plaintiffs_NN
sought_VBD
remedies_NN
including_VBG [WZPRES]
compensatory_JJ
,_,
punitive_JJ
and_ANDC
which_WDT
was_VBD [BEMA]
the_DT
licence_NN
holder_NN
and_PHC
manufacturer_NN
of_PIN
the_DT
product_NN
._.
statutory_JJ
damages_NN
and_CC
the_DT
cost_NN
of_PIN
a_DT
fund_NN
for_PIN
medical_JJ
monitoring_GER
._.
In_PIN
2003_CD
,_,
a_DT
federal_JJ
judge_NN
in_PIN
the_DT
US_FPP1
District_NN
Court_NN
for_PIN
the_DT
Central_NN
District_NN
Following_VBG [WZPRES]
the_DT
withdrawal_NN
,_,
Bayer_NN
and_PHC
GSK_NN
have_VPRT [PEAS]
been_VBN [PASS]
named_VBN
as_IN
of_PIN
California_NN
denied_VBD [PUBV]
class_NN
action_NOMZ
certifications_NOMZ
for_PIN
a_DT
nationwide_JJ
class_NN
defendants_NN
in_PIN
thousands_NN
of_PIN
lawsuits_NN
filed_VBN [WZPAST]
in_PIN
state_NN
and_CC
federal_JJ
courts_NN
and_CC
a_DT
California_NN
statewide_JJ
class_NN
as_IN
to_PIN
cases_NN
filed_VBN [WZPAST]
in_PIN
federal_JJ
court_NN
in_PIN
that_DEMO
in_PIN
the_DT
USA_NN
on_PIN
behalf_NN
of_PIN
both_DT
individuals_NN
and_CC
putative_JJ
classes_NN
of_PIN
former_JJ
district_NN
._.
Subsequently_TIME
,_,
on_PIN
petition_NOMZ
from_PIN
plaintiffs_NN
counsel_NN
all_QUAN
federal_JJ
Baycol_NN
users_NN
._.
A_DT
number_NN
of_PIN
the_DT
suits_NN
allege_VPRT [PUBV]
that_THVC
the_DT
plaintiffs_NN
have_VPRT
court_NN
cases_NN
were_VBD [PASS]
transferred_VBN
to_PIN
that_DEMO
District_NN
Court_NN
for_PIN
consolidation_NOMZ
suffered_VBD
personal_JJ
injuries_NN
,_,
including_VBG
rhabdomyolosis_NN
,_,
from_PIN
the_DT
use_NN
of_PIN
in_PIN
Multidistrict_NN
Litigation_NOMZ
MDL_NN
._.
In_PIN
January_NN
2006_CD
,_,
the_DT
Group_NN
concluded_VBD [PRIV]
Baycol_NN
._.
Others_NN
claim_VPRT [PUBV]
that_THVC
persons_NN
who_WP [WHSUB]
took_VBD
Baycol_NN
,_,
although_CONC
not_XX0
settlement_NOMZ
of_PIN
more_EMPH
than_PIN
90_CD
%_NN
of_PIN
the_DT
pending_VBG
claims_NN
based_VBN [WZPAST]
on_PIN
injured_JJ
,_,
may_POMD
be_VB [BEMA]
at_PIN
risk_NN
of_PIN
future_JJ
injury_NN
or_CC
may_POMD
have_VB [PEAS]
suffered_VBN
economic_JJ
symptoms_NN
on_PIN
discontinuing_VBG
Paxil_NN
treatment_NOMZ
._.
Most_EMPH
of_PIN
the_DT
pending_VBG
damages_NN
from_PIN
purchasing_VBG
and_PHC
using_VBG
Baycol_NN
._.
Plaintiffs_NN
seek_VPRT
remedies_NN
purported_JJ
class_NN
actions_NOMZ
are_VPRT
being_VBG [PASS]
dismissed_VBN
as_IN
part_NN
of_PIN
the_DT
settlement_NOMZ
._.
including_VBG
compensatory_JJ
,_,
punitive_JJ
and_PHC
statutory_JJ
damages_NN
and_PHC
creation_NOMZ
The_DT
Group_NN
did_VBD
not_XX0
,_,
as_IN
part_NN
of_PIN
the_DT
settlement_NOMZ
,_,
admit_VPRT [PUBV]
any_QUAN
liability_NOMZ
with_PIN
of_PIN
funds_NN
for_PIN
medical_JJ
monitoring_GER
._.
respect_NN
to_PIN
the_DT
allegations_NOMZ
in_PIN
any_QUAN
of_PIN
the_DT
suits_NN
._.
Litigation_NOMZ
in_PIN
respect_NN
of_PIN
GSK_NN
and_PHC
Bayer_NN
Corporation_NOMZ
,_,
the_DT
principal_JJ
US_FPP1
subsidiary_NN
of_PIN
Bayer_NN
AG_NN
,_,
the_DT
balance_NN
of_PIN
the_DT
lawsuits_NN
,_,
including_VBG [PRESP]
a_DT
purported_JJ
class_NN
action_NOMZ
in_PIN
have_VPRT [PEAS]
signed_VBN
an_DT
allocation_NOMZ
agreement_NOMZ
under_IN
which_WDT
Bayer_NN
Corporation_NOMZ
California_NN
state_NN
court_NN
,_,
continues_VPRT
._.
has_VPRT [PEAS]
agreed_VBN [SUAV] [PUBV]
to_TO
pay_VB
95_CD
%_NN
of_PIN
all_QUAN
settlements_NOMZ
and_CC
compensatory_JJ
damages_NN
The_DT
Group_NN
has_VPRT [PEAS]
received_VBN
numerous_JJ
claims_NN
and_PHC
lawsuits_NN
alleging_VBG [PUBV] [WZPRES]
that_THVC
judgments_NOMZ
with_PIN
each_QUAN
party_NN
retaining_VBG [WZPRES]
responsibility_NOMZ
for_PIN
its_PIT
own_JJ
treatment_NOMZ
with_PIN
Paxil_NN
has_VPRT [PEAS]
caused_VBN
homicidal_JJ
or_CC
suicidal_JJ
behavior_NN
attorneys_NN
fees_NN
and_CC
any_QUAN
punitive_JJ
damages_NN
._.
The_DT
federal_JJ
cases_NN
have_VPRT [PEAS]
exhibited_VBN
by_PIN
users_NN
of_PIN
the_DT
product_NN
._.
None_INPR
of_PIN
these_DEMP
are_VPRT
or_CC
purport_VPRT
to_TO
be_VB [PASS]
been_VBN [PASS]
consolidated_VBN
in_PIN
a_DT
multidistrict_JJ
litigation_NOMZ
proceeding_GER
in_PIN
the_DT
US_FPP1
class_NN
actions_NOMZ
._.
In_PIN
January_NN
2005_CD
,_,
the_DT
FDA_NN
approved_VBD
a_DT
black_JJ
box_NN
warning_VBG [PUBV] [WZPRES]
District_NN
Court_NN
for_PIN
the_DT
District_NN
of_PIN
Minnesota_NN
._.
Numerous_JJ
cases_NN
are_VPRT
about_IN
suicidal_JJ
thoughts_NN
or_CC
behavior_NN
in_PIN
paediatric_JJ
patients_NN
and_CC
other_JJ
scheduled_VBN
for_PIN
trial_NN
in_PIN
state_NN
and_CC
federal_JJ
courts_NN
during_PIN
2006_CD
._.
To_TO
date_VB
two_CD
strengthened_VBD
warnings_GER
for_PIN
selective_JJ
serotonin_NN
reuptake_NN
inhibitor_NN
SSRI_NN
statewide_JJ
class_NN
actions_NOMZ
have_VPRT [PEAS]
been_VBN [PASS]
certified_VBN [PUBV]
a_DT
medical_JJ
monitoring_GER
products_NN
,_,
including_VBG
Paxil_NN
,_,
as_IN
a_DT
class_NN
._.
case_NN
in_PIN
Pennsylvania_NN
and_CC
a_DT
Consumer_NN
Fraud_NN
and_PHC
Deceptive_NN
Business_NOMZ
Practices_NN
Act_NN
case_NN
in_PIN
Illinois_NN
._.
The_DT
medical_JJ
monitoring_GER
action_NOMZ
was_VBD [BYPA]
Avandia_NN
dismissed_VBN [WZPAST]
by_PIN
the_DT
court_NN
on_PIN
summary_NN
judgment_NOMZ
._.
Another_DT
class_NN
action_NOMZ
,_,
The_DT
Group_NN
has_VPRT [PEAS]
received_VBN
lawsuits_NN
and_PHC
claims_NN
filed_VBN [WZPAST]
in_PIN
state_NN
and_CC
federal_JJ
in_PIN
which_WDT [PIRE]
GSK_NN
was_VBD [PASS]
not_XX0
named_VBN
as_IN
a_DT
defendant_NN
,_,
has_VPRT [PEAS]
been_VBN [PASS]
certified_VBN [PUBV]
in_PIN
courts_NN
in_PIN
the_DT
USA_NN
on_PIN
behalf_NN
of_PIN
numerous_JJ
patients_NN
alleging_VBG [PUBV] [WZPRES]
that_THVC
Oklahoma_NN
._.
A_DT
substantial_JJ
number_NN
of_PIN
claims_NN
for_PIN
death_NN
or_CC
serious_JJ
injury_NN
rosiglitazone_NN
the_DT
active_JJ
ingredient_NN
in_PIN
Avandia_NN
has_VPRT [PEAS]
caused_VBN
congestive_JJ
have_VPRT [PEAS]
been_VBN [PASS]
settled_VBN
and_CC
many_QUAN
others_NN
alleging_VBG [PUBV] [WZPRES]
muscle_NN
aches_NN
and_PHC
pains_NN
heart_NN
failure_NN
or_CC
liver_NN
damage_NN
._.
None_INPR
of_PIN
the_DT
cases_NN
purports_VPRT
to_TO
be_VB [BEMA]
a_DT
class_NN
have_VPRT [PEAS]
been_VBN
voluntarily_RB
or_CC
involuntarily_RB
dismissed_VBN
._.
Most_EMPH
of_PIN
the_DT
cases_NN
are_VPRT [BEMA]
in_PIN
their_TPP3
early_TIME
stages_NN
._.
Phenylpropanolamine_NN
Following_VBG [WZPRES]
a_DT
report_NN
from_PIN
the_DT
Yale_NN
Haemorrhagic_NN
Stroke_NN
Project_NN
that_TSUB
found_VBD [PRIV]
a_DT
suggestion_NOMZ
of_PIN
an_DT
association_NOMZ
between_PIN
first_JJ
use_NN
of_PIN
phenylpropanolamine_NN
PPA_NN
decongestant_JJ
and_PHC
hemorrhagic_JJ
stroke_NN
,_,
the_DT
Group_NN
and_CC
most_EMPH
other_JJ
manufacturers_NN
have_VPRT [SPAU] [PEAS]
voluntarily_RB
withdrawn_VBN
consumer_NN
healthcare_NN
products_NN
in_PIN
which_WDT [PIRE]
PPA_NN
was_VBD [BEMA]
an_DT
active_JJ
ingredient_NN
._.
Since_OSUB
the_DT
PPA_NN
product_NN
withdrawal_NN
the_DT
Group_NN
has_VPRT [PEAS]
been_VBN [PASS]
named_VBN
as_IN
a_DT
defendant_NN
in_PIN
numerous_JJ
personal_JJ
injury_NN
and_PHC
class_NN
action_NOMZ
lawsuits_NN
filed_VBN [WZPAST]
in_PIN
state_NN
and_CC
federal_JJ
courts_NN
alleging_VBG [PUBV] [WZPRES]
personal_JJ
injury_NN
or_CC
increased_VBN
risk_NN
of_PIN
injury_NN
from_PIN
use_NN
of_PIN
products_NN
containing_VBG [WZPRES]
PPA_NN
and_CC
unfair_JJ
and_PHC
deceptive_JJ
business_NOMZ
practices_NN
._.
Plaintiffs_NN
seek_VPRT
remedies_NN
including_VBG [WZPRES]
compensatory_JJ
and_PHC
punitive_JJ
damages_NN
and_PHC
refunds_NN
._.
GSK_NN
Annual_JJ
Report_NN
2005_CD
160_CD
FINANCIAL_NN
STATEMENTS_NOMZ
Notes_NN
to_PIN
the_DT
financial_JJ
statements_NOMZ
continued_VBD
Sales_NN
and_PHC
marketing_GER
and_PHC
regulation_NOMZ
41_CD
Legal_NN
proceedings_GER
continued_VBD
Fen-Phen_NN
Marketing_GER
and_PHC
promotion_NOMZ
In_PIN
1997_CD
,_,
the_DT
FDA_NN
became_VBD
aware_JJ
of_PIN
reports_NN
of_PIN
cardiac_JJ
valvular_JJ
In_PIN
February_NN
2004_CD
,_,
GSK_NN
received_VBD
a_DT
subpoena_NN
from_PIN
the_DT
US_FPP1
Attorneys_NN
problems_NN
in_PIN
individuals_NN
for_PIN
whom_WP [PIRE]
fenfluramine_VPRT
or_CC
dexfenfluramine_VPRT
office_NN
in_PIN
Colorado_NN
regarding_VBG [WZPRES]
the_DT
Groups_NN
sales_NN
and_CC
promotional_JJ
alone_RB
or_CC
in_PIN
combination_NOMZ
with_PIN
phentermine_NN
was_VBD [PASS]
prescribed_VBN
as_IN
part_NN
of_PIN
practices_NN
relating_VBG [WZPRES]
to_PIN
nine_CD
of_PIN
its_PIT
largest_JJ
selling_GER
products_NN
for_PIN
the_DT
period_NN
a_DT
regimen_NN
of_PIN
weight_NN
reduction_NOMZ
and_CC
requested_VBD [SUAV]
the_DT
voluntary_JJ
from_PIN
January_NN
1997_CD
to_PIN
the_DT
present_NN
._.
In_CONJ
particular_NULL
the_DT
government_NOMZ
has_VPRT
withdrawal_NN
of_PIN
fenfluramine_NN
and_PHC
dexfenfluramine_NN
from_PIN
the_DT
market_NN
._.
inquired_VBN
about_IN
alleged_JJ
promotion_NOMZ
of_PIN
these_DEMO
drugs_NN
for_PIN
off-label_JJ
uses_NN
as_IN
The_DT
reports_NN
of_PIN
cardiac_JJ
valvular_JJ
problems_NN
and_CC
the_DT
subsequent_JJ
well_NN
as_IN
Group_NN
sponsored_VBD
continuing_VBG
medical_JJ
education_NOMZ
programs_NN
,_,
withdrawal_NN
of_PIN
those_DEMO
products_NN
from_PIN
the_DT
market_NN
spawned_VBD
numerous_JJ
other_JJ
speaker_NN
events_NN
,_,
special_JJ
issue_NN
boards_NN
,_,
advisory_JJ
boards_NN
,_,
speaker_NN
product_NN
liability_NOMZ
lawsuits_NN
filed_VBN [WZPAST]
against_PIN
the_DT
manufacturers_NN
and_PHC
training_GER
programs_NN
,_,
clinical_JJ
studies_NN
,_,
and_ANDC
related_JJ
grants_NN
,_,
fees_NN
,_,
travel_NN
distributors_NN
of_PIN
fenfluramine_NN
,_,
dexfenfluramine_NN
and_PHC
phentermine_NN
._.
Although_CONC
the_DT
original_JJ
subpoena_NN
issued_VBN [WZPAST]
from_PIN
the_DT
one_CD
of_PIN
a_DT
number_NN
of_PIN
manufacturers_NN
of_PIN
phentermine_NN
,_,
the_DT
Group_NN
US_FPP1
Attorneys_NN
office_NN
in_PIN
Colorado_NN
,_,
the_DT
scope_NN
of_PIN
the_DT
inquiry_NN
is_VPRT
remains_VPRT
a_DT
defendant_NN
in_PIN
approximately_RB
two_CD
hundred_CD
of_PIN
several_QUAN
nationwide_JJ
._.
The_DT
Group_NN
is_VPRT
co-operating_VBG
with_PIN
the_DT
investigation_NOMZ
and_CC
thousand_CD
lawsuits_NN
that_TSUB
were_VBD [PASS]
filed_VBN
in_PIN
various_JJ
state_NN
and_CC
federal_JJ
district_NN
providing_VBG [WZPRES]
the_DT
requested_VBN [SUAV]
information_NOMZ
._.
The_DT
Group_NN
had_VBD [SPAU] [PEAS]
earlier_TIME
responded_VBD
courts_NN
in_PIN
the_DT
USA_NN
against_PIN
the_DT
Group_NN
and_CC
other_JJ
defendants_NN
._.
to_PIN
an_DT
October_NN
2002_CD
letter_NN
from_PIN
the_DT
FDAs_NN
Division_NN
of_PIN
Drug_NN
Marketing_GER
,_,
Advertising_GER
and_PHC
Communication_NOMZ
requesting_VBG [SUAV] [WZPRES]
information_NOMZ
on_PIN
the_DT
Most_EMPH
of_PIN
the_DT
lawsuits_NN
seek_VPRT
relief_NN
including_VBG [WZPRES]
some_QUAN
combination_NOMZ
of_PIN
Groups_NN
alleged_VBN [PUBV]
promotion_NOMZ
of_PIN
Wellbutrin_NN
SR_NN
for_PIN
off-label_JJ
use_NN
._.
compensatory_JJ
and_PHC
punitive_JJ
damages_NN
,_,
medical_JJ
monitoring_GER
and_PHC
refunds_NN
In_PIN
June_NN
2005_CD
,_,
the_DT
Group_NN
and_CC
other_JJ
pharmaceutical_JJ
manufacturers_NN
for_PIN
purchases_NN
of_PIN
drugs_NN
._.
In_PIN
1997_CD
,_,
the_DT
Judicial_NN
Panel_NN
on_PIN
Multidistrict_NN
received_VBD
a_DT
letter_NN
from_PIN
the_DT
Senate_NN
Finance_NN
Committee_NN
in_PIN
which_WDT [PIRE]
the_DT
Litigation_NOMZ
issued_VBD
an_DT
order_NN
consolidating_VBG [WZPRES]
and_PHC
transferring_VBG
all_QUAN
federal_JJ
Committee_NN
expressed_VBD
concern_NN
that_TOBJ
educational_JJ
grants_NN
were_VBD
being_VBG
actions_NOMZ
to_PIN
the_DT
District_NN
Court_NN
for_PIN
the_DT
Eastern_NN
District_NN
of_PIN
Pennsylvania_NN
._.
improperly_RB
used_VBN
to_TO
promote_VB
drug_NN
products_NN
and_CC
requesting_VBG [SUAV]
that_THVC
each_QUAN
That_DEMO
court_NN
approved_VBD
a_DT
global_JJ
settlement_NOMZ
proposed_VBN [SUAV] [WZPAST]
by_PIN
defendant_NN
company_NN
provide_VPRT
detailed_JJ
information_NOMZ
and_PHC
documents_NOMZ
about_IN
its_PIT
use_NN
Wyeth_NN
,_,
which_WDT [SERE]
sold_VBD
fenfluramine_NN
and_PHC
dexfenfluramine_NN
._.
The_DT
settlement_NOMZ
,_,
of_PIN
educational_JJ
grants_NN
._.
In_PIN
January_NN
2006_CD
,_,
the_DT
Group_NN
and_CC
the_DT
same_JJ
subsequently_TIME
approved_VBN
by_PIN
the_DT
Third_NN
Circuit_NN
Court_NN
of_PIN
Appeals_NN
,_,
does_VPRT
not_XX0
manufacturers_NN
received_VBD
a_DT
second_JJ
letter_NN
from_PIN
the_DT
Committee_NN
asking_VBG [SUAV] [WZPRES]
include_VPRT
any_QUAN
of_PIN
the_DT
phentermine_NN
defendants_NN
,_,
including_VBG [PRESP]
the_DT
Group_NN
._.
for_PIN
additional_JJ
information_NOMZ
on_PIN
the_DT
Groups_NN
internal_JJ
grant_NN
approval_NN
Individual_JJ
plaintiffs_NN
may_POMD
elect_VB
to_TO
opt_VB
out_PIN
of_PIN
the_DT
class_NN
settlement_NOMZ
and_PHC
process_NN
,_,
grants_NN
to_PIN
medical_JJ
physician_NN
professional_JJ
organizations_NOMZ
,_,
pursue_VB
their_TPP3
claims_NN
individually_RB
and_CC
tens_NN
of_PIN
thousands_NN
of_PIN
plaintiffs_NN
academic_JJ
institutions_NOMZ
or_CC
state_NN
agencies_NN
to_TO
support_VB
journal_NN
articles_NN
and_CC
have_VPRT [PEAS]
elected_VBN
to_TO
do_VB
so_RB
._.
Wyeth_NN
continues_VPRT
to_TO
settle_VB
individual_JJ
state_NN
court_NN
other_JJ
publications_NOMZ
and_PHC
grants_NN
to_PIN
patient_JJ
education_NOMZ
or_CC
advocacy_NN
cases_NN
before_IN
trial_NN
and_CC
the_DT
Group_NN
continues_VPRT
to_TO
be_VB [PASS]
dismissed_VBN
from_PIN
groups_NN
._.
The_DT
Group_NN
is_VPRT
co-operating_VBG
in_PIN
the_DT
Committees_NN
investigation_NOMZ
lawsuits_NN
as_IN
they_TPP3
are_VPRT [BYPA]
settled_VBN
by_PIN
Wyeth_NN
._.
and_ANDC
providing_VBG
the_DT
requested_VBN [SUAV]
information_NOMZ
._.
Thimerosal_NN
GSK_NN
,_,
along_IN
with_PIN
a_DT
number_NN
of_PIN
other_JJ
pharmaceutical_JJ
companies_NN
,_,
has_VPRT
On_PIN
22nd_JJ
February_NN
2006_CD
,_,
the_DT
FDA_NN
approved_VBD
an_DT
ANDA_NN
filed_VBN [WZPAST]
by_PIN
Roxane_NN
been_VBN [PASS]
named_VBN
as_IN
a_DT
defendant_NN
in_PIN
numerous_JJ
individual_JJ
personal_JJ
injury_NN
Laboratories_NN
for_PIN
a_DT
generic_JJ
form_NN
of_PIN
Flonase_NN
nasal_JJ
spray_NN
and_CC
denied_VBD [PUBV]
two_CD
lawsuits_NN
in_PIN
state_NN
and_CC
federal_JJ
district_NN
courts_NN
in_PIN
the_DT
USA_NN
alleging_VBG [PUBV] [WZPRES]
that_THVC
citizens_NN
petitions_NOMZ
that_TSUB
had_VBD [PEAS]
been_VBN [BYPA]
filed_VBN
by_PIN
the_DT
Group_NN
concerning_VBG [WZPRES]
thimerosal_JJ
,_,
a_DT
preservative_JJ
used_VBN
in_PIN
the_DT
manufacture_NN
of_PIN
vaccines_NN
,_,
causes_VPRT
regulatory_JJ
criteria_NN
that_TSUB
should_NEMD
be_VB [PASS]
applied_VBN
in_PIN
determining_VBG [SUAV] [PRIV]
whether_IN [WHCL]
neurodevelopmental_JJ
disorders_NN
and_CC
other_JJ
injuries_NN
,_,
including_VBG
autism_NN
._.
proposed_VBN [SUAV] [THATD]
generic_JJ
products_NN
are_VPRT [BEMA]
bioequivalent_PRED
to_TO
,_,
and_ANDC
have_VPRT
the_DT
same_JJ
Three_CD
of_PIN
the_DT
cases_NN
are_VPRT [BEMA]
purported_JJ
class_NN
actions_NOMZ
although_CONC
there_EX
has_VPRT
quality_NOMZ
control_NN
standards_NN
as_RB
,_,
Flonase_NN
._.
On_PIN
23rd_JJ
February_NN
the_DT
US_FPP1
District_NN
been_VBN [BEMA]
no_SYNE
determination_NOMZ
whether_IN
any_QUAN
of_PIN
those_DEMO
cases_NN
will_PRMD
be_VB [PASS]
permitted_VBN
Court_NN
for_PIN
the_DT
District_NN
of_PIN
Maryland_NN
granted_VBD [SUAV]
a_DT
temporary_JJ
restraining_VBG
to_TO
proceed_VB
as_IN
a_DT
class_NN
action_NOMZ
._.
A_DT
number_NN
of_PIN
purported_JJ
class_NN
actions_NOMZ
in_PIN
order_NN
suspending_VBG [WZPRES]
the_DT
FDAs_NN
approval_NN
of_PIN
the_DT
Roxane_NN
ANDA_NN
for_PIN
ten_CD
other_JJ
jurisdictions_NOMZ
have_VPRT [PEAS]
been_VBN [PASS]
withdrawn_VBN
or_CC
dismissed_VBN
._.
The_DT
Group_NN
will_PRMD
file_VB
a_DT
motion_NOMZ
for_PIN
a_DT
preliminary_JJ
injunction_NOMZ
to_PIN
remedies_NN
including_VBG [WZPRES]
compensatory_JJ
,_,
punitive_JJ
and_PHC
statutory_JJ
damages_NN
continue_VPRT
the_DT
interim_JJ
relief_NN
granted_VBN [SUAV] [WZPAST]
in_PIN
the_DT
temporary_JJ
restraining_VBG
order_NN
and_CC
the_DT
cost_NN
of_PIN
a_DT
fund_NN
for_PIN
medical_JJ
monitoring_GER
and_PHC
research_NN
._.
As_IN
of_PIN
the_DT
and_CC
will_PRMD
request_VB [SUAV]
a_DT
ruling_NN
on_PIN
such_JJ
motion_NOMZ
before_IN
the_DT
temporary_JJ
date_NN
of_PIN
this_DEMO
report_NN
there_EX
are_VPRT
no_SYNE
cases_NN
scheduled_VBN [WZPAST]
for_PIN
trial_NN
in_PIN
2006_CD
._.
restraining_VBG
order_NN
as_IN
it_PIT
may_POMD
be_VB [PASS]
extended_VBN
for_PIN
up_RB
to_PIN
an_DT
additional_JJ
ten_CD
days_NN
expires_VPRT
._.
Lotronex_NN
In_PIN
February_NN
2003_CD
,_,
the_DT
Verona_NN
Public_NN
Prosecutor_NN
commenced_VBD
a_DT
criminal_JJ
Following_VBG
the_DT
voluntary_JJ
withdrawal_NN
of_PIN
Lotronex_NN
in_PIN
the_DT
USA_NN
in_PIN
investigation_NOMZ
into_PIN
GSKs_NN
sales_NN
and_PHC
marketing_GER
practices_NN
in_PIN
Italy_NN
._.
Specific_JJ
November_NN
2000_CD
a_DT
number_NN
of_PIN
lawsuits_NN
have_VPRT [PEAS]
been_VBN [PASS]
filed_VBN
against_PIN
the_DT
areas_NN
of_PIN
investigation_NOMZ
include_VPRT
medical_JJ
education_NOMZ
programs_NN
,_,
clinical_JJ
Group_NN
in_PIN
state_NN
and_CC
federal_JJ
district_NN
courts_NN
,_,
including_VBG
individual_JJ
personal_JJ
studies_NN
and_PHC
congresses_NN
as_RB
well_RB
as_IN
the_DT
interaction_NOMZ
between_PIN
GSK_NN
injury_NN
actions_NOMZ
and_CC
purported_JJ
class_NN
actions_NOMZ
asserting_VBG [PUBV] [WZPRES]
product_NN
liability_NOMZ
representatives_NN
and_PHC
physicians_NN
._.
Similar_JJ
issues_NN
are_VPRT
being_VBG [BYPA]
investigated_VBN
by_PIN
and_CC
consumer_NN
fraud_NN
claims_NN
._.
Plaintiffs_NN
seek_VPRT
remedies_NN
including_VBG [WZPRES]
the_DT
Bari_NN
public_JJ
prosecutor_NN
._.
The_DT
USSecurities_NOMZ
and_PHC
Exchange_NN
compensatory_JJ
,_,
punitive_JJ
and_PHC
statutory_JJ
damages_NN
._.
The_DT
class_NN
previously_TIME
Commission_NN
SEC_NN
staff_NN
has_VPRT [PEAS]
initiated_VBN
an_DT
informal_JJ
investigation_NOMZ
into_PIN
certified_VBN [PUBV]
in_PIN
West_NN
Virginia_NN
has_VPRT [PEAS]
been_VBN [PASS]
decertified_VBN
and_CC
the_DT
action_NOMZ
has_VPRT [PEAS]
been_VBN [BEMA]
the_DT
allegations_NOMZ
._.
The_DT
Group_NN
is_VPRT
co-operating_VBG
with_PIN
all_QUAN
these_DEMO
investigations_NOMZ
._.
A_DT
large_JJ
number_NN
of_PIN
claims_NN
brought_VBD
following_VBG
the_DT
withdrawal_NN
have_VPRT [SPAU] [PEAS]
now_TIME
been_VBN [PASS]
settled_VBN
._.
Lotronex_NN
was_VBD [PASS]
reintroduced_VBN
in_PIN
the_DT
USA_NN
in_PIN
2002_CD
In_PIN
February_NN
2006_CD
,_,
the_DT
Group_NN
received_VBD
a_DT
subpoena_NN
from_PIN
the_DT
SEC_NN
in_PIN
subject_JJ
to_PIN
a_DT
risk_NN
management_NOMZ
plan_NN
imposing_VBG [WZPRES]
additional_JJ
protections_NOMZ
respect_NN
of_PIN
the_DT
Groups_NN
participation_NOMZ
in_PIN
the_DT
United_NN
Nations_NOMZ
Oil_NN
for_PIN
Food_NN
around_PLACE
the_DT
prescribing_GER
and_PHC
dispensing_GER
of_PIN
Lotronex_NN
._.
The_DT
Group_NN
is_VPRT
co-operating_VBG
with_PIN
the_DT
SEC_NN
and_CC
providing_VBG
documents_NOMZ
responsive_JJ
to_PIN
the_DT
subpoena_NN
._.
GSK_NN
Annual_JJ
Report_NN
2005_CD
161_CD
FINANCIAL_NN
STATEMENTS_NOMZ
Notes_NN
to_PIN
the_DT
financial_JJ
statements_NOMZ
continued_VBD
Paxil_NN
Seroxat_NN
41_CD
Legal_NN
proceedings_GER
continued_VBD
Following_VBG
announcement_NOMZ
of_PIN
the_DT
New_NN
York_NN
State_NN
Attorney_NN
Generals_NN
Average_NN
wholesale_JJ
price_NN
office_NN
of_PIN
the_DT
states_NN
lawsuit_NN
,_,
subsequently_TIME
settled_VBN
in_PIN
August_NN
2004_CD
,_,
GSK_NN
has_VPRT [PEAS]
responded_VBN
to_PIN
subpoenas_NN
from_PIN
the_DT
Office_NN
of_PIN
the_DT
Inspector_NN
alleging_VBG [PUBV] [WZPRES]
failure_NN
to_TO
disclose_VB [PUBV]
data_NN
on_PIN
the_DT
use_NN
of_PIN
Paxil_NN
in_PIN
children_NN
and_PHC
General_NN
of_PIN
the_DT
US_FPP1
Department_NOMZ
of_PIN
Health_NN
and_PHC
Human_NN
Services_NN
HHS_NN
,_,
adolescents_NN
,_,
similar_JJ
cases_NN
,_,
some_QUAN
of_PIN
which_WDT [PIRE]
purport_VPRT
to_TO
be_VB
class_NN
actions_NOMZ
,_,
the_DT
US_FPP1
Department_NOMZ
of_PIN
Justice_NN
and_CC
the_DT
states_NN
of_PIN
Texas_NN
and_PHC
California_NN
have_VPRT [PEAS]
been_VBN [PASS]
filed_VBN
in_PIN
state_NN
and_CC
federal_JJ
and_PHC
Canadian_JJ
courts_NN
by_PIN
private_JJ
in_PIN
connection_NOMZ
with_PIN
allegations_NOMZ
that_TOBJ
pharmaceutical_JJ
companies_NN
,_,
plaintiffs_NN
._.
The_DT
Group_NN
is_VPRT
responding_VBG
to_PIN
discovery_NN
requests_NN
in_PIN
those_DEMO
cases_NN
._.
including_VBG
GSK_NN
,_,
have_VPRT [PEAS]
violated_VBN
federal_JJ
fraud_NN
and_PHC
abuse_NN
laws_NN
such_JJ
as_IN
the_DT
Federal_NN
False_NN
Claims_NN
Act_NN
and_CC
,_,
with_PIN
respect_NN
to_PIN
Texas_NN
and_PHC
California_NN
,_,
In_PIN
the_DT
UK_NN
an_DT
investigation_NOMZ
remains_VPRT
pending_VBG
by_PIN
the_DT
UK_NN
Medicines_NN
and_CC
comparable_JJ
state_NN
laws_NN
as_CONJ
a_NULL
result_NULL
of_PIN
the_DT
way_NN
average_JJ
wholesale_JJ
price_NN
Healthcare_NN
products_NN
Regulatory_NN
Agency_NN
MHRA_NN
to_TO
determine_VB [SUAV] [PRIV]
AWPSNNP
was_VBD [PASS]
determined_VBN [SUAV] [PRIV]
and_PHC
reported_VBN [PUBV]
for_PIN
certain_JJ
drugs_NN
and_CC
the_DT
way_NN
whether_IN
the_DT
Group_NN
has_VPRT [PEAS]
complied_VBN
with_PIN
its_PIT
pharmacovigilence_NN
the_DT
Medicare_NN
and_PHC
Medicaid_NN
programs_NN
reimburse_VPRT
for_PIN
those_DEMO
drugs_NN
._.
obligations_NOMZ
in_PIN
reporting_VBG [PUBV]
data_NN
from_PIN
clinical_JJ
trials_NN
for_PIN
Seroxat_NN
Paxil_NN
in_PIN
In_PIN
September_NN
2005_CD
,_,
the_DT
Group_NN
reached_VBD
a_DT
civil_JJ
settlement_NOMZ
with_PIN
the_DT
US_FPP1
children_NN
and_PHC
adolescents_NN
._.
Department_NOMZ
of_PIN
Justice_NN
,_,
the_DT
US_FPP1
Attorney_NN
for_PIN
the_DT
District_NN
of_PIN
Cidra_NN
,_,
Puerto_NN
Rico_NN
manufacturing_VBG [WZPRES]
site_NN
Massachusetts_NN
and_CC
the_DT
Office_NN
of_PIN
the_DT
Inspector_NN
General_NN
for_PIN
HHS_NN
._.
The_DT
Following_VBG
FDA_NN
inspections_NOMZ
in_PIN
October_NN
2003_CD
and_CC
November_NN
2004_CD
Group_NN
agreed_VBD [SUAV] [PUBV]
to_TO
pay_VB
the_DT
government_NOMZ
a_DT
civil_JJ
settlement_NOMZ
of_PIN
$_$
149_CD
which_WDT
resulted_VBD
in_PIN
observations_NOMZ
of_PIN
possible_JJ
deficiencies_NN
in_PIN
million_CD
._.
As_IN
part_NN
of_PIN
the_DT
settlement_NOMZ
the_DT
corporate_JJ
integrity_NOMZ
agreement_NOMZ
manufacturing_VBG [WZPRES]
practices_NN
at_PIN
the_DT
Groups_NN
manufacturing_VBG [WZPRES]
facility_NOMZ
in_PIN
Cidra_NN
,_,
which_WDT [SERE]
the_DT
Group_NN
signed_VBD
in_PIN
April_NN
2003_CD
in_PIN
connection_NOMZ
with_PIN
a_DT
prior_JJ
Puerto_NN
Rico_NN
,_,
in_PIN
March_NN
2005_CD
the_DT
FDA_NN
halted_VBD
distribution_NOMZ
of_PIN
supplies_NN
of_PIN
government_NOMZ
investigation_NOMZ
of_PIN
Medicaid_NN
rebate_NN
issues_NN
was_VBD [PASS]
amended_VBN
to_PIN
Paxil_NN
CR_NN
and_PHC
Avandamet_NN
due_JJ
to_TO
manufacturing_VBG
issues_NN
._.
The_DT
FDA_NN
address_NN
issues_NN
raised_VBN [WZPAST]
in_PIN
the_DT
course_NN
of_PIN
this_DEMO
investigation_NOMZ
._.
observations_NOMZ
related_VBN [WZPAST]
to_PIN
certain_JJ
aspects_NN
of_PIN
production_NOMZ
controls_NN
,_,
process_NN
validation_NOMZ
and_PHC
laboratory_NN
investigations_NOMZ
._.
Subsequent_JJ
to_PIN
the_DT
initial_JJ
subpoenas_NN
,_,
several_QUAN
states_NN
through_PIN
their_TPP3
respective_JJ
attorneys_NN
general_JJ
and_CC
several_QUAN
counties_NN
in_PIN
New_NN
York_NN
state_NN
The_DT
Cidra_NN
site_NN
is_VPRT [PASS]
engaged_VBN
in_PIN
tableting_GER
and_PHC
packaging_GER
for_PIN
a_DT
range_NN
of_PIN
filed_VBN
civil_JJ
lawsuits_NN
in_PIN
state_NN
and_CC
federal_JJ
court_NN
against_PIN
GSK_NN
and_CC
several_QUAN
GSK_NN
products_NN
primarily_RB
for_PIN
the_DT
US_FPP1
market_NN
including_VBG [WZPRES]
Paxil_NN
,_,
Paxil_NN
CR_NN
,_,
other_JJ
drug_NN
companies_NN
._.
The_DT
actions_NOMZ
claim_VPRT [PUBV]
,_,
on_PIN
behalf_NN
of_PIN
the_DT
states_NN
as_IN
Coreg_NN
,_,
Avandia_NN
and_PHC
Avandamet_NN
._.
In_PIN
April_NN
2005_CD
,_,
the_DT
Group_NN
reached_VBD
payers_NN
and_CC
on_PIN
behalf_NN
of_PIN
in-state_JJ
patients_NN
as_IN
consumers_NN
,_,
damages_NN
and_PHC
agreement_NOMZ
with_PIN
the_DT
FDA_NN
on_PIN
a_DT
Consent_NN
Decree_NN
._.
The_DT
Consent_NN
Decree_NN
restitution_NOMZ
due_JJ
to_PIN
AWPSbased_JJ
price_NN
reporting_GER
for_PIN
an_DT
undefined_JJ
set_NN
of_PIN
provides_VPRT
for_PIN
an_DT
independent_JJ
expert_NN
to_TO
review_VB
manufacturing_VBG
pharmaceutical_JJ
products_NN
covered_VBN [WZPAST]
by_PIN
the_DT
states_NN
Medicaid_NN
processes_VPRT
at_PIN
the_DT
site_NN
for_PIN
compliance_NN
with_PIN
FDA_NN
Good_NN
Manufacturing_GER
programs_NN
._.
In_CONJ
addition_NULL
,_,
private_JJ
payer_NN
class_NN
action_NOMZ
lawsuits_NN
have_VPRT [PEAS]
been_VBN
Practice_NN
GMP_NN
requirements_NOMZ
._.
As_IN
provided_VBN
in_PIN
the_DT
Consent_NN
Decree_NN
,_,
the_DT
filed_VBN
against_PIN
GSK_NN
in_PIN
several_QUAN
federal_JJ
district_NN
and_PHC
state_NN
courts_NN
._.
All_QUAN
the_DT
Group_NN
provided_VBD
a_DT
report_NN
to_PIN
the_DT
FDA_NN
on_PIN
the_DT
deficiencies_NN
identified_VBN [WZPAST]
in_PIN
federal_JJ
cases_NN
have_VPRT [PEAS]
been_VBN [PASS]
consolidated_VBN
in_PIN
a_DT
multidistrict_JJ
litigation_NOMZ
this_DEMO
review_NN
,_,
setting_VBG [PRESP]
out_PIN
a_DT
corrective_JJ
plan_NN
and_PHC
timetable_NN
for_PIN
completion_NOMZ
._.
proceeding_VBG [PRESP]
in_PIN
the_DT
US_FPP1
District_NN
Court_NN
for_PIN
the_DT
District_NN
of_PIN
Massachusetts_NN
._.
FDA_NN
inspectors_NN
recently_TIME
conducted_VBD
a_DT
general_JJ
GMP_NN
inspection_NOMZ
and_CC
In_PIN
August_NN
2005_CD
,_,
the_DT
judge_NN
in_PIN
that_DEMO
MDL_NN
proceeding_GER
granted_VBN [SUAV] [WZPAST]
in_PIN
part_NN
follow-up_NN
to_PIN
the_DT
Groups_NN
report_NN
._.
In_PIN
January_NN
2006_CD
,_,
the_DT
FDA_NN
issued_VBD
a_DT
and_CC
denied_VBN [PUBV]
in_PIN
part_NN
the_DT
private-payer_NN
plaintiffs_NN
motion_NOMZ
for_PIN
class_NN
Form_NN
483_CD
,_,
listing_VBG [PRESP]
five_CD
observations_NOMZ
that_TSUB
were_VBD [PASS]
made_VBN
during_PIN
the_DT
certification_NOMZ
,_,
thereby_RB
narrowing_VBG
the_DT
scope_NN
of_PIN
the_DT
class_NN
claim_NN
._.
Fact_NN
inspection_NOMZ
to_PIN
which_WDT [PIRE]
the_DT
Group_NN
responded_VBD
in_PIN
February_NN
._.
Those_DEMO
discovery_NN
in_PIN
that_DEMO
proceeding_GER
closed_VBD
as_RB
to_PIN
the_DT
Group_NN
at_PIN
the_DT
end_NN
of_PIN
observations_NOMZ
were_VBD [BEMA]
consistent_PRED
with_PIN
the_DT
findings_GER
of_PIN
the_DT
independent_JJ
August_NN
2005_CD
and_CC
expert_JJ
discovery_NN
is_VPRT
under_IN
way_NN
._.
Discovery_NN
is_VPRT [BEMA]
expert_PRED
and_CC
effectively_RB
already_RB
included_VBN
as_IN
part_NN
of_PIN
the_DT
Groups_NN
proceeding_VBG [WZPRES]
in_PIN
some_QUAN
of_PIN
the_DT
suits_NN
filed_VBN [WZPAST]
by_PIN
state_NN
attorneys_NN
general_JJ
in_PIN
remediation_NOMZ
plan_NN
for_PIN
the_DT
site_NN
._.
The_DT
Group_NN
remains_VPRT
fully_AMP
committed_VBN
to_PIN
state_NN
courts_NN
._.
working_VBG [PRESP]
co-operatively_RB
with_PIN
the_DT
FDA_NN
to_TO
address_VB
any_QUAN
issues_NN
in_PIN
a_DT
timely_JJ
Nominal_JJ
pricing_GER
fashion_NN
._.
The_DT
Group_NN
has_VPRT [PEAS]
resumed_VBN
manufacture_NN
of_PIN
products_NN
at_PIN
the_DT
site_NN
._.
The_DT
Group_NN
responded_VBD
to_PIN
two_CD
letter_NN
requests_NN
from_PIN
the_DT
US_FPP1
Senate_NN
No_SYNE
financial_JJ
penalties_NN
have_VPRT [PEAS]
been_VBN [PASS]
imposed_VBN
under_IN
the_DT
Consent_NN
Decree_NN
._.
Committee_NN
on_PIN
Finance_NN
,_,
dated_VBN
April_NN
2004_CD
and_CC
February_NN
2005_CD
,_,
for_PIN
The_DT
Consent_NN
Decree_NN
allows_VPRT [SUAV]
for_PIN
potential_JJ
future_JJ
penalties_NN
up_IN
to_PIN
a_DT
documents_NOMZ
and_PHC
information_NOMZ
relating_VBG [WZPRES]
to_PIN
the_DT
nominal_JJ
price_NN
exception_NOMZ
maximum_NN
of_PIN
$_$
10_CD
million_CD
a_DT
year_NN
if_COND
the_DT
Group_NN
fails_VPRT
to_TO
meet_VB
the_DT
terms_NN
to_PIN
the_DT
best_JJ
price_NN
reporting_GER
requirements_NOMZ
under_IN
the_DT
Medicaid_NN
Drug_NN
of_PIN
the_DT
Decree_NN
._.
There_EX
has_VPRT [PEAS]
been_VBN
no_SYNE
further_JJ
activity_NOMZ
in_PIN
connection_NOMZ
with_PIN
this_DEMO
inquiry_NN
by_PIN
the_DT
Committee_NN
as_IN
to_PIN
the_DT
Group_NN
since_OSUB
September_NN
The_NN
Group_NN
was_VBD [SPAU] [PASS]
also_RB
required_VBN [SUAV]
to_TO
post_VB
a_DT
bond_NN
to_TO
ensure_VB [SUAV] [PRIV]
that_THVC
product_NN
2005_CD
._.
In_PIN
May_POMD
2004_CD
,_,
the_DT
Group_NN
was_VBD [BYPA]
advised_VBN
by_PIN
the_DT
US_FPP1
Department_NOMZ
of_PIN
previously_TIME
seized_VBN
by_PIN
the_DT
FDA_NN
was_VBD [SPAU] [PASS]
appropriately_RB
destroyed_VBN
or_CC
Justice_NN
that_TOBJ
they_TPP3
are_VPRT
investigating_VBG
certain_JJ
of_PIN
the_DT
Groups_NN
nominal_JJ
reconditioned_VBN
._.
The_DT
Group_NN
has_VPRT [PEAS]
met_VBN
all_QUAN
the_DT
requirements_NOMZ
of_PIN
the_DT
bond_NN
,_,
pricing_VBG
arrangements_NOMZ
to_TO
determine_VB [SUAV] [PRIV]
whether_IN [WHCL]
those_DEMO
arrangements_NOMZ
which_WDT [WHSUB]
expires_VPRT
in_PIN
March_NN
2006_CD
._.
qualify_VB
under_IN
the_DT
exception_NOMZ
to_PIN
the_DT
best_JJ
price_NN
reporting_GER
requirements_NOMZ
In_PIN
April_NN
2005_CD
,_,
the_DT
Group_NN
received_VBD
a_DT
subpoena_NN
from_PIN
the_DT
US_FPP1
Attorneys_NN
or_CC
violate_VPRT
civil_JJ
statutes_NN
or_CC
laws_NN
._.
The_DT
Group_NN
is_VPRT [BEMA]
co-operating_PRED
in_PIN
that_DEMO
Office_NN
in_PIN
Boston_NN
requesting_VBG [SUAV] [WZPRES]
production_NOMZ
of_PIN
records_NN
regarding_VBG [WZPRES]
investigation_NOMZ
and_CC
has_VPRT [PEAS]
provided_VBN
documents_NOMZ
and_PHC
information_NOMZ
to_PIN
the_DT
manufacturing_GER
at_PIN
the_DT
Cidra_NN
site_NN
covering_VBG [WZPRES]
the_DT
same_JJ
type_NN
of_PIN
information_NOMZ
Department_NOMZ
of_PIN
Justice_NN
regarding_VBG [WZPRES]
nominal_JJ
pricing_GER
arrangements_NOMZ
for_PIN
a_DT
as_IN
that_DEMP
collected_VBN
by_PIN
the_DT
US_FPP1
government_NOMZ
in_PIN
Puerto_NN
Rico_NN
in_PIN
2003_CD
._.
number_NN
of_PIN
the_DT
Groups_NN
products_NN
._.
GSK_NN
Annual_JJ
Report_NN
2005_CD
162_CD
FINANCIAL_NN
STATEMENTS_NOMZ
Notes_NN
to_PIN
the_DT
financial_JJ
statements_NOMZ
continued_VBD
Relafen_NN
41_CD
Legal_NN
proceedings_GER
continued_VBD
In_PIN
August_NN
2001_CD
,_,
the_DT
US_FPP1
District_NN
Court_NN
for_PIN
the_DT
District_NN
of_PIN
Massachusetts_NN
Anti-trust_NN
ruled_VBD [SUAV]
the_DT
Groups_NN
patent_NN
for_PIN
nabumetone_NN
Relafen_NN
invalid_JJ
for_PIN
anticipatory_JJ
art_NN
and_CC
unenforceable_JJ
on_PIN
the_DT
grounds_NN
of_PIN
inequitable_JJ
Paxil_NN
Seroxat_NN
conduct_NN
._.
In_PIN
August_NN
2002_CD
,_,
the_DT
CAGC_NN
issued_VBD
a_DT
decision_NN
affirming_VBG [PUBV] [WZPRES]
the_DT
In_PIN
the_DT
paroxetine_JJ
patent_NN
infringement_NOMZ
actions_NOMZ
brought_VBN [WZPAST]
by_PIN
the_DT
Group_NN
District_NN
Court_NN
judgment_NOMZ
of_PIN
invalidity_NOMZ
but_CC
declining_VBG
to_TO
rule_VB [SUAV]
on_PIN
the_DT
as_IN
described_VBN
under_IN
Intellectual_NN
property_NN
above_PLACE
,_,
Apotex_NN
,_,
Alphapharm_NN
,_,
judgment_NOMZ
of_PIN
inequitable_JJ
conduct_NN
._.
BASF_NN
and_PHC
Sumike_NN
have_VPRT [PEAS]
filed_VBN
anti-trust_JJ
and_PHC
unfair_JJ
competition_NOMZ
counterclaims_NN
against_PIN
the_DT
Group_NN
in_PIN
the_DT
US_FPP1
District_NN
Court_NN
for_PIN
the_DT
Following_VBG
the_DT
District_NN
Court_NN
decision_NN
,_,
anti-trust_JJ
claims_NN
alleging_VBG [PUBV] [WZPRES]
Eastern_NN
District_NN
of_PIN
Pennsylvania_NN
based_VBN [WZPAST]
on_PIN
allegations_NOMZ
that_TOBJ
the_DT
Group_NN
competitive_JJ
injury_NN
and_PHC
overcharges_NN
were_VBD [BYPA]
filed_VBN
by_PIN
Teva_NN
and_PHC
Eon_NN
monopolised_VBD
a_DT
market_NN
for_PIN
Paxil_NN
by_PIN
bringing_VBG
allegedly_RB
sham_JJ
patent_NN
Pharmaceuticals_NN
,_,
generic_JJ
manufacturers_NN
of_PIN
nabumetone_NN
,_,
by_PIN
litigation_NOMZ
and_CC
allegedly_RB
abusing_VBG
the_DT
regulatory_JJ
procedures_NN
for_PIN
the_DT
purported_JJ
classes_NN
of_PIN
direct_JJ
and_PHC
indirect_JJ
purchasers_NN
and_PHC
payers_NN
and_CC
by_PIN
listing_GER
of_PIN
patents_NN
in_PIN
the_DT
FDA_NN
Orange_NN
Book_NN
._.
Whilst_OSUB
the_DT
Apotex_NN
matter_NN
individual_JJ
retail_JJ
chains_NN
._.
All_QUAN
aspects_NN
of_PIN
this_DEMO
litigation_NOMZ
have_VPRT [PEAS]
been_VBN
remains_NN
in_PIN
the_DT
discovery_NN
stage_NN
,_,
the_DT
three_CD
other_JJ
actions_NOMZ
have_VPRT [PEAS]
been_VBN [PASS]
concluded_VBN [PRIV]
with_PIN
the_DT
exception_NOMZ
of_PIN
an_DT
appeal_NN
taken_VBN [WZPAST]
by_PIN
certain_JJ
indirect_JJ
stayed_VBN
._.
purchasers_NN
to_PIN
the_DT
trial_NN
judges_NN
order_NN
giving_VBG [WZPRES]
final_JJ
approval_NN
to_PIN
the_DT
In_PIN
November_NN
2000_CD
,_,
the_DT
US_FPP1
Federal_NN
Trade_NN
Commission_NN
FTC_NN
staff_NN
settlement_NOMZ
with_PIN
that_DEMO
class_NN
._.
The_DT
appeal_NN
is_VPRT
pending_VBG
before_IN
the_DT
US_FPP1
Circuit_NN
advised_VBD
the_DT
Group_NN
that_TOBJ
they_TPP3
were_VBD
conducting_VBG
a_DT
non-public_JJ
Court_NN
of_PIN
Appeals_NN
for_PIN
the_DT
First_NN
Circuit_NN
._.
investigation_NOMZ
to_TO
determine_VB [SUAV] [PRIV]
whether_IN [WHCL]
the_DT
Group_NN
was_VBD
violating_VBG
Section_NOMZ
Canadian_JJ
importation_NOMZ
5_CD
of_PIN
the_DT
Federal_NN
Trade_NN
Commission_NN
Act_NN
by_PIN
monopolizing_VBG
or_CC
The_DT
Group_NN
,_,
along_IN
with_PIN
eight_CD
other_JJ
pharmaceutical_JJ
companies_NN
,_,
has_VPRT
attempting_VBG
to_TO
monopolize_VB
the_DT
market_NN
for_PIN
paroxetine_JJ
hydrochloride_NN
been_VBN [PASS]
named_VBN
in_PIN
seven_CD
purported_JJ
class_NN
action_NOMZ
lawsuits_NN
._.
Following_VBG [PRESP]
the_DT
by_PIN
preventing_VBG
generic_JJ
competition_NOMZ
to_PIN
Paxil_NN
and_CC
requested_VBD [SUAV]
the_DT
Group_NN
Groups_NN
actions_NOMZ
in_PIN
2003_CD
to_TO
reduce_VB
illegal_JJ
importation_NOMZ
of_PIN
prescription_NOMZ
to_TO
submit_VB [PUBV]
certain_JJ
information_NOMZ
in_PIN
connection_NOMZ
with_PIN
that_DEMO
investigation_NOMZ
._.
drugs_NN
from_PIN
Canada_NN
,_,
the_DT
lawsuits_NN
alleged_VBD [PUBV]
that_THVC
the_DT
companies_NN
entered_VBD
In_PIN
October_NN
2003_CD
the_DT
FTC_NN
closed_VBD
its_PIT
investigation_NOMZ
on_PIN
the_DT
basis_NN
of_PIN
its_PIT
into_PIN
an_DT
unlawful_JJ
conspiracy_NN
to_TO
prevent_VB
Canadian_JJ
pharmacies_NN
from_PIN
finding_VBG [PRIV]
that_THVC
no_SYNE
further_JJ
action_NOMZ
was_VBD [PASS]
warranted_VBN
._.
selling_VBG [PRESP]
their_TPP3
products_NN
to_PIN
US_FPP1
customers_NN
._.
Those_DEMO
lawsuits_NN
were_VBD [PASS]
consolidated_VBN
into_PIN
one_CD
action_NOMZ
before_IN
the_DT
US_FPP1
District_NN
Court_NN
for_PIN
the_DT
Following_VBG
public_JJ
reference_NN
to_PIN
the_DT
FTC_NN
investigation_NOMZ
regarding_VBG [WZPRES]
Paxil_NN
,_,
District_NN
of_PIN
Minnesota_NN
._.
The_DT
Groups_NN
motion_NOMZ
to_TO
dismiss_VB
the_DT
consolidated_JJ
purported_JJ
class_NN
actions_NOMZ
were_VBD [PASS]
filed_VBN
in_PIN
the_DT
US_FPP1
District_NN
Court_NN
for_PIN
the_DT
action_NOMZ
was_VBD [BYPA]
granted_VBN [SUAV]
by_PIN
the_DT
court_NN
and_CC
that_DEMO
decision_NN
was_VBD [PASS]
appealed_VBN
to_PIN
Eastern_NN
District_NN
of_PIN
Pennsylvania_NN
on_PIN
behalf_NN
of_PIN
indirect_JJ
purchasers_NN
based_VBN
the_DT
US_FPP1
Circuit_NN
Court_NN
of_PIN
Appeals_NN
for_PIN
the_DT
Eighth_NN
Circuit_NN
._.
As_IN
of_PIN
the_DT
date_NN
on_PIN
allegations_NOMZ
similar_JJ
to_PIN
those_DEMO
in_PIN
the_DT
anti-trust_JJ
counterclaims_NN
brought_VBN [WZPAST]
of_PIN
this_DEMO
report_NN
no_SYNE
date_NN
for_PIN
oral_JJ
argument_NOMZ
had_VBD [PEAS]
been_VBN [PASS]
announced_VBN [PUBV]
._.
Similar_JJ
actions_NOMZ
were_VBD [BYPA]
filed_VBN
by_PIN
the_DT
City_NOMZ
of_PIN
New_NN
York_NN
in_PIN
the_DT
Eastern_NN
District_NN
of_PIN
Pennsylvania_NN
and_CC
by_PIN
indirect_JJ
purchasers_NN
in_PIN
Florida_NN
,_,
In_PIN
relation_NOMZ
to_PIN
the_DT
same_JJ
matter_NN
,_,
the_DT
Minnesota_NN
state_NN
attorney_NN
general_JJ
California_NN
and_PHC
Minnesota_NN
._.
The_DT
Pennsylvania_NN
class_NN
actions_NOMZ
have_VPRT [PEAS]
been_VBN
has_VPRT [PEAS]
filed_VBN
a_DT
civil_JJ
investigative_JJ
demand_NN
and_CC
,_,
subsequently_TIME
,_,
a_DT
complaint_NN
settled_VBD
and_CC
the_DT
class_NN
settlements_NOMZ
have_VPRT [PEAS]
been_VBN [PASS]
approved_VBN
,_,
although_CONC
alleging_VBG [PUBV]
that_THVC
the_DT
Group_NN
has_VPRT [PEAS]
violated_VBN
state_NN
anti-trust_NN
and_CC
commercial_JJ
certain_JJ
objectors_NN
have_VPRT [PEAS]
appealed_VBN
the_DT
approval_NN
of_PIN
the_DT
indirect_JJ
purchaser_NN
laws_NN
._.
The_DT
Group_NN
has_VPRT [PEAS]
filed_VBN
a_DT
motion_NOMZ
to_TO
dismiss_VB
the_DT
complaint_NN
._.
The_DT
City_NOMZ
of_PIN
New_NN
York_NN
action_NOMZ
has_VPRT [PEAS]
been_VBN [PASS]
settled_VBN
,_,
the_DT
action_NOMZ
argument_NOMZ
on_PIN
that_DEMO
motion_NOMZ
was_VBD [PASS]
completed_VBN
in_PIN
November_NN
2005_CD
but_CC
as_RB
in_PIN
Minnesota_NN
and_CC
one_CD
of_PIN
the_DT
California_NN
actions_NOMZ
have_VPRT [PEAS]
been_VBN [PASS]
dismissed_VBN
of_PIN
the_DT
date_NN
of_PIN
this_DEMO
report_NN
no_SYNE
decision_NN
has_VPRT [PEAS]
been_VBN [PASS]
announced_VBN [PUBV]
._.
and_ANDC
the_DT
Florida_NN
action_NOMZ
and_CC
another_DT
California_NN
action_NOMZ
have_VPRT [PEAS]
been_VBN [PASS]
stayed_VBN
._.
The_DT
Group_NN
has_VPRT [SPAU] [PEAS]
also_RB
been_VBN [PASS]
named_VBN
as_IN
a_DT
defendant_NN
,_,
along_IN
with_PIN
thirteen_CD
The_DT
Group_NN
has_VPRT [SPAU] [PEAS]
also_RB
settled_VBN
similar_JJ
threatened_VBN
claims_NN
by_PIN
a_DT
group_NN
of_PIN
other_JJ
drug_NN
companies_NN
,_,
in_PIN
a_DT
state_NN
court_NN
action_NOMZ
in_PIN
California_NN
,_,
in_PIN
which_WDT [PIRE]
chain_NN
drug_NN
stores_NN
and_CC
has_VPRT [SPAU] [PEAS]
conditionally_RB
settled_VBN
threatened_VBN
claims_NN
by_PIN
the_DT
plaintiffs_NN
,_,
independent_JJ
pharmacies_NN
,_,
allege_VPRT [PUBV]
that_THVC
the_DT
defendants_NN
state_VPRT [PUBV]
attorneys_NN
general_JJ
,_,
but_CC
it_PIT
remains_VPRT
to_TO
be_VB [PASS]
seen_VBN [PRIV]
how_RB [WHCL]
many_QUAN
states_NN
unlawfully_RB
conspired_VBD
to_TO
keep_VB
prices_NN
artificially_RB
high_JJ
in_PIN
the_DT
USA_NN
to_PIN
the_DT
will_PRMD
join_VB
in_PIN
the_DT
settlement_NOMZ
._.
Similar_JJ
class_NN
actions_NOMZ
have_VPRT [PEAS]
been_VBN [PASS]
filed_VBN
in_PIN
detriment_NOMZ
of_PIN
the_DT
plaintiffs_NN
._.
The_DT
parties_NN
are_VPRT [PASS]
involved_VBN
in_PIN
extensive_JJ
provincial_JJ
courts_NN
in_PIN
Canada_NN
on_PIN
behalf_NN
of_PIN
direct_JJ
and_PHC
indirect_JJ
purchasers_NN
._.
A_DT
trial_NN
date_NN
has_VPRT [PEAS]
been_VBN [PASS]
set_VBN
for_PIN
25th_JJ
September_NN
2006_CD
._.
All_QUAN
those_DEMO
cases_NN
are_VPRT [BEMA]
in_PIN
their_TPP3
early_TIME
stages_NN
._.
In_PIN
October_NN
2005_CD
,_,
the_DT
Competition_NOMZ
Directorate_NN
of_PIN
the_DT
European_JJ
Wellbutrin_NN
SR_NN
Commission_NN
initiated_VBD
an_DT
inspection_NOMZ
concerning_VBG [WZPRES]
allegations_NOMZ
that_TOBJ
the_DT
In_PIN
December_NN
2004_CD
,_,
and_ANDC
January_NN
and_PHC
February_NN
2005_CD
,_,
lawsuits_NN
,_,
several_QUAN
Group_NN
has_VPRT [PEAS]
abused_VBN
a_DT
dominant_JJ
position_NOMZ
in_PIN
the_DT
marketplace_NN
concerning_VBG [WZPRES]
of_PIN
which_WDT [PIRE]
purported_JJ
to_TO
be_VB
class_NN
actions_NOMZ
,_,
were_VBD [PASS]
filed_VBN
in_PIN
the_DT
US_FPP1
District_NN
enforcement_NOMZ
of_PIN
its_PIT
intellectual_JJ
property_NN
rights_NN
,_,
litigation_NOMZ
surrounding_VBG [WZPRES]
Court_NN
for_PIN
the_DT
Eastern_NN
District_NN
of_PIN
Pennsylvania_NN
against_PIN
the_DT
Group_NN
on_PIN
regulatory_JJ
approvals_NN
and_PHC
marketing_GER
of_PIN
Seroxat_NN
in_PIN
Europe_NN
._.
The_DT
Group_NN
behalf_NN
of_PIN
direct_JJ
and_PHC
indirect_JJ
purchasers_NN
of_PIN
Wellbutrin_NN
SR._NN
._.
The_DT
is_VPRT [BEMA]
co-operating_JJ
fully_AMP
with_PIN
the_DT
Commission_NN
._.
complaints_NN
allege_VPRT [PUBV]
violations_NOMZ
of_PIN
US_FPP1
anti-trust_JJ
laws_NN
through_PIN
sham_NN
litigation_NOMZ
and_PHC
fraud_NN
on_PIN
the_DT
patent_NN
office_NN
by_PIN
the_DT
Group_NN
in_PIN
obtaining_VBG
and_PHC
enforcing_VBG
patents_NN
covering_VBG [WZPRES]
Wellbutrin_NN
SR._NN
._.
The_DT
complaints_NN
follow_VPRT
the_DT
introduction_NOMZ
of_PIN
generic_JJ
competition_NOMZ
to_PIN
Wellbutrin_NN
SR_NN
in_PIN
April_NN
2004_CD
after_IN
district_NN
and_CC
appellate_JJ
court_NN
rulings_GER
that_TOBJ
a_DT
generic_JJ
manufacturer_NN
did_VBD
not_XX0
infringe_VB
the_DT
Groups_NN
patents_NN
._.
Oral_JJ
argument_NOMZ
on_PIN
the_DT
Groups_NN
motion_NOMZ
to_TO
dismiss_VB
was_VBD [PASS]
completed_VBN
in_PIN
February_NN
2006_CD
but_CC
as_IN
of_PIN
the_DT
date_NN
of_PIN
this_DEMO
report_NN
no_SYNE
decision_NN
has_VPRT [PEAS]
been_VBN [PASS]
announced_VBN [PUBV]
._.
GSK_NN
Annual_JJ
Report_NN
2005_CD
163_CD
FINANCIAL_NN
STATEMENTS_NOMZ
Notes_NN
to_PIN
the_DT
financial_JJ
statements_NOMZ
continued_VBD
41_CD
Legal_JJ
proceedings_GER
continued_VBD
Commercial_JJ
and_PHC
corporate_JJ
Relenza_NN
In_PIN
May_POMD
2004_CD
,_,
Biota_NN
Holdings_GER
Limited_NN
filed_VBD
a_DT
complaint_NN
in_PIN
the_DT
Victorian_JJ
Supreme_NN
Court_NN
in_PIN
Australia_NN
alleging_VBG [PUBV] [WZPRES]
that_THVC
the_DT
Group_NN
had_VBD [PEAS]
failed_VBN
to_TO
fulfil_VB
its_PIT
development_NOMZ
,_,
promotion_NOMZ
and_PHC
production_NOMZ
obligations_NOMZ
for_PIN
zanamivir_NN
Relenza_NN
under_IN
the_DT
terms_NN
of_PIN
the_DT
licence_NN
agreement_NOMZ
between_PIN
the_DT
Group_NN
and_PHC
Biota_NN
._.
Biota_NN
is_VPRT
seeking_VBG
substantial_JJ
cash_NN
damages_NN
._.
The_DT
Group_NN
believes_VPRT [PRIV]
that_THVC
it_PIT
has_VPRT [PEAS]
adhered_VBN
to_PIN
its_PIT
obligations_NOMZ
under_IN
the_DT
licence_NN
agreement_NOMZ
._.
The_DT
parties_NN
are_VPRT [PASS]
involved_VBN
in_PIN
extensive_JJ
discovery_NN
._.
Securities_NOMZ
class_NN
action_NOMZ
In_PIN
September_NN
2005_CD
,_,
attorneys_NN
representing_VBG [WZPRES]
a_DT
purported_JJ
class_NN
of_PIN
purchasers_NN
of_PIN
GSK_NN
shares_NN
and_CC
American_JJ
Depositary_NN
Shares_NN
ADSs_NN
filed_VBD
a_DT
second_JJ
amended_VBN
securities_NOMZ
class_NN
action_NOMZ
complaint_NN
against_PIN
the_DT
Group_NN
in_PIN
the_DT
US_FPP1
District_NN
Court_NN
for_PIN
the_DT
Southern_NN
District_NN
of_PIN
New_NN
York_NN
alleging_VBG [PUBV] [WZPRES]
that_THVC
the_DT
Group_NN
violated_VBD
US_FPP1
securities_NOMZ
laws_NN
through_PIN
failure_NN
to_TO
disclose_VB [PUBV]
unfavourable_JJ
clinical_JJ
data_NN
from_PIN
studies_NN
on_PIN
Paxil_NN
,_,
misrepresentation_NOMZ
of_PIN
the_DT
remaining_VBG
patent_NN
protection_NOMZ
for_PIN
Paxil_NN
and_PHC
Augmentin_NN
and_PHC
violation_NOMZ
of_PIN
the_DT
Federal_NN
False_NN
Claims_NN
Act_NN
on_PIN
the_DT
basis_NN
of_PIN
the_DT
Groups_NN
recent_JJ
AWPSNNP
settlement_NOMZ
with_PIN
the_DT
government_NOMZ
._.
The_DT
Group_NN
has_VPRT [PEAS]
filed_VBN
a_DT
motion_NOMZ
to_TO
dismiss_VB
._.
Environmental_NN
matters_VPRT
GSK_NN
has_VPRT [PEAS]
been_VBN [PASS]
notified_VBN
of_PIN
its_PIT
potential_JJ
responsibility_NOMZ
relating_VBG [WZPRES]
to_PIN
past_JJ
operations_NOMZ
and_CC
its_PIT
past_JJ
waste_NN
disposal_NN
practices_NN
at_PIN
certain_JJ
sites_NN
,_,
primarily_RB
in_PIN
the_DT
USA_NN
._.
Some_QUAN
of_PIN
these_DEMO
matters_NN
are_VPRT [BEMA]
the_DT
subject_NN
of_PIN
litigation_NOMZ
,_,
including_VBG
proceedings_GER
initiated_VBN [WZPAST]
by_PIN
the_DT
US_FPP1
federal_JJ
or_CC
state_NN
governments_NOMZ
for_PIN
waste_NN
disposal_NN
site_NN
remediation_NOMZ
costs_NN
and_PHC
tort_NN
actions_NOMZ
brought_VBN [WZPAST]
by_PIN
private_JJ
parties_NN
._.
GSK_NN
has_VPRT [PEAS]
been_VBN [PASS]
advised_VBN
that_DEMO
it_PIT
may_POMD
be_VB [BEMA]
a_DT
responsible_JJ
party_NN
at_PIN
approximately_RB
28_CD
sites_NN
,_,
of_PIN
which_WDT [PIRE]
14_CD
appear_VPRT [SMP]
on_PIN
the_DT
National_NN
Priority_NOMZ
List_NN
created_VBN [WZPAST]
by_PIN
the_DT
Comprehensive_NN
Environmental_NN
Response_NN
Compensation_NOMZ
and_PHC
Liability_NOMZ
Act_NN
Superfund_NN
._.
These_DEMO
proceedings_GER
seek_VPRT
to_TO
require_VB [SUAV]
the_DT
operators_NN
of_PIN
hazardous_JJ
waste_NN
facilities_NOMZ
,_,
transporters_NN
of_PIN
waste_NN
to_PIN
the_DT
sites_NN
and_PHC
generators_NN
of_PIN
hazardous_JJ
waste_NN
disposed_VBD
of_PIN
at_PIN
the_DT
sites_NN
to_TO
clean_VB
up_RP
the_DT
sites_NN
or_CC
to_TO
reimburse_VB
the_DT
government_NOMZ
for_PIN
cleanup_NN
costs_NN
._.
In_PIN
most_EMPH
instances_NN
,_,
GSK_NN
is_VPRT [PASS]
involved_VBN
as_IN
an_DT
alleged_JJ
generator_NN
of_PIN
hazardous_JJ
waste_NN
although_CONC
there_EX
are_VPRT
a_DT
few_QUAN
sites_NN
where_RB
GSK_NN
is_VPRT [PASS]
involved_VBN
as_IN
a_DT
current_JJ
or_CC
former_JJ
operator_NN
of_PIN
the_DT
facility_NOMZ
._.
Although_CONC
Superfund_NN
provides_VPRT
that_DEMO
the_DT
defendants_NN
are_VPRT
jointly_RB
and_PHC
severally_RB
liable_JJ
for_PIN
cleanup_NN
costs_NN
,_,
these_DEMO
proceedings_GER
are_VPRT [SPAU] [PASS]
frequently_RB
resolved_VBN [SUAV]
on_PIN
the_DT
basis_NN
of_PIN
the_DT
nature_NN
and_PHC
quantity_NOMZ
of_PIN
waste_NN
disposed_VBN [WZPAST]
of_PIN
at_PIN
the_DT
site_NN
by_PIN
the_DT
generator_NN
._.
GSKs_NN
proportionate_VPRT
liability_NOMZ
for_PIN
cleanup_NN
costs_NN
has_VPRT [PEAS]
been_VBN [SPAU] [PASS]
substantially_RB
determined_VBN [SUAV] [PRIV]
for_PIN
about_RB
20_CD
of_PIN
the_DT
sites_NN
referred_VBD
to_PIN
above_PLACE
._.
GSKs_NN
potential_JJ
liability_NOMZ
varies_VPRT
greatly_AMP
from_PIN
site_NN
to_PIN
site_NN
._.
While_OSUB
the_DT
cost_NN
of_PIN
investigation_NOMZ
,_,
study_NN
and_PHC
remediation_NOMZ
at_PIN
such_JJ
sites_NN
could_POMD
,_,
over_IN
time_NN
,_,
be_VB [BEMA]
substantial_PRED
,_,
GSK_NN
routinely_RB
accrues_VPRT
amounts_NN
related_VBN [WZPAST]
to_PIN
its_PIT
share_NN
of_PIN
the_DT
liability_NOMZ
for_PIN
such_JJ
matters_NN
._.
Tax_NN
matters_VPRT
Pending_GER
tax_NN
matters_NN
,_,
including_VBG
disclosure_NN
of_PIN
the_DT
tax_NN
liability_NOMZ
of_PIN
2.3_CD
billion_CD
2004_CD
1.8_CD
billion_CD
,_,
are_VPRT [PASS]
described_VBN
in_PIN
Note_NN
12_CD
,_,
Taxation_NOMZ
._.
GSK_NN
Annual_JJ
Report_NN
2005_CD
164_CD
FINANCIAL_NN
STATEMENTS_NOMZ
GlaxoSmithKline_JJ
plc_NN
Directors_NN
statements_NOMZ
of_PIN
responsibility_NOMZ
Directors_NN
statement_NOMZ
of_PIN
responsibility_NOMZ
in_PIN
relation_NOMZ
to_TO
Going_VBG
concern_NN
basis_NN
the_DT
companys_NN
financial_JJ
statements_NOMZ
After_IN
making_VBG
enquiries_NN
,_,
the_DT
Directors_NN
have_VPRT
a_DT
reasonable_JJ
The_DT
Directors_NN
are_VPRT
:_:
expectation_NOMZ
that_TOBJ
the_DT
company_NN
has_VPRT
adequate_JJ
resources_NN
to_TO
continue_VB
in_PIN
operational_JJ
existence_NN
for_PIN
the_DT
foreseeable_JJ
future_NN
._.
For_PIN
this_DEMO
reason_NN
,_,
they_TPP3
responsible_JJ
for_PIN
ensuring_VBG [SUAV] [PRIV]
the_DT
maintenance_NN
of_PIN
proper_JJ
accounting_GER
continue_VPRT
to_TO
adopt_VB
the_DT
going_VBG
concern_NN
basis_NN
in_PIN
preparing_VBG
the_DT
financial_JJ
records_NN
,_,
which_WDT [SERE]
disclose_VPRT [PUBV]
with_PIN
reasonable_JJ
accuracy_NN
the_DT
financial_JJ
statements_NOMZ
._.
position_NOMZ
of_PIN
the_DT
company_NN
at_PIN
any_QUAN
time_NN
and_CC
from_PIN
which_WDT [PIRE]
financial_JJ
statements_NOMZ
can_POMD
be_VB [PASS]
prepared_VBN
to_TO
comply_VB
with_PIN
the_DT
Companies_NN
The_DT
Combined_NN
Code_NN
Act_NN
1985_CD
The_NN
Board_NN
considers_VPRT [PRIV]
that_THVC
GlaxoSmithKline_NN
plc_NN
applies_VPRT
the_DT
principles_NN
of_PIN
required_VBN [SUAV]
by_PIN
law_NN
to_TO
prepare_VB
financial_JJ
statements_NOMZ
for_PIN
each_QUAN
financial_JJ
the_DT
Combined_NN
Code_NN
on_PIN
Corporate_NN
Governance_NN
of_PIN
the_DT
Financial_JJ
period_NN
which_WDT [WHSUB]
give_VPRT
a_DT
true_JJ
and_PHC
fair_JJ
view_NN
of_PIN
the_DT
state_NN
of_PIN
affairs_NN
of_PIN
the_DT
Reporting_GER
Council_NN
,_,
as_IN
described_VBN
under_IN
Corporate_JJ
governance_NN
on_PIN
company_NN
as_RB
at_PIN
the_DT
end_NN
of_PIN
the_DT
financial_JJ
period_NN
and_CC
of_PIN
the_DT
profit_NN
or_CC
pages_NN
27_CD
to_PIN
36_CD
,_,
and_ANDC
has_VPRT [PEAS]
complied_VBN
with_PIN
its_PIT
provisions_NN
except_PIN
as_IN
loss_NN
for_PIN
that_DEMO
period_NN
described_VBN [WZPAST]
on_PIN
pages_NN
35_CD
and_CC
36_CD
._.
responsible_JJ
also_RB
for_PIN
ensuring_VBG [SUAV] [PRIV]
the_DT
operation_NOMZ
of_PIN
systems_NN
of_PIN
As_IN
required_VBN [SUAV]
by_PIN
the_DT
Listing_GER
Rules_NN
of_PIN
the_DT
Financial_NN
Services_NN
Authority_NOMZ
,_,
the_DT
internal_JJ
control_NN
and_CC
for_PIN
taking_VBG
reasonable_JJ
steps_NN
to_TO
safeguard_VB
the_DT
auditors_NN
have_VPRT [PEAS]
considered_VBN [PRIV]
the_DT
Directors_NN
statement_NOMZ
of_PIN
compliance_NN
in_PIN
assets_NN
of_PIN
the_DT
company_NN
and_CC
for_PIN
preventing_VBG
and_PHC
detecting_VBG
fraud_NN
and_PHC
relation_NOMZ
to_PIN
those_DEMO
points_NN
of_PIN
the_DT
Combined_NN
Code_NN
which_WDT [WHSUB]
are_VPRT [PASS]
specified_VBN
other_JJ
irregularities_NOMZ
._.
The_DT
balance_NN
sheet_NN
for_PIN
the_DT
year_NN
ended_VBD
31st_CD
December_NN
2005_CD
,_,
and_ANDC
supporting_VBG
notes_NN
are_VPRT [PASS]
set_VBN
out_PIN
on_PIN
pages_NN
167_CD
to_PIN
170_CD
of_PIN
this_DEMO
report_NN
._.
The_DT
Directors_NN
confirm_VPRT [PUBV]
that_THVC
suitable_JJ
accounting_GER
policies_NN
have_VPRT [PEAS]
been_VBN [SPAU] [PASS]
consistently_RB
applied_VBN
in_PIN
the_DT
preparation_NOMZ
of_PIN
the_DT
financial_JJ
statements_NOMZ
,_,
supported_VBN [PASTP]
by_PIN
reasonable_JJ
and_PHC
prudent_JJ
judgements_NOMZ
and_PHC
estimates_NN
as_IN
necessary_JJ
:_:
applicable_JJ
accounting_GER
standards_NN
have_VPRT [PEAS]
been_VBN [PASS]
followed_VBN
,_,
and_ANDC
the_DT
financial_JJ
statements_NOMZ
have_VPRT [PEAS]
been_VBN [PASS]
prepared_VBN
on_PIN
the_DT
going_VBG
Sir_NN
Christopher_NN
Gent_NN
concern_NN
basis_NN
._.
Chairman_NN
1st_CD
March_NN
2006_CD
The_DT
responsibilities_NOMZ
of_PIN
the_DT
auditors_NN
in_PIN
relation_NOMZ
to_PIN
the_DT
financial_JJ
statements_NOMZ
are_VPRT [PASS]
set_VBN
out_PIN
in_PIN
the_DT
Independent_NN
Auditors_NN
report_VPRT [PUBV]
page_NN
166_CD
._.
The_DT
Annual_JJ
Report_NN
2005_CD
is_VPRT [PASS]
published_VBN
in_PIN
hard-copy_JJ
printed_VBN
form_NN
and_CC
made_VBN
available_JJ
on_PIN
the_DT
website_NN
._.
The_DT
Directors_NN
are_VPRT [BEMA]
responsible_PRED
for_PIN
the_DT
maintenance_NN
and_PHC
integrity_NOMZ
of_PIN
the_DT
Annual_JJ
Report_NN
on_PIN
the_DT
website_NN
in_PIN
accordance_NN
with_PIN
UK_NN
legislation_NOMZ
governing_VBG [WZPRES]
the_DT
preparation_NOMZ
and_PHC
dissemination_NOMZ
of_PIN
financial_JJ
statements_NOMZ
._.
Access_NN
to_PIN
the_DT
website_NN
is_VPRT [BEMA]
available_PRED
from_PIN
outside_PLACE
the_DT
UK_NN
,_,
where_RB
comparable_JJ
legislation_NOMZ
may_POMD
be_VB [BEMA]
different_PRED
._.
Directors_NN
remuneration_VPRT
The_DT
Remuneration_NOMZ
Report_NN
on_PIN
pages_NN
37_CD
to_PIN
54_CD
sets_NN
out_PIN
the_DT
remuneration_NOMZ
policies_NN
operated_VBN [WZPAST]
by_PIN
GlaxoSmithKline_NN
and_PHC
disclosures_NN
on_PIN
Directors_NN
remuneration_NOMZ
and_CC
other_JJ
disclosable_JJ
information_NOMZ
relating_VBG [WZPRES]
to_PIN
Directors_NN
and_PHC
officers_NN
and_CC
their_TPP3
interests_NN
._.
It_PIT
has_VPRT [PEAS]
been_VBN [PASS]
prepared_VBN
in_PIN
accordance_NN
with_PIN
the_DT
Companies_NN
Act_NN
1985_CD
and_CC
complies_VPRT
with_PIN
Section_NOMZ
B_NN
of_PIN
the_DT
Combined_NN
Code_NN
on_PIN
Corporate_NN
Governance_NN
._.
GSK_NN
Annual_JJ
Report_NN
2005_CD
165_CD
FINANCIAL_NN
STATEMENTS_NOMZ
GlaxoSmithKline_JJ
plc_NN
Independent_NN
Auditors_NN
report_VPRT [PUBV]
to_PIN
the_DT
members_NN
of_PIN
GlaxoSmithKline_NN
plc_NN
We_FPP1
have_VPRT [PEAS]
audited_VBN
the_DT
parent_NN
company_NN
financial_JJ
statements_NOMZ
of_PIN
Basis_NN
of_PIN
audit_NN
opinion_NN
GlaxoSmithKline_NN
plc_NN
for_PIN
the_DT
year_NN
ended_VBD
31st_CD
December_NN
2005_CD
which_WDT
We_FPP1
conducted_VBD
our_FPP1
audit_NN
in_PIN
accordance_NN
with_PIN
International_NN
Standards_NN
comprise_VPRT
the_DT
balance_NN
sheet_NN
,_,
and_ANDC
the_DT
related_JJ
notes_NN
._.
These_DEMO
parent_NN
on_PIN
Auditing_VBG
UK_NN
and_PHC
Ireland_NN
issued_VBN [WZPAST]
by_PIN
the_DT
Auditing_GER
Practices_NN
Board_NN
._.
company_NN
financial_JJ
statements_NOMZ
have_VPRT [PEAS]
been_VBN [PASS]
prepared_VBN
under_IN
the_DT
An_DT
audit_NN
includes_VPRT
examination_NOMZ
,_,
on_PIN
a_DT
test_NN
basis_NN
,_,
of_PIN
evidence_NN
relevant_JJ
accounting_GER
policies_NN
set_VBN [WZPAST]
out_PIN
therein_RB
._.
We_FPP1
have_VPRT [SPAU] [PEAS]
also_RB
audited_VBN
the_DT
to_PIN
the_DT
amounts_NN
and_PHC
disclosures_NN
in_PIN
the_DT
parent_NN
company_NN
financial_JJ
information_NOMZ
in_PIN
the_DT
Directors_NN
Remuneration_NOMZ
Report_NN
that_DEMP
is_VPRT [PASS]
described_VBN
statements_NOMZ
and_CC
the_DT
part_NN
of_PIN
the_DT
Directors_NN
Remuneration_NOMZ
Report_NN
to_TO
be_VB
as_IN
having_VBG [PEAS]
been_VBN [PASS]
audited_VBN
._.
It_PIT
also_RB
includes_VPRT
an_DT
assessment_NOMZ
of_PIN
the_DT
significant_JJ
estimates_NN
and_PHC
judgments_NOMZ
made_VBN [WZPAST]
by_PIN
the_DT
directors_NN
in_PIN
the_DT
preparation_NOMZ
of_PIN
the_DT
parent_NN
We_FPP1
have_VPRT [PEAS]
reported_VBN [PUBV]
separately_RB
on_PIN
the_DT
group_NN
financial_JJ
statements_NOMZ
of_PIN
company_NN
financial_JJ
statements_NOMZ
,_,
and_ANDC
of_PIN
whether_IN
the_DT
accounting_GER
policies_NN
GlaxoSmithKline_NN
plc_NN
for_PIN
the_DT
year_NN
ended_VBD
31st_CD
December_NN
2005_CD
._.
are_VPRT [BEMA]
appropriate_PRED
to_PIN
the_DT
companys_NN
circumstances_NN
,_,
consistently_RB
applied_VBN
Respective_NN
responsibilities_NOMZ
of_PIN
directors_NN
and_PHC
auditors_NN
and_CC
adequately_RB
disclosed_VBN [PUBV]
._.
The_DT
directors_NN
responsibilities_NOMZ
for_PIN
preparing_VBG
the_DT
Annual_JJ
Report_NN
,_,
the_DT
We_FPP1
planned_VBD
and_PHC
performed_VBD
our_FPP1
audit_NN
so_RB
as_IN
to_TO
obtain_VB
all_QUAN
the_DT
Directors_NN
Remuneration_NOMZ
Report_NN
and_CC
the_DT
parent_NN
company_NN
financial_JJ
information_NOMZ
and_PHC
explanations_NOMZ
which_WDT [WHOBJ]
we_FPP1
considered_VBD [PRIV]
necessary_JJ
in_PIN
statements_NOMZ
in_PIN
accordance_NN
with_PIN
applicable_JJ
law_NN
and_PHC
United_NN
Kingdom_NN
order_NN
to_TO
provide_VB
us_FPP1
with_PIN
sufficient_JJ
evidence_NN
to_TO
give_VB
reasonable_JJ
Accounting_GER
Standards_NN
United_NN
Kingdom_NN
Generally_RB
Accepted_JJ
assurance_NN
that_TOBJ
the_DT
parent_NN
company_NN
financial_JJ
statements_NOMZ
and_CC
the_DT
part_NN
Accounting_GER
Practice_NN
are_VPRT [PASS]
set_VBN
out_PIN
in_PIN
the_DT
Statement_NOMZ
of_PIN
Directors_NN
of_PIN
the_DT
Directors_NN
Remuneration_NOMZ
Report_NN
to_TO
be_VB [PASS]
audited_VBN
are_VPRT [BEMA]
free_PRED
from_PIN
Responsibilities_NOMZ
._.
material_NN
misstatement_NOMZ
,_,
whether_IN
caused_VBN
by_PIN
fraud_NN
or_CC
other_JJ
irregularity_NOMZ
Our_FPP1
responsibility_NOMZ
is_VPRT
to_TO
audit_VB
the_DT
parent_NN
company_NN
financial_JJ
statements_NOMZ
or_CC
error_NN
._.
In_PIN
forming_VBG
our_FPP1
opinion_NN
we_FPP1
also_RB
evaluated_VBD
the_DT
overall_JJ
and_CC
the_DT
part_NN
of_PIN
the_DT
Directors_NN
Remuneration_NOMZ
Report_NN
to_TO
be_VB [PASS]
audited_VBN
in_PIN
adequacy_NN
of_PIN
the_DT
presentation_NOMZ
of_PIN
information_NOMZ
in_PIN
the_DT
parent_NN
company_NN
accordance_NN
with_PIN
relevant_JJ
legal_JJ
and_PHC
regulatory_JJ
requirements_NOMZ
and_CC
financial_JJ
statements_NOMZ
and_CC
the_DT
part_NN
of_PIN
the_DT
Directors_NN
Remuneration_NOMZ
International_NN
Standards_NN
on_PIN
Auditing_GER
UK_NN
and_PHC
Ireland_NN
._.
This_DEMO
report_NN
,_,
Report_NN
to_TO
be_VB [PASS]
audited_VBN
._.
including_VBG [PRESP]
the_DT
opinion_NN
,_,
has_VPRT [PEAS]
been_VBN [PASS]
prepared_VBN
for_PIN
and_CC
only_DWNT
for_PIN
the_DT
Opinion_NN
companys_VPRT
members_NN
as_IN
a_DT
body_NN
in_PIN
accordance_NN
with_PIN
Section_NOMZ
235_CD
of_PIN
the_DT
In_PIN
our_FPP1
opinion_NN
:_:
Companies_NN
Act_NN
1985_CD
and_CC
for_PIN
no_SYNE
other_JJ
purpose_NN
._.
We_FPP1
do_VPRT
not_XX0
,_,
in_PIN
giving_VBG
this_DEMO
opinion_NN
,_,
accept_VB [PRIV]
or_CC
assume_VB [PRIV]
responsibility_NOMZ
for_PIN
any_QUAN
other_JJ
purpose_NN
or_CC
the_DT
parent_NN
company_NN
financial_JJ
statements_NOMZ
give_VPRT
a_DT
true_JJ
and_PHC
fair_JJ
view_NN
,_,
to_PIN
any_QUAN
other_JJ
person_NN
to_PIN
whom_WP [PIRE]
this_DEMO
report_NN
is_VPRT [PASS]
shown_VBN [PRIV]
or_CC
into_PIN
whose_WPS [PIRE]
in_PIN
accordance_NN
with_PIN
United_NN
Kingdom_NN
Generally_RB
Accepted_JJ
Accounting_GER
hands_NN
it_PIT
may_POMD
come_VB
save_IN
where_RB
expressly_RB
agreed_VBN [SUAV] [PUBV]
by_PIN
our_FPP1
prior_JJ
consent_NN
Practice_NN
,_,
of_PIN
the_DT
state_NN
of_PIN
the_DT
companys_NN
affairs_NN
as_IN
at_PIN
31st_CD
December_NN
in_PIN
writing_VBG [PUBV]
._.
2005_CD
:_:
and_ANDC
We_FPP1
report_VPRT [PUBV]
to_PIN
you_SPP2
our_FPP1
opinion_NN
as_IN
to_PIN
whether_IN
the_DT
parent_NN
company_NN
the_DT
parent_NN
company_NN
financial_JJ
statements_NOMZ
and_CC
the_DT
part_NN
of_PIN
the_DT
financial_JJ
statements_NOMZ
give_VPRT
a_DT
true_JJ
and_PHC
fair_JJ
view_NN
and_ANDC
whether_IN
the_DT
Directors_NN
Remuneration_NOMZ
Report_NN
to_TO
be_VB [PASS]
audited_VBN
have_VPRT [PEAS]
been_VBN [BEMA]
properly_RB
parent_JJ
company_NN
financial_JJ
statements_NOMZ
and_CC
the_DT
part_NN
of_PIN
the_DT
Directors_NN
prepared_VBN [WZPAST]
in_PIN
accordance_NN
with_PIN
the_DT
Companies_NN
Act_NN
1985_CD
._.
Remuneration_NOMZ
Report_NN
to_TO
be_VB [PASS]
audited_VBN
have_VPRT [PEAS]
been_VBN [SPAU] [PASS]
properly_RB
prepared_VBN
in_PIN
accordance_NN
with_PIN
the_DT
Companies_NN
Act_NN
1985_CD
._.
We_FPP1
also_RB
report_VPRT [PUBV]
to_PIN
you_SPP2
if_COND
,_,
in_PIN
our_FPP1
opinion_NN
,_,
the_DT
Directors_NN
Report_NN
is_VPRT [BEMA]
not_XX0
consistent_PRED
with_PIN
the_DT
parent_NN
company_NN
financial_JJ
statements_NOMZ
,_,
if_COND
the_DT
company_NN
has_VPRT [PEAS]
not_XX0
kept_VBN
LLP_NN
proper_JJ
accounting_GER
records_NN
,_,
if_COND
we_FPP1
have_VPRT [PEAS]
not_XX0
received_VBN
all_QUAN
the_DT
Chartered_NN
Accountants_NN
and_PHC
Registered_NN
Auditors_NN
information_NOMZ
and_PHC
explanations_NOMZ
we_FPP1
require_VPRT [SUAV]
for_PIN
our_FPP1
audit_NN
,_,
or_CC
if_COND
London_NN
information_NOMZ
specified_VBN [WZPAST]
by_PIN
law_NN
regarding_VBG [WZPRES]
directors_NN
remuneration_NOMZ
and_CC
1st_CD
March_NN
2006_CD
other_JJ
transactions_NOMZ
is_VPRT [PASS]
not_XX0
disclosed_VBN [PUBV]
._.
We_FPP1
read_VBD
other_JJ
information_NOMZ
contained_VBN [WZPAST]
in_PIN
the_DT
Annual_JJ
Report_NN
and_CC
consider_VB [PRIV]
whether_IN [WHCL]
it_PIT
is_VPRT [BEMA]
consistent_PRED
with_PIN
the_DT
audited_JJ
parent_NN
company_NN
financial_JJ
statements_NOMZ
._.
The_DT
other_JJ
information_NOMZ
comprises_VPRT
only_DWNT
the_DT
joint_JJ
statement_NOMZ
by_PIN
the_DT
Chairman_NN
and_PHC
Chief_NN
Executive_NN
,_,
the_DT
financial_JJ
summary_NN
,_,
description_NOMZ
of_PIN
business_NOMZ
,_,
the_DT
corporate_JJ
governance_NN
statement_NOMZ
and_CC
the_DT
operating_GER
and_CC
financial_JJ
review_NN
and_PHC
prospects_NN
._.
We_FPP1
consider_VPRT [PRIV]
the_DT
implications_NOMZ
for_PIN
our_FPP1
report_NN
if_COND
we_FPP1
become_VPRT
aware_JJ
of_PIN
any_QUAN
apparent_JJ
misstatements_NOMZ
or_CC
material_NN
inconsistencies_NN
with_PIN
the_DT
parent_NN
company_NN
financial_JJ
statements_NOMZ
._.
Our_FPP1
responsibilities_NOMZ
do_VPRT
not_XX0
extend_VB
to_PIN
any_QUAN
other_JJ
information_NOMZ
._.
GSK_NN
Annual_JJ
Report_NN
2005_CD
166_CD
FINANCIAL_NN
STATEMENTS_NOMZ
GlaxoSmithKline_NN
plc_NN
Company_NN
balance_NN
sheet_NN
UK_NN
GAAP_NN
at_PIN
31st_CD
December_NN
2005 2004 2005_CD
restated_VBN
Notes_NN
m_FW
m_FW
Investment_NOMZ
in_PIN
subsidiary_NN
companies_NN
18,727_CD
18,616_CD
Fixed_VBN
assets_NN
D_NN
18,727_CD
18,616_CD
Debtors_NN
E_NN
237_CD
218_CD
Cash_NN
at_PIN
bank_NN
5_CD
22_CD
Current_JJ
assets_NN
242_CD
240_CD
Creditors_NN
:_:
amounts_NN
due_JJ
within_PIN
one_CD
year_NN
F_NN
8,862_CD
6,825_CD
Net_JJ
current_JJ
liabilities_NOMZ
8,620_CD
6,585_CD
Net_JJ
assets_NN
10,107_CD
12,031_CD
Capital_NN
and_PHC
reserves_NN
Called_VBN
up_RP
share_NN
capital_NN
G_NN
1,491_CD
1,484_CD
Share_NN
premium_NN
account_NN
G_NN
549_CD
304_CD
Other_JJ
reserves_NN
H_NN
902_CD
767_CD
Profit_NN
and_PHC
loss_NN
account_NN
H_NN
7,165_CD
9,476_CD
Equity_NOMZ
shareholders_NN
funds_NN
10,107_CD
12,031_CD
Approved_VBN
by_PIN
the_DT
Board_NN
on_PIN
1st_CD
March_NN
2006_CD
Sir_NN
Christopher_NN
Gent_NN
Chairman_NN
GSK_NN
Annual_JJ
Report_NN
2005_CD
167_CD
FINANCIAL_NN
STATEMENTS_NOMZ
GlaxoSmithKline_NN
plc_NN
Notes_NN
to_PIN
the_DT
company_NN
balance_NN
sheet_NN
UK_NN
GAAP_NN
at_PIN
31st_CD
December_NN
2005_CD
Taxation_NOMZ
A_NN
Presentation_NOMZ
of_PIN
the_DT
financial_JJ
statements_NOMZ
Current_JJ
tax_NN
is_VPRT [PASS]
provided_VBN
at_PIN
the_DT
amounts_NN
expected_VBN [PRIV]
to_TO
be_VB [PASS]
paid_VBN
applying_VBG
Description_NOMZ
of_PIN
business_NOMZ
tax_NN
rates_NN
that_TSUB
have_VPRT [PEAS]
been_VBN [PASS]
enacted_VBN
or_CC
substantially_RB
enacted_VBN
by_PIN
the_DT
GlaxoSmithKline_NN
plc_NN
is_VPRT [BEMA]
the_DT
parent_NN
company_NN
of_PIN
GSK_NN
,_,
a_DT
major_JJ
global_JJ
balance_NN
sheet_NN
date_NN
._.
healthcare_NN
group_NN
which_WDT [WHSUB]
is_VPRT [PASS]
engaged_VBN
in_PIN
the_DT
creation_NOMZ
and_PHC
discovery_NN
,_,
development_NOMZ
,_,
manufacture_NN
and_PHC
marketing_GER
of_PIN
pharmaceutical_JJ
The_DT
company_NN
accounts_VPRT
for_PIN
taxation_NOMZ
which_WDT [WHSUB]
is_VPRT [PASS]
deferred_VBN
or_CC
accelerated_VBN
products_NN
,_,
including_VBG
vaccines_NN
,_,
over-the-counter_JJ
OTC_NN
medicines_NN
and_CC
by_PIN
reason_NN
of_PIN
timing_NN
differences_NN
which_WDT [WHSUB]
have_VPRT [PEAS]
originated_VBN
but_CC
not_XX0
reversed_VBD
health-related_JJ
consumer_NN
products_NN
._.
by_PIN
the_DT
balance_NN
sheet_NN
date_NN
._.
Deferred_JJ
tax_NN
assets_NN
are_VPRT [SPAU] [PASS]
only_DWNT
recognized_VBN [PRIV]
to_PIN
the_DT
extent_NN
that_TOBJ
they_TPP3
are_VPRT [PASS]
considered_VBN [PRIV]
recoverable_JJ
against_PIN
future_JJ
taxable_JJ
Preparation_NOMZ
of_PIN
financial_JJ
statements_NOMZ
profits_NN
._.
The_DT
financial_JJ
statements_NOMZ
are_VPRT [PASS]
drawn_VBN
up_RP
in_PIN
accordance_NN
with_PIN
UK_NN
Deferred_NN
tax_NN
is_VPRT [PASS]
measured_VBN
at_PIN
the_DT
average_JJ
tax_NN
rates_NN
that_TSUB
are_VPRT [PASS]
expected_VBN [PRIV]
generally_RB
accepted_VBN [PRIV]
accounting_GER
principles_NN
UK_NN
GAAP_NN
and_CC
with_PIN
UK_NN
to_TO
apply_VB
in_PIN
the_DT
periods_NN
in_PIN
which_WDT [PIRE]
the_DT
timing_NN
differences_NN
are_VPRT [PASS]
expected_VBN [PRIV]
accounting_GER
presentation_NOMZ
as_IN
at_PIN
31st_CD
December_NN
2005_CD
,_,
with_PIN
comparative_JJ
to_TO
reverse_VB
._.
Deferred_JJ
tax_NN
liabilities_NOMZ
and_PHC
assets_NN
are_VPRT [PASS]
not_XX0
discounted_VBN
._.
As_IN
permitted_VBN
by_PIN
s._NN
230_CD
of_PIN
the_DT
Companies_NN
Act_NN
1985_CD
,_,
the_DT
profit_NN
and_PHC
loss_NN
C_NN
New_NN
accounting_GER
policies_NN
account_VPRT
of_PIN
the_DT
company_NN
is_VPRT [PASS]
not_XX0
presented_VBN
in_PIN
this_DEMO
Annual_JJ
Report_NN
._.
The_DT
Accounting_GER
Standards_NN
Board_NN
ASB_NN
issued_VBD
Financial_NN
Reporting_GER
Accounting_GER
convention_NOMZ
and_PHC
standards_NN
Stanard_NN
FRS_NN
20_CD
Share_NN
Based_VBD
Payments_NOMZ
in_PIN
April_NN
2004_CD
._.
Although_CONC
the_DT
The_DT
balance_NN
sheet_NN
has_VPRT [PEAS]
been_VBN [PASS]
prepared_VBN
using_VBG
the_DT
historical_JJ
cost_NN
company_NN
does_VPRT
not_XX0
incur_VB
a_DT
charge_NN
under_IN
this_DEMO
standard_NN
,_,
the_DT
issuance_NN
convention_NOMZ
and_PHC
complies_NN
with_PIN
applicable_JJ
UK_NN
accounting_GER
standards_NN
._.
by_PIN
the_DT
company_NN
to_PIN
its_PIT
subsidiaries_NN
of_PIN
a_DT
grant_NN
over_IN
the_DT
companys_NN
Accounting_GER
principles_NN
and_PHC
policies_NN
options_NOMZ
,_,
represents_VPRT
additional_JJ
capital_NN
contributions_NOMZ
by_PIN
the_DT
company_NN
The_DT
preparation_NOMZ
of_PIN
the_DT
balance_NN
sheet_NN
in_PIN
conformity_NOMZ
with_PIN
generally_RB
in_PIN
its_PIT
subsidiaries_NN
._.
An_DT
additional_JJ
investment_NOMZ
in_PIN
subsidiaries_NN
results_NN
with_PIN
accepted_VBN [PRIV]
accounting_GER
principles_NN
requires_VPRT [SUAV]
management_NOMZ
a_DT
corresponding_JJ
increase_NN
in_PIN
shareholders_NN
equity_NOMZ
._.
The_DT
additional_JJ
capital_NN
to_TO
make_VB
estimates_NN
and_PHC
assumptions_NOMZ
that_TSUB
affect_VPRT
the_DT
reported_VBN [PUBV]
amounts_NN
contribution_NOMZ
is_VPRT [PASS]
based_VBN
on_PIN
the_DT
fair_JJ
value_NN
of_PIN
the_DT
grant_NN
issued_VBD
allocated_VBN
of_PIN
assets_NN
and_PHC
liabilities_NOMZ
and_PHC
disclosure_NN
of_PIN
contingent_NN
over_IN
the_DT
underlying_VBG
grants_NN
vesting_VBG [WZPRES]
period_NN
._.
assets_NN
and_PHC
liabilities_NOMZ
at_PIN
the_DT
date_NN
of_PIN
the_DT
balance_NN
sheet_NN
._.
Actual_JJ
amounts_NN
The_DT
ASB_NN
issued_VBD
FRS_NN
21_CD
Events_NN
after_IN
the_DT
balance_NN
sheet_NN
date_NN
in_PIN
May_POMD
could_POMD
differ_VB
from_PIN
those_DEMO
estimates_NN
._.
This_DEMO
standard_JJ
replaced_VBN
Statement_NOMZ
of_PIN
Standard_NN
Accounting_GER
Practice_NN
17_CD
Accounting_GER
for_PIN
post_NN
balance_NN
sheet_NN
events_NN
and_CC
the_DT
main_JJ
The_DT
balance_NN
sheet_NN
has_VPRT [PEAS]
been_VBN [PASS]
prepared_VBN
in_PIN
accordance_NN
with_PIN
the_DT
effect_NN
of_PIN
this_DEMO
change_NN
is_VPRT
to_TO
prohibit_VB
the_DT
recording_GER
of_PIN
a_DT
provision_NN
for_PIN
a_DT
companys_NN
accounting_VBG [WZPRES]
policies_NN
approved_VBN [WZPAST]
by_PIN
the_DT
Board_NN
and_CC
described_VBD
proposed_VBN [SUAV]
dividend_NN
where_RB
the_DT
dividend_NN
is_VPRT [PASS]
declared_VBN [PUBV]
after_IN
the_DT
balance_NN
in_PIN
Note_NN
B._NN
sheet_NN
date_NN
._.
FRS_NN
21_CD
is_VPRT [BEMA]
applicable_PRED
for_PIN
accounting_GER
periods_NN
beginning_VBG [WZPRES]
on_PIN
or_CC
after_IN
1st_CD
January_NN
2005_CD
._.
Therefore_CONJ
final_JJ
dividends_NN
are_VPRT
now_TIME
only_DWNT
B_NN
Accounting_GER
policies_NN
recognized_VBN [PRIV] [WZPAST]
in_PIN
the_DT
profit_NN
and_PHC
loss_NN
account_NN
when_RB
shareholders_NN
have_VPRT
Foreign_JJ
currency_NN
transactions_NOMZ
approved_VBD
such_JJ
amount_NN
and_CC
interim_JJ
dividends_NN
are_VPRT [SPAU] [PASS]
only_DWNT
recognized_VBN [PRIV]
Foreign_JJ
currency_NN
transactions_NOMZ
are_VPRT [PASS]
recorded_VBN
at_PIN
the_DT
exchange_NN
rate_NN
ruling_NN
when_RB
paid_VBN
._.
on_PIN
the_DT
date_NN
of_PIN
transaction_NOMZ
,_,
or_CC
at_PIN
the_DT
forward_JJ
rate_NN
if_COND
hedged_VBN
by_PIN
a_DT
forward_RB
exchange_NN
contract_NN
._.
Foreign_JJ
currency_NN
assets_NN
and_PHC
liabilities_NOMZ
are_VPRT [BEMA]
During_PIN
the_DT
year_NN
the_DT
company_NN
also_RB
adopted_VBD
FRS_NN
23_CD
The_DT
Effects_NN
of_PIN
translated_VBN
at_PIN
rates_NN
of_PIN
exchange_NN
ruling_NN
at_PIN
the_DT
balance_NN
sheet_NN
date_NN
,_,
or_CC
at_PIN
Changes_NN
in_PIN
Foreign_NN
Exchange_NN
Rates_NN
,_,
FRS_NN
25_CD
Financial_NN
Instruments_NOMZ
:_:
the_DT
forward_JJ
rate_NN
._.
Disclosure_NN
and_PHC
Presentation_NOMZ
,_,
FRS26_NN
Financial_NN
Instruments_NOMZ
:_:
Measurement_NOMZ
,_,
and_ANDC
FRS_NN
28_CD
Corresponding_VBG
Amounts_NN
._.
The_DT
adoption_NOMZ
Dividends_VPRT
paid_VBN
and_PHC
received_VBN
of_PIN
these_DEMO
standards_NN
has_VPRT [PEAS]
not_XX0
had_VBD
a_DT
material_NN
impact_NN
on_PIN
the_DT
companys_NN
Dividends_NN
paid_VBD
and_PHC
received_VBD
are_VPRT [PASS]
included_VBN
in_PIN
the_DT
accounts_NN
in_PIN
the_DT
period_NN
balance_NN
sheet_NN
._.
in_PIN
which_WDT [PIRE]
the_DT
related_JJ
dividends_NN
are_VPRT [SPAU] [PASS]
actually_RB
paid_VBN
or_CC
received_VBN
._.
Expenditure_NN
Expenditure_NN
is_VPRT [PASS]
recognized_VBN [PRIV]
in_PIN
respect_NN
of_PIN
goods_NN
and_PHC
services_NN
received_VBN
when_RB
supplied_VBN
in_PIN
accordance_NN
with_PIN
contractual_JJ
terms_NN
._.
Provision_NN
is_VPRT [PASS]
made_VBN
when_RB
an_DT
obligation_NOMZ
exists_VPRT
for_PIN
a_DT
future_JJ
liability_NOMZ
in_PIN
respect_NN
of_PIN
a_DT
past_JJ
event_NN
and_ANDC
where_RB
the_DT
amount_NN
of_PIN
the_DT
obligation_NOMZ
can_POMD
be_VB [SPAU] [PASS]
reliably_RB
estimated_VBN [PRIV]
._.
Investments_NOMZ
in_PIN
subsidiary_NN
companies_NN
Investments_NOMZ
in_PIN
subsidiary_NN
companies_NN
are_VPRT [PASS]
held_VBN [PRIV]
at_PIN
cost_NN
less_JJ
any_QUAN
provision_NN
for_PIN
permanent_JJ
diminution_NOMZ
in_PIN
value_NN
._.
GSK_NN
Annual_JJ
Report_NN
2005_CD
168_CD
FINANCIAL_NN
STATEMENTS_NOMZ
GlaxoSmithKline_NN
plc_NN
Notes_NN
to_PIN
the_DT
company_NN
balance_NN
sheet_NN
UK_NN
GAAP_NN
at_PIN
31st_CD
December_NN
2005_CD
D_NN
Fixed_VBN
assets_NN
2004_CD
2005_CD
restated_VBN
m_NN
m_NN
Shares_NN
in_PIN
GlaxoSmithKline_NN
Finance_NN
plc_NN
17,888_CD
17,888_CD
Shares_NN
in_PIN
GlaxoSmithKline_NN
Services_NN
Unlimited_NN
24_CD
Shares_NN
in_PIN
GlaxoSmithKline_NN
Holdings_GER
one_CD
Limited_JJ
18_CD
18_CD
17,906_CD
17,930_CD
Capital_NN
contribution_NOMZ
relating_VBG [WZPRES]
to_TO
share_VB
based_VBN
payments_NOMZ
821_CD
686_CD
18,727_CD
18,616_CD
Subsequent_JJ
to_PIN
the_DT
year-end_NN
the_DT
company_NN
formed_VBD
a_DT
new_JJ
subsidiary_NN
,_,
GlaxoSmithKline_NN
Holdings_GER
Limited_NN
,_,
and_ANDC
sold_VBD
the_DT
entire_JJ
share_NN
holding_VBG [PRIV] [WZPRES]
in_PIN
GlaxoSmithKline_NN
Finance_NN
plc_NN
to_PIN
it_PIT
._.
GlaxoSmithKline_NN
Holdings_GER
Limited_NN
issued_VBD
new_JJ
shares_NN
to_PIN
the_DT
company_NN
as_IN
consideration_NOMZ
._.
E_NN
Debtors_NN
2005_CD
2004_CD
m_NN
m_NN
Amounts_NN
due_JJ
within_PIN
one_CD
year_NN
:_:
Corporate_JJ
tax_NN
127_CD
110_CD
Amounts_NN
owed_VBN [WZPAST]
by_PIN
Group_NN
undertakings_GER
110 108 237 218_CD
F_NN
Creditors_NN
2004_CD
2005_CD
restated_VBN
m_NN
m_NN
Amounts_NN
due_JJ
within_PIN
one_CD
year_NN
:_:
Dividends_NN
payable_JJ
4_CD
4_CD
Amounts_NN
owed_VBN [WZPAST]
to_PIN
Group_NN
undertakings_GER
8,857_CD
6,821_CD
Other_JJ
creditors_NN
1_CD
8,862_CD
6,825_CD
G_NN
Share_NN
capital_NN
and_PHC
share_NN
premium_NN
account_NN
Share_NN
Ordinary_NN
shares_NN
of_PIN
25p_JJ
each_QUAN
premium_NN
Number_NN
m_FW
m_FW
Share_NN
capital_NN
authorised_VBN [WZPAST]
At_PIN
31st_CD
December_NN
2004_CD
10,000,000,000_CD
2,500_CD
At_PIN
31st_CD
December_NN
2005_CD
10,000,000,000_CD
2,500_CD
Share_NN
capital_NN
issued_VBN
and_CC
fully_AMP
paid_VBN
At_PIN
1st_CD
January_NN
2004_CD
5,949,463,628_CD
1,487_CD
264_CD
Issued_VBN
under_IN
share_NN
option_NOMZ
schemes_NN
6,300,203_CD
2_CD
40_CD
Purchased_VBN
and_PHC
canceled_VBN
18,075,000_CD
5_CD
At_PIN
31st_CD
December_NN
2004_CD
5,937,688,831_CD
1,484_CD
304_CD
Issued_VBN
under_IN
share_NN
option_NOMZ
schemes_NN
25,162,425_CD
7_CD
245_CD
At_PIN
31st_CD
December_NN
2005_CD
5,962,851,256_CD
1,491_CD
549_CD
31st_CD
December_NN
31st_CD
December_NN
2005_CD
2004_CD
Number_NN
000_CD
of_PIN
shares_NN
issuable_JJ
under_IN
outstanding_JJ
options_NOMZ
221,293_CD
276,954_CD
Number_NN
000_CD
of_PIN
unissued_JJ
shares_NN
not_XX0
under_IN
option_NOMZ
3,815,856_CD
3,785,358_CD
At_PIN
31st_CD
December_NN
2005_CD
,_,
of_PIN
the_DT
issued_VBN
share_NN
capital_NN
,_,
167,436,200_CD
shares_NN
were_VBD [PASS]
held_VBN [PRIV]
in_PIN
the_DT
ESOP_NN
Trust_NN
,_,
142,779,678_CD
shares_NN
were_VBD [PASS]
held_VBN [PRIV]
as_IN
Treasury_NN
shares_NN
and_CC
5,652,635,378_CD
shares_NN
were_VBD [BEMA]
in_PIN
free_JJ
issue_NN
._.
GSK_NN
Annual_JJ
Report_NN
2005_CD
169_CD
FINANCIAL_NN
STATEMENTS_NOMZ
GlaxoSmithKline_NN
plc_NN
Notes_NN
to_PIN
the_DT
company_NN
balance_NN
sheet_NN
UK_NN
GAAP_NN
at_PIN
31st_CD
December_NN
2005_CD
Other_JJ
Profit_NN
and_PHC
H_NN
Reserves_NN
reserves_NN
loss_NN
account_NN
Total_JJ
restated_VBN
restated_VBN
restated_VBN
m_FW
m_FW
m_FW [BEMA]
At_PIN
1st_CD
January_NN
2004_CD
,_,
as_IN
previously_TIME
reported_VBN [PUBV]
76_CD
8,905_CD
8,981_CD
Prior_RB
year_NN
adjustment_NOMZ
implementation_NOMZ
of_PIN
FRS_NN
20 476 476_CD
Prior_RB
year_NN
adjustment_NOMZ
implementation_NOMZ
of_PIN
FRS_NN
21_CD
1,328_CD
1,328_CD
At_PIN
1st_CD
January_NN
2004_CD
552_CD
10,233_CD
10,785_CD
Profit_NN
attributable_JJ
to_PIN
shareholders_NN
2,719_CD
2,719_CD
Dividends_NN
to_PIN
shareholders_NN
2,476_CD
2,476_CD
Ordinary_NN
shares_NN
purchased_VBD
and_PHC
canceled_VBD
5_CD
201_CD
196_CD
Ordinary_JJ
shares_NN
purchased_VBN
and_PHC
held_VBN [PRIV]
as_IN
Treasury_NN
shares_NN
799_CD
799_CD
Capital_NN
contribution_NOMZ
relating_VBG [WZPRES]
to_TO
share_VB
based_VBN
payments_NOMZ
210_CD
210_CD
At_PIN
31st_CD
December_NN
2004_CD
767_CD
9,476_CD
10,243_CD
Profit_NN
attributable_JJ
to_PIN
shareholders_NN
1,079_CD
1,079_CD
Dividends_NN
to_PIN
shareholders_NN
2,390_CD
2,390_CD
Ordinary_NN
shares_NN
purchased_VBD
and_PHC
held_VBD [PRIV]
as_IN
Treasury_NN
shares_NN
1,000_CD
1,000_CD
Capital_NN
contribution_NOMZ
relating_VBG [WZPRES]
to_TO
share_VB
based_VBN
payments_NOMZ
135_CD
135_CD
At_PIN
31st_CD
December_NN
2005_CD
902_CD
7,165_CD
8,067_CD
The_DT
profit_NN
of_PIN
GlaxoSmithKline_NN
plc_NN
for_PIN
the_DT
year_NN
was_VBD [BEMA]
1,079_CD
million_CD
2004_CD
2,719_CD
million_CD
,_,
which_WDT [SERE]
after_IN
dividends_NN
of_PIN
2,390_CD
million_CD
2004_CD
2,476_CD
million_CD
,_,
gave_VBD
a_DT
retained_VBN
loss_NN
of_PIN
1,311_CD
million_CD
2004_CD
profit_NN
243_CD
million_CD
._.
After_IN
the_DT
cost_NN
of_PIN
shares_NN
purchased_VBN
and_PHC
canceled_VBN
of_PIN
nil_NN
2004_CD
201_CD
million_CD
and_CC
shares_NN
purchased_VBN
and_PHC
held_VBN [PRIV]
as_IN
Treasury_NN
shares_NN
of_PIN
1,000_CD
million_CD
2004_CD
799_CD
million_CD
,_,
the_DT
profit_NN
and_PHC
loss_NN
account_NN
reserve_NN
at_PIN
31st_CD
December_NN
2005_CD
stood_VBD
at_PIN
7,165_CD
million_CD
2004_CD
9,476_CD
million_CD
,_,
of_PIN
which_WDT [PIRE]
4,096_CD
million_CD
is_VPRT [BEMA]
unrealised_PRED
2004_CD
4,096_CD
million_CD
._.
GSK_NN
Annual_JJ
Report_NN
2005_CD
170_CD
FINANCIAL_NN
STATEMENTS_NOMZ
Investor_NN
information_NOMZ
This_DEMO
section_NOMZ
includes_VPRT
the_DT
financial_JJ
record_NN
presenting_VBG [WZPRES]
historical_JJ
information_NOMZ
analyzed_VBD
in_PIN
accordance_NN
with_PIN
current_JJ
reporting_GER
practice_NN
._.
The_DT
transition_NOMZ
date_NN
to_PIN
IFRS_NN
for_PIN
GSK_NN
is_VPRT [BEMA]
1st_CD
January_NN
2003_CD
._.
Therefore_CONJ
,_,
the_DT
2005_CD
,_,
2004_CD
and_CC
2003_CD
information_NOMZ
included_VBN [WZPAST]
in_PIN
the_DT
Five_CD
Year_NN
Record_NN
is_VPRT [BEMA]
in_PIN
accordance_NN
with_PIN
IFRS_NN
._.
The_DT
2002_CD
and_CC
2001_CD
information_NOMZ
is_VPRT [BEMA]
in_PIN
accordance_NN
with_PIN
UK_NN
GAAP_NN
._.
To_TO
provide_VB
a_DT
link_NN
between_PIN
IFRS_NN
and_PHC
UK_NN
GAAP_NN
,_,
2003_CD
information_NOMZ
is_VPRT [PASS]
presented_VBN
also_RB
under_IN
UK_NN
GAAP_NN
._.
The_DT
accounting_GER
policies_NN
used_VBN [WZPAST]
in_PIN
the_DT
preparation_NOMZ
of_PIN
the_DT
UK_NN
GAAP_NN
information_NOMZ
are_VPRT [PASS]
disclosed_VBN [PUBV]
in_PIN
the_DT
2004_CD
Annual_JJ
Report_NN
._.
Information_NOMZ
prepared_VBN
under_IN
IFRS_NN
is_VPRT
not_XX0
directly_RB
comparable_PRED
with_PIN
information_NOMZ
prepared_VBN
under_IN
UK_NN
GAAP_NN
._.
The_DT
Five_CD
year_NN
record_NN
also_RB
presents_VPRT
information_NOMZ
in_PIN
accordance_NN
with_PIN
US_FPP1
GAAP_NN
._.
This_DEMO
section_NOMZ
also_RB
discusses_VPRT
shareholder_NN
return_NN
,_,
in_PIN
the_DT
form_NN
of_PIN
dividends_NN
and_PHC
share_NN
price_NN
movements_NOMZ
,_,
and_ANDC
provides_VPRT
other_JJ
information_NOMZ
for_PIN
shareholders_NN
._.
Financial_NN
record_NN
Quarterly_JJ
trend_NN
172_CD
Five_CD
year_NN
record_NN
178_CD
Shareholder_NN
information_NOMZ
182_CD
Taxation_NOMZ
information_NOMZ
for_PIN
shareholders_NN
186_CD
GSK_NN
Annual_JJ
Report_NN
2005_CD
171_CD
INVESTOR_NN
INFORMATION_NOMZ
